Annual Report - Department of Medicine

Transcription

UBC DEPARTMENT OF MEDICINE
2004
ANNUAL REPORT
TABLE OF CONTENTS
INTRODUCTION.………………………………………………………………………………3
MISSION STATEMENT.……………………………………………………………………….7
ORGANIZATION CHART.…………………………………………………………………….9
UBC DEPARTMENT OF MEDICINE COMMITTEES..…………………………………..11
Department Heads, Associate Heads, UBC Division Heads,
Educational Program Directors & Associate Directors.…………………………………………13
Committee for Appointments, Reappointments, Promotion and Tenure.………………………. 15
Teaching Effectiveness Office.…………………………………………………………………..19
DIVISION REPORTS.…………………………………………………………………………21
Allergy & Immunology.………………………………………………………………………… 23
Cardiology.……………………………………………………………………………………….27
Critical Care Medicine.…………………………………………………………………………..35
Dermatology.…………………………………………………………………………………….39
Endocrinology.………………………………………………………………………………….. 43
Gastroenterology.…………………………………………………………………………….…. 47
General Internal Medicine.………………………………………………………………………51
Geriatric Medicine.………………………………………………………………………………55
Hematology.…………………………………………………………………………………….. 59
Infectious Diseases.………………………………………………………………………………63
Medical Oncology.……………………………………………………………………………… 69
Nephrology.…………………………………….……………………………………………..…75
Neurology.……………………………………….……………………………………………....79
Physical Medicine & Rehabilitation.…………………………………………………………….95
Respiratory Medicine.……………………………………………………………………………99
Rheumatology.…………………………………………………………………………………. 103
EDUCATIONAL PROGRAMS.…………………………………………………………….. 109
Clinical Investigator Program.…………………………………………………………………. 111
Continuing Medical Education Program..……………….…………………………..………… 115
Graduate Studies Program in Experimental Medicine….………………………………………117
HIV/AIDS Research Program..…………………………………………………………………121
Postgraduate Education Program.………………………………………………………………127
Undergraduate Education Program.…………………………………………………………….129
PUBLICATIONS….………………………………………………………………………….. 131
GRANTS AND RESEARCH AWARDS.………………………………………………..….. 185
UBC Department of Medicine
Page 1
Annual Report 2004
INTRODUCTION
Graydon S. Meneilly, MD, FRCPC
Eric W. Hamber Professor & Head
I am pleased to provide this overview for the 2004 annual report on behalf of the UBC
Department of Medicine. This report is also available on the internet at www.medicine.ubc.ca.
Overview
The UBC Department of Medicine provides research, teaching and clinical services related to the
nature, cause and prevention of adult diseases. We are the largest Department in the Faculty of
Medicine and we consist of sixteen divisions: Allergy and Immunology, Cardiology, Critical
Care, Dermatology, Endocrinology, Gastroenterology, Geriatric Medicine, Internal Medicine,
Hematology, Infectious Diseases, Medical Oncology, Nephrology, Neurology, Physical
Medicine and Rehabilitation, Respiratory Medicine and Rheumatology.
People
As you read through this document you encounter the many different aspects of our Department
and the things we have achieved over the past year. I would like to take this opportunity to
highlight some of the wonderful accomplishments of our members. Recruitment and retention
are a large part of our business. We have appointed 3 Professors, 4 Associate Professors, 8
Assistant Professors, 1 Clinical Associate Professor, 10 Clinical Assistant Professors, 21 Clinical
Instructors and 4 Associate Members. We have promoted 12 Faculty members effective July 1,
2004.
Our faculty received 16 CIHR Scholarship/Scientist awards, 27 Michael Smith
Scholarships/Scientist awards, 6 CRC Scientist awards and 16 Scholarship/Scientist awards from
other peer reviewed agencies.
Page 3
Annual Report 2004
I am particularly pleased to announce the appointment of Dr. Paul Man as Associate Head of
Medicine at UBC and Chair, Department of Medicine, Providence Health Care in March 2004.
Paul is already taking a major leadership role in the activities of the Department.
In addition, the following Division Heads and Program Directors have also been appointed: Paul
Keown, Head, UBC Division of Nephrology, March 1, 2004; Chris Buller, Head, UBC
Division of Cardiology, January 1, 2004; Mark FitzGerald, Head, VGH Division of Respiratory
Medicine, July 1, 2004; Larry Dian, Acting Head, Division of Geriatric Medicine, July 1, 2004;
Joseph Connors, Acting Head, Division of Medical Oncology (while Susan O'Reilly is on
sabbatical); Adeera Levin and Anita Palepu, Directors, Clinical Investigator Program, July 1,
2004; Vince Duronio, Director, Experimental Medicine Program, July 1, 2004; Doris Doudet,
Associate Head, Research, Vancouver Acute, July 1, 2004; John Mancini, Director, CME
Program, March 1, 2004; Mark Roberts, Director, Postgraduate Education Program, October 1,
2004; Roger Wong, Associate Director, Postgraduate Education Program, October 1, 2004;
Barry Kassen, Associate Director, Postgraduate Education Program, October 1, 2004; Rose
Hatala, Associate Director, Postgraduate Education Program, October 1, 2004; Janet KushnerKow, Director, Expansion & New Programs, Undergraduate Education Program, July 1, 2004.
Awards
The Department extends its warmest congratulations to these outstanding individuals who
received the following Departmental awards. The Fay R. Dirks Awards for Excellence in
Teaching were awarded to Drs. Hartmut Henning (Cardiology) and John Kelsall
(Rheumatology). The Martin M. Hoffman Awards for Excellence in Research were awarded to
Drs. Gary Quamme (Nephrology) and Stephen van Eeden (Respiratory). The Donald M.
Whitelaw Awards for Outstanding Grand Rounds were given to Drs. Philip Teal (Neurology)
and John Webb (Cardiology). The Master Teacher Awards were given to Drs. Gillian Gibson
(Neurology) and Clifford Chan-Yan (Nephrology).
In addition, members of the department were recognized by the faculty and other bodies for their
excellence in teaching and research. Dr. Peter Pare (Respiratory) was awarded the UBC Izaak
Walton Killam Research Prize in the Senior Science category. Dr. Yu Tian Wang (Neurology)
was awarded the UBC Izaak Walton Killam Research Prize in the Junior Science category. Dr.
Jerilynn Prior (Endocrinology) was awarded the UBC Medical Alumni Association Honorary
Alumni Award. Dr. Theo van Rijn (Physical Medicine & Rehabilitation) was awarded the
First Annual Theo van Rijn Award for Outstanding Contribution to the UBC Physical Medicine
& Rehabilitation Residency Program. Dr. Peter Tsang (Hematology) was awarded the PAR-BC
Award for Excellence in Clinical Teaching. Dr. John Schrader (Hematology) was awarded the
CSCI Distinguished Scientist Award. Dr. Tony Chow (Infectious Diseases) was awarded the
Janssen Ortho-Canadian Infectious Disease Society Distinguished Service Award. Dr. Richard
Arseneau (General Internal Medicine) was awarded the Leadership Award in the BC 2004
Innovations Awards in Educational Technology. Dr. Barry Kassen (General Internal
Medicine) was awarded the Osler Award for Excellence in GIM. Dr. Eric Yoshida
(Gastroenterology) was awarded the Astra Zeneca Canada Teaching Award in
Gastroenterology.
Dr. Alastair McLeod (Dermatology) was awarded the Canadian
Dermatology Association Award of Merit. Dr. Richard Crawford (Dermatology) was
awarded the Canadian Dermatology Association Residents and Fellows Section Teaching
Page 4
Annual Report 2004
Award. Dr. Alastair Carruthers (Dermatology) was elected Vice-President of the American
Society for Dermatologic Surgery. Dr. Hugh Chaun (Gastroenterology) became Governor of
the American College of Gastroenterology representing the region of the Western Provinces.
Dr. Diane Lacaille (Rheumatology) was elected to the Young Investigator Subcommittee of the
American College of Rheumatology (ACR) Committee on Research.
One of the Department's most important strategic initiatives is the creation of the Academic
Enhancement Endowment Fund and the Academic Enhancement Fund competition process.
These awards are provided in an effort to ensure greater protected research time for individuals
undertaking meritorious research. This fund has taken on greater importance as the endowment
has grown and as the awards have increased. The recipients of the Academic Enhancement
Endowment Fund awards in 2004 were Drs. Jolanda Cibere (Rheumatology), Vinay Dhingra
(Critical Care), Kevin McElwee (Dermatology), Kerry Savage (Medical Oncology), and
Jennifer Wilson (Respiratory). Recipients are termed Departmental Scholars.
Research
Once again the department was extremely successful in attracting research support. The
department received $21,563,014 in peer reviewed grants and $19,150,111 in non-peer reviewed
grants.
In order to move forward the Department has implemented a strategic planning process in
Research and has appointed a new Associate Head Research at VGH and UBC, Dr. Doris
Doudet. The culmination of these plans within the next academic year will give the Department
a framework for success.
Summary
In closing I would like to take this opportunity to once again acknowledge the contributions of
all Faculty and Staff and to thank them for their hard work, outstanding achievements and
dedication to the success of the Department of Medicine.
Sincerely,
Page 5
Annual Report 2004
MISSION STATEMENT
We, the members of the Department of Medicine of the University of British Columbia, will
work with all our partners to provide the highest possible standard of excellence in patient care,
teaching and research. We will pursue this mission while emphasizing open communication and
ethical behavior, and while recognizing that it is a privilege to provide responsible and
innovative stewardship of human, financial and all other resources. We will always:
1.
2.
3.
4.
5.
respect the dignity, individuality and needs of our patients,
strive to discover new knowledge that will advance state-of-the- art care,
ensure effective and innovative teaching of our students,
optimize our organization to promote both professional and personal fulfillment,
value the efforts and achievements of teams and individuals who work to face the
challenges of modern medicine.
These activities will ensure the respect of our peer organizations and recognition as a world-class
Department of Medicine.
Page 7
Annual Report 2004
ORGANIZATION CHART
Dean
UBC Faculty of Medicine
Head
Associate Heads,
UBC Dept. of Medicine
Heads, Hosp. Dept. of Medicine
Heads & Directors of Divisions
& Programs of UBC
Department of Medicine
Heads & Directors of Divisions
& Programs of the Hospital
Departments of Medicine
Members, Divisions & Programs
of the Hospital Departments of
Medicine
Page 9
Annual Report 2004
UBC DEPARTMENT OF MEDICINE COMMITTEES
Page 11
Annual Report 2004
DEPARTMENT HEADS, ASSOCIATE HEADS, UBC DIVISION
HEADS, EDUCATIONAL PROGRAM DIRECTORS &
ASSOCIATE DIRECTORS
DEPARTMENT HEADS
Department of Medicine UBC & Vancouver Acute
S. F. Paul Man, MD, FRCPC
Chair, Department of Medicine,
Providence Health Care
UBC ASSOCIATE HEADS
Dr. Harvey Lui, Associate Head of Medicine, Vancouver Acute
Dr. S. F. Paul Man, Associate Head of Medicine, Providence Health Care, (March 1, 2004 -)
Dr. Doris Doudet, Associate Head Research, Vancouver Acute (July 1, 2004 -)
Dr. Peter Paré, Associate Head Research, Providence Health Care
UBC DIVISION HEADS
Allergy & Immunology
Cardiology
Critical Care Medicine
Dermatology
Endocrinology & Metabolism
Gastroenterology
General Internal Medicine
Geriatric Medicine
Dr. Robert Schellenberg
Dr. Chris Buller
Dr. John Fenwick
Dr. Harvey Lui
Dr. David Thompson
Dr. Urs Steinbrecher
Dr. Iain Mackie, (Acting)
Dr. Graydon Meneilly, (Jan-June 30, 2004)
Dr. Larry Dian, (Acting) (July 1, 2004 - )
Hematology/Bone Marrow Transplantation Dr. Michael Barnett
Infectious Diseases
Dr. Neil Reiner
Medical Oncology
Dr. Susan O'Reilly, (on sabbatical)
Dr. Joseph Connors, (Acting), (July 1, 2004 - )
Nephrology
Dr. Eugene C. Cameron, (Jan-Feb 28, 2004)
Dr. Paul Keown, (March 1, 2004 - )
Neurology
Dr. Howard Feldman
Physical Medicine & Rehabilitation
Dr. Theo Van Rijn
Respiratory Medicine
Dr. John Fleetham
Rheumatology
Dr. John Esdaile
Page 13
Annual Report 2004
EDUCATIONAL PROGRAM DIRECTORS & ASSOCIATE DIRECTORS
Clinical Investigator Program Directors
Dr. Anita Palepu, (July 1, 2004 - )
Dr. Adeera Levin, (July 1, 2004 - )
Continuing Medical Education Director
Dr. Graydon S. Meneilly, (Interim)
(Jan-Feb 28, 2004)
Dr. G. B. John Mancini, (March 1, 2004 - )
Graduate Studies Program in
Experimental Medicine Director
Dr. Norman Wong, (Jan-June 30, 2004)
Dr. Vince Duronio, (July 1, 2004 - )
HIV/AIDS Research Program Director
Dr. Julio Montaner
Postgraduate Education Program
Director
Dr. Iain Mackie, (Jan - Sept 30, 2004)
Dr. J. Mark Roberts, (Oct 1, 2004 - )
Associate Directors
Dr. Roger Wong, (Oct 1, 2004 - )
Dr. Rose Hatala, (Oct 1, 2004 - )
Dr. Barry Kassen, (Oct 1, 2004 - )
Undergraduate Education Program Director Dr. Grant Stiver
Associate Directors
Dr. Jim Dunne, 3rd year, St Paul's
Dr. Jim Busser, 3rd year, VGH
Dr. Reva Adler, 4th year
Dr. Janet Kushner-Kow, Expansion & New
Programs, (July 1, 2004 - )
Page 14
Annual Report 2004
COMMITTEE FOR APPOINTMENTS, REAPPOINTMENTS,
PROMOTION AND TENURE
Chair:
Co-Chair:
Administrative Secretary:
Dr. G. S. Meneilly, Professor
Dr. H. Lui, Professor
Ellen Wong (Jan to Feb/04), Jeannie Stacey (Mar to Dec/04)
January 2004 to December 2004:
Dr. K. Gelmon, Clinical Professor, Medical Oncology
Dr. B. Koehler, Clinical Professor, Rheumatology
Dr. N. Murray, Clinical Professor, Medical Oncology
Dr. D. Ricci, Clinical Professor, Cardiology
Dr. D. Doudet, Professor, Neurology
Dr. J. Esdaile, Professor, Rheumatology
Dr. K. Humphries, Professor, Hematology
Dr. H. Lui, Professor, Dermatology
January 2004 to June 2004:
Dr. R. Levy, Associate Professor, Respiratory Medicine
Dr. YT Wang, Professor, Neurology
Dr. V. Bernstein, Clinical Professor, Cardiology
Dr. L. Lawson, Clinical Professor, Respiratory Medicine
July 2004 to December 2004:
Dr. N. Buskard, Clinical Professor, Hematology
Dr. J. Cairns, Professor, Cardiology
Dr. P Hoskins, Clinical Professor, Medical Oncology
Dr. J. Mancini, Professor, Cardiology
Dr. P. Keown, Professor, Nephrology
This dedicated group of committed Departmental members is charged with facilitating the career
advancement of our members while upholding consistent and rigorous standards as set out by
UBC. As usual, this Committee invested a great deal of thoughtful energy to support the
additions and promotions listed below. We are very proud of the following:
NEW APPOINTMENTS
Anderson, Helen, Medical Oncology, Clinical Assistant Professor
Baillie, Hector, General Internal Medicine, Clinical Assistant Professor
Barton, Jason, Neurology, Professor
Bergman, Jamess, Dermatology, Clinical Assistant Professor
Bouttell, Elaine, Medical Oncology, Clinical Instructor
Briemberg, Hannah, Neurology, Clinical Assistant Professor
Broady, Raewyn, Hematology, Clinical Instructor
Buller, Christopher, Cardiology, Professor
Page 15
Annual Report 2004
Chapman, Kristine, Neurology, Clinical Instructor
Chatur, Nazira, Gastroenterology, Clinical Instructor
Cibere, Jolanda, Rheumatology, Assistant Professor
Cook, Victoria, Respiratory Medicine, Assistant Professor
Deutscher, Timothy, General Internal Medicine, Clinical Instructor
Eng, Janice, Physical Medicine & Rehabilitation, Associate Member
Fung, Michelle, Endocrinology & Metabolism, Clinical Instructor
Gill, Karamjit, Medical Oncology, Clinical Assistant Professor
Gill, Sharlene, Medical Oncology, Assistant Professor
Haber, Richard, Dermatology, Clinical Associate Professor
Hallam, Bradley, Neurology, Clinical Instructor
Hsiung, Ging-Yuek (Robin), Neurology, Assistant Professor
Kenyon, Michael, General Internal Medicine, Clinical Instructor
Kopec, Jacek, Rheumatology, Associate Member
Lai, Kevin, General Internal Medicine, Clinical Instructor
Laskin, Janessa, Medical Oncology, Clinical Assistant Professor
Lee, Philip, Geriatric Medicine, Clinical Instructor
Leger, Chantal, Hematology, Clinical Instructor
Leitch, Heather, Hematology, Clinical Assistant Professor
Li, David, Neurology, Associate Member
Man, SF Paul, Respiratory Medicine, Professor
McElwee, Kevin, Dermatology, Assistant Professor
McKeown, Martin, Neurology, Associate Professor
O’Connor, Russell, Physical Medicine and Rehabilitation, Clinical Instructor
Phillips, Elizabeth, Infectious Diseases, Associate Professor
Ramji, Alnoor, Gastroenterology, Clinical Instructor
Richmond, Allistair, General Internal Medicine, Clinical Assistant Professor
Rossi, Sikina, Dermatology, Clinical Instructor
Savage, Kerry, Medical Oncology, Assistant Professor
Saw, Jacqueline, Cardiology, Clinical Assistant Professor
Sin, Donald, Respiratory Medicine, Associate Professor
Skinnider, Doug, No Division, Clinical Instructor
Smythe, Penelope, Neurology, Clinical Instructor
Son, Wai Kon, General Internal Medicine, Clinical Instructor
Souliere, Sheila, Medical Oncology, Clinical Instructor
Tebbutt, Scott, Respiratory Medicine, Clinical Assistant Professor
Telford, Jennifer, Gastroenterology, Clinical Assistant Professor
Towle, Angela, No Division, Assistant Professor
Tremlett, Helen, Neurology, Assistant Professor
Walker, Shannon, No Division, Clinical Instructor
Williams, Dorothy, No Division, Clinical Instructor
Winkler, Lawrence, General Internal Medicine, Clinical Instructor
Wong, Graham, Cardiology, Clinical Assistant Professor
Wood, Evan, Infectious Diseases, Clinical Assistant Professor
Yassi, Annalee, Physical Medicine and Rehabilitation, Associate Member
Page 16
Annual Report 2004
PROMOTIONS
Professor:
Chalmers, Andrew, Rheumatology
Associate Professor:
Sahl, Baljinder, Gastroenterology
Tyndall, Mark, Infectious Diseases
Clinical Associate Professor:
Gray, James, Gastroenterology
Kunimoto, Brian, Dermatology
Shojania, Kamran, Rheumatology
Clinical Assistant Professor:
Jastrzebski, Jacek, Nephrology
Kiaii, Mercedeh, Nephrology
Li, Charles, Hematology
Rabinowitz, Alan, Cardiology
Singh, Rajinder, Nephrology
Traboulsee, Anthony, Neurology
Page 17
Annual Report 2004
TEACHING EFFECTIVENESS OFFICE
Dr. James Busser
Chair; Member, UBC Division of General Internal Medicine
Mrs. Jennifer Golinski
Administrator; Undergraduate Education, UBC Department of
Medicine
Reports to:
Committee for Appointments, Reappointments, Promotions and Tenure
Functions:
1.
Provides Faculty member with "Guidelines" for producing necessary back-up
documentation to Teaching Dossier.
2.
Meets with Faculty member to discuss necessary back-up documentation and process
involved in review for promotion/tenure/reappointment.
3.
Liaises with various program offices: Undergraduate, Postgraduate, Continuing Medical
Education, Graduate Studies to obtain information regarding teaching effectiveness of
candidate. Where necessary, requests additional peer review of teaching.
4.
Reviews teaching dossier, back-up documentation, peer review and prepares draft report
for Committee for Appointments, Reappointments, Promotions and Tenure.
5.
Forwards draft report to Faculty member to ensure that important information has not
been omitted.
6.
Finalizes report and forwards to Committee for Appointments, Reappointments,
Promotions and Tenure.
In the year 2003, the Teaching Effectiveness Committee prepared 19 letters on behalf of GFT
and Clinical Faculty. Subsequent promotions for these faculty have included:
(1) Associate Professor
(6) Clinical Assistant Professor
(3) Clinical Associate Professor
In the year 2004 we met with another 18 faculty, and have prepared 18 letters to support their
review and/or consideration of promotion.
Page 19
Annual Report 2004
DIVISION REPORTS
Page 21
Annual Report 2004
ALLERGY & IMMUNOLOGY
Dr. R. Robert Schellenberg
Professor & Head
Faculty Members
Professor & Head
Clinical Associate Professor
Clinical Instructor
Associate Member
Schellenberg, Dr. Robert
Mandl, Dr. Michael
Stark, Dr. Donald
Wong, Dr. HC George
Kanani, Dr. Amin
Stephenson, Dr. Mary
SPH
SPH
SPH
VA
Vancouver
Divisional Overview
Our small division is involved in providing clinical teaching in allergy and immunology at all
levels. This includes major initiatives in patient education, CME programs for physicians, and
elective rotations for residents and medical students. Despite not offering a training program at
UBC, members are involved nationally in the nucleus committee of the Royal College as well as
the examination committee for our subspecialty. Members are actively involved with lay
organizations in medical advisory positions as well as in educational initiatives.
Teaching
All members of the Division are actively involved in teaching students, residents, community
physicians and lay persons.
Dr. Schellenberg provides a lecture to Medicine I students on the basic mechanisms of allergic
inflammation as well as for the Pathology 521 course. All members actively participate in casebased subspecialty teaching seminars for Med III / IV students. All members provide individual
office-based teaching of students who have chosen an elective rotation in the subspecialty. In
addition, each member teaches in the Clinical Skills block for Med I students and conducts
Bedside teaching sessions with Med II students. The month-long elective rotation for residents in
Internal Medicine and its subspecialties has become increasingly popular in the recent year.
Major initiatives have been undertaken in community medical education to physicians, other
health care professionals and to the lay public.
Page 23
Annual Report 2004
CME programs organized by Dr. George Wong through the auspices of the UBC Community
Programs are given in various communities in British Columbia and the Northwest Territories.
These have received excellent evaluations and are highly appreciated by physicians in outlying
areas. Each member contributes to these programs.
Dr. Michael Mandl has continued to expand his asthma education program initiated through the
Health Transition Fund to raise awareness and specific information in management of asthma in
communities in BC. Five geographical sites have been targeted for evaluation of the
effectiveness of this intensive education program to the public.
Dr. George Wong has developed specific expertise in evaluation of complementary and
alternative medicine practices and has presented a number of interesting papers on these aspects
at meetings in the USA and Canada.
Dr. Mandl and Dr. Schellenberg have been involved in video conference initiatives to provide
information to the lay public in various communities in BC and provide a forum to answer
questions from those participating at other sites.
Research
The members at St. Paul’s hospital have a major interest in management of primary immune
deficiency and have initiated a number of research projects as well as interactions with the lay
organization. Dr. Amin Kanani is the principal investigator on a new grant-in-aid (coinvestigators Dr. Stark and Dr. Schellenberg) from Bayer Inc. study evaluating the quality of life
and health outcome parameters of patients with primary immunodeficiency using two different
dosing regimens of IVIG to determine optimal dosing requirements.
Dr. Stark is the principal investigator in a study evaluating a new IV immunoglobulin product.
Dr. Wong is conducting studies assessing the use and potential harmful effects of herbal and
Chinese medicines.
Dr. Schellenberg is continuing studies of the mechanisms of excessive airway narrowing in
asthma with emphasis on the role of degradative enzyme effects on extracellular matrix
components in the airway wall using laser capture microdissection and molecular biologic
techniques.
Clinical Services
All members are actively involved in providing clinical consultative services in Allergy and
Immunology to the community. Dr. Mandl has outreach clinics in Dease Lake, Stewart,
Hazelton, Bella Bella, Campbell River, Parksville and Bamfield. Dr. Stark provides outreach
clinics in Prince George and Sechelt. He has been active with the hospitals in establishing
protocols for the management of latex allergy in hospitals. Dr. Wong has had a specific interest
in complimentary medicine practices and the potential harmful effects of specific treatments.
Page 24
Annual Report 2004
National and International Initiatives
Drs. Stark and Schellenberg co-chaired the local arrangements committee for the highly
successful World Allergy Congress (International Congress of Allergy and Clinical
Immunology) in Vancouver in September 2003. All members were involved in this large
undertaking. Dr. Schellenberg was a member of the International Program Planning Committee
for this meeting.
Dr. Schellenberg completed his 2-year term as president of the Canadian Society of Allergy and
Clinical Immunology in Oct. ’04 and remains on its Board of Directors. He is also the deputy
chair of the Royal College Examination Committee for this subspecialty and is the program
director for the annual scientific meeting of the Canadian Society of Allergy and Clinical
Immunology. In addition, he is a member of the Medical Advisory Committee of the Canadian
Immune Deficiency Patient Organization.
Dr. Stark chairs the Nucleus Committee for Clinical Immunology and Allergy of the Royal
College of Physicians and Surgeons of Canada.
Dr. Stark and Dr. Schellenberg are members of the Board of Directors for the Canadian
Foundation for Allergy and Clinical Immunology, a charitable organization of which Dr. Stark
was the founder.
All members are actively involved in local, national and international committees dealing with
their areas of interest.
Page 25
Annual Report 2004
CARDIOLOGY
Dr. Christopher E. Buller
Clinical Professor & Head
Faculty Members
Professor
Professor
Professor
Professor
Assistant Professor
Clinical Professor
Clinical Professor
Clinical Professor
Clinical Professor
Clinical Professor
Clinical Professor
Clinical Assistant Professor
Clinical Instructor
Buller, Dr. Christopher
Rabkin, Dr. Simon
Mancini, Dr. G B John
Kerr, Dr. Charles
Cairns, Dr. John
Humphries, Dr. Karin
Bernstein, Dr. Victoria
Dodek, Dr. Arthur
Hamburger, Dr. Jaap
Huckell, Dr. Victor
Penn, Dr. Ian
Ricci, Dr. Donald
Carere, Dr. Ronald
Fung, Dr. Anthony
Gin, Dr. Kenneth
Ignaszewski, Dr. Andrew
Kiess, Dr. Marla
Macdonald, Dr. Ian
Thompson, Dr. Christopher
Webb, Dr. John
Yeung-Lai-Wah, Dr. John
Aymong, Dr. Eve
Chan, Dr. Sammy
Heilbron, Dr. Brett
Isserow, Dr. Saul
Jue, Dr. John
Lee, Dr. Pui Kee
Rabinowitz, Dr. Alan
Saw, Dr. Jacqueline
Straatman, Dr. Lynn
Wong, Dr. Graham
Munt, Dr. Bradley
Page 27
SPH/VA
VA
VA
SPH
VA
SPH
VA
SPH
VA/SPH
VA
VA
VA
SPH
VA
VA
SPH
SPH
SPH
SPH
SPH
SPH
SPH
SPH
SPH
VA
VA
VA
SPH
VA
SPH
VA
SPH
Annual Report 2004
Clinical Instructor
Adjunct Professor
Professor (Emeritus)
*Associate Professor (Emeritus)
Clinical Professor (Emeritus)
Tung, Dr. Kei Kwong (Stanley)
Lear, Dr. Scott
Mizgala, Dr. Henry
Henning, Dr. Hartmut
Boone, Dr. John
Kavanagh-Gray, Dr. Doris
Peretz, Dr. Dwight
Shaw, Dr. Melville
Walters, Dr. Max
SPH
SPH
Vancouver
VA
SPH
West Vancouver
Vancouver
*Appointed to Honorary Staff at VHHSC July 1st
Divisional Overview
The Division of Cardiology consists of 32 active faculty including 28 clinical faculty and 7 fulltime faculty distributed over two large tertiary programs at St. Paul’s Hospital and Vancouver
Acute (including UBC site). Beginning January 1st 2004, Dr. Christopher Buller was appointed
Sauder Family Heart & Stroke Foundation Chair in Cardiology and Head, UBC Division of
Cardiology, as well as Head, Divisions of Cardiology at both St. Paul’s and Vancouver Acute.
Dr. Donald Ricci was appointed Associate Division Head, Vancouver Acute.
The UBC Division of Cardiology provides a complete range of tertiary and quaternary
cardiology sub-specialty services and programs, including ambulatory and impatient consultative
cardiology, cardiac intensive care, electrodiagnostics, cardiac ultrasound, interventional
cardiology, electrophysiology, nuclear cardiology, adult congenital heart disease, atherosclerosis
risk reduction and cardiac rehabilitation.
Teaching
Undergraduate:
Cardiovascular clinical assessment constitutes a core skill set for general physicians and many
specialists and thus undergraduate teaching of the cardiovascular history and physical
examination constitutes a substantial teaching load. The Division of Cardiology provided 90
hours of structured bedside teaching, and an additional 33.5 hours in seminars, lectures and casebased learning sessions during 2004. Reflecting the make-up of our Division, the substantial
majority of this teaching was provided by our clinical faculty. Beginning in 2003, Dr. Saul
Isserow has developed and implemented standardized instruction in the method of clinical
examination for the undergraduate curriculum. To further advance undergraduate clinical skills
teaching, the Division supports creating Directors of Undergraduate Education within Divisions
or groups of Divisions carrying large undergraduate teaching loads. These positions would be
responsible not only for optimizing the clinical content of the curriculum, but also for improving
teaching effectiveness and consistency through application of objective metrics.
Page 28
Annual Report 2004
Postgraduate:
The UBC Postgraduate Program in Cardiology (Ken Gin, Director) continues to expand with 4
Ministry funded residents and 7 externally funded residents. In 2004, the Division itself funded
one additional resident using internal resources, and negotiated the creation of another 3-year
position through partnership with the Healthy Heart Society. In all, our program enjoys 12 core
residents in cardiology distributed over the three-year Royal College program
Academic aspects of the program continue to strengthen with an extensive weekly curriculum of
structured bedside teaching, internal and guest faculty lectures, resident-led presentations, and
journal club reviews of contemporary literature comprising 6-10 hours of structured teaching
weekly. A highly rated course in cardiac epidemiology was created and presented by division
member Karin Humphries. Research mentoring has been enhanced by the appointment of two
hospital-based Postgraduate Research Directors, John Jue and Sammy Chan.
All UBC candidates who took the Royal College examinations in Cardiology were successful.
Moreover, all of our core program graduates from 2003 have secured positions for advanced
subspecialty training. A scheduled Royal College review of the program will occur in 2005.
9 subspecialty trainees are also enrolled in a variety of sub-specialty programs including
Interventional Cardiology, Electrophysiology, Echocardiography, Heart Function/Transplant.
Continuing Medical Education
Internal Rounds
Across sites, the Division of Cardiology presents a rich curriculum of regular lectures and
rounds. Cardiology Grand Rounds is presented weekly at each hospital. In addition, a variety of
city-wide and hospital-based rounds are held regularly as follows:
•
•
•
•
•
•
•
•
Interventional Cardiology (weekly, city-wide)
Combined Cardiology/Cardiac Surgery (weekly, both sites)
M&M (weekly at SPH, monthly at VH)
Echocardiography (weekly, VGH)
Resident Noon rounds (weekly, SPH)
Research Rounds (bi-weekly, SPH)
Journal Club (monthly, city-wide)
UBC City-Wide Rounds (bi-monthly)
Distinguished Speakers in Cardiovascular Medicine
This year saw the initiation of a new monthly series of guest lectures entitled Distinguished
Speakers in Cardiovascular Medicine. Hosted jointly with the UBC Division of Cardiac Surgery,
this program is directed by Drs. Ken Gin and Andrew Ignaszewski and brings prominent experts
to Vancouver for 1-2 days of academic activity and interaction including research seminars,
Page 29
Annual Report 2004
resident teaching, and the Distinguished Speaker Lecture itself. A broad range of academic and
regional community cardiovascular specialists attend this special lecture. It affords a unique
opportunity for basic scientists, clinical and academic physicians, cardiac surgeons, and faculty
from pharmacy and other allied health disciplines to meet and interact. The inaugural lecture in
this series was presented by Dr. Peter Liu of the University of Toronto entitled “How Much
Molecular Genetics Do Clinical Cardiologists Require?” The series is supported by unrestricted
educational grants from industry, but control of the agenda and speaker selection rests entirely
with the Division.
Course & Convention Leadership
The 14th Annual Whistler Course (January 2004)
Christopher Buller, Course Director
This 3-day course aimed at General Cardiologists from BC and Ontario was co-hosted in 2004
by the Division of Cardiology at St. Michael’s Hospital, University of Toronto and held at
Chateau Whistler .
The 5th Annual Innovations in Interventional Cardiology Course (December 2004)
Ronald Carere, Course Director
This 3-day course for Interventional Cardiologists attracts attendees from across Canada. It
emphasizes technology uptake and utilization and the underlying health care policy decisions.
Annual Practical Cardiology Course Vancouver (September 2004)
Vicki Bernstein, Course Director
This one-day course serves as a Cardiology update for family physicians and general internists
and has been chaired by Dr. Bernstein for more than a decade and showcases our diverse
Divisional faculty. Always well subscribed (with attendance at around 120 per session) it
consistently receives outstanding reviews. In 2005 Dr. Bernstein will pass the reigns of Course
Director to Dr. Brett Heilbron.
Trans-Catheter Therapeutics Convention, Washington DC (September 2004)
Jaap Hamburger, Vancouver broadcast coordinator
The excellence and diversity of our city-wide UBC Interventional Cardiology program resulted
in a second invitation to broadcast live interventional procedures to this preeminent international
course. Six cases were presented by our group over a four hour broadcast window.
CME Committee
The Division created a formal CME committee in 2004 chaired by Dr. Rabkin, and including Drs.
Heilbron, Isserow, Ignaszewski, Huckell and Mancini. This committee is charged with developing an
annual provincial conference for community internists and cardiologists, as well as coordinating other
CME activities.
Page 30
Annual Report 2004
Research
Dr. Eve Aymong continues to focus on understanding the pathophysiology of cardiogenic shock
with a competitive pilot grant investigating a variety of biomarkers as part of the multicenter
SHOCK-2 clinical trial. Other areas of interest include clinical outcomes of patients undergoing
cardiac catheterization and angioplasty. In addition, she has collaborated with both Vancouver
and New York based investigators on several grants in patients with cardiac disease that are
currently under review by CIHR and the NIH.
Dr. Christopher Buller is active in clinical trials and outcomes research. His interest in
occluded coronary arteries and the ‘open artery hypothesis’ has led to his inclusion on the
Executive Steering Committee, Operations Committee and Publications Committee of the
NIH/NHLBI funded Open Artery Trial, an international multi-center clinical trial initiated in
1998 and scheduled for completion in 2007. Dr. Buller directs all aspects of the trial related to
PCI (the experimental strategy), is Co-Director of the Core Angiographic Laboratory, and is Coprincipal Investigator of the NIH/NHLBI funded angiographic substudy TOSCA-2. Dr. Buller
will also be the Canadian Principal Investigator for the NIH/NHLBI funded FREEDOM trial, a
120 centre international trial comparing drug eluting stent to coronary bypass surgery in patients
with diabetes and multi-vessel coronary heart disease.
Dr. Sammy Chan is active in clinical trials and mechanistic research. His area of interest is
preventive cardiology and endothelial function. He has recently collaborated in the Canadian
wide MARGAUX study. He was awarded a 2 year grant in aid from the Heart & Stroke
Foundation of BC and Yukon for a proposal involving aging, endothelial progenitor cells and
endothelial function.
Dr. Jaap Hamburger is centrally involved in translational research addressing myocardial
repair by autologues bone marrow stem cells in both small (mouse) and large (pig) animal
models. This project operates in collaboration with the Terry Fox laboratory (BC Cancer
Agency), the Jack Bell Laboratory and ICapture. Dr. Hamburger has also organized existing
cardiovascular clinical research facilities and expertise into a pilot network termed CardiABC
intended to support and facilitate locally developed clinical trials. Local network participants
include an Angiographic Core Laboratory (Dr. John Mancini), Nuclear Cardiology Core
Laboratory (Dr. Anthony Fung), ECG Core Laboratory (Dr. Marla Kiess), Cardiovascular
Pathology Core Laboratory (Dr. B. McManus). In 2004, CardiABC successfully conducted its
first multi center trial, the CRAFT on behalf of Kerberos, a California based device company.
The study was performed in hospitals in Vancouver, Toronto and Montreal.
Dr. Karin Humphries' areas of interest include sex differences in CVD presentation, treatment
and outcomes; Health Services research focused on secondary prevention; population-based rates
of treatment, including PCI, CABG, and pharmacological therapy; and atrial fibrillation. Dr.
Humphries has led B.C.’s team of contributors to the Canadian Cardiovascular Outcomes
Research Team (CCORT) project. A growing area of interest for Karin is investigator-driven
randomized controlled trials. With her advanced theoretical and extensive practical knowledge,
she supports and informs many such initiatives within the Division. As Principal Investigator,
Dr. Humphries presently holds a New Investigator Award from the Michael Smith Foundation.
Page 31
Annual Report 2004
Dr. Charles Kerr is a clinical electrophysiologist and carries out an active research program in
cardiac arrhythmia management. His main area of interest has been atrial fibrillation (AF). He
has directed the Canadian Registry of Atrial Fibrillation since 1990. CARAF I has followed 1100
patients from their initial diagnosis of AF over 10 years, providing insight into progression of
disease and clinical and laboratory outcomes. CARAF II has followed a more recent cohort to
more carefully evaluate medical therapy provided by community physicians. He is also involved
in drug trials of new antiarrhythmic and antithrombotic agents, as well as research trials of
pacemakers and defibrillators.
Dr. John Mancini has been active in clinical trials through his Cardiovascular Imaging Research
Core Laboratory which provides measurements of endothelial dysfunction (brachial artery
ultrasound), carotid ultrasound, quantitative coronary intravascular ultrasound and quantitative
coronary angiography. In addition, Dr. Mancini has expanded his research interests to include
both clinical and molecular projects attempting to unravel the interplay between pulmonary
diseases and cardiovascular events. Clinical projects assessing the impact of Chronic Positive
Airway Pressure on carotid atherosclerosis and endothelial dysfunction in patients with
Obstructive Sleep Apnea are underway. Cellular and molecular projects assessing the effects of
statins and angiotensin receptor blockers on animal models and in-vitro cellular models of lung
injury are also underway.
Dr. Jaqueline Saw arrived as a recruit from the Cleveland Clinic in 2004. She has research
interests in several areas of cardiovascular medicine. Aspirin and clopidogrel resistance is being
evaluated in a substudy of BRIEF-PCI (a locally developed multicenter RCT) and in ELAPSE, a
dedicated study of clopidogrel resistance developing during long-term administration and due to
start enrollment in 2005. Dr. Saw is also involved in outcome studies evaluating both comorbidities and therapies in patients undergoing percutaneous peripheral arterial and carotid
revascularization procedures.
Dr. John Webb is director of interventional cardiology research at St. Paul's Hospital.
Myocardial infarction and cardiogenic shock have been an interest with a number of publications
in these fields. Last year saw two multicenter studies completed as overall principle investigator.
A major focus has been the development, animal and initial human trials of a number of
interventional devices. Landmarks this year include the development of a transarterial aortic
valve implantation procedure, the first successful percutaneous aortic valve implantations in
North America and the first ever percutaneous mitral annuloplasty procedures. A number of
additional valvular procedures are under development.
Dr. Graham C. Wong is active in clinical trials of acute coronary care with a particular focus on
optimizing epicardial reperfusion. He is also interested in population-based outcomes following
mechanical and pharmacological reperfusion for ST elevation myocardial infarction. Dr. Wong
is currently the principal investigator for the inflammatory markers substudy of the BRIEF PCI
study comparing an abbreviated versus a standard infusion of eptifibatide following
percutaneous coronary intervention. Ongoing research projects include a comparison of
outcomes for octogenarians undergoing fibrinolytic therapy and primary angioplasty for ST
elevation MI. Dr. Wong is also the senior investigator on a submitted grant proposal in
collaboration with the Department of Emergency Medicine that is investigating the predictors of
delayed door to balloon time for primary angioplasty.
Page 32
Annual Report 2004
Dr. John Yeung has a major research interest in the mechanisms of clinical arrhythmias and in
developing the techniques for both mapping and ablating complex myocardial arrhythmic
circuits. Currently he is evaluating modulation of vagus nerve inputs to the left atrium in patients
who undergo linear pulmonary vein ablation for atrial fibrillation. Other interests include the role
of implantable cardioverter defibrillator (ICD) devices and biventricular pacing (cardiac resynchronization).
Clinical Sub-Programs
•
•
•
•
•
•
•
•
•
Healthy Heart Program (risk reduction and rehabilitation)
o Andrew Ignaszewski** Saul Isserow*
Cardiac Electrodiagnostics
o Marla Kiess** John Jue*
Acute Coronary Care
o Alan Rabinowitz** Graham Wong*
Interventional Cardiology & Cardiac Catheterization
o John Webb** Donald Ricci*
Cardiac Ultrasound
o Christopher Thompson** John Jue*
Heart Function and Cardiac Transplantation
o Andrew Ignaszewski**
Adult Congenital Heart Disease
o Marla Kiess**
Arrhythmia Management
o Charles Kerr**
Consultative Cardiology (inpatient and outpatient)
** SPH Director
*VGH Director
Administration
Substantial program budgets and operational complexity have led to the development of the
Heart Centre program at St. Paul’s (Ronald Carere, Medical Director) and the Cardiac Sciences
program at Vancouver Hospital (Donald Ricci, Medical Director). These hospital-based
programmatic structures are superimposed upon traditional academic Divisional/Departmental
structures. The resulting matrix relies upon close collaboration between divisional and program
leaders who report through independent lines.
In 2004, Vancouver Coastal Health Authority identified Cardiovascular Sciences as a program
warranting regional coordination through the One Acute Network initiative. A search process led
to the selection of one of our Division members (Dr. Ronald Carere) to lead this important work.
Region-wide planning subcommittees have been created in most sub-program areas and are
chaired by members of the Division from both SPH and VH sites.
Page 33
Annual Report 2004
Future Directions
Optimal distribution of specialized Cardiology sub-programs across our two sites remains an
important but difficult ongoing discussion within the Division. Centralization of certain subprograms at one site has advantages with regard to critical mass, efficiency, and academic
interaction. Conversely, rapid progress in clinical science and practice has moved certain subspecialties from the realm of esoteric to that of mainstream tertiary service. As examples, the
capacity for on-site programs in Electrophysiology and advanced heart failure (Heart Function)
have been identified as critical needs for VH by the VH-based Division. Addressing those needs
not only requires significant new capital, operational and human resources, but also coordination
and planning in partnership with existing programs at the alternate site.
The proposal for a new Legacy hospital at False Creek site has opened discussion regarding the
feasibility and desirability of combining VH-based and SPH-based cardiac programs to create a
single, city-wide institute-like program. While the facility opportunities created by such a
venture are enormous, so too are the challenges.
The progress of clinical science and technology in cardiology continues to accelerate and is
creating both opportunites and strains. Examples of key trends in our specialty include:
•
•
•
•
•
•
•
explosive growth in evidence-based demand for expensive technologies, including
implantable defibrillators, cardiac re-synchronization therapy, drug-eluting coronary
stents, and ventricular assist devices
advances in percutaneous cardiac procedures including ASD/PFO closure devices, valve
replacement and repair, complex multi-vessel PCI
extension of interventional cardiology into non-cardiac vascular territories, including
carotid, renal and peripheral vascular disease
an epidemic of heart failure as new therapies extend survival in all common types of
heart disease upstream
improved survival of children with complex congenital heart disease requiring rapid
expansion of capacity for their long-term care as adults
adoption of clinical nurse practitioners to improve efficiency and quality, and to extend
existing physician manpower within both inpatient and outpatient settings
an imminent revolution in non-invasive anatomic and functional cardiac imaging (cardiac
CT angiography, cardiac MRI)
Special Honours and Awards
Dr. Hartmut Henning: The Fay R. Kirks Award for Excellence in Teaching
Dr. John Webb: The Donald M. Whitelaw Award for Outstanding Grand Rounds Presentation
Dr. Ian Penn: Funding for STAAR study (UBC Office of the Vice President Research: $3,600
Page 34
Annual Report 2004
CRITICAL CARE MEDICINE
Dr. John Fenwick
Clinical Assistant Professor & Head
Faculty Members
Professor
Professor
Associate Professor
Assistant Professor
Clinical Instructor
Visiting Scientist
Fenwick, Dr. John
Russell, Dr. James
Walley, Dr. Keith
Dodek, Dr. Peter
Dorscheid, Dr. Delbert
Tsang, Dr. John
Chittock, Dr. Dean
Dhingra, Dr. Vinay
Forrest, Dr. David
Grant, Dr. Gregory
Keenan, Dr. Sean
Ronco, Dr. Juan
Craig, Dr. Katherine
Wattanathum, Dr. Anan
VA
SPH
SPH
SPH
SPH
VGH
VA
VA
VA
SPH
SPH
VA
VA
SPH
Divisional Overview
The UBC Division of Critical Care Medicine is multidisciplinary in structure, with 13 faculty
members, all qualified critical care specialists from Medicine, Surgery and Anaesthesia
backgrounds participating in patient care at St. Paul’s, Royal Columbian and Vancouver
Hospital. The two-year Critical Care Medicine subspecialty training program is fully accredited
and accepts two trainees per year. The Research Program in Critical Care Medicine is
comprehensive, spanning from molecular and cellular biology through large animal models to
clinical research in critically ill adults. The basic science research program is based in the
Cardiopulmonary Laboratories at St. Paul’s Hospital and the Jack Bell Research Institute at
Vancouver Hospital. The clinical research program is focused in the intensive care units of St.
Paul’s and Vancouver Hospital.
Teaching
The University of British Columbia Adult Critical Care Medicine Training Program, under the
direction of Dr. Juan Ronco, continued at the British Columbia Children’s, St. Paul’s and
Page 35
Annual Report 2004
Vancouver Hospitals. In 2004 there were 5 trainees in the Adult Critical Care Medicine
Fellowship Training Program. Trainees entering the program in 2004 will be the first to receive
subspecialty certification through examination by the Royal College of Physicians and Surgeons
of Canada. Under the Direction of Dr. Juan Ronco, the Division hosted the 4th annual National
Acute Critical Events Simulation (ACES) Program. The ACES Program is offered to all firstyear residents entering Canadian Critical Care Medicine Training.
The ICU rotations for specialty residents from Medicine, Anaesthesia and Surgery continued to
be highly rated at both St. Paul’s and Vancouver Hospital. Under the direction of Dr.Vinay
Dhingra participation in the SCCM Critical Care Support Course was expanded to include core
residents from all Departments.
Research
The Research Program in Critical Care Medicine is comprehensive, spanning from molecular
and cellular biology through large animal models to clinical research in critically ill adults. The
basic science research program is based in the Cardiopulmonary Laboratories at St. Paul’s
Hospital and the Jack Bell Research Institute at Vancouver Hospital. The clinical research
program is focused in the intensive care units of St. Paul’s and Vancouver Hospitals.
The basic science research program continues to investigate corticosteroid and
ischemia/reperfusion induced airway epithelial cell apoptosis (Dr. Dorscheid), endothelins and
the mechanism of hypoxemia in acute pulmonary embolism (Dr.Tsang), the molecular and
cellular biology of leukocyte induced myocardial dysfunction in septic shock (Dr. Walley) and
immunomodulation in the treatment of sepsis and acute lung injury (Drs. Russell and Walley).
The clinical research program remains strong at St. Paul’s and Vancouver Hospital with studies
on the role of genotype on phenotype in sepsis and systemic inflammatory states (Drs. Walley
and Russell), genetics of ARDS (Dr. Russell), mechanisms of exercise-induced hypoxemia (Drs.
Russell and Walley), glucose control and outcomes in the critically ill (Drs. Dhingra, Chittock,
Ronco, Dodek and Fenwick), clinical studies of therapeutic interventions for viral infections (Dr.
Grant), recognition, quantification and treatment of delirium in the ICU (Dr. Chittock), the role
of organizational factors in outcomes of critical care (Drs. Dodek and Keenan), treatment of
catheter related bloodstream infections (Drs. Ronco and Dhingra), role of non-invasive
ventilation in critical illness (Dr. Keenan), effect of sedation and agitation on duration of
mechanical ventilation (Dr. Chittock), adrenal function in sepsis (Drs. Fenwick, Chittock and
Ronco), communication and decision making in end of life care (Dr. Dodek), post cardiac arrest
decision making (Dr. Forrest), ventilator associated pneumonia (Dr. Dodek), fluid resuscitation
in septic shock (Dr. Dhingra), vasopressin in septic shock (Drs. Russell, Walley, Chittock and
Ronco) and blood transfusion and cerebral oxygenation in head injury (Drs. Chittock and
Fenwick).
Clinical Services
The ICUs at St. Paul’s and Vancouver Hospital continued to experience an increase in
occupancy and workload with over 1700 admissions at the two sites. The ICU at St. Paul’s
Hospital added 4 new beds for a total of 15 and the ICU at VGH added 3 new beds for a total of
Page 36
Annual Report 2004
27. Division members from St. Paul’s and VGH participated in the development of a regional
integrated critical care service delivery model. Collaborative strategies to improve funding for
critical care services at both sites continue to be developed.
Future Directions
In 2005, under the direction of Dr. Dean Chittock, the Division will hold the second annual
Canadian Critical Care Conference at Whistler, BC. Under the direction of Dr. Vinay Dhingra,
the Division will continue to expand the implementation of the SCCM Fundamentals in Critical
Care Medicine Support Course as part of the core residency training program. It is anticipated
that the SCCM course will, in the future, become a successful CME activity within the
Department of Medicine, attracting critical care providers from around the province. Drs. Ronco
and Dingra, in collaboration with the Center for Excellence in Surgical Education and
Innovation, continue to develop simulator models for the teaching of technical and patient
management skills to critical care trainees. The Division continues to develop a strategy to
strengthen its University Multidisciplinary Program and has begun to explore the possibility of
Departmental status within the Faculty of Medicine.
Dr. Dean Chittock organized and served as a session moderator at the Canadian Critical Care
Conference, Whistler, BC.
Dr. Vinay Dhingra received a Department of Medicine Departmental Scholar Award and was an
invited speaker at the Canadian Critical Care Conference, Whistler, BC.
Dr. Peter Dodek was an invited speaker at the Toronto Critical Care Medicine Symposium,
Toronto, Ontario, the Canadian Critical Care Conference, Whistler, BC, the Centre Hospitalier
Universitaire Lapeyronie, the Centre Hospitalier Universitaire St. Eloi, Montpellier, France, the
Fondation Hospital St. Joseph and Hospital Henri Mondor, Paris, France and the Centre
Hospitalier Universitaire Caremeau, Nimes, France.
Dr. Del Dorscheid was an invited speaker and Chair of the VanSeaPort Respiratory Research
Conference, Crystal Mountain, Washington and an invited speaker at the Canadian Critical Care
Conference, Whistler, BC.
Dr. Sean Keenan was an invited speaker at the Advances in Respiratory and Critical Care
Medicine Conference, Whistler, BC and the American College of Chest Physicians Annual
Meeting, Seattle, Washington.
Dr. Juan Ronco was an invited speaker at the Canadian Critical Care Conference, Whistler, BC,
the Advances in Respiratory and Critical Care Medicine Conference, Whistler, BC, and the
Toronto Critical Care Medicine Symposium, Toronto, Ontario.
Dr. Jim Russell was an invited speaker at the Australia and New Zealand Intensive Care Society
Annual Meeting, Melbourne, Australia, the Society of Critical Care Medicine Annual Congress,
Orlando, Florida, the Toronto Critical Care Medicine Symposium, Toronto, Ontario, and
Page 37
Annual Report 2004
Scientific Advisor and Convenor, Rocky Mountain Critical Care Conference, Lake Louise,
Alberta.
Dr. John Tsang was an invited speaker for the Department of Medicine, University of
Washington, Seattle, Washington.
Dr. Keith Walley was an invited speaker at the Society of Critical Care Medicine Annual
Congress, Orlando, Florida, the American Burn Association Annual Meeting, Vancouver, BC
and the Rocky Mountain/American College of Internal Medicine Meeting, Banff, Alberta.
Page 38
Annual Report 2004
DERMATOLOGY
Dr. Harvey Lui
Professor & Head
Faculty Members
Professor & Head
Professor
Professor
Professor
Associate Professor
Associate Professor
Associate Professor
Assistant Professor
Assistant Professor
Clinical Professor
Clinical Professor
Clinical Professor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Associate Member
Lui, Dr. Harvey
Ho, Dr. Vincent
McLean, Dr. David
Rivers, Dr. Jason
Dutz, Dr. Jan
Kitson, Dr. C.
Li, Dr. Gang
McElwee, Dr. Kevin
Zhou, Dr. Youwen
Carruthers, Dr. Alastair
Shapiro, Dr. Jerry
Warshawski, Dr. Laurence
Conklin, Dr. Robert
Haber, Dr. Richard
Kunimoto, Dr. Brian
Ongley, Dr. Roberta
Schlappner, Dr. Otto
Bergman, Dr. James
Gregory, Dr. Brian
Kenny, Dr. Patrick
Morton, Dr. Charles
Prihoda, Dr. Marie
Thomas, Dr. D. Richard
Tuyp, Dr. Evert
Zloty, Dr. David
Amiss, Dr. John
Au, Dr. Sheila
Davis, Dr. Anne
Hong, Dr. Chih-ho
Rossi, Dr. Sikina
Shokravi, Dr. Mohammad
Ball, Dr. Nigel
Page 39
VA
VA
VA
VA
VA
VA
VA
VA
VA
VA
VA
VA
VA
Victoria
VA
VA
SPH
Vancouver
VA
Royal Jubilee
VA
VA
VA
VA
VA
Victoria
VA
VA
SPH
Victoria
North Vancouver
VA
Annual Report 2004
Associate Member
Associate Member
Associate Member
Associate Member
Associate Member
Adjunct Professor
Crawford, Dr. Richard
Gallagher, Dr. Richard
Martinka, Dr. Magdalena
Prendiville, Dr. Juliette
Zeng, Dr. Haishan
Thewalt, Dr. Jenifer
Maddin, Dr. Stuart
McLeod, Dr. W.
SPH
Vancouver
VA
C&W Health Centre
BCCA
Burnaby
VA
VA
In 2004 the Division of Dermatology formally recruited new faculty members within the Island
and Northern Medical Programs, and launched the first of a series of “pilot” clerkships for
undergraduate medical students in Victoria. This initiative represents the first concrete step
towards expanding our Division in concert with the overall medical school expansion. Another
major milestone for the Division was that 2004 marked the first year that all of our research
laboratories achieved funding support from the Canadian Institutes of Health Research.
The other overarching divisional initiative in 2004 was the formal discussion within the Faculty
of Medicine surrounding the creation of the UBC Department of Dermatology and Skin Science.
This has been a longstanding goal of the Division of Dermatology and was supported this year
by the Department of Medicine. Early in 2004 the Dean of Medicine agreed to receive a proposal
for creating a new department from the current division, and in the fall of 2004, the Faculty
Executive Committee agreed to pursue this in greater detail. Among other things, departmental
status will facilitate greater academic opportunities for Dermatology and Skin Science, enhance
fundraising efforts, assist with faculty and trainee recruitment, and provide recognition of the
unique scope and accomplishments of our academic unit.
Teaching
Undergraduate: Dr. Jerry Shapiro, Director. Over the last year Dr. Shapiro has attended
innumerable committee meetings and worked tirelessly on the medical school expansion project.
Over the next several years, we will eventually need to find clerkship experiences for twice the
current number of medical students. “Pilot” rotations are being tested in advance of the full roll
out of Dermatology Clerkships in the expanded medical school by the fall of 2006. Following the
initial successful pilots in Victoria in 2004, additional pilot programs will be set up in Prince
George and the Fraser Valley in 2005.
Postgraduate: Directors: Dr. Jason Rivers (January-September), Dr. Larry Warshawski
(September- ). Dr. Jason Rivers completed his term as Postgraduate Program Director in 2004
and has been succeeded by Dr. Larry Warshawski. During Dr. Rivers’ overall term, the training
program earned full Royal College accreditation status and graduated the first dermatology
residents in our joint training program with the University of Manitoba. Other milestones
included an overhaul of the core resident rotations to better reflect the changing face of
dermatologic practice. We are grateful to Dr. Rivers for his dedication to training our next
generation of dermatologists in his leadership role. Dr. Larry Warshawski has initiated work on
expanding the number of training slots in dermatology, both through CARMS and re-entry
pathways.
Page 40
Annual Report 2004
All three of our graduates in 2004, Dr. Michelle Withers, Dr. Hana Alkhayat, and Dr. Rochelle
VanDeVelde, were successful with their Royal College examinations in Dermatology. Dr.
Alkhayat has stayed on as a Clinical Research Fellow in Photomedicine and Lasers at UBC.
Advanced clinical fellows in hair, micrographic surgery, dermatopathology, and photomedicine
rounded out our clinical trainees in Dermatology. These fellowships combine clinical training
with research and the fellows hail from New York, Korea, Toronto, and Saudi Arabia.
Experimental Medicine: The Division continues to attract a very healthy number of graduate
students, particularly in the Skin Cancer Biology Laboratory under Dr. Gang Li. Graduate
students interact with the clinical program in a number of ways including the Annual UBC
Dermatology Research Day and the MEDI 535 Journal Club course that is run in conjunction
with the residency program under the direction of Dr. Jan Dutz.
Continuing Medical Education: CME courses offerings for 2004 included:
Spring Dermatology Update for Family Physicians (March 5-6, 2004)
Course Director: Dr. Brian Kunimoto
Dermatology Update 2004 (November 14-16, 2004)
Course Director: Dr. Stuart Maddin
Living Well with Diabetes (November 20-21, 2004)
Course Co-Director: Dr. Brian Kunimoto
Research
All of our dermatology and skin research laboratories achieved national level (e.g. CIHR, NCIC)
peer-reviewed funding in 2004. UBC Dermatology Research Day (March 13, 2004) was well
attended by scientists, clinicians, clinical and graduate student trainees, as well as nurses and
ancillary staff.
Dr. Kevin McElwee joined the Division of Dermatology as an Assistant Professor. He will work
with Dr. Jerry Shapiro in the UBC Hair Treatment and Research Program, and has expertise in
autoimmune follicular disorders and hair biology. Dr. McElwee’s recruitment to UBC helps to
solidify UBC’s reputation as the most comprehensive academic hair biology and treatment centre
in North America. Dr. McElwee’s recruitment was supported in part through the generosity of
the VGH & UBC Hospital Foundation as well as patient donations to the hair program.
In the fall of 2004, several Division of Dermatology members helped to convene and lead two
CIHR-sponsored workshops in Vancouver and Toronto on future Canadian directions in skin
research. The “CIHR Skin Health Research Priority Workshop” brought together, for the first
time in Canada, scientists, clinicians, patients, industry, and government to brainstorm ideas on
how to best advance the skin research agenda. Recommendations from the workshop included
the establishment of a patient advocacy alliance, defining four key areas of research, and
building capacity through training and research networks. Dr. Dutz and Lui served as the cochairs of the workshop.
Page 41
Annual Report 2004
Clinical Services
A generous donation from the Hamzavi Foundation to the Division of Dermatology in 2004 will
be used to establish a vitiligo treatment facility at the Skin Care Centre. Planning also got
underway for new clinic facilities at VGH for the Wound Healing Clinic in the new Academic
Ambulatory Care Centre. The overall clinical program at VGH will remain at the Skin Care
Centre. Dermatology services as a whole continue to be in high demand, particularly for skin
cancer screening and treatment.
Dr. Kevin McElwee, Appointment as Assistant Professor and Departmental Scholar Award,
Department of Medicine
Dr. W. Alastair McLeod, Award of Merit, Canadian Dermatology Association
Dr. Richard Crawford, Promotion to Clinical Professor and Teaching Award, Residents &
Fellows Section, Canadian Dermatology Association
Dr. Richard Haber, Appointment as Clinical Associate Professor
Dr. Sikina Rossi, Appointment as Clinical Instructor
Dr. Nhiem Nguyen, Practitioner of the Year, BC Dermatology Society
Dr. Youwen Zhou, Departmental Scholar Award, Department of Medicine
Dr. Alastair Carruthers: Elected as Vice-President, American Society for Dermatologic
Surgery
Dr. Harvey Lui, President-Elect, Canadian Dermatology Association
Dr. Hana Alkhayat, Resident Teaching Award, Residents & Fellows Section, Canadian
Dermatology Association
Ms. Alison Karst, Trainees awards from the Michael Smith Foundation for Health Research and
the Natural Sciences and Engineering Research Council (supervisor Dr. Gang Li)
Page 42
Annual Report 2004
ENDOCRINOLOGY
Dr. David Thompson
Faculty Members
Professor
Clinical Professor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Associate Member
Associate Member
Associate Member
Associate Member
Adjunct Professor
Associate Professor (Emeritus)
Thompson, Dr. David
Prior, Dr. Jerilynn
Wilkins, Dr. Graeme
Tildesley, Dr. Hugh
Bebb, Dr. Richard
Dahl, Dr. Marshall
Elliott, Dr. Thomas
Kendler, Dr. David
Kreisman, Dr. Stuart
Wallace, Dr. Clarissa
Gill, Dr. Sabrina
Johnson, Dr. Michelle
Kong, Dr. Jason
Mase, Dr. Robert
Sirrs, Dr. Sandra
Bondy, Dr. Greg
Kitson, Dr. Hilary
Rothstein, Dr. Ralph
Stewart, Dr. Laura
Finegood, Dr. Diane
Dawson, Dr. Keith
Cairns, Dr. Alexander
VA
VA
VA
SPH
SPH
VA
VA
VA
SPH
VA
SPH
SPH
VA
SPH
VA
SPH
C&W Health Centre
C&W Health Centre
Burnaby
Vancouver
VA
Divisional Overview
The UBC Division of Endocrinology continued to expand with the addition of one new faculty
member in 2004. The clinical activity in both outpatient and inpatient settings is growing to
meet increased demand. Most faculty members are involved in clinical research and participate
in fundraising activities to help support the many activities of the division. Division members
also serve on a large number of local, provincial, national and international committees for
clinical and research activities.
Page 43
Annual Report 2004
Teaching
The division remained very active in teaching at both an undergraduate and postgraduate level.
Undergraduate: Medical students are able to choose a selective in endocrinology where they
get exposure to endocrine ambulatory clinics including general endocrinology offices and the
diabetes centre. Several faculty members (Drs. Sirrs, Gill, Fung, Prior, Bondy) and the
endocrine fellows served as tutors in the endocrinology and metabolism problem based learning
sessions. Endocrinologists are heavily involved in both the endocrinology and musculoskeletal
blocks, providing lectures and case materials as well as serving as PBL tutors.
With the expansion of the medical school, it is anticipated that the division will have to double
its capacity to provide endocrinology selectives to medical students, as well as provide teaching
to students at sites where there are no endocrinologists.
Postgraduate: The UBC division provided endocrinology electives to 36 rotating residents
from internal medicine in the 2004 / 5 academic year. Electives were also provided to residents
from other programs (e.g. genetics, dermatology, family practice) and to residents from out of
province. The evaluations of the endocrinology rotation by internal medicine residents have
improved markedly. Endocrinology rotations at VH are the highest rated among UBC rotations
with a service requirement, and rotations at SPH are now rated 6 overall. The strengths of the
rotations include their emphasis on a mix of both ambulatory and inpatient responsibilities and a
structured academic half day component to provide appropriate teaching.
The division had two subspecialty residents in the second year of their program in 2004 / 5. The
current level of funded subspecialty training positions in adult endocrinology is 0.5
positions/year. With the projected increase of postgraduate training positions to accommodate
the medical school expansion, it is anticipated that the division will have funding for 1 adult
subspecialty resident per year in 2006 with an increase to 2 training positions per year after that.
Community
The division participates in a number of continuing medical education activities. Some, such as
the Diabetes Directors Symposium and the BC Endocrine Days, have been running for a number
of years. In addition, division members give many invited lectures to community physicians.
Research
The islet cell program was very active during the past year and is now among the leading
programs in the world in this area. Research is being carried out at both basic and clinical levels,
involving collaborations with other active centres.
Many division members are participating in a number of multi-centre trials involving various
aspects of diabetes, lipid and cardiovascular outcomes. Dr. Kreisman is involved in an NIH trial
in the management of cystic fibrosis and diabetes.
Page 44
Annual Report 2004
The Women’s Health research program, led by Drs. Prior and Gill, continues to expand and the
related Osteoporosis research continues at a very active level.
Dr. Sirrs remains heavily involved in Adult Metabolic Diseases clinical research.
Both divisions have established fundraising programs to provide support for research and
educational activities.
Clinical Services
The demand for both outpatient and inpatient services continues to grow at both sites. We are
developing new multidisciplinary clinics, especially in collaboration with nephrology, bone
marrow and solid organ transplantation. Improved management of inpatient diabetes is being
recognized throughout the hospital as important in improving quality of care and this will require
the division to develop new strategies to accomplish this important goal.
Awards
Dr. Keith Dawson: Canadian Diabetes Association Outstanding Dedication Award 2004
Dr. G.E. Wilkins: Career Award for Teaching Excellence from UBC
Future Directions
In addition to expanding the above activities, there appear to be several areas that the division
will focus on over the next year. Detailed planning will be required to ensure adequate
undergraduate training in endocrinology as the medical school expands both in number of
students and the sites where they are being trained. Optimal inpatient diabetes care throughout
the hospital will place an increased demand on the resources of both the division and the diabetes
centre staffs. There is considerable interest in developing a regional approach to diabetes care
that will result in patients receiving the care that they need in the most appropriate setting. It is
increasingly recognized that certain groups, such as the elderly, require diabetes care that is
tailored to their special needs. Proper design and implementation of such a program will require
a great deal of work and resources. The St. Paul’s division plans to establish a multidisciplinary
approach for the assessment and treatment of osteoporosis.
Page 45
Annual Report 2004
GASTROENTEROLOGY
Dr. Urs Steinbrecher
Professor & Head
Faculty Members
Professor & Head
Professor
Associate Professor
Associate Professor
Assistant Professor
Clinical Professor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Associate Member
Associate Member
Visiting Professor
Clinical Associate Professor (Emeritus)
Steinbrecher, Dr. Urs
Freeman, Dr. Hugh
Salh, Dr. Baljinder Singh
Yoshida, Dr. Eric
Tai, Dr. Isabella
Halparin, Dr. Lawrence
Byrne, Dr. Michael
Gray, Dr. James
Kwan, Dr. Peter
Weiss, Dr. Alan
Amar, Dr. Jack
Enns, Dr. Robert
Erb, Dr. Siegfried
Telford, Dr. Jennifer
Whittaker, Dr. J.
Chatur, Dr. Nazira
Fishman, Dr. Martin
Lam, Dr. Eric
Ramji, Dr. Alnoor
Gill, Dr. Sharlene
McManus, Dr. Bruce
Gomez-Munoz, Dr. Antonio
Chaun, Dr. Hugh
Stordy, Dr. Stanford
Anderson, Dr. Frank
MacDonald, Dr. Walter
Carr, Dr. Donald
VA
VA
VA
VA
VA
SPH
VA
VA
VA
VA
SPH
SPH
VA
Vancouver
SPH
VA
Richmond
SPH
SPH
BCCA
SPH
VA
SPH
SPH
VA
VA
VA
Divisional Overview
The UBC Division of Gastroenterology consists of 5 UBC full-time faculty members, 14 clinical
faculty members, 2 associate members, 5 emeritus professors, and one visiting professor. These
Page 47
Annual Report 2004
staff are based at St. Paul’s Hospital, Vancouver General Hospital, UBC Hospital, Vancouver
Cancer Centre, B.C. Transplant Society, and Richmond General Hospital. There are active
gastroenterology inpatient/consult services at Vancouver General Hospital and St. Paul’s
Hospital as well as a liver transplant unit at Vancouver General Hospital and B.C. Transplant
Society. The ambulatory care facilities include a hospital-based clinic at Vancouver General
Hospital, as well as hospital-based or adjacent offices at St. Paul’s, UBC Hospital, and
Richmond. The GI subspecialty training program currently has 5 trainees. The basic research
focus of the division is on molecular and biochemical abnormalities, underlying GI cancer, and
inflammatory bowel disease. The division is also engaged in an active and multifaceted clinical
research and clinical trials program. As a result of recruitment initiatives over the past year, we
have attracted three new academic clinicians to the division's faculty (Drs. Chatur, Ramji, and
Telford). Dr. Chatur’s role will be in undergraduate and postgraduate medical education. Dr.
Ramji will focus on clinical research in hepatology. Dr. Telford will focus on therapeutic
endoscopy and clinical research in luminal gastroenterology.
Teaching
Undergraduate: The GI Division plays a key role in the enhancement and ongoing
improvement of the GI block in phase II of the undergraduate curriculum. In addition to updates
and revisions to the cases, lectures, and labs, priorities for 2005 are to plan for the expansion of
the medical school class size over the next 4 years, to increase the quality, quantity, and
accessibility of exhibits associated with the block cases, and to renew online resources for the
block. Dr. Nazira Chatur was appointed Undergraduate Program Director for GI.
Postgraduate: Dr. Peter Kwan is Director of the GI training program and Dr. Chatur is coDirector. The division is proud of the excellent trainees currently enrolled in the program (Drs.
Stacy Shapira and Jaber Al-Ali for 2003-5, and Dr. Henry Chung, Dr. Jin-Kee Ho and Dr. Nasser
Al-Masri for 2004-2006).
Experimental Medicine: Dr. Bill Salh coordinates the GI components of the Experimental
Medicine Program. There are currently 4 graduate students from the GI Division registered in
Experimental Medicine. In addition, one international PhD student, two summer students, and
two post-doctoral fellows are supervised by GI division members.
Continuing Medical Education: In 2004, the UBC GI Division organized several accredited
CME courses, including the eighth Annual Digestive Disease Week Review Course for
subspecialists, and an Update in Gastroenterology course. The St. Paul’s Division of
Gastroenterology organized several additional CME courses for specialists. All were wellattended and highly-rated events.
Research
Division members generated more than 50 publications in peer-reviewed journals in 2004, and
associate members added an additional 15 papers. Several division members including Drs.
Salh, Steinbrecher, and Tai conduct active basic research programs supported by national and
regional granting agencies (CIHR, HSFC, CCFC, and Canadian Society for Intestinal Research).
The Division is expanding clinical research and clinical trials activities, and is involved in more
Page 48
Annual Report 2004
than 30 trials in a variety of clinical areas including viral hepatitis, liver transplantation,
inflammatory bowel disease, esophageal reflux disease, peptic ulcer disease, and functional
bowel disorders. Drs. Anderson, Enns, Yoshida, Gray, Kwan, and Whittaker have been
particularly active in clinical trials. As a result of recruitment initiatives over the past year, we
have attracted three new clinician-investigators to the division's faculty (Drs. Chatur, Ramji, and
Telford) who will build on existing clinical research strengths in the division.
Administration and Future Directions
A search will be conducted in 2005 for a new UBC Division Head in Gastroenterology.
Several division members serve on or chair committees of professional organizations, editorial
boards of medical and scientific publications, and on grant review committees of major peerreviewed granting agencies. Of note, Dr. Hugh Chaun was elected Secretary-General, Bockus
International Society of Gastroenterology and is Chair, Press and Congress News Committee,
2005 World Congress of Gastroenterology Canadian Organizing Committee, Governor of the
American College of Gastroenterology representing the region of the Western Provinces, and
Chair, Governing Board, Canadian Digestive Health Foundation. Dr. Rob Enns is Chair,
Endoscopy Committee, Canadian Association of Gastroenterology, Member of the 2005 World
Congress of Gastroenterology Scientific and Clinical Planning Committees, and a member of the
Canadian Digestive Disease Health Foundation Committee. Dr. James Gray is President, B.C.
Society of Gastroenterology. Dr. Eric Yoshida is Chair, Membership Committee, Canadian
Association for the Study of the Liver and Head, B.C. Hepatitis Program. Dr. Urs Steinbrecher
serves on the CIHR Metabolism Grant Panel, is Chair, Heart and Stroke Foundation of B.C. and
Yukon Research Committee, and Chair, AHFMR Clinical Investigator Review Committee.
Page 49
Annual Report 2004
GENERAL INTERNAL MEDICINE
Dr. Iain Mackie
Clinical Professor & Acting Head
Faculty Members
Professor
Professor
Associate Professor
Associate Professor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Mackie, Dr. Iain
Page, Dr. Gordon
Wright, Dr. James (Jim)
Palepu, Dr. Anita
Studney, Dr. Donald
Hatala, Dr Rose
Kassen, Dr. Barry
Kennedy, Dr. James
Onrot, Dr. John (Jake)
Arseneau, Dr. Richard
Ayotte, Dr. Brian
Baillie, Dr. Hector
Busser, Dr. James
Dunne, Dr. James
Magee, Dr. Laura
Ong-Lam, Dr. May
Perry, Dr. Thomas
Richmond, Dr. Allister
Wakefield, Dr. Robert
Auersperg, Dr. Edward
Broder, Dr. Sarah
Caswell, Dr. Sherri
Chan, Dr. Alex Chong Hen
Cunningham, Dr. Kenneth
Deutscher, Dr. Timothy
Duke, Dr. Stephen
Ervin, Dr. Francis (Frank)
Hawley, Dr. Philippa
Holmes, Dr. Cheryl
Kenyon, Dr. Michael
Khan, Dr. Nadia
Kincade, Dr. David
Page 51
VA
VA
VA
SPH
VA
SPH
VA
SPH
SPH
SPH
Sushwap Lake
Nanaimo
VA
VA
Women's Health Centre
SPH
VA
Chilliwack
VA
Pitt Meadows
Penticton
VA
VA
SPH
Nanaimo
Victoria
Maple Ridge
VA
Kelowna
Nanaimo
SPH
Kamloops
Annual Report 2004
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Associate Member
Associate Member
Lai, Dr. Kevin
McKay, Dr. Rhonda
Purkiss, Dr. Susan
Roberts, Dr. James
Son, Dr. Wai Kon
Sunderwood, Dr. Jennifer
Winkler, Dr. Lawrence
Wong, Dr. Steven
Birmingham, Dr. Carl Laird
Zaidel, Dr. Patrick
Schulzer, Dr. Michael
Johnson, Dr. Archibald
McDonnell, Dr. C. Edward
Paige, Dr. Bruce
Rennie, Dr. Charles
Nanaimo
SPH
C&W Health Centre
VA
Chilliwack
VA
Nanaimo
VA
SPH
Burnaby
VA
SPH
VA
VA
The Division of General Internal Medicine forms an integral part of the UBC Department of
Medicine, with faculty active in a variety of generalist and subspecialty areas. The main foci of
the Division include teaching, research and administration. In 2004 the Division benefited from
the recruitment of Dr. Irene Ma, who has subspecialty training in both general medicine and
nephrology. Dr. Ma will have a major research commitment. Her area of research interest is
ethnicity and its impact on disease.
Members of the Division were granted major research awards in 2004. Dr. Anita Palepu was
awarded a CIHR research grant for work on the development of a quality of life instrument for
homeless persons and street youth, as well as a major Michael Smith Foundation Award as a
senior scholar in population urban health. Dr. Laura Magee continues to hold a Michael Smith
Foundation Scholar Award until 2008. Dr. Magee holds numerous Michael Smith, CIHR and
other grants related primarily to her research expertise in hypertension in pregnancy. Dr. Nadia
Khan also won a CIHR award for her work on ethnicity and cardiovascular disease. Dr. Don
Studney continues his research in diabetic neuropathy with major industry grants.
Drs. Rose Hatala, Barry Kassen, Mark Roberts and Iain Mackie were granted funds from the
Royal College of Physicians and Surgeons to compare a brief, observed clinical examination
(mini-CEX) with outcomes on the Royal College internal medicine examination. As a result of
this work, a new series of observed mini-CEX examinations will be implemented as an
evaluation tool within the core Internal Medicine residency training programme. Dr. Iain
Mackie served as a member of the Drug Safety Monitoring Board for Tibotec Corporation for a
new protease inhibitor for use in HIV positive patients.
Drs. Khan and Palepu, between them, had 17 publications and 2 book chapters in 2004. Dr.
Palepu published her work in major HIV/AIDS journals. Dr. Khan and colleagues published
new guidelines for hypertension on behalf of the Canadian Cardiovascular Society in the
Canadian Journal of Cardiology. These guidelines will have significant impact on the care of
patients with hypertension in Canada. Dr. Laura Magee published 14 journal articles and
presented 12 abstracts on topics related to medical problems of pregnancy. Dr. Rose Hatala had
2 articles on evidence-based medicine published in 2004 in the Canadian Medical Association
Page 52
Annual Report 2004
Journal. Dr. Pippa Hawley published a major survey on physicians’ attitudes and knowledge of
cancer pain management in the journal Pain Research and Management. She has been
instrumental in the development of a palliative care training programme at UBC.
Division members continue to play a major role in the administration of the Department of
Medicine and its programmes. Dr. Mark Roberts was appointed Programme Director for the
Internal Medicine Residency Training Programme, replacing Dr. Iain Mackie who stepped down
after seven years. Drs. Barry Kassen (community programme development) and Dr. Rose Hatala
(evaluations) were appointed as Associate Directors of the training programme. Dr. Anita
Palepu was appointed as co-chair of the Clinical Investigator Programme for the Department of
Medicine. Dr. Iain Mackie was appointed as Director of the Assessment of Competence
Programme for the Department of Medicine. This new programme evaluates the clinical
competence of international medical graduates. Dr. Barry Kassen was appointed to the Faculty
of Medicine’s Faculty Development Committee.
Dr. Barry Kassen continues as Chair of the Internal Medicine Oral Examination Board at the
Royal College of Physicians and Surgeons. Drs. Hatala, Mackie, Roberts and Dr. Jake Onrot
continue as members of the Oral Examination Board of the Royal College of Physicians and
Surgeons. Dr. Kassen sits on the Board of the Canadian Society of Internal Medicine. Dr. Nadia
Khan is a member of the organizing committee for the Rocky Mountain Internal Medicine
Conference. Dr. Palepu is a member of the organizing committee for the 3rd International
Conference on Urban Health, and was the co-chair of the Epidemiology section of the Canadian
Association of HIV Research.
At the annual meeting of the Canadian Society of Internal Medicine, Dr. Palepu was honoured
with the “Young Investigator Award” for her work on HIV infection and injection drug users.
Dr. Rose Hatala won the Dr. Shelly Naiman Award for Clinical Teacher of the Year at St. Paul’s
Hospital.
On a lighter note, Dr. Tom Perry celebrated a “prime-number” birthday and celebrated this midlife crisis by canoeing down the Turnagain River in northern BC. Both he, Dr. Bob Rangno and
Dr. Jim Wright continue to play major roles in the Therapeutics Initiative and the Cochrane
Collaborative.
Overall this has been a year of ongoing successes for the Division of General Internal Medicine.
Division members continue to demonstrate excellence in research, teaching and administration,
winning major local and national awards for their excellence in teaching and research.
Page 53
Annual Report 2004
GERIATRIC MEDICINE
Dr. Graydon S. Meneilly
Professor & Head
(January-June 30, 2004)
Dr. Larry Dian
Clinical Associate Professor &
Acting Head (July 1, 2004 - )
Faculty Members
Professor & Head, Dept. of Medicine
Clinical Associate Professor &
Acting Head
Professor
Assistant Professor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Meneilly, Dr. Graydon
Dian, Dr. Larry
VA
VA
Beattie, Dr. B
Madden, Dr. Kenneth
Adler, Dr. Reva
Martini, Dr. Janet
Chung, Dr. Maria
Hill, Dr. Amanda
O'Connor, Dr. Peter
Rauscher, Dr. Christopher
Wong, Dr. Roger
Barnett, Dr. Kim
Bater, Dr. Marilyn
Bell, Dr. Kathryn
Cook, Dr. Wendy
King, Dr. Kim
Kushner-Kow, Dr. Janet
Lee, Dr. Philip
Malone, Dr. Marilyn
Menezes, Dr. Janice
Ranchod, Dr. Hetesh
Williams, Dr. Dorothy
VA
VA
VA
SPH
SPH
VA
RCH
VA
VA
SPH
Royal Jubilee
VA
SPH
Nanaimo
Mount St. Joseph
SPH
VA
SPH
Mount St. Joseph
Victoria
Page 55
Annual Report 2004
Divisional Overview
The Division of Geriatric Medicine currently has 15 faculty at PHC and VA and 4 faculty in
distributed sites. It delivers a wide range of clinical services spanning all sites of Providence
Health Care and VA, including active geriatric consultation services, in-patient acute care for
elders (ACE), geriatric activation and assessment beds, geriatric day hospitals and multiple
outpatient clinics. Clinical services are provided in the community through outreach and through
one faculty member who works primarily with community provider teams. Research by division
members is in health service provision, diabetes, medical education, dementia, osteoporosis, falls
prevention and cardiovascular disease.
Teaching
Undergraduate: Dr. Reva Adler coordinates Phase V for the Undergraduate Education
Committee of the Department of Medicine and will coordinate this phase for the medical school
expansion. Dr. Janet Kushner-Kow is the Undergraduate representative for the UBC Division of
Geriatric Medicine and she is the chair for the dementia week block in Brain and Behaviour in
PBL. Currently the division also organizes and teaches two sessions in Clinical Skills on
assessment of confusion and function. Dr. Kushner-Kow is also the director for expansion for
the Department of Medicine Undergraduate Program and is on the Undergraduate Education
Committee.
Dr. Kushner-Kow and Dr. Hetesh Ranchod are participating in teaching International Medical
Graduates at Mount St. Joseph Hospital.
Postgraduate: Dr. Janet Kushner-Kow is the new Program Director of the Geriatric Medicine
Training Program. We presently have two trainees, one gulf state resident finishing his third
year in geriatrics before returning to Saudi Arabia and one other resident. We have a new
resident starting in July 2005. The internal review of the program will be conducted in Spring
2005. In addition, Division members teach Internal Medicine residents and fellows the
principles of the care of the frail elderly by working on Clinical Teaching Units and teaching
noon rounds and academic half days. Dr. Roger Wong has been appointed the Associate
Program Director, Postgraduate Medical Education.
Continuing Medical Education: In 2004 the Division members were active participants in
numerous CME events which included programs in osteoporosis, falls and fractures, dementia,
diabetes and other topics. Dr. Janet Kushner-Kow organizes weekly division rounds which has
local and international speakers. She is active in evaluating an interprofessional module series
which teaches geriatrics to trainee and practicing health care professionals interested in the Care
of the Elderly. This series has been used in Vancouver, the Fraser Health Region and three rural
sites. The Division hosted a conference on Osteoporosis and Renal Disease that focused on the
management and fracture risks in patients with end stage renal disease.
Research
Dr. Meneilly is a member of the board of the CIHR Institute for Aging and is also a member of
the Steering Committee for the Canadian Longitudinal Study on Aging and he conducts several
Page 56
Annual Report 2004
research projects on diabetes in the elderly. Dr. Larry Dian is the Principal Investigator of a
study of the prevalence of osteoporosis in nursing home patients. Dr. Roger Wong continues to
conduct research in medical education. He is currently investigating the role of electronic
academic detailing in teaching medical concepts to physicians. He is also involved in clinical
outcomes research on the measurement and determinants of physical function in acutely ill
seniors in ACE units. Dr. Janet Kushner-Kow is conducting research on optimal interactive
multimedia education strategies for distance learning in the new distributed medical school
curriculum. Dr. Beattie is involved in multiple research projects related to dementia, serves on
the Clinical Research Ethical Board (CREB) committee, chairs the Research Policy Committee
for the Alzheimer Society of Canada. She has been a member of a Michael Smith Foundation
for Health Research Initiative to set up an Aging Network. Dr. Reva Adler has represented
Canada at a number of international conferences on genocide in the past two years. She holds a
grant from the Vancouver Foundation to research access to health services for older immigrants
to Canada. Dr. Marilyn Malone is involved in collaboration with colleagues at SFU and UBC in
developing a falls prevention program. Dr. Ken Madden has implemented his research program
in cardiovascular physiology and pathophysiology in aging. He has two projects currently
ongoing. The first study is an examination of the effects of hyperinsulinemic euglycemic clamps
on cardiovascular and cerebrovascular control mechanisms (arterial baroreceptors, autonomic
nervous system and cerebral autoregulation) that maintain blood flow to the brain during upright
tilt. His second study is examination of the effects of a central alpha agonist (clonidine) on
carotid sinus hypersensitivity in older adults that present to the emergency department with
frequent falls. Dr. Janet Martini and her colleagues in Providence Health Care are developing a
research focus in performance review and continuous quality improvement with ongoing
evaluation of service delivery. Dr. Wendy Cook is working on an ongoing cohort study based in
Toronto with nephrologist Dr. Vanita Jassal on the prevalence and incidence of falls in elderly
dialysis patients. She is a co-investigator in a randomized study of exercise for fall prevention in
elderly emergency department fallers. She has submitted a paper on the prevalence of falls. Dr.
Philip Lee is doing research on behavioral neurology and dementia. He was recently awarded a
CIHR Fellowship. Dr. Hill is collaborating with Dr. Thornton from Simon Fraser University and
Dr. Shapiro from the Division of Nephrology, looking at cognition in predialysis patients.
Clinical Services
At both Providence Health Care and Vancouver Hospital clinical activities continue to increase.
At the Vancouver Hospital the volume of in-patient consults has also increased. We have
established a SAFE Geriatric assessment unit with a focus on regional and provincial needs
which operates at the UBC hospital site. The Division is actively involved in patient assessment
and management at the VGH STAT Centre and will participate in planning future communitybased GEM services in Vancouver Community Health Services. Dr. Amanda Hill with Dr. Mark
Roberts is developing a Congestive Heart Failure protocol. Dr. Chris Rauscher through self
study and through his extensive involvement in planning and implementation of quality
improvement initiatives related to chronic disease management and health system re-design is
now a recognized expert in these areas. He was co-chair of the BC Congestive Heart Failure
Collaborative and he is the physician lead for chronic disease management for Vancouver
Coastal Health. He has been extensively involved in population health planning with the
Ministry of Health Services and he is chairing working groups on Dementia and on the Frail
Elderly. He is a member of the MOH/BCMA Guidelines and Protocols Committee and has
Page 57
Annual Report 2004
developed a number of guidelines for physicians related to chronic diseases. He has presented
on his work in numerous local workshops and conferences. Dr. Philip Lee is attending physician
for Geriatric Medicine and the CTU at SPH and an attending physician at the Alzheimer’s and
related disorders clinic at UBC Hospital.
Administration
Dr. Larry Dian is Acting Head, UBC Division of Geriatric Medicine and Head, VGH Division
Geriatric Medicine. Dr. B. Lynn Beattie is Acting Head, Division of Geriatric Medicine at
Providence Health. Dr. Janice Menezes is the Physician Operations Leader at St. Paul’s. Dr.
Meneilly is the Chairman of the UBC and VGH Department of Medicine. Dr. Reva Adler is the
Medical Director of the VGH STAT Centre. Dr. Amanda Hill continues in her role as Medical
Director, Community and Specialty Medicine. Dr. Roger Wong is the Medical Director,
Geriatric Consultation Program and Medical Manager, ACE unit at VGH and the Associate
Program Director, Postgraduate Medical Education, UBC Department of Medicine.
Dr. Reva Adler is doing Fulbright scholarship sponsored research in Rwanda on prevention of
massacres.
Dr. Roger Wong was awarded an interdisciplinary research grant and the “In it for Life” research
grant by the Vancouver Coastal Health Research Institute. He was also appointed the Associate
Program Director, Postgraduate Medical Education, UBC Department of Medicine.
Dr. Wendy Cook has been a volunteer physician at the Manang Aid Post for the Himalayan
Rescue Association, Nepal from September to December 2004.
Page 58
Annual Report 2004
HEMATOLOGY
Dr. Michael Barnett
Faculty Members
Professor
Professor
Professor
Associate Professor
Clinical Professor
Clinical Professor
Clinical Professor
Clinical Professor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Associate Member
Associate Member
Associate Member
Barnett, Dr. Michael
Eaves, Dr. Allen
Humphries, Dr. Richard Keith
Schrader, Dr. John
Smith, Dr. Clayton
Ballem, Dr. Penny
Buskard, Dr. Noel
Hogge, Dr. Donna
Lansdorp, Dr. Peter
Benny, Dr. Barrett
Nantel, Dr. Stephen
Nevill, Dr. Thomas
Shepherd, Dr. John
Sutherland, Dr. Heather
Vickars, Dr. Linda
Forrest, Dr. Donna
Leitch, Dr. Heather
Li, Dr. Charles
Toze, Dr. Cynthia
Broady, Dr. Raewyn
Galbraith, Dr. Paul
Lavoie, Dr. Julye
Leger, Dr. Chantal
Petraszko, Dr. Tanya
Song, Dr. Kevin
Sreenivasan, Dr. Gayatri
Tsang, Dr. Peter
Coupland, Dr. Robert
Eaves, Dr. Connie
Horsman, Dr. Douglas
Page 59
VA/BCCA
BCCA
BCCA
UBC
VA/BCCA
C&W Health Centre
VA
VA/BCCA
BCCA
VA
VA/BCCA
VA/BCCA
VA/BCCA
VA/BCCA
SPH
VA/BCCA
SPH
SPH
VA/BCCA
VA
SPH
VA/BCCA
SPH
VA
VA/BCCA
VA
VA
VA
BCCA
BCCA
Annual Report 2004
Divisional Overview
The UBC Division of Hematology includes 27 staff and 3 associate staff members based at the
Vancouver General Hospital (VGH), the Vancouver Cancer Centre (VCC) and the Terry Fox
Laboratory (TFL) of the British Columbia Cancer Agency, St. Paul’s Hospital (SPH), BC
Women’s & Children’s Hospital and UBC. In 2004, laboratory research programs at TFL and
UBC brought in peer-reviewed operating support of $2.9 million and CFI equipment funds of
$2.1 million and clinical research at VGH and SPH brought in $240,000. There was a total of 45
peer-reviewed publications. Training and patient care remained at the forefront of clinical
activities. Trainees in the Division as a whole included 4 Hematology fellows, 5 Leukemia/BMT
fellows, 19 laboratory post-doctoral fellows and 6 graduate students.
Teaching
Undergraduate: This was the 6th year of the Blood & Lymphatics Block in the Problem Based
Learning course.
Postgraduate: A total of 32 Residents in the Internal Medicine Program took hematology-based
electives during the past year. These were one or two month blocks spent on the Hematology
Consultation Service at VGH or SPH.
Subspecialty Training: Four General Hematology fellows were based at VGH. Rotations
included the General Hematology Consultation Service, Leukemia/BMT Service, Blood
Transfusion Service, Cell Separator Unit, Out-patient Clinics and Hematopathology. Rotations
were also taken at SPH, VCC, BC Women’s and Children’s Hospital. These positions were
filled by Dr. Ahmad Al Saeed, Dr. Lynda Foltz, Dr. Yulia Lin and Dr. Carolyn Owen.
Leukemia/Bone Marrow Transplantation Fellowship: The Leukemia/BMT Program had five
positions available for clinical training in the management of patients with leukemia and those
undergoing hematopoietic stem cell transplantation. These positions were filled by Dr. Yasser
Abou Mourad, Dr. Birgit Christ, Dr. Richard Doocey, Dr. Genevieve Gallagher and Dr. Sharif
Khan.
Postdoctoral Training: Division Members conducting bench research at the TFL and UBC
trained 19 postdoctoral fellows, of whom 7 were PhD’s and 12 were MD’s.
Experimental Medicine: In the TFL, the Experimental Medicine Program accommodated 9
graduate students, one of whom held a MSFHR studentship.
Continuing Medical Education: Division Members attended numerous national and
international meetings both as attendees and speakers.
Research
Clinical research continued to be focused on hematological malignancies at VGH/VCC and
thrombosis at SPH. As well as in-house studies, significant contributions were made to national
and international trials. Laboratory research based at the TFL involved the regulation of normal
Page 60
Annual Report 2004
and malignant hematopoietic cell growth and differentiation with special emphasis on the
myeloid leukemias, Hox genes and telomeres. The molecular characterization of regulatory
pathways was the focus at UBC.
Clinical Services
The clinical services at VGH/VCC and SPH continued to cope with a high workload in terms of
both inpatient and outpatient activities. At SPH, Dr. Heather Leitch was appointed as a staff
hematologist and Dr. Leslie Zypchen provided locum coverage for a maternity leave.
Administration
Dr. Linda Vickars (Head of Hematology at SPH), Dr. Stephen Nantel (Director of the Clinical
Practice Unit for Hematology/BMT at VGH), Dr. Barrett Benny (Director of the Cell Separator
Unit at VGH), Dr. Peter Tsang (Director of the Hematology Training Program) and Dr. Charles
Li (Coordinator of Undergraduate Teaching) continued in leadership positions.
Future Directions
The main research goals will be to enhance activity at the laboratory/clinical interface in
hematological malignancy and to expand efforts in thrombosis. In addition, new initiatives, e.g.,
HIV-related lymphoma and collaborations, e.g., with the Centre for Blood Research at UBC will
be pursued. In regard to clinical services, a priority will be to achieve a full complement of
appropriately funded staff.
Dr. Donna Hogge – Served on the scientific review panel for the Leukemia Research Fund of
Canada
Dr. Keith Humphries – 20 Year Service Award, Terry Fox Laboratory, BC Cancer Agency
Dr. John Schrader – Distinguished Scientists Distinction, awarded by the Canadian Society for
Clinical Investigation
Dr. Clayton Smith – Named to “Celebrating Scholarships”, Academic Excellence at UBC
Dr. Peter Tsang – Professional Association of Residents – British Columbia Award for
Excellence in Clinical Teaching
Dr. Linda Vickars – President, North Pacific Society of Internal Medicine
Page 61
Annual Report 2004
INFECTIOUS DISEASES
Dr. Neil E Reiner, Professor & Head
Dr. H Grant Stiver, Professor & Assistant Head
Faculty Members
Professor & Head
Professor & Assistant Head
Professor
Professor
Professor
Professor
Associate Professor
Associate Professor
Associate Professor
Assistant Professor
*Assistant Professor
Assistant Professor
Assistant Professor
Assistant Professor
Clinical Professor
Clinical Professor
Clinical Professor
Clinical Professor
Clinical Instructor
Associate Member
Associate Member
Associate Member
Associate Member
Associate Member
Associate Member
Associate Member
Adjunct Professor
Visiting Scientist
Reiner, Dr. Neil
Stiver, Dr. H.
Bowie, Dr. William
Brunham, Dr. Robert
Chow, Dr. Anthony
Montaner, Dr. Julio
Av-Gay, Dr. Yossef
Phillips, Dr. Elizabeth
Tyndall, Dr. Mark
Cherkasov, Dr. Artem
de Haan, Dr. Marie
Grigg, Dr. Michael
Hmama, Dr. Zakaria
Steiner, Dr. Theodore
Burdge, Dr. David
Chan, Dr. Robert
Phillips, Dr. Peter
Rekart, Dr. Michael
Harrigan, Dr. Paul
Montessori, Dr. Valentina
Press, Dr. Natasha
Wood, Dr. Evan
Reynolds, Dr. Robert
Isaac-Renton, Dr. Judith
Jewesson, Dr. Peter
Marra, Dr. Fawziah
McMaster, Dr. Robert
Money, Dr. Deborah
O'Shaughnessy, Dr. Michael
Patrick, Dr. David
Sanghera, Dr. Jasbinder
Lopez, Dr. Martin
Page 63
VA
VA
VA
UBC/BCCDC
VA
SPH
VA
SPH
SPH
VA
VA
VA
VA
VA
C&W Health Centre
SPH
SPH
BCCDC
SPH
SPH
SPH
SPH
VA
BCCDC
VA
BCCDC
C&W Health Centre
C&W Health Centre
SPH
BCCDC
Vancouver
VA
Annual Report 2004
Visiting Scientist
Visiting Scientist
Papavinasasundaram, Mr.
Kadambavanasundaram
Shamir-Elron, Dr. Yael
VA
VA
*Inactive Member
Divisional Overview
Growth and achievements in the Division of Infectious Diseases in the past year can be attributed
to a highly industrious faculty which now includes 16 MD’s and 5 PhD’s who are located at
Vancouver General, St. Paul’s and BC Children’s and Women’s Hospitals as well as at the
BCCDC. Among the faculty are nationally and internationally recognized investigators with
expertise and interests in areas including microbial pathogenesis, host defense, microbial
genomics, HIV, clinical epidemiology, sexually transmitted diseases, respiratory, urinary tract,
fungal infections, and vaccine studies.
The Division was pleased to welcome Dr. Elizabeth Phillips who was recruited from the
University of Toronto/Sunnybrook Hospital to an Associate Professor position based at SPH. As
Head of Clinical Pharmacology within the BC Centre for Excellence in HIV/AIDS, she is
responsible for Clinical Pharmacology and Toxicology. Robert Chan, a longstanding faculty
member, returned to private practice in downtown Vancouver after an extended period working
in Hong Kong.
An External Review of the Division acknowledged significant developments and
accomplishments that have taken place over the past ten years, particularly in research. The
Review recommendations recognized and provided support for the challenges which lie ahead,
including faculty recruitment, salary support, and replacement of research space.
Teaching
Teaching continues to be a major strength of the Division of Infectious Diseases. Members of
the Division make substantial contributions to the education of undergraduate and postgraduate
students, residents and fellows from the Faculty of Medicine. In addition, as many as 15 visiting
undergraduate and postgraduate medical students and residents representing most Canadian
medical programs received elective training in Infectious Diseases at Vancouver General
Hospital and St. Paul’s Hospital this year.
Undergraduate: The Division’s significant commitment to undergraduate teaching includes the
highly regarded Host Defense Infection Block in the Problem Based Learning course. Clinical
Clerkship Half Days and inpatient rotations are also highly regarded by students. Dr. Grant
Stiver continues his significant contribution to the Program as Director of Undergraduate
Education for the Faculty of Medicine.
Postgraduate: Among the strengths of the Residency Training Program are the leadership of
Dr. Valentina Montessori, Program Director, (shared with Dr. Grant Stiver during Dr.
Montessori’s maternity leave this year), and the outstanding caliber of the Infectious Diseases
Subspecialty trainees. The two year Royal College Subspecialty Training Program provides high
Page 64
Annual Report 2004
quality clinical and research training in order to equip fellows for an academic career in
infectious diseases. Dr. Richard Lester won the Best Poster Prize at Residents Research Day
(Staphylococcal heat shock protein 60 – responses in innate immune cells). Since completing
his training he has begun a position in Kenya, in a University of Manitoba sponsored HIV
Research Program. Senior ID Fellow, Dr. Mark Hull was joined in the Program by Drs. Ghassan
Wali, and Abeer Alshukairi in July. Dr. Julie Stone, an OB/GYN specialist, began a year of
Infectious Diseases training under the joint supervision of Drs. Valentina Montessori and
Deborah Money. Training at the residency level included inpatient and outpatient rotations at St
Paul’s Hospital and Vancouver General Hospital for 49 residents from Medicine, Dermatology,
Neurology, Medical Microbiology, Anaesthesia and Pharmacy.
Graduate Students: Through Experimental Medicine as well as the Departments of Laboratory
Medicine and Microbiology and Immunology, Infectious Diseases Faculty supervised 20
graduate students and 10 post doctoral research fellows at Vancouver General Hospital, BCCDC
and St Paul’s Hospital. As well, Kenna Sleigh, an RN who has been active in clinical research
with Grant Stiver for many years, received her PhD.
UBC MD/PhD Program: Dr Anthony Chow is a Director of the UBC MD/PhD Program
jointly administered by the Faculty of Medicine and the Faculty of Graduate Studies. This
integrated combined degree program prepares the students to pursue a research-intensive track of
residency and postdoctoral training in a specialty or discipline of their choice, ultimately leading
to an independent clinician-investigator career. The program enrolled 13 trainees this past year,
engaged in a wide range of research including: cancer, cardiovascular disease, lipid metabolism,
infectious disease pathogenesis, gene mutations and chromosomal abnormalities, host defense
mechanisms, and social factors that determine access to health care. MD/PhD students have won
prestigious awards such as the BC Cancer Research Centre Lloyd Skarsgard Research
Excellence Prize, Canadian Society for Clinical Investigation’s Young Investigator Award,
Western Society for Clinical Research Student Medical Research Forum Best Oral Presentation
Award.
TRID Program: Dr. Anthony Chow is also Director of the CIHR-UBC Strategic Training
Program for Translational Research in Infectious Diseases (TRID). Specific aims of this Program
are: 1) To promote and strengthen the national capacity for translational research in infectious
diseases through an integrative training program encompassing all 4 pillars of health research as
defined by CIHR and MSFHR; 2) To raise the national standards in the training of health
researchers, and 3) To cultivate and facilitate transdisciplinary and translational research in
infectious diseases. Trainees include undergraduate co-op and summer research students,
MD/PhD students, PhD students, and postdoctoral research fellows. In 2004 the Program
administered 34 TRID studentships or fellowships involving 25 TRID faculty members. TRID
trainees published 3 and submitted 7 papers, and presented 33 conference presentations. TRID
held two thematic research symposia “Deciphering Global Host-Microbe Interactions”, and
“Application of Basic and Clinical Research to Epidemiological Problems”. For details of TRIDsupported
students,
their
research
supervisors,
and
research
projects
http://cmdr.ubc.ca/trainingprogram.
Continuing Medical Education: Dr. Joshua Fierer, Professor of Medicine and Chief, Division
of Infectious Diseases, University of California at San Diego, was a Visiting Professor sponsored
Page 65
Annual Report 2004
by the UBC TRID Program and the Division. He presented his research on Coccidiomycosis at a
special seminar, and also met with faculty, students and fellows. A special presentation on
Prevention of fungal infections post-BMT was given by another invited guest, Dr Kieren Marr,
from the University of Washington, and Program in Infectious Diseases, Fred Hutchinson Cancer
Research Center. The weekly Academic Rounds Plenary Presentations included visiting
speakers Drs. George Zhanel and Daryl Hoban, Medical Microbiologists from the University of
Manitoba.
Research
As noted in the External Review of the Division, “The Division has a strong record of
achievement in research. The recruitment of five basic scientists to the Division makes this one
of the strongest ID divisions in the country.” The total amount of research grant funding
awarded to division faculty at all sites in Vancouver for the year was in the range of $5.5 M.
Immunity and Infection Research: The Division maintains an active basic research program in
molecular microbial pathogenesis and host defense. Pathogens under study included M.
tuberculosis, Leishmania, Toxoplasma, E. coli, Staphylococci, Streptococci and Chlamydia. In
addition to addressing mechanisms of pathogenesis, ongoing research is concerned with both
innate and acquired immune responses to infection including vaccine development. The
Division’s research program has an important bioinformatics focus with additional state-of-the
art expertise in molecular modeling and computer-aided drug design.
HIV/AIDS Research Program: The AIDS Research Program, which involves seven faculty
members at the St. Paul’s site, continues to study the role of antiretroviral therapy for the
treatment of HIV infection. The main areas of research encompass epidemiology, clinical
management and basic sciences. The epidemiology group has been actively developing and
maintaining long-term analyses of drug treatment programs in Vancouver including harm
reduction strategies. The group has been investigating the natural history of injection drug use
including: study of HIV and Hepatitis C and other hazards related to injection drug use, scientific
evaluation of North America’s first supervised injection site, examination of illicit opiate
addiction, treatment and policy in Canada. The clinical science research focuses on issues
important to the medical management of patients with HIV including multidrug-resistant virus,
pharmacokinetics of antiretrovirals, and adherence to antiretroviral therapy regimens, drug
toxicities, viral co-infections and primary care initiatives. The basic science program has a major
focus on HIV resistance to antiretroviral therapy and mechanisms of toxicity. Other research
within the Program includes pathophysiology and management of hypersensitivity reactions and
adverse drug reactions associated with antiretroviral drugs; genetic screening and diagnostic
testing for hypersensitivity reactions associated with antiretroviral therapy; mitochondrial
toxicity of antiretrovirals, hepatitis C therapy in HIV/HCV co-infected patients; liver disease
associated with HIV/HCV co-infected patients; and observational studies of HIV-related immune
reconstitution syndromes.
Epidemiological Research: Dr. Bill Bowie is a co-investigator, along with Dr. Jerry Spiegel, for
a CIDA operating grant of $5M for 7 years which is entitled Sustainably managing
environmental health risks. He is also a co-applicant for a CIHR funded initiative – The spread
Page 66
Annual Report 2004
and evolution of SARS corona viruses through contact networks: prediction, recognition and
control.
Clinical Research: Dr. Grant Stiver continues his timely research in respiratory tract infections,
particularly influenza and FluInsure vaccine efficacy. Other current trials include assessment of
a new antibiotic Telavacin against MRSA skin and soft tissue infections and Gram positive
nosocomial pneumonia, as well as further studies on oral gel formulations to treat C. difficile
colitis.
Clinical Services
The Division maintains two highly active and intense consultation services, one located at SPH
and one at VGH. In addition, an AIDS inpatient service based at SPH is also staffed by ID
physicians. The consultation services see the usual full range of general ID cases. At the same
time, there is a particular wealth of clinical material related to reconstructive orthopedics
including spine, neurosurgery, bone marrow and solid organ transplant, tuberculosis, infections
related to IVDU and infections in other marginalized populations.
Future Directions
- Development of recruitment plans is recognized as being critical, especially as the medical
school expansion begins to increase the teaching component of activities.
- Development of a definite relocation plan for the VGH Division including research laboratory
space.
Dr. Robert Brunham – Thomas Parran Award from The American Sexually Transmitted
Diseases Association, and was a member of the National Advisory Committee for the Toronto
Conference on Global Infectious Diseases
Dr. Anthony Chow – Canadian Infectious Disease Society Janssen-Ortho Distinguished Service
Award
Dr. Julio Montaner – Distinguished Service Award, Department of Medicine, St. Paul’s
Hospital
Dr. Mark Tyndall – Promoted to Clinical Associate Professor
Page 67
Annual Report 2004
MEDICAL ONCOLOGY
Dr. Susan E. O'Reilly
(on sabbatical)
Dr. Joseph M. Connors
(June 2004 – February 2005)
Faculty Members
Assistant Professor
Assistant Professor
Assistant Professor
Assistant Professor
Clinical Professor
Clinical Professor
Clinical Professor
Clinical Professor
Clinical Professor
Clinical Professor
Clinical Professor
O'Reilly, Dr. Susan
Connors, Dr. Joseph
Chi, Dr. Kim
Chia, Dr. Stephen
Gill, Dr. Sharlene
Savage, Dr. Kerry
Gelmon, Dr. Karen
Hoskins, Dr. Paul
MacLean, Dr. Grant
Murray, Dr. Robert Nevin
Shah, Dr. Amil
Swenerton, Dr. Kenneth
Weinerman, Dr. Brian
Coppin, Dr. Christopher
Klasa, Dr. Richard
Klimo, Dr. Paul
Ragaz, Dr. Joseph
Wilson, Dr. Kenneth
Allan, Dr. Sharon
Anderson, Dr. Helen
Bernstein, Dr. Vanessa
Bryce, Dr. Cicely
Gill, Dr. Karamjit
Page 69
BCCA/Vancouver
BCCA/Vancouver
BCCA/Vancouver
BCCA/Vancouver
VA
VA
BCCA/Vancouver
BCCA/Vancouver
BCCA/Victoria
BCCA/Vancouver
BCCA/Vancouver
BCCA/Vancouver
BCCA/Victoria
BCCA/Fraser Valley
BCCA/Vancouver
Lion’s Gate Hospital
BCCA
BCCA/Victoria
BCCA/Victoria
Victoria
BCCA/Victoria
BCCA/Vancouver
Surrey
Annual Report 2004
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Honorary Professor
Associate Member
Associate Member
Khoo, Dr. Kong
Knowling, Dr. Margaret (Meg)
Laskin, Dr. Janessa
Lee, Dr. Ursula
MacPherson, Dr. Nicol
Melosky, Dr. Barbara
Noble, Dr. R.
Norris, Dr. Brian
Sawhney, Dr. Ravinder
Sehn, Dr. Laurie
Shenkier, Dr. Tamara
Stuart, Dr. David
Taylor, Dr. Marianne
Bouttell, Dr. Elaine
Ellard, Dr. Susan
Fenton, Dr. David
Fitzgerald, Dr Catherine
Lee, Dr. Christopher
MacNeil, Dr. Mary
Martin, Dr. Lee Ann
Martins, Dr. Heidi
Souliere, Dr. Sheila
Sutherland, Dr. Judith
Bruchovsky, Dr. Nicholas
Brigden, Dr. Malcolm
Ling, Dr. Victor
Goldie, Dr. James
Klaassen, Dr. David
Plenderleith, Dr. Ian
Silver, Dr. Hulbert
BCCA/Kelowna
BCCA/Fraser Valley
BCCA
BCCA/Fraser Valley
BCCA/Victoria
BCCA/Vancouver
RCH
BCCA/Fraser Valley
BCCA/Fraser Valley
BCCA/Vancouver
BCCA/Vancouver
Burnaby
BCCA/Victoria
Kelowna
VA
BCCA/Kelowna
BCCA/Victoria
BCCA/Fraser Valley
BCCA/Victoria
BCCA/Fraser Valley
BCCA/Victoria
Victoria
BCCA/Kelowna
BCCA/Emeritus
Victoria
BCCRC
BCCA/Emeritus
BCCA/Emeritus
BCCA/Emeritus
BCCA/Emeritus
Divisional Overview
The Division of Medical Oncology, UBC, comprises the Medical Oncology and scientific staff at
the Vancouver Center, Fraser Valley Center, Surrey, Vancouver Island Center, Victoria and the
Center for the Southern Interior, Kelowna, as well as community oncologists in Burnaby, North
Vancouver, Nanaimo and the Royal Columbian Hospital, New Westminster.
In addition to the clinical division, there is a laboratory section (Advanced Therapeutics), which
is located in the British Columbia Cancer Research Center. It comprises four senior scientists
and six clinical investigators who have appointments at the Vancouver Cancer Center,
Department of Medical Oncology.
Medical Oncology clinical services are organized as a Provincial Systemic Therapy Program
reaching across the Province of British Columbia including the four cancer centers and outreach
programs in more than ten additional community hospitals in smaller urban centers.
Undergraduate and postgraduate teaching occurs primarily at the Vancouver Cancer Center with
Page 70
Annual Report 2004
additional elective opportunities available at all four cancer centers including Victoria, Fraser
Valley and Kelowna. UBC clinical faculty at all centers participate in undergraduate teaching
modules.
The next five years will pose some exciting challenges and opportunities. More medical
oncologists and hematologists specializing in neoplastic diseases will be needed to address the
rising incidence of cancer, related to the aging population and, even more importantly, the
increasingly complex treatment programs incorporating new targeted small molecules and
immunotherapeutic agents. Adding to the challenges of increased incidence and treatment
complexity is the very high cost of new therapeutic agents. For example, the current standard of
practice for metastatic colorectal cancer treatment has changed from simply administered single
agent chemotherapy to complex multi-agent programs costing more than 100 times as much in
just the last five years. Expanded opportunities for clinical and translational research is readily
available based on the rapid emergence of new knowledge in cancer biology especially insights
derived from genomic and gene expression studies.
The new $100,000,000 B.C. Cancer Research Center building opened in early 2005. This stateof-the-art research facility houses a wide range of laboratory research programs including
molecular oncology, the Terry Fox Laboratory focusing on hematologic cellular biology and
leukemias and core programs in genomic analysis, gene expression profiling, novel imaging and
tumor modeling and population based epidemiology and biostatics. The BC Cancer Agency
Genome Sciences Centre has moved into a large laboratory facility nearby but continues to forge
collaborative projects with several tumor groups within Medical Oncology including breast
cancer, gastrointestinal cancer and lymphoproliferative neoplasms.
Teaching
The Medical Oncology Undergraduate Training Committee, chaired by Dr. Amil Shah is active
in providing and planning teaching modules and clinical bedside teaching in Internal Medicine.
An elective in Medical Oncology is available to UBC and visiting medical students.
The Postgraduate Training Committee, chaired by Dr. Tamara Shenkier, offers popular twomonth electives in Medical Oncology to internal medicine residents from UBC and other
universities. Approximately 10-16 residents per year from these and other specialty disciplines
spend elective periods at the Vancouver Cancer Center. Opportunities are available for electives
at all of our regional cancer centers and some financial support for travel and accommodation is
available for residents choosing one of these options.
The Postgraduate Training Committee also plans and supervises the two-year subspecialtytraining program in Medical Oncology. This program is based at the Vancouver Cancer Center
with elective opportunities at all other centers and in community oncology practice. The sixmonth elective period may also be applied to laboratory or clinical research. One or two month
electives at centers elsewhere in Canada or in other countries may also be considered. This
program, now one of the largest two such programs in Canada, has expanded to enroll four first
year and four second year residents and is fully approved by the Royal College of Physicians and
Surgeons of Canada and has consistently received excellent reviews. Additional training
positions for overseas residents result in eight or nine trainees participating in this two-year
Page 71
Annual Report 2004
program at any one time. Currently, residents participate in academic oncology training with
excellent exposure to clinical practice, ambulatory care and clinical trials. Residents are
expected to conduct clinical research and have a number of publications and presentations to
their credit. At least half of our residents from each year recently have competed successfully
for post-residency academic subspecialty fellowships that have launched them on promising
academic careers. Opportunities to pursue laboratory research projects are available.
Continuing Medical Education: All medical staff are active in continuing medical education
courses organized by the British Columbia Cancer Agency, other provincial, national and
international bodies. Several of our faculty members have emerged as international leaders in
their field and are actively sought out to provide leadership within the major international
societies including the American Society of Clinical Oncology, the American Society of
Hematology and the American Association for Cancer Research in addition to their contributions
to the National Cancer Institute of Canada and its Clinical Trials Group.
Research
Members of the Division are involved in a wide variety of phase I, II, III and IV clinical trials.
These include the development of new anti-cancer drugs, the evaluation of new doses schedules
and combinations of drugs in the phase II setting and the participation in multi-institutional phase
III studies and post marketing phase IV trials evaluating effective new treatments on specific
categories of malignancy.
Our phase I investigational new drug program has grown rapidly as a reflection of the energy and
enthusiasm of the scientists and physicians in the Advanced Therapeutics section of Medical
Oncology and in response to the increasing availability of new agents for testing in North
America.
Our Advanced Therapeutics Section is able to evaluate new biological response modifiers, gene
therapy and pharmaceutical agents through all stages from in-vitro testing in the laboratory to
evaluation in human volunteers. The Vancouver Cancer Center has the only Clean Room in an
academic center in Canada that is equipped and licensed for the packaging and formulation of
pharmaceutical agents in small quantities for clinical testing.
At the pre-clinical level, studies are being carried out in evaluating anti-angiogenesis agents,
gene modifiers, enzyme inhibitors, experimental drug modulators, pre-clinical drug toxicities and
molecularly targeted agents such as the new tyrosine kinase inhibitors, immunotherapeutic
agents targeted against breast cancer, colorectal cancer, lung cancer and lymphomas. Currently,
the BCCA manages its own grants and these are not listed in this report.
Clinical Services
The four B.C. Cancer Centers now provide medical oncology consultations for 7,000 new
patients annually with more than 50,000 ambulatory care visits to these centers. The Provincial
Systemic Therapy Program, headed by Dr. Susan O’Reilly manages the $80,000,000 oncology
drug budget, which supports the care of more than 24,000 patients annually, both within BCCA
centers and in community hospitals. Opportunities for health services research projects are
Page 72
Annual Report 2004
available and linkages with the Provincial Tumour Registry and Vital Statistics are readily
available. We are uniquely positioned to further develop province-wide population-based
research in health outcomes for cancer patients and regularly take advantage of this special
opportunity.
Future Directions
The major academic goal of the Division is to continue to build an outstanding translational
research unit that combines the excellent basic science research at the British Columbia Research
Center, the input from the Genome Science Centre, the resources of our academic medical
oncologists and the participation of our large patient population.
British Columbia has consistently shown the best cancer survival statistics in Canada and we are
in a unique position to carry out province-wide treatment programs in both clinical and
translational research. We are continuously expanding our research agenda in these areas and in
those of health outcomes and economic analyses.
Page 73
Annual Report 2004
NEPHROLOGY
Dr. Paul A. Keown
Professor & Head
Faculty Members
Professor & Head
Professor
Professor
Assistant Professor
Clinical Professor
Clinical Professor
Clinical Professor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Keown, Dr. Paul
Quamme, Dr. Gary
Wong, Dr. Norman
Gill, Dr. John
Chan-Yan, Dr. Clifford
Levin, Dr. Adeera
Werb, Dr. Ronald
Chan, Dr. Victor
Landsberg, Dr. David
Shapiro, Dr. Jean
Taylor, Dr. Paul
Yeung, Dr. Choi Kit
Chiu, Dr. Anthony
De Luca, Dr. Linda
Duncan, Dr. John
Jastrzebski, Dr. Jacek
Kiaii, Dr. Mercedeh
Singh, Dr. Rajinder
Copland, Dr. Michael
Jamal, Dr. Abeed
Jung, Dr. Beverly
Cameron, Dr. Eugene
Price, Dr. John
Sutton, Dr. Roger
Rae, Dr. Angus
VA
VA
VA
SPH
SPH
SPH
SPH
RCH
SPH
VA
SPH
VA
SPH
SPH
VA
VA
SPH
VA
VA
SPH
SPH
VA
VA
VA
SPH
Divisional Overview
The Division of Nephrology includes 21 members based at three principal sites: St. Paul’s
Hospital, Vancouver General Hospital, and the UBC Campus, who provide provincial leadership
in research, education, and clinical care within the field of renal medicine. The Division has a
strong clinical base and provides integrated and decentralized nephrology care throughout
Page 75
Annual Report 2004
Vancouver Coastal Health including Richmond, North Vancouver and coastal areas. The
Division has an important role in the UBC undergraduate medical curriculum, and has one of the
largest nephrology postgraduate training programs in Canada. Research activities range from
genetic and molecular sciences to innovative trials in renal disease and transplantation, with
novel measures of health status and economic outcomes. Members of the Division assume
leadership roles in the advancement of nephrology at provincial, national and international levels
through their positions in the BC Provincial Renal Agency, BC Transplant Society, the Kidney
Foundation of Canada, the Canadian and International Societies of Nephrology, the International
Transplantation Society, and US National Kidney Foundation.
Teaching
Undergraduate: Division of Nephrology members have contributed significantly in developing
and implementing the medical school’s distributed curriculum in 2004/5. From first year to
fourth year clinical exams, they have been involved in all areas of undergraduate education.
In the first phase (P2P1), Dr. Suneet Singh and Dr. Mike Copland give physiology lectures
laying the groundwork for the curriculum blocks to follow. In the second phase (P2P2), Dr.
Suneet Singh is the key person in the development and delivery of five week FERGU block. She
is the week 4 chair and week 5 co-chair. She works with Dr. Colin White (block chair) in the
design and coordination of the block. Teachers in the block include Dr. Mike Copland, Dr.
Mercedeh Kiaii, Dr. Adeera Levin, Dr. Clifford Chan-Yan and Dr. Abeed Jamal. The
Nephrology subspecialty residents are also involved in the clinical case sessions.
In the clinical years, members of the Division contribute to the academic half days, bedside
teaching and oral examinations for the medical students. Dr. Ron Werb, Dr. Anthony Chiu, Dr.
John Duncan, Dr. Abeed Jamal, Dr. Paul Taylor, Dr. Mercedeh Kiaii, Dr. Beverly Jung and Dr.
Suneet Singh are prominent clinicians in these areas.
Dr. Singh was a member of the Medical School Admissions Committee in 2004. Dr. Abeed
Jamal participated in the newly formed 4th Year Curriculum Committee. Dr. Singh and Dr.
Levin coordinate medical student rotations through Nephrology at the VGH and SPH sites
respectively, with Dr. Jamal being the students’ contact, along with administration staff at both
sites, for electives and selectives. These rotations receive excellent evaluations and many
students return as residents.
Postgraduate: After several years successfully crafting an outstanding training program, Dr. A.
Levin handed the reins over to Dr. J. Duncan who took over the role of Director of the
Postgraduate Training Program in Nephrology in July 2004. The Division is proud of the
excellent trainees currently enrolled in the first year (four) and the second year (one) of core
nephrology training and one in the UBC American Society of Transplantation Renal Transplant
Fellowship Program. We look forward to welcoming three more outstanding trainees to our
program in 2005. There are also three trainees continuing post-fellowship research training at
UBC, Harvard and Oxford Universities.
Residents and fellows remain active in clinical research with submission and presentation of
abstracts at meetings of the American Society of Nephrology, the Canadian Society of
Page 76
Annual Report 2004
Nephrology, the American Society of Transplant Physicians, the Canadian Transplant Society,
and the UBC Resident Research Day. Current fellows continuing training hold funding from the
Clinician Investigator Program of the University of British Columbia (Debbie Rosenbaum, and
Nadia Zalunardo), the Kidney Foundation of Canada (Jennifer Macrae) and competitive
applications have been submitted for continued funding from the Michael Smith Foundation, the
Kidney Foundation of Canada, and the KRESCENT program.
Experimental Medicine: Dr. Norman Wong stepped down in June 2004 after serving 10 years
as the Director of the Experimental Medicine Program. His successor is Dr. Vincent Duronio
(see separate report). This Program had 117 trainees including those supervised by Dr. Paul A.
Keown.
Continuing Medical Education: The annual BC Nephrology Day was held in October 2004.
This was a highly successful multidisciplinary meeting attracting over 300 participants from all
renal care dialysis centers in British Columbia.
Members of the Division participated in Continuing Medical Education activities at the local,
provincial, national and international levels. Drs. Duncan, Copland, Landsberg and Gill were
involved in a number of CME activities for both general practioners, internists and subspecialists
within and outside the Vancouver area. In addition, CME activities organized for patients and
caregivers, by both the Kidney Foundation and other groups, highlighted divisional members in
culturally sensitive environments.
Included in CME activities are those activities created by and for the division: divisional rounds
have been re-organized to ensure twice-monthly scheduling of visiting and divisional speakers.
All divisional members participate in Fellow’s rounds for the division, and have been asked to
speak at various subspecialty rounds (Internal Medicine, Cardiology).
Drs. A. Levin and P. Keown maintained active speaking schedules in national and international
meetings, presenting both reviews of key topics and original research.
Research
Clinical Research: The clinical research in the Division of Nephrology emphasized outcomes
research and clinical trials. The Division was actively involved in both industry-sponsored and
peer-reviewed research in the areas of chronic kidney disease, dialysis and transplantation.
Division members held grants from the Kidney Foundation grants, BC Research, BC Transplant
Foundation, Michael Smith Foundation for Health Research, and other operating grants.
The scope of clinical research included patient care prior to dialysis, cardiovascular disease in
patients with kidney disease - determinants of outcomes and severity, vascular access monitoring
and tracking programs, the relationship of monitoring systems to patient outcomes, mineral
metabolism and patient outcomes, the evaluation of new medications on patient parameters, the
evaluation of new immunosuppressive medications on transplant outcome, gender studies in
renal disease, and ethics studies related to genetic identification of polycystic renal disease.
Page 77
Annual Report 2004
Basic Research: The laboratory of Dr. N. Wong studies the role of vasoactive peptide in
regulating the expression of vasopressin V2 receptor expression in the inner medullary collecting
duct of the kidney. Dr. G. Quamme’s laboratory continues research on the magnesium response
element that controls magnesium transport. Dr. P. Keown’s research projects funded by the
Michael Smith Foundation for Health Research and Genome Canada include the genetic control
of immune response in transplantation and arthritis, analysis of immune response gene
polymorphisms, genomic and proteomic analysis in organ transplantation, and
immunopharmacokinetics and dynamics.
Administration
Dr. Eugene C. Cameron stepped down in 2004 after serving 10 years as Head of the Division of
Nephrology. His successor is Dr. Paul A. Keown. Dr. Keown is Professor of Medicine, Director
of Immunology, and Director, VCH Regional Renal Program, Departments of Medicine,
Pathology and Laboratory Medicine. Dr. Keown graduated in Medicine from the University of
Manchester, and pursued postgraduate training in England, France, and Canada. He holds
research Doctorates in both Medicine and in Science from the University of Manchester, and an
MBA from Simon Fraser University in British Columbia. Dr. Keown's research focuses
particularly on the immune response in transplantation and autoimmune disease, and ranges from
molecular genetics to healthcare economics.
Future Directions
The Division will continue to build on its strengths to ensure the highest quality of academic and
clinical activity for the University, the health system, and the community. It is anticipated that
the Division will take a major role in Renal & Fluid and Electrolyte teaching in the expanded
Medical School, continue leadership in nephrology postgraduate education, pursue integration of
laboratory and clinical research in nephrology, and introduce innovative initiatives in the
delivery of care to patients with renal disease.
Special Honors and Awards
Dr. Gary Quamme
The Martin M. Hoffman Award for Excellence in Research in
2004, Department of Medicine, UBC
Dr. Clifford Chan-Yan
The Master Teacher Award for 2004, Department of Medicine,
UBC
Dr. Paul A. Keown
Bringing Clinical Renown to VA Award
Dr. Paul A. Keown
2004 Genome Canada Award
Dr. John Gill
Michael Smith Clinical Investigator Award
Page 78
Annual Report 2004
NEUROLOGY
Dr. Howard Feldman
Professor & Head
Faculty Members
Professor & Head
Professor
Professor
Professor
Professor
Professor
Professor
Professor
Associate Professor
Associate Professor
Assistant Professor
Assistant Professor
Assistant Professor
Assistant Professor
Feldman, Dr. Howard
Barton, Dr. Jason
Doudet, Dr. Doris
Oger, Dr. Joel
Pelech, Dr. Steven
Stoessl, Dr. A
Tsui, Dr. Joseph
Wang, Dr. Yu Tian
Kastrukoff, Dr. Lorne
McKeown, Dr. Martin
Hsiung, Dr. Robin
Lee, Dr. Chong
Spacey, Dr. Sian
Tremlett, Dr. Helen
Hooge, Dr. John
Javidan, Dr. Manouchehr
Jones, Dr. Michael
Krieger, Dr. Charles
Robinson, Dr. Gordon
Beckman, Dr. Jeff
Briemberg, Dr. Hannah
Clarke, Dr. Stephen
Foti, Dr. Dean
Gibson, Dr. Gillian
Johnston, Dr. Dean
Keyes, Dr. Robert
Martzke, Dr. Jeffrey
Mezei, Dr. Michelle
Prout, Dr. Alister
Teal, Dr. Phillip
Thiessen, Dr. Brian
Traboulsee, Dr. Anthony
Page 79
VA
VA
VA
VA
VA
VA
VA
VA
VA
VA
SPH
VA
VA
VA
SPH
VA
VA
VA
VA
VA
VA
SPH
VA
VA
SPH
SPH
VA
VA
SPH
VA
VA
VA
Annual Report 2004
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Associate Member
Associate Member
Associate Member
Associate Member
Associate Member
Associate Member
Associate Member
Associate Member
Associate Member
Associate Member
Associate Member
Adjunct Professor
Adjunct Professor
Adjunct Professor
Visiting Assistant Professor
Chapman, Dr. Kristine
Costantino, Dr. Anthony
Devonshire, Dr. Virginia
Hallam, Dr. Bradley
Murphy, Dr. Colleen
Smyth, Dr. Penelope
Tai, Dr. Charles
Tessler, Dr. Barry
Varelas, Dr. Michael
Woolfenden, Dr. Andrew
Anderson, Dr. Duncan
Forwell, Dr. Susan
Graeb, Dr. Douglas
Hurwitz, Dr. Trevor
Leavitt, Dr. Blair
Li, Dr. David
Moore, Dr. Wayne
Raymond, Dr. Lynn
Sadovnick, Dr. Adele
Stowe, Dr. Robert
Wilkinson, Dr. Rosemary
Bub, Dr. Daniel
Ruth, Dr. Thomas
Sossi, Dr. Vesna
Al-Araji, Dr. Adnan
Calne, Dr. Donald
Eisen, Dr. Andrew
Kim, Dr. Seung
Pate, Dr. Brian
Sweeney, Dr. Vincent
Anzarut, Dr. Andre
Bratty, Dr. Paul
Hashimoto, Dr. Stanley
Jones, Dr. David
Wong, Dr. Milton
SPH
VA
VA
VA
VA
VA
SPH
RCH
VA
VA
VA
VA
VA
VA
VA
VA
VA
UBC
VA
VA
VA
U Victoria
VA
VA
VA
VA
VA
VA
VA
SPH
VA
VA
VA
SPH
Divisional Overview
The Division of Neurology is the largest division within the Department of Medicine. It has its
major teaching, research and clinical activities at Vancouver General Hospital, UBC Hospital
and St. Paul’s Hospital. There are 40 Neurology faculty members whose primary appointment is
in the Division, with another 11 appointed as associate members, 2 as adjunct professors and 10
as emeritae.
The Division is nationally and internationally recognized for its clinical and research programs in
neurodegenerative, demyelinative, neuromuscular and cerebrovascular diseases. It has been
consistently very productive in obtaining peer reviewed grant funding, and makes important
Page 80
Annual Report 2004
contributions to both basic neuroscience and clinical neurological literature. This past year
divisional members published more than 115 papers in peer-reviewed journals. The Division
provides neurological care province wide including tertiary and quaternary care for a variety of
neurological disorders. The division has clinical outreach to many communities around the
province. Faculty are actively involved in teaching and supervising all levels of students and
trainees from undergraduate to post doctoral fellows.
Amongst the highlights for the Division in the past year has been the recruitment and arrival of a
number of full-time faculty who will be adding their clinical, teaching and research expertise to
the division. Dr. Jason Barton was recruited from Harvard to UBC in September 2004 to take up
a position as Tier II Canada Research Chair and Michael Smith Scholar, as well as Section head
of the division of Neuro-ophthalmology. His research activities will center on cognitive
neuroscience with collaborations within the Brain Research Center and with a number of
divisions and departments across the university. Dr. Robin Hsiung, has been recruited to the
Division to work at the interface of neurogenetics and neurodegenerative diseases particularly
the dementias. He has completed a Michael Smith post-doctoral fellowship prior to taking up this
junior faculty appointment in the Division. He will be contributing clinically within the SPH
division and will be attending at the UBCH Alzheimer Clinic. Dr. Hannah Briemberg was
recruited from Harvard to UBC to take up a clinical faculty appointment in the Neuromuscular
Disease Unit. She completed her clinical fellowship training in neuromuscular diseases at the
Brigham Hospital where she had been appointed as junior faculty member. She will add
expertise within neuromuscular diseases and will be developing a research program in muscle
diseases.
The Division was deeply moved by the passing of Dr. Donald Paty at the end of 2004. Dr. Paty
had been Division Head from 1980-1996. He was an outstanding clinician scientist, educator and
administrator who created the academic tradition of the division both by his own example and by
his leadership. An Endowment Fund in his name is in place within the Division to honour his
accomplishments. It will provide funding to aspiring academic neurologists in the early years of
their career with the goal of building the academic mission of the Division.
Teaching
Undergraduate: Division members continue to be involved as PBL facilitators and teachers in
the Brain and Behaviour block during 2nd year, providing lectures and bedside sessions in
clinical skills. As in previous years student evaluations for the clinical skills sessions give
neuroscience tutors outstanding reviews. The Division is particularly grateful to the community
neurologists who have faithfully supported this teaching activity.
Seminars and bedside sessions are provided in 3rd year and a 4th year clerkship is available as an
elective/selective. The clerkship is based on an inpatient and outpatient experience allowing
students to take advantage of all of the resources within the Division. As well as UBC students
the clerkship attracts students from other medical schools in Canada and other countries.
Divisional members are an integral part of Phase VI providing curricula designed to encourage
critical evidence-based management of clinical problems.
Page 81
Annual Report 2004
Postgraduate: The Post Graduate Residency Training in Neurology is fully accredited with the
Royal College of Physicians and Surgeons. It currently has 16 residents at various levels of
training from PGY1 to PGY5. In the first two years of the program, the residents rotate through
various subspecialties in Internal Medicine, ICU, Emergency, as well as doing their first
Neurology rotations. The PGY3-5 years are core Neurology training years. Residents do their
inpatient training at Vancouver General Hospital and St. Paul's Hospital. Many outpatient
subspecialty clinics are done at UBC Hospital. During their training the residents in Neurology
are actively involved in various research projects. In 2004 there were 6 resident poster
presentations at various international meetings and 4 papers published in peer-reviewed journals.
Dr. Brian Buck, the chief resident in Neurology was awarded a Resident Scholarship Award for
the American Academy of Neurology Annual Meeting in 2004. A number of residents also
presented at the BC Neuroscience Day held in March 2004.
Dr. Colleen Murphy undertook a new teaching initiative within the Division in 2004, developing
a 32-hour course, which she presented to the residents from September 2003 to February 2004,
on Neuroanatomy and its applications within Neurology. This course was extremely highly rated
by the residents.
Fellowship Training and Awards: The Division of Neurology appointed the following
individuals to fellowship and post-doctoral fellowship training in 2004:
Multiple Sclerosis Program: Dr. Helen Tremlett (post doctoral fellow of the MS Society), Dr.
Penny Smyth and Dr. Cavit Boz (clinical fellow).
Alzheimer’s Disease and Related Disorders: Dr Claudia Jacova (CIHR and Michael Smith
Training Award) post-doctoral fellowship.
Parkinson’s Disease and Movement Disorders (Pacific Parkinson’s Research Center): Dr. John
Adams, Dr. Andre Troiano and Dr. Wing Lok Au (clinical fellows).
Basic Neuroscience Research: Dr. Nadege Chery, Dr. Tara Gaertner and Dr. Changiz
Taghibiglou (postdoctoral fellows).
Neuropsychology: Dr. Jane Kucera was appointed clinical fellow in Neuropsychology under the
supervision of Dr. Jeff Martzke.
Vancouver General Hospital Neurology Service (Clinical Teaching Unit)
The in-patient service at VGH consists of a 14 bed unit located on T5-B of the Pattison Pavilion.
This unit is the only dedicated in-patient Neurology clinical teaching unit (CTU) in the province
and has within its mandate the provision of tertiary care for complex neurological disorders. The
inpatient program features a specialized epilepsy monitoring unit (2 beds), a stroke service (6
beds) and an allotted 6 beds for general neurology. Life and Limb policies are in place for
accepting acute stroke patients, as well as neuromuscular disorders requiring plasmapheresis.
Over the last year substantial improvements to stroke care have been made within VGH. A very
large percentage of all stroke patients presenting or referred to VGH are now admitted to the
Page 82
Annual Report 2004
Neurology service for acute management during the first 5-7 days of their post stroke care. From
there the stroke pathway includes transfer to the UBCH Subacute Stroke Unit before moving on
to appropriate rehabilitation facilities or home. This has resulted in an increase in the number of
stroke patients cared for on neurology with a reduction in patients requiring a prolonged stay on
the unit.
The VGH and UBCH neurologists provide important consultation services within Vancouver
Acute. Neurological diagnostic services at VGH include electroencephalography (EEG),
intraooperative monitoring (IOM) and electromyography (EMG) are based at VGH.
Ambulatory services provided include subspecialty clinics for Movement Disorders, Multiple
Sclerosis, Alzheimer’s Disease and dementias, Stroke, Neuromuscular Disease, Amyotrophic
Lateral Sclerosis Epilepsy and Neuro-oncology. These clinics integrate with a strong research
environment for each of these programs, which in turn forms the core of the academic mission of
the Division. The clinics also provide important post-graduate educational activities for trainees
within the Division. There are subspecialist clinical neurologists within the division dedicated to
care of patients with headache (Dr. Gordon Robinson), pregnancy complications (Dr. Robert
Keyes) and HIV (SPH).
St. Paul's Hospital Division of Neurology
The St. Paul’s Hospital Division of Neurology is an important part of the clinical and teaching
program of the UBC Division of Neurology. Dr. Robert Keyes is the division head of SPH. This
division provides tertiary referral care for the Providence Health Care network as well as to the
province more widely. The SPH division participates in an important and extensive outreach
program to communities in northern BC and the Yukon territory. It is additionally involved in
providing inpatient consultation services to the Mount St. Joseph’s Hospital site and Women’s
Hospital. The division has opened an outpatient neurology clinic at the Mount St. Joseph’s
Hospital Site to meet the needs of the patient population it serves. At SPH there is a Rapid
Access Neurology Clinic where patients requiring urgent but not emergent care are seen and
provide clinical service especially to the patient population arising from the downtown core.
The members of the Division of Neurology at SPH includes a wide cross section of subspecialty
interests including clinical neurophysiology, neuromuscular disease, multiple sclerosis,
neurological diseases in pregnancy, cerebrovascular disease and neurological diseases in HIV
and AIDS. A close link between the Division of Neurology at SPH and the Department of
Pediatrics and the Department of Obstetrics continues by virtue of the subspecialty interests of
Dr. Keyes. The appointment of Dr. Robin Hsiung has added expertise in neurogenetics
especially in neurodegenerative disease. Dr. Hsiung will conduct lab research in collaboration
with the I-Capture Center at SPH.
Research
Alzheimer’s Disease and Related Dementias
Clinical Activities: The UBCH Alzheimer Clinic evaluated about 1000 patients in 2004 making
it one of the largest clinics of its kind in Canada. It is the main tertiary care referral center in BC
Page 83
Annual Report 2004
for dementia assessment. New referrals include a range of multidisciplinary assessments
including Genetics, Social Work, Neuropsychology, Geriatric Psychiatry and
Neurological/Medical.
The UBC Alzheimer’s Clinical Trials Program has been active in applications for peer-reviewed
grants in 2004. Success in CIHR funding for projects on Frontotemporal Dementia (3 years) and
Primary Prevention of dementia (1 year) has just been announced. The research unit will also
participate in an NIH project developing biomarkers for AD and related dementias (ADNI). This
50 million dollar initiative is one of the largest grants ever provided through NIH and continues a
line of collaborative research with the US Alzheimer research community reflecting the
international recognition of the unit.
Divisional faculty participating include: Dr. Howard Feldman (Director), Dr. Dean Foti, Dr. Jeff
Beckman, and Dr. Robin Hsiung. The research group includes: Dr. Lynn Beattie, Dr. Philip Lee,
Dr. Kiran Rabheru, Dr. Brad Hallam, Dr. Ian Mackenzie, Dr. Claudia Jacova (post-doctoral
fellow), Ms. Sandra Tam (data management core), Jacob Grand (graduate student) and Dr. Alan
Donald (statistician), and a dedicated group of research assistants and research coordinators.
The ACCORD study, a longitudinal multicenter cohort study of subjects referred with cognitive
symptoms received funding to complete final visit data on all subjects. This national study has
been led by the coordinating center at UBC. Dr. Howard Feldman is the National Principal
Investigator for this study.
Peer reviewed research funding from CIHR/Alzheimer Society of Canada has been ongoing for a
longitudinal study of novel MRI techniques in mild cognitive impairment (2002-4).
Clinical trials have continued to focus in the past year on studies of mild cognitive impairment as
a precursor state to AD, with completion of a series of large clinical trials investigating the
potential for delay of time to the diagnosis of AD. A core group of very experienced nurse
coordinators and research assistants are critical to the success of the clinical trials program.
Teaching and Education: The Clinic has been very active in providing teaching to trainees of
multiple disciplines at many levels. A formal one-day preceptorship training program for family
physicians and specialists is in place. Clinic members participated extensively in CME activities,
and on expert national international working groups and advisory committees. The Clinic is very
active in public education.
Stroke and Cerebrovascular Program
The VGH serves as the tertiary referral centre for stroke and cerebrovascular diseases in B.C. To
support this clinical role the VGH Stroke Program maintains a dedicated on-call system with the
commitment of six neurologists. A “Stroke Hot Line” pager system is available 24/7 to triage
patients from around the lower mainland and southern British Columbia. The VGH Stroke Team
consists of stroke neurologists, diagnostic and interventional neuroradiologists,
neurointerventional/neurovascular neurosurgeons, and vascular surgeons. The program provides
state-of-the-art care to cerebrovascular patients. Neuroradiology provides superb diagnostic and
interventional services. In cooperation with the BC Bedline the program has successfully
Page 84
Annual Report 2004
developed an acute stroke referral system for the provision of thrombolytic and interventional
stroke care.
The VGH Stroke Unit provides intensive care nursing for the treatment of acute stroke patients
who are critically ill or who have received interventional therapies. Organized delivery of stroke
care at the VGH and the development of a regional stroke care strategy will permit patients to
flow from the Acute Stroke Unit to the Subacute Stroke Unit to Rehab and reintegration into the
community. Efforts are now underway to develop a British Columbia Stroke Strategy in
collaboration with the Heart and Stroke Foundation.
The Stroke Prevention Clinic is busy two days a week and provides same day clinical and
diagnostic services to patients. This clinic provides a critical resource for patients at risk of
stroke and to emergency departments and physicians. Prompt and expert care reduces the need
for hospitalization through the rapid evaluation of patients.
The VGH Stroke Program has had an extremely busy year in educational activities. Vancouver
served as the host city for the 5th World Stroke Congress which attracted 2500 international
delegates. The 8th International Thrombolysis and Acute Stroke Meeting was held at Whistler as
a satellite meeting to the World Stroke Congress. Both meetings were widely acknowledged the
most successful held to date. The Annual Western Canada Stroke Conference was again highly
successful in its mission to provide stroke education to neurologists from B.C. and western
Canada. Weekly stroke rounds are held to provide education to residents and medical students.
Residents and students spend time in the Stroke Prevention Clinic evaluating and making
decisions on urgent cases. The Stroke neurologists continue to give Grand Rounds, medical
rounds and talks at CME events to educate physicians around the province. Public forums have
been held by the Heart and Stroke Foundation with the participation of stroke neurologists and
others. On an international level, members of the Stroke Program delivered posters and platform
presentations at the American Stroke Association meeting, the Canadian Congress of
Neurological Sciences, the American Academy of Neurology, and the European Stroke
Conference.
Multiple Sclerosis
The 2004 census of Clinic activity included 4517 active charts with 3239 patient visits during the
year and with 285 new patients confirmed to have Multiple Sclerosis.
There were several new faculty appointed to the Division with special expertise in MS. Dr.
Penelope Smyth completed her fellowship and was recruited to the division as clinical faculty to
assist in building the clinic core while Dr. Helen Tremlett (Ph.D PharmD) was appointed to the
division as Assistant Professor with a 5 year grant support from the Multiple Sclerosis Society of
Canada. Dr. Tremlett will be focusing her research on the side-effects of the immune modulatory
drugs and, in collaboration with Dr. V. Devonshire, has initiated a research program on the
natural history of multiple sclerosis using the COSTAR database created by Drs. Paty and
Studney. These appointments bring the Clinic to a faculty of 7 consultant neurologists (Drs. V.
Devonshire, S. Hashimoto, J. Hooge, L. Kastrukoff, J. Oger, P. Smyth and (A) T. Traboulsee.
There is an active recruitment process underway to fill an Endowed Chair in MS-MRI as well as
to replace Dr. Don Paty in providing academic leadership to the program.
Page 85
Annual Report 2004
Dr. Adnan Al-Araji completed his MS clinic fellowship (Dupré Fellowship from the
International Federation of Multiple Sclerosis London UK) and has taken up an appointment as a
Consultant Neurologist at the University Hospital of North Staffordshire in Stoke on Trent (UK).
The Clinic continues to maintain important interdepartmental collaborations to provide best care
to affected patients. In particular the close collaboration of Dr. A. Jiwa (psychiatric care), Dr. S.
Elliot (sexual medicine care), Drs. J. Barton and D. Anderson (for neuroophthalmologic care)
and neuro-urology.
The clinic has provided outreach to 3 satellite clinics in Victoria (800 patients registered),
Kelowna (600 patients), and Prince George (250 patients), as well as providing outreach through
clinic activities in Comox. Each clinic is organized in the local hospital under the umbrella of the
local health board around a full time coordinating nurse. The UBC consultants and local
neurologists work together in providing the highest quality MS care within a multidisciplinary
setting that includes critical contributions from Physiotherapy, Occupational Therapy and Social
work. The genetic counseling team provides an important resource to patients with their
activities that are centered at the UBC MS clinic office.
In collaboration with Pharmacare and with educational funding from the pharmaceutical industry
it has been possible to continue the valuable “MS Special Therapy” program to help educate
patients in the choice and management of adverse effects of Disease Modifying Therapies
(DMT). We are now following over 1500 treated patients.
Under the leadership of Sandra Burnham (PT) the Clinic has produced an educational videotape
for “newly diagnosed patients” which has already received international recognition.
The MS clinical trial group: Through this research program of the Clinic MS clinic patients can
participate in innovative clinical trials that have resulted in major advances in therapy. In 2004
clinical trials included a study of high dose interferon versus copaxone®. studies of new oral
immunosuppressors and modulators and vaccines to induce tolerance to myelin proteins.
Rehabilitation Programs: Our rehabilitation team has been very active in setting-up the website
of the International Consortium of MS Centers (T. Jiwa), as well as representing us on the
Editorial Board of the Journal of MS Care (S. Forwell). S. Forwell is now doing her PhD in OT
at UCSF (J.O. member of Committee) after focusing on MS fatigue (paper submitted). S.
Burnham (PT) has presented at the Consortium of MS Centers meeting. Sandy Burnham has
received the Silver Quill Award of the PT Association of Canada. Drs. Oger and Tremlett are
recipients of a research grant from the MS Society of Canada. This grant will permit Dr. Tremlett
to work on the World database on MS at the Sylvia Lowry Centre in Munich (Germany) where
she will collaborate in 2005.
Neuro-immunology Laboratories: The lab has added new assays on antibodies to interferons
fulfilling a need identified by the Canadian Network of MS clinics to have this testing available
for clinical use in Canada.
Genetics of MS: Dr. Sadovnick, a Michael Smith Distinguished Scholar, has received a 3 million
dollar grant from the MS Foundation of Canada to pursue further studies on the genetic
Page 86
Annual Report 2004
susceptibility to MS. She has also initiated a North American pregnancy registry under the
auspices of the Consortium.
MS/MRI: The MS/MRI Research Group, directed by Drs. Li and Traboulsee, continues to
provide internationally recognized high quality MRI analyses for multicentre research as well as
developing a 4-terabyte database for future natural history studies. Innovative analytic techniques
have been developed that allow semi-automated lesion load and brain volumetric measures.. In
collaboration with the Consortium of MS Centres, Drs. Li and Traboulsee have developed
international guidelines for clinical MR imaging in the diagnosis and management of Multiple
Sclerosis. The MS/MRI Research Group has fostered translational research in MS by supporting
basic physics research (Alex MacKay) and pathological correlation studies (Drs. Moore and
Dorovini-Zis).
Neurogenetics
The initiatives in Neurogenetics have brought together a group of researchers including Dr. Sian
Spacey, Dr. Michelle Mezei, Dr. Blair Leavitt, Dr. Robin Hsiung, Dr. Dessa Sadovnick, Dr.
Lynn Raymond and a group of genetic counselors.
At the UBCH the Neurogenetics clinic is a referral center for British Columbia providing over
300 outpatient visits in 2004. The patients seen have a wide range of inherited peripheral and
central CNS disorders. The most common include the ataxias, channelopathies, hereditary
spastic paraparesis, the phakomatoses, myotonic dystrophy, CMT, ALS, and mitochondrial
disease. Many of these patients are participants in genetic research run through the UBC
Neurogenetics Unit and have donated DNA to the clinic DNA bank. As well there are
Neurogenetic arms of the Alzheimer and MS Clinics which provide genetic counseling to
patients and families with these disorders.
The research focus of the program overall spans both translational and basic science research.
Dr. Blair Leavitt has been involved in ongoing clinical research on the hereditary movement
disorders, specifically the various forms of ataxias, hyperkinetic syndromes, and chorea-form
disorders, as well as being involved in post-mortem studies of HD, SCA and FTD. His lab has
directed attention at identifying novel forms of CAG repeat disorders and he has been involved
in ongoing clinical trials looking for novel Biomarkers or testing new therapeutic agents.
Dr. Spacey’s primary clinical interests are the hereditary CNS disorders, in particular the ataxias
and the channelopathies. Dr. Spacey runs a translational research program through the
Neurogenetics clinic. The clinic is the point of contact between the patients and her basic
science activity. The main focus of Dr. Spacey’s research is the molecular genetics of the
channelopathies and ataxia. Dr. Spacey was recently awarded an operating grant from the CIHR
to investigate the genetics and pathogenic mechanism of the paroxysmal dyskinesias.
Additionally she holds operating grants from the National Ataxia Foundation (USA) and the
Vancouver Costal Health Authority for investigation into the pathogenesis of the hereditary
ataxias.
Dr. Mezei’s primary interest is in the hereditary neuromuscular diseases with a special interest in
mitochondrial disease and ALS. She is currently involved in a number of research projects
Page 87
Annual Report 2004
ranging from Predictive Testing in SOD-1 familial ALS, to Comparison of brain MR spectoscopy
with measurement of brain myelin content in individuals with cognitive deficits related to
phenylketonuria.
Neuromuscular Diseases Program
The Neuromuscular Diseases Unit at VGH has a variety of specialized programs which attract
patients from around the province for their care.
1. Peripheral Neuropathy Program – Drs. Chapman and Gibson continue to be active in the
development of the Peripheral Neuropathy Clinic. They have several ongoing diabetic
neuropathy and CIDP trials. The recruitment of Dr. Hannah Briemberg has added her expertise
in nerve and muscle biopsy to the program.
2. Myasthenia Gravis Program – This program includes the MG Clinic at VGH which has
expanded with the involvement of Drs. Oger, Gibson, Mezei, Chapman and Briemberg. Its
current projects include a formal review of the clinical course of antibody negative myasthenia
gravis and an epidemiological study of the incidence and course of myasthenia gravis in the
Asian BC population.
3. Muscle Diseases Program – Dr. Briemberg additionally brings a new expertise to muscle
diseases. Clinical muscle pathology Rounds are scheduled monthly and the NDU at VGH has
strengthened its association with the pediatric neuromuscular program with Dr. Briemberg
attending the weekly pediatric neuromuscular clinic at BCCH.
4. ALS Program – Drs. Gibson and Eisen have continued their successful activities in
fundraising in support of the merged VGH-GF Strong ALS Clinic. These efforts have added to
those of UBC, the Vancouver Hospital Foundation and the ALS Society of BC. The new
Vancouver Coastal ALS Centre will open at the G.F. Strong site in March 2005. This clinic will
stand as a legacy to the many contributions that Dr. Andrew Eisen made in the diagnosis and
treatment of ALS patients throughout his career. Dr. Eisen formally retired as the Director of the
ALS Clinic in December 2004 with Dr. Charles Krieger assuming the role of Interim Director.
In addition to his active involvement in the ALS Clinic, Dr. Charles Krieger continues with his
research in the murine mouse model of ALS and examining the role of protein kinases in the
disease.
The Neuromuscular Diseases Unit and the UBC Division of Neurology will welcome Dr. Neil
Cashman as the new Director of the Vancouver Coastal ALS Centre in July 2005.
Dr. Michelle Mezei has been active in her role as the Director of Residency Training in the
Neuromuscular Program and electromyography. In addition to supervising weekly
Neurophysiology Rounds, she is actively involved in the monthly Muscle Pathology Rounds and
Clinical Neuromuscular Rounds. Dr. Mezei is further developing her focus in the metabolic
myopathies and genetic neuromuscular diseases, attending clinics in the Adult Metabolic
Diseases Unit and the Adult Neurogenetics Clinic at UBC.
Page 88
Annual Report 2004
Neuro-Oncology Program
The Neuro-Oncology program is a multidisciplinary program involving members of the
Divisions of Neurology, Radiation Oncology, Neurosurgery and Medical Oncology. Its goal is
to provide comprehensive care for patients with CNS malignancies and establish both clinical
and translational research programs in Neuro-Oncology.
In the realm of patient care, the program has continued to supply patients with advanced surgical
and radiotherapeutic management of brain tumors including a well-established linear accelerator
based stereotactic radiation program. Molecular diagnostic technology has advanced our
understanding of oligodendrogliomas and improved our management and chemotherapeutic
strategies for these tumors.
Over the 2004 year, grant supported research into ILK inhibition in gliomas has completed with
publication of results in peer-reviewed literature. Research into molecular genetic changes in
oligodendroglioma and other gliomas is ongoing with grant support from the Brain Tumour
Foundation of Canada.
New clinical research trials include a phase II trial of a novel tyrosine kinase inhibitor
GW572016 for relapsed glioblastoma multiforme. A phase 1 trial using the oncolytic virus
Reolysin in glioblastoma multiforme may open in 2005.
Neuro-Ophthalmology
The UBC Neuro-ophthalmology Division provides neuro-ophthalmic clinical, teaching, and
research services at St. Paul’s Hospital Eye Clinic, Vancouver Hospital Eye Care Centre, UBC
Hospital MS Clinic, and consulting services at VH, SPH, GF Strong and BC Children’s Hospital
and outreach programs. There are 10 neuro-ophthalmology clinics per week. Medical students,
ophthalmology and neurology residents and fellows rotate through the neuro-ophthalmology
service and we supply approximately 60 hours of clinical teaching per week. During the year
2,150 patients were seen at SPH site, 640 at UBC site, 1,400 at Eye Care Centre site.
The neuro-ophthalmology members have all been involved with presentations both locally and
nationally. The neuro-ophthalmology clinics continue to attract consultations from all over the
province and provide an excellent database for ongoing research studies, as well as for teaching
purposes. The program had 2 international clinical fellows and provided a remarkable teaching
dossier of 1536 hours of instruction of fellows, 588 hours for residents and 688 for medical
students.
Pacific Parkinson’s Research Centre
Teaching
The Movement Disorders Clinic provides ambulatory teaching to medical students and to
residents in neurology, geriatrics, psychiatry and family medicine.
Page 89
Annual Report 2004
Faculty members of the Pacific Parkinson’s Research Centre participate in the Brain &
Behaviour course and provide training to trainees at the MSc. and PhD. levels in the
Experimental Medicine and Graduate Neuroscience programs. Dr. McKeown took over as codirector of the Motor Systems module of the Systems Neuroscience (Neuroscience 501) core
course in the Graduate Neuroscience program. Faculty members within the Centre serve as
mentors in the CIHR-funded Neuroscience Training Initiative. One of the first group of training
award recipients has joined our program as a PhD student this past year.
Research
During the past year, successful CIHR grant applications included The Natural History of
Sporadic and Inherited Parkinson’s (Stoessl/Lee et al.), Neural Mechanisms Underlying
Response Changes to Levodopa in PD (Lee/Phillips et al.), and Development of Radiotracers
based on Oligonucleotide Labeling (Ruth et al.). Additionally, both Drs. Sossi and Ruth obtained
NSERC funding, for Quantitative High Resolution PET Imaging and Gas Targetry, respectively.
The Centre was awarded one of only a few National Parkinson Foundation Center of Excellence
awards. This award provides support for clinical services and outreach, as well as a research
award to Dr. McKeown for Spatial & Temporal Aspects of Compensatory Mechanisms in PD.
Finally, Dr. McKeown is co-PI on a successful CFI application for development of a Biomedical
Signal and Image Computing Laboratory.
One of the major collaborations of our Centre is with the neurogenetics program at the Mayo
Clinic, Jacksonville. During the past year, this collaboration resulted in identification of a novel
gene mutation underlying dominantly inherited Parkinson’s. The paper describing this mutation
appeared in Neuron. Imaging studies helped identify preclinical disease in some members of the
pedigrees that were studied.
The backbone of the Centre’s research program continues to be the close partnership with the
UBC-TRIUMF PET program. During the past year, development work and preliminary
experiments were conducted on the new small animal PET tomograph, as well as the highresolution, high sensitivity human research tomograph. Dr. Doudet has continued work on
understanding the mechanisms underlying benefit from retinal pigmented epithelial cell implants
and electroconvulsive therapy in PD.
In addition to our basic and imaging research program, a number of clinical trials continued.
Clinical
The Movement Disorders Clinic provided more than 3,500 outpatient visits in 2004. The
majority of these are for patients with Parkinson’s disease or focal dystonia. This reflects on the
increasing emphasis on outpatient care with the extremely restricted access to in patient beds.
The program is heavily supported by nurse coordinators, who provide education and counseling
to patients, families and other health care professionals.
Page 90
Annual Report 2004
Epilepsy
The comprehensive Epilepsy Program was established almost 20 years ago by Dr. Sherrill
Purves and Dr. Barry Woodhurst, with assistance from hospital administration, and with funding
from the B.C. Government to recognize the uniqueness of this program. Dr. Michael Jones is
currently the program director.
This multidisciplinary program is the only one in the province that evaluates patients for surgical
epilepsy management. The Epilepsy Program team includes Dr. W. Barry Woodhurst
(Neurosurgery), Dr. David Katz (Neuropsychologist), and Dr. Mano Javidan (Epilepsy
Neurologist). The program benefits from an excellent nurse clinician in Janice Henrikson, plus
the unique expertise and support of the EEG technology service. There is capable administrative
support from Jean A’Bear.
Epilepsy Education is a very important and active part of the program. Both Dr. Jones and
Javidan provide CME around the province and country. Dr. Woodhurst is currently doing a
large in-depth analysis of program’s surgical results.
Over the past year a new state of the art digital telemetry system has been implemented.
The program also assists patients with “fits, faints, and funny turns”, and specifically the topic of
non-epileptic seizures, a spectrum of problems that are costly and labour intensive to reconcile
diagnostically. In its clinical research the program participates in multicenter drug trials of
emerging therapeutics for epilepsy.
SPH Research
A number of clinical research projects are ongoing at SPH including neuroprotective studies in
cerebrovascular disease, and carnitine use in HIV and AIDS related peripheral neuropathy.
Basic Neurosciences
The lab of Dr. Yu Tian Wang has continued to receive international accolades with outstanding
academic productivity. Dr. Wang’s research focuses on understanding the molecular mechanisms
responsible for regulating the function and intracellular trafficking of neurotransmitter receptors
critical for brain functions such as learning, memory and cognition. He is investigating the
manner by which these mechanisms may be altered in central nervous disease processes. His
goal is to be able to treat central nervous disorders such as stroke, epilepsy and drug addiction by
designing new therapeutics which specifically target these receptors and their pathways.
Amongst his current lab projects is a study of the molecular mechanisms mediating neuronal
death following stroke. A major research focus of this project is to develop new therapeutic
agents that will interfere with cell-death inducing glutamate receptor signaling pathways by
disrupting interactions of the glutamate receptors, particularly the NMDA subtype (NMDAR),
with scaffolding and signaling proteins. His lab has been a strong training environment with 3
post doctoral fellows appointed in 2004.
Page 91
Annual Report 2004
Appointments and Promotions
Dr. Anthony Traboulsee was promoted from the rank Clinical Instructor to Clinical Assistant
Professor with effect from July 1, 2004.
Dr. Jason Barton was appointed to the rank of Associate Professor with effect from September 1,
2004.
Dr. Hannah Briemberg was appointed to the rank of Clinical Assistant Professor with effect from
October 1, 2004.
Dr. Robin Hsiung was appointed to the rank of Assistant Professor with effect from September 1,
2004.
Dr. Helen Tremlett was appointed to the rank of Assistant Professor with effect from October 1,
2004.
Dr. Bradley Hallam was appointed to the rank of Clinical Instructor with effect from July 1,
2004.
Dr. Penelope Smyth was appointed to the rank of Clinical Instructor with effect from September
1, 2004.
Dr. Doris Doudet served as External Reviewer, National Institute of Health (NIH) - Center for
Scientific Research as well as serving as an External Reviewer, CIHR, BSB in October 2004.
Dr. Philip Teal was awarded the Donald M. Whitelaw Award for Outstanding Grand Rounds
Presentation in the UBC Department of Medicine in 2004.
Dr. Gillian Gibson was awarded the Master Teacher Award in the UBC Department of Medicine
for 2004.
Dr. Lynn Raymond was promoted to the rank of Full Professor and was awarded the Killam
Research Prize, Senior Science Category in the amount of $5000 in 2004.
Dr. Charles Krieger won the Vancouver Hospital and Health Science Centre and University of
British Columbia Scholarship Award in 2004.
Dr. Gordon Robinson was the chair and convener at the 2004 Annual Forefronts in Neurology
meeting for the neurologists of BC.
Dr. Howard Feldman convened a national conference on regulatory guidelines for the
development of antidementia drugs in Canada. This conference received peer reviewed funds
from Canadian Institutes of Health Research (CIHR) Institute on Aging. He was invited to
deliver plenary lectures at the 9th International Conference on Alzheimer’s Disease and Related
Page 92
Annual Report 2004
Disorders as well as the 7th International Springfield Montreal Conference on Therapy in
Alzheimer’s Disease.
Dr. Helen Tremlett was awarded a travel grant for young investigators (Euro400) by the
ECTRIMS Scientific Committee to attend the annual conference in Vienna 2004.
Dr. Y.T. Wang was awarded the J.A.F. Stevenson Professor of the Canadian Physiological
Society and the UBC Killam Research Prize in 2004.
Dr. Donald W. Paty was awarded the Meritorious Service Decorations (civil division) by the
Governor General of Canada in 2004.
Dr. Colleen Murphy became a diplomate of the American Board of Psychiatry and Neurology.
Dr. Mano Javidan holds the positions of Examiner, Canadian Society of Clinical
Neurophysiology-EEG and Evoked Potentials, Secretary Treasure Canadian Society of Clinical
Neurophysiology, Member of Executive Board, Canadian Congress of Neurological Sciences,
Member, Liaison Committee, Canadian Congress of Neurological Sciences and Vice Chair,
Diagnostic Accreditation Program (Neurodiagnostics), British Columbia, 2004.
Dr. Martin McKeown was awarded a large peer reviewed grant from the Canadian Foundation
of Innovation New Opportunities Fund and the BCKDF with contributions, cash and in kind,
from the Department of Electrical and Computer Engineering, the Brain Research Center
(Faculty of Medicine/UBC Hospital), ICICS, and equipment vendors. This funding will be used
to equip the Biomedical Signal and Image Computing Lab (BiSICL). He was also awarded the
Vancouver Coastal Health Research Institute Interdisciplinary Award for a project on the novel
assessments of motor performance in patient populations.
Page 93
Annual Report 2004
PHYSICAL MEDICINE & REHABILITATION
Dr. Theo van Rijn
Faculty Members
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Honorary Professor
Associate Member
Associate Member
Associate Member
van Rijn, Dr. Theo
Anton, Dr. Hubert
Hahn, Dr. George
Schamberger, Dr. Wolfgang
Travlos, Dr. Andrew
Dhawan, Dr. Pankaj
Hirsch, Dr. Gabriel
Jung, Dr. Susan
Mortifee, Dr. Peter
Townson, Dr. Andrea
Vondette, Dr. Michael
Weeks, Dr. Claire
Adrian, Dr Mark
Crossman, Dr. Mark
Dawson, Dr. Andrew
Hughes, Dr. Barbara
Koo, Dr. David
Lau, Dr. Herman
O'Connor, Dr. Russell
Reebye, Dr. Nittin
Underwood, Dr. Heather
Weiss, Dr. Elliott
Willms, Dr. Rhonda
Yao, Dr. Jennifer
Kaplan, Dr. Paul
Eng, Dr. Janice
Miller, Mr. William
Yassi, Dr. Annalee
Murray, Dr. Duncan
Robinson, Dr. Cecil
Pinkerton, Dr. Alexander
Page 95
VA
VA
VA
Burnaby
VA
VA
VA
VA
VA
VA
VA
VA
VA
Vancouver
VA
VA
VA
SPH
VA
VA
VA
SPH
VA
VA
USA
Vancouver
VA
Vancouver
Annual Report 2004
Divisional Overview
The UBC Division of Physical Medicine & Rehabilitation currently has twenty-four active
faculty members who are involved with patient care, teaching and research. Our members
consult and provide rehabilitation services to persons ranging from the very young to the very
old. We manage inpatient and outpatient programs for persons who have suffered spinal cord
injury, acquired brain injury, neuromuscular abnormalities and cardio/pulmonary dysfunction.
Inpatient services are provided at several sites, including Vancouver Acute/GF Strong Rehab
Center, St. Paul’s Hospital, Holy Family Hospital, Eagle Ridge Hospital, Sunny Hill Health
Center, as well as consultation services to the Vancouver teaching hospitals, BC Children’s
Hospital, Royal Columbian Hospital and Burnaby General Hospital. Our staff is actively
involved in teaching of residents and undergraduate students, as well as undergraduate students
in related disciplines. Research activity deals with disease specific issues related to our patient
population, as well as disability issues for the population at large.
Undergraduate
Dr. David Koo has continued to serve as the Undergraduate Coordinator. Nine members of our
Division participated in the Undergraduate curriculum including half-day lectures on disability,
impairment and handicap, problem-based learning, MSK clinical skills sessions, mentorship and
specialty-specific discussions on impairment and disability. Our Division continues to be
actively involved in teaching elective medical students who have an interest in our specialty.
Postgraduate
There were seven residents in the program at the end of 2004. All residents from PGY2 onwards
now have a formal half day of research experience throughout their academic years. Resident
teaching is done at the bedside and in ambulatory clinics. Formalized seminars are undertaken
during weekly Academic Half Days. Residents continue to participate in a scheduled monthly
Journal Club supervised by members of the Division, in order to learn critical assessment of
journal articles.
Four of our Physiatry residents were active at the Annual Department of Medicine Research
Day. Dr. Andrei Krassioukov won an award for ‘Best Resident Presentation – PGY3/4.’ Our
residents also participated in the Canadian Association of Physical Medicine & Rehabilitation
Annual Meeting on a yearly basis.
Continuing Medical Education
Dr. Theo van Rijn served as a coordinator for CPD activities for the Division in the academic
year. Our Division continues to enjoy a vibrant CPD schedule attended by Division and nonDivision members who have an interest in topics presented. The CPD Committee meets biannually to review upcoming CPD activities and to formulate ways to enrich ongoing education
of our membership. The CPD committee continues to encourage members to develop innovative
teaching methods, as well as utilizing panel discussions and experts from other sub-specialties
for broader educational experience.
Page 96
Annual Report 2004
Research
Dr. Hugh Anton served as the Research Coordinator and Chair of the UBC/PM&R Divisional
Research Committee and helped organize monthly Committee meetings for the Division.
Collectively the Division has embarked on several projects that share common interest to our
members.
Caroline Abramson and Catherine Tadey served as Research Coordinators for Divisional
Research and Research activities during the year.
Dr. Drew Dawson was the principal investigator of 1 research project dealing with
cardiovascular fitness following stroke and co-investigator of 2 research projects at GF.
Dr. David Koo was principal investigator of one study involving spinal epidural abscess.
Dr. Andrew Travlos was principal investigator of two studies: one dealing with spasticity and
another with care issues regarding ALS patients.
Dr. Andrea Townson was co-investigator of 2 research projects dealing with issues regarding
spinal cord dysfunction.
Dr. Andrei Krassioukov, PGY4, was the primary investigator of six research projects dealing
with neurological dysfunction following brain and/or spinal cord injury, as well as coinvestigator in one other spinal cord related project.
Clinical Services
Many members of our Division continue to provide consultation services to Vancouver Acute,
St. Paul’s Hospital, as well as other hospitals in the Fraser Health Authority. Dr. Elliot Weiss is
the leader for rehabilitation of Providence Health Care. Dr. Travlos and team members continue
to provide clinical services and direction to the rehabilitation programs for persons suffering
from ALS. While Drs. Rhonda Willms and Heather Underwood took maternity leave absences
this year, they have actively supported and will continue to participate in services for persons
requiring orthotics and/or prosthetics. Dr. George Hahn continues to provide consultation
services for the BC Children’s Hospital, Vancouver Acute, and Sunnyhill Health Center.
Administration
Dr. Andrew Travlos served as a Chair of Specialty Committee in Physical Medicine &
Rehabilitation of the Royal College of Physicians and Surgeons of Canada.
Dr. Pankaj Dhawan served as examiner for the Specialty of PM&R at the Royal College.
Dr. Gabriel Hirsch served as Chair of the Section of PM&R for the BC Medical Association.
Dr. Theo van Rijn served as the Medical Director of GF Strong Rehab Center, as well as Head,
Division of PM&R.
Page 97
Annual Report 2004
Drs. Andrea Townson, Andrew Travlos, and Rida Baruni served as medical managers assisting
in program related issues at G.F. Strong Rehabilitation Center.
Drs. Theo van Rijn and Pankaj Dhawan were invited speakers at the Annual Canadian
Association of PM&R Conference in Prince Edward Island in June 2004.
Drs. Janice Eng, Bill Miller and Annalee Yassi were appointed Associate Members of the
Division Physical Medicine & Rehabilitation. Drs. Eng and Miller, both faculty of the School of
Rehabilitation Sciences, are actively involved with mentoring and collaborating in research with
many of our members. Dr. Annalee Yassi, has a specialty in Community & Occupational
Medicine. She will be teaching our residents and joining us in some collaborative research
projects in years to come.
Future Directions
Following a successful retreat in December 2004, the Division will be undertaking a new
initiative in Undergraduate Education. Selected second year medical students will be given the
opportunity to answer physical exam skills by participating in a collaborative staff/resident
teaching project undertaken by Division members in a pilot project.
The Division also is undertaking a longer term initiative to foster a post-graduate
education/teaching initiative which will be part of a larger national endeavor to promote
academic excellence in our specialty.
Page 98
Annual Report 2004
RESPIRATORY MEDICINE
Dr. John Fleetham
Professor & Head
Faculty Members
Professor & Head
Professor
Professor
Professor
Professor
Professor
Professor
Professor
Professor
Associate Professor
Associate Professor
Associate Professor
Associate Professor
Associate Professor
Associate Professor
Associate Professor
Assistant Professor
Assistant Professor
Assistant Professor
Clinical Professor
Clinical Professor
Clinical Instructor
Honorary Professor
Honorary Professor
Associate Member
Associate Member
Associate Member
Associate Member
Fleetham, Dr John
Bai, Dr. Tony
Duronio, Dr. Vincent
Fitzgerald, Dr. J. Mark
Lam, Dr. Stephen
Man, Dr. Paul S F
Ostrow, Dr. David
Pare, Dr. Peter
Road, Dr. Jeremy
Khalil, Dr. Nasreen
Levy, Dr. Robert
Ryan, Dr. Francis (Frank)
Sin, Dr. Donald
Van Eeden, Dr. Stephan
Ward, Dr. Helen
Wilcox, Dr. Pearce
Ayas, Dr. Najib
Cook, Dr. Victoria
Sandford, Dr. Andrew
Champion, Dr. Paul
Lawson, Dr. Lindsay
Elwood, Dr. Richard
Nakielna, Dr. Barbara Edina
Fera, Dr. Tharwat
Turner, Dr. Mark
Wilson, Dr. Jennifer
Lertzman, Dr. Morley
Tan-Hogg, Dr. Wan
Brauer, Dr. Michael
Lowe, Dr. Alan
Muller, Dr. Nestor
Roberts, Dr. Clive
Page 99
VA
SPH
VA
VA
VA
SPH
VA
SPH
VA
BCCDC
SPH
VA
SPH
SPH
VA
SPH
VA
VA
SPH
VA
SPH
BCCDC
SPH
VA
VA
VA
VA
SPH
Vancouver
Vancouver
VA
Vancouver
Annual Report 2004
Visiting Scientist
De Jong, Dr. Pieter Arie (Pim)
Abboud, Dr. Raja
Bates, Dr. David
Yeung, Dr. Moira
Allen, Dr. Edward
VA
VA
Divisional Overview
The UBC Respiratory Division consists of 31 faculty members who are located at Vancouver
Acute (Vancouver General Hospital, UBC Hospital), Providence Health Care (St. Paul’s
Hospital, Mt. St. Joseph Hospital) Vancouver Cancer Centre, BC Centre for Disease Control and
BC Transplant Society. There are active respiratory medicine in-patient and ambulatory care
programs at Vancouver General Hospital and St. Paul’s Hospital. The two year subspecialty
respiratory medicine training program accepts one provincially funded trainee per year.
Respiratory Medicine is considered a centre of research excellence at both Providence Health
Care and Vancouver Acute. Respiratory Medicine is a major component in the iCapture Centre
primarily based at St. Paul’s Hospital. Respiratory Medicine is the primary component of the
Lung and Critical Care Research Program at Vancouver Coastal Health Institute. The UBC
Respiratory Division is developing a strategic plan for clinical care, research and teaching of
Respiratory Medicine within the Vancouver Coastal Health Authority, which incorporates an
academic funding contract for all divisional members. Dr. Paul Man was appointed Head of
Medicine, Providence Health Care March 1st 2004, and is also a member of the UBC Respiratory
Division. Dr. Victoria Cook joined the UBC Respiratory Division July 1st 2004 and performs
research and clinical work with the Division of TB Control, BC Centre for Disease Control and
is also based at VGH.
Teaching
Undergraduate: The UBC Respiratory Division continues to have a major responsibility for the
five week pulmonary block in the undergraduate curriculum. Dr. F. Ryan continues as chair of
the pulmonary block. Division members participate in undergraduate teaching either as tutors or
clinical skills instructors.
Postgraduate: The UBC Respiratory Medicine Training Program, directed by Dr. P. Wilcox,
continues to attract a large number of highly qualified applicants from across Canada. The
program has full approval from the Royal College. This two year clinical program is based at
both Vancouver General Hospital and St. Paul's Hospital. There are elective opportunities at
community based centres throughout BC and the program offers an optional third year of
research training. Our current trainees are Dr. M. Al Ajmi (Kuwait), Dr. T. Shaipanich
(Thailand), Dr. J. Swiston (Vancouver), Dr. M. Molavi (Omaha, NE). The UBC Respiratory
Division proposes to expand the number of trainees from one to two per year and to offer a three
year combined fellowship program in Respiratory Medicine/ICU.
Experimental Medicine: The UBC Respiratory Division continues to make significant
contributions to the Departmental Experimental Medicine program with MSc. and PhD students
being trained in both the Jack Bell Research Laboratory at Vancouver General Hospital and the
iCapture Centre at St. Paul's Hospital.
Page 100
Annual Report 2004
Continuing Medical Education: Dr. Mark FitzGerald is primarily responsible for continuing
medical education within the UBC Respiratory Division and organizes a three day annual
international CME course on critical care and respiratory medicine in spring at Whistler. A
weekly research seminar series for the UBC respiratory community is held between SeptemberMay. Division members are very active in CME in a large variety of provincial, national and
international forums.
Research
Respiratory Medicine is considered a centre of research excellence at both Providence Health
Care and Vancouver Acute. Respiratory Medicine is a major component in the iCapture Centre
primarily based at St. Paul’s Hospital. Respiratory Medicine is the primary component of the
Lung and Critical Care Research Program at Vancouver Coastal Health Institute (VCHI). The
iCapture Centre was created with CFI funds to examine how abnormal genes change the
structure and function of cells, tissues and organs to cause lung disease. The major respiratory
medicine research interests at the VCHI Lung and Critical Care Research Program are
respiratory sleep and neuromuscular disease, environmental and occupational lung disease and
emphysema. The prevention and early diagnosis of lung cancer is the primary research focus at
the Vancouver Cancer Centre and research into tuberculosis and mycobacterial disease is the
major interest at the BC Centre for Disease Control. Research in lung transplantation takes place
at both Vancouver Acute and the BC Transplant Society.
Clinical Services
Active respiratory medicine in-patient and ambulatory care programs continue at both
Vancouver General Hospital and St. Paul's Hospital. Ambulatory care space has been developed
within St. Paul’s Hospital for the members of the St. Paul’s Hospital Respiratory Division.
Administration
Dr. John Fleetham is the Head of the UBC Respiratory Division. Dr. Robert Levy is Head of the
Providence Health Care Respiratory Division. Dr. Mark FitzGerald took over leadership of the
Vancouver Acute Respiratory Division effective July 1, 2004. Bernice Robillard continues to
work to support the administrative activities of the UBC Respiratory Division with major
responsibilities for the postgraduate program. An external review of the UBC Respiratory
Division was performed in November by Dr. Denis O’Donnell and Dr. Paul Keown.
Future Directions
The UBC Respiratory Division proposes to develop a strategic plan for clinical care, research
and teaching of Respiratory Medicine within the Vancouver Coastal Health Authority, which
incorporates an academic funding contract for all divisional members.
Special Honours And Awards
Dr. Najib Ayas was the recipient of a Michael Smith Health Research Foundation Scholar award.
Dr. Victoria Cook was awarded a VCHRI In-It-For-Life Mentored Clinician Scientist award. Dr.
Page 101
Annual Report 2004
Mark FitzGerald was awarded a Michael Smith Health Research Foundation Distinguished
Scholar Award. Dr. John Fleetham headed a group of UBC Respiratory Medicine members and
was awarded a Michael Smith Health Research Foundation Research Unit award for Respiratory
Sleep Disorders. Dr. Peter Pare was awarded the 2004 UBC Killam Research Prize. Dr. Jennifer
Wilson was the recipient of a Department of Medicine Academic Enhancement Fund award. Dr.
Stephan van Eeden was awarded the Martin M. Hoffman Award for Excellence in Research.
Page 102
Annual Report 2004
RHEUMATOLOGY
Dr. John M. Esdaile
Professor & Head
Faculty Members
Professor & Head
Professor
Assistant Professor
Assistant Professor
Clinical Professor
Clinical Professor
Clinical Instructor
Clinical Instructor
Clinical Instructor
Honorary Professor
Visiting Professor
Associate Member
Esdaile, Dr. John
Chalmers, Dr. Andrew
Cibere, Dr. Jolanda
Lacaille, Dr. Diane
Blocka, Dr. Kenneth
Koehler, Dr. Barry
Huang, Dr. Simon
Patterson, Dr. A. Caroline
Reid, Dr. Graham
Shojania, Dr. Kamran
Wade, Dr. John
Ensworth, Dr. Stephanie
Kelsall, Dr. John
Klinkhoff, Dr. Alice
Shuckett, Dr. Rhonda
Fenton, Dr. Stanley
Gillies, Dr. Jean
Watterson, Dr. John
Stein, Dr. Howard
Pouchot, Dr. Jacques
Kopec, Dr. Jacek
Ford, Dr. Denys
Robinson, Dr. Harold
Tsang, Dr. Ian
VA
VA
VA
VA
VA
Richmond General
SPH
VA
VA
VA
VA
VA
SPH
VA
SPH
RCH
SPH
VA
Divisional Overview
The UBC Division of Rheumatology has 18 active faculty members, one associate member, 3
emeritus members, and one honorary member. Rheumatology consultation services are offered at
Vancouver Acute, St. Paul’s Hospital, BC Women’s Hospital & Health Centre, and G.F. Strong
Rehabilitation Centre. Ambulatory care services are available at the Mary Pack Arthritis Centre,
St. Paul’s Hospital, BC Women’s Hospital & Health Centre, and in private practices throughout
Page 103
Annual Report 2004
Vancouver. The Arthritis Society (BC & Yukon Division) provides excellent patient education
and resources available through the Learning Centre based at the Mary Pack Arthritis Centre.
Many divisional faculty are members of the Arthritis Research Centre of Canada (ARC), a
multidisciplinary clinical research and clinical trials facility affiliated with both the University of
British Columbia and the Vancouver Coastal Health Research Institute. ARC is based at the
Mary Pack Arthritis Centre. It includes faculty from Rheumatology, Orthopaedics, Epidemiology
& Health Care, Pharmaceutical Sciences and the School of Rehabilitation Sciences. ARC
focuses on "Practical Research for Everyday Living" for people with arthritis.
The two-year Postgraduate Training Program in Rheumatology continues to be the secondlargest clinical rheumatology training centre in Canada. The program accepts one Ministryfunded trainee every year and two trainees funded by The Arthritis Society of Canada as well as
one to two internationally-funded trainees. Active in-patient, ambulatory care and research
training is done at Vancouver Acute, St. Paul’s Hospital, G.F. Strong, BC Women’s Hospital &
Health Centre, the Arthritis Research Centre of Canada, and in private practices throughout the
Lower Mainland and elsewhere in the province.
In recognition of his many contributions, Dr. Ian Tsang was honoured with an appointment as a
Clinical Professor Emeritus at the University of British Columbia. Dr. Andrew Chalmers was
promoted to full Professor of Medicine (see “Distinctions and Awards” for further details). Dr.
Jolanda Cibere was newly appointed in 2004 as an Assistant Professor of Medicine upon
completing her PhD in Health Care & Epidemiology on the topic of the effectiveness of
glucosamine sulfate in osteoarthritis of the knee. She has also joined the active staff at
Vancouver Acute. As well, Dr. Kam Shojania was promoted to Clinical Associate Professor. Dr.
Jacques Pouchot, a Visiting Professor to the Division from August 2003 to August 2004,
completed his sabbatical and returned to Paris. His interaction with the Division members and
the mentorship he provided to the trainees will be greatly missed.
Teaching
Dr. Simon Huang continues to direct undergraduate rheumatology program with several
members of faculty teaching in the Musculoskeletal Block each year. In 2004, the Vancouver
Acute training program adopted the Patient Partners Program, an arthritis consumer-led seminar
designed to teach medical students and residents the basics of musculoskeletal examination early
in their rotation. Dr. Kenneth Blocka has led this program for several years and has been using it
with great success in the St. Paul’s Hospital training program. The Vancouver Acute group found
it similarly beneficial and has noted improved musculoskeletal examination skills in residents
rotating through the service.
Dr. John Esdaile continues as the Program Director for the Postgraduate Training Program and
the hospital programs continue to be led by Drs. Kenneth Blocka and John Esdaile at SPH and
VHHSC, respectively. This year, Dr. John Watterson took on the role of hospital program
director at G.F. Strong. We would like to thank Dr. Graham Reid for many years of dedicated
service in this capacity. He continues to be a valued teacher in many other areas of the
postgraduate program.
Page 104
Annual Report 2004
The postgraduate program is currently comprised of three first-year residents, two second-year
residents, and two doctoral candidates. We expect three new residents to commence in July
2005. The clinical trainees continue to be involved in outreach clinics in Trail, Cranbrook, Fort
St. John and other rural communities throughout B.C. Both UBC and The Arthritis Society (BC
& Yukon Division) provided support for travel and accommodation for these outreach clinics.
The residents also participate in mandatory rotations at Vancouver Acute, St. Paul’s Hospital,
G.F. Strong, BC Children’s Hospital, Allan McGavin Sports Medicine Centre, and in numerous
drug/disease monitoring clinics and community rheumatology practices throughout their training.
For the fourth year, a basic skills course for rheumatology fellows was given in the first week of
July to provide detailed instruction on the clinical examination of the musculoskeletal exam, as
well as the essentials of emergency arthritis care. The course was organized by Dr. Kam
Shojania and involved the majority of the divisional faculty.
Dr. Janet Pope from the University of Western Ontario visited in May 2004 to perform mock
oral examinations for the clinical fellows. This two-day event, which included a physical
examination seminar, mock oral examinations, noon rounds and academic half-day teaching, was
extremely helpful and much appreciated. Dr. Howard Stein acted as the Co-Examiner.
Dr. Raheem Kherani, a second-year rheumatology clinical fellow, developed a website for the
rheumatology program to facilitate teaching and communication between trainees. This has
received high praise both from the other trainees and from the Postgraduate Medical Education
Office. Similar designs are being considered for other programs. The trainees and the faculty
have now completed the development of new comprehensive learning objectives for all the
rotations.
Dr. Howard Stein continues to volunteer his time teaching the clinical fellows every week at the
weekly Academic Half-Day. The clinical fellows have also benefited from weekly guest
speakers from many other divisions at their Academic Half-Day. As well, both the Division and
the postgraduate program have benefited from a number of visiting professors including Drs.
Nancy Lane (University of California, San Francisco), Walter Maksymowych (University of
Alberta), Hyon Choi (Harvard University), Art Lipman (University of Utah), Janet Pope
(University of Western Ontario), Sasha Bernatsky (McGill University), Eric Sasso (formerly
University of Washington), and Rick Adachi (McMaster University).
Research
Members of the Division continue to be active in the Arthritis Research Centre of Canada
(ARC). ARC includes faculty from the Division of Rheumatology, the Department of
Orthopedics, the Department of Epidemiology and Health Care, the Department of
Pharmaceutical Sciences and the School of Rehabilitation Sciences, as well as from the Centre
for Health Evaluation and Outcome Studies at St. Paul’s Hospital and the Centre for Clinical
Epidemiology and Evaluation at Vancouver Acute.
Current research includes a large team grant involving researchers from across Canada
evaluating the development and treatment of early osteoarthritis.
Page 105
Annual Report 2004
Dr. John Esdaile, Dr. Jolanda Cibere and others received a grant from the Canadian Institutes of
Health Research to study prevention of knee injuries in young soccer players. Dr. Esdaile and
others also received funding from the Lupus Research Institute to develop a virtual network
between lupus researchers around North America.
The Canadian Foundation for Innovation funded a $5.2 million infrastructure grant to build the
Centre for Hip Health at the Vancouver Acute site (PI: Dr. Thomas Oxland), and all the members
of the Arthritis Research Centre of Canada were participants. A secondary hospital competition
later in the year was also successful bringing the total award to $10.8 million.
Dr. Jolanda Cibere received funding from The Arthritis Society of Canada to continue her study
of MRI and value of biomarkers in assessing progress in knee osteoarthritis. She, Dr. Ian Tsang
and Dr. John Esdaile received funding from the Lotte & John Hecht Foundation to study the
effect of the Chinese herb, Tripterygium wilfordii, in rheumatoid arthritis in collaboration with
researchers at the Guangdong University of Traditional Chinese Medicine in Guangzhou, China.
Finally, Dr. Cibere was awarded a Clinician Scientist Phase II Award from the Canadian
Institutes for Health Research as well as a Department Scholar Award from the UBC Department
of Medicine.
Dr. Jacek Kopec, a clinical epidemiologist and Associate Member of the Division of
Rheumatology, received funding from the Canadian Institutes of Health Research to study
physical activity and joint health using an adaptive web-based tool that he has developed. He
also received funding from the Workers’ Compensation Board to measure quality of life in
patients suffering from back pain.
Dr. Antonio Avina-Zubieta, a rheumatologist from Mexico, began doctoral studies in the
Department of Experimental Medicine and will be working closely with Dr. Diane Lacaille.
This year, the Canadian Arthritis Network went through the grueling process of applying for
renewal of funding from the Networks of Centres of Excellence. Dr. John Esdaile formed part of
a small team that was responsible for this application, which was successfully renewed for a
second seven-year term.
Drs. Maziar Badii, Ken Blocka, Andrew Chalmers, Jan Dutz, John Kelsall, Alice Klinkhoff,
Graham Reid, and Kam Shojania continue to study novel modalities for persons with arthritis in
BC. There are over 50 new biologic therapies that are currently either in the development or
testing phase and our clinical trials group is participating in the testing of several of these for use
in rheumatoid arthritis and other inflammatory conditions such as psoriatic arthritis, ankylosing
spondylitis and systemic lupus erythematosus. They are also involved in trials of treatments for
osteoarthritis and chronic pain.
Clinical Services
The Mary Pack Arthritis Centre (operated by Vancouver Coastal Health) is the largest centre for
ambulatory care in the province headed up by Dr. Alice Klinkhoff. Many faculty members from
both Vancouver Acute and St. Paul’s Hospital participate in the programs offered here.
Extensive drug monitoring and disease monitoring clinics have been established, several of
Page 106
Annual Report 2004
which have developed international reputations. Dr. Andrew Chalmers is the Director of the
world’s largest Cyclosporine Monitoring Program and Dr. Alice Klinkhoff is pursuing
innovative methods of treatment in the Gold Clinic. Dr. Stephanie Ensworth is the Director of
the Provincial Lupus Program, one of 9 such programs across Canada participating in
coordinated lupus research. In addition, arthritis-specific treatment services offered in
physiotherapy, occupational therapy, social work, patient education and vocational counseling
are valuable resources for the members of the Division and their patients. This program also
coordinates the travels of divisional faculty to 28 rural locations throughout the province to
provide consultation and treatment services.
Several ambulatory care clinics are also offered at St. Paul’s Hospital for scleroderma (run by
Dr. James Dunne) and low back pain (run by Dr. Jean Gillies) as well as a rapid-access program
(run by Dr. John Kelsall). Dr. Stephanie Ensworth runs the Reproductive Rheumatology Clinic
(one of only two such clinics in Canada) and the Rheumatic Diseases in Pregnancy Program at
BC Women’s Hospital & Health Centre.
The Arthritis Unit at G.F. Strong Rehabilitation Hospital offers post-operative and rehabilitative
services to rheumatology patients along with specialized physiotherapy, occupational therapy
and vocational counseling. In-patient services are offered at Vancouver Acute, St. Paul’s
Hospital, and BC Women’s Hospital & Health Centre.
Administration
Dr. John Esdaile is Head of the UBC Division of Rheumatology, the Vancouver Acute Division
of Rheumatology, and the UBC Postgraduate Training Program in Adult Rheumatology. Dr. Ken
Blocka is the Head of the St. Paul’s Hospital Division of Rheumatology and also oversees the
hospital training program there. Dr. John Watterson oversees the hospital training program at
G.F. Strong Hospital. Dr. Alice Klinkhoff is Director of the Mary Pack Arthritis Centre. Dr. John
Esdaile is also the Scientific Director of the Arthritis Research Centre of Canada.
Future Directions
In 2005, the Division will continue to pursue excellence in research, teaching and clinical care. A
rapid-access clinic for rheumatoid arthritis patients is under consideration. We expect the Mary
Pack Chair in Rheumatology Research (endowed by The Arthritis Society, BC & Yukon
Division) to be filled this year. In addition to an academic appointment in the UBC Division of
Rheumatology, the Chair will also be appointed to the Vancouver Acute and the Arthritis
Research Centre of Canada. The Arthritis Research Centre of Canada is looking forward to
breaking ground for the new Centre for Hip Health in the summer of 2005.
Distinctions and Awards
Dr. Maziar Badii completed his Masters of Health Sciences degree in the Department of Health
Care and Epidemiology in November 2004. He will be appointed as Clinical Assistant Professor
in the Division of Rheumatology in the coming year. He will continue his research on low back
pain.
Page 107
Annual Report 2004
In recognition of his many contributions to both the UBC Division of Rheumatology as Past
Head and the UBC Medical School as Past Associate Dean of Undergraduate Medicine, Dr.
Andrew Chalmers was promoted to full Professor of Medicine. Dr. Chalmers was key in the
development of the new Undergraduate Medicine curriculum for the UBC Medical School and
has played a major role in the continued excellence of the UBC Rheumatology Training
Program.
Dr. Jolanda Cibere was awarded the Vancouver Coastal Health Research Institute’s Prize for
Graduating Doctoral Students for her work on the efficacy of glucosamine sulfate. Dr. Cibere
was also honored with a Young Innovator Award from the Networks of Centres of Excellence.
She was one of only three young Canadian scientists to receive this award and was presented
with this award in Ottawa in early December.
Dr. John Esdaile is chairing the American College of Rheumatology’s Committee on Practice
Guidelines.
Dr. Diane Lacaille was one of three to be appointed to the new Young Investigators
Subcommittee of the American College of Rheumatology. This committee will function as a
liaison between young research scientists and the larger American College of Rheumatology
Committee on Research identifying their research needs.
Page 108
Annual Report 2004
EDUCATIONAL PROGRAMS
Page 109
Annual Report 2004
CLINICAL INVESTIGATOR PROGRAM
Dr. Adeera Levin
Clinical Professor & Co-Director
Dr. Anita Palepu
Associate Professor & Co-Director
The Clinical Investigator Program (CIP) program is an integral component of the Department of
Medicine. Its main goals are to integrate promising medical students, residents and fellows into
an academic environment that sustains and nurtures academic interests. This year, Drs. Palepu
and Levin, were selected as co-directors of this program, after Dr. Peter Pare stepped down from
the position. The CIP program is a resource which permits divisions within the DOM to
leverage funding opportunities in order to support the academic endeavors of those divisions.
The Faculty Clinical Investigator Program is a 2-year program, which has the potential to fund at
least 4 individuals each year. Current CIP young investigators enrolled in the DOM CIP program
from 2004 include: Dr. Warren Davidson (2nd year), Respirology, Dr. Nadia Zalunardo (1st year)
Nephrology, and Dr. Debbie Rosenbaum (1st year) Nephrology.
Accomplishments of those individuals are listed in the appendix below.
Given the importance of the CIP program to the growth and sustainability of research programs,
the co-directors have been more formally integrated into key activities of the DOM. This has
included presentations to the DOM business meetings at both PHC and VGH sites, and ongoing
interaction with Division Heads at the UBC DOM Division Heads meeting held monthly.
There is currently a dedicated office administrative assistant, who works in conjunction with the
other staff in the DOM administrative offices at both sites, to facilitate communication and serve
as a resource for the enrollees.
The CIP directors are currently surveying program and department heads to estimate the number
of research fellows who are currently in the Faculty of Medicine. The intent is to learn of
existing educational curricula and develop an abbreviated curriculum that would be useful to
junior clinician researchers in training.
Page 111
Annual Report 2004
APPENDIX
Dr. Warren Davidson (Year 2)
Division of Respirology
Supervisor: Dr. Tony Bai
Abstracts
A Comparison of the Leicester Cough Questionnaire with the St. George’s Respiratory
Questionnaire in the Evaluation of Treatment Response in Patients with Chronic Cough. ATS
Meeting, May 2005.
Publications
Davidson W. Helical Computed Tomography has a Role in the Screening of Lung Cancer: The
Con Argument. Canadian Respiratory Journal 2004; 11(3): 217-218.
Davidson W, Bai T. Asthma: Clearing the Way. The Canadian Journal of Diagnosis November
2003.
Presentations
Davidson W, Patel M. Helical CT for Lung Cancer Screening - PRO/CON Debate. Canadian
Thoracic Society - American College of Chest Physicians, Orlando. October 26, 2003.
Davidson W. A Comparison of the Leicester Cough Questionnaire with the St. George’s
Respiratory Questionnaire in the Evaluation of Treatment Response in Patients with Chronic
Cough. 12th Canadian Resident Fellow Competition in Respiratory Research. Montreal.
November 29, 2004.
Degree Programs currently enrolled
Master of Health Science Degree
Department of Health Care & Epidemiology, UBC
Dr. Nadia Zalunardo (Year 1)
Division of Nephrology
Supervisor: Dr. Adeera Levin
Abstracts
Harris M, Zalunardo N, Yip B, Werb R, Valyi M, Hogg R, Montaner J. Nephrotoxicity of
tenofovir DF. Canadian Journal of Infectious Diseases 2003; 14 (suppl. A): 31A.
Harris M, Zalunardo N, Bonner S, Werb R, Valyi M, Montaner JSG. Use of estimated
glomerular filtration rate to predict renal toxicity in patients receiving tenofovir DF. 11th
Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA, February 811, 2004. Abstract 750.
Page 112
Annual Report 2004
Publications
Zalunardo N, Tuttle KR. Atherosclerotic renal artery stenosis: current status and future
directions. Current Opinion in Nephrology and Hypertension. 2004; 13:613-21.
Zalunardo N, Lemaire M, Davids MR, Halperin ML. Acidosis in a patient with cholera: A need
to redefine concepts. Quarterly Journal of Medicine 2004; 97:681-96.
Degree Programs currently enrolled
Masters in Science, Epidemiology
Harvard School of Public Health
Expected completion June 2006
Grants applied for 2005-6
Kidney Foundation Fellowship Grant
Michael Smith Fellowship Grant
KRESCENT Program Fellowship Grant
Dr. Debbie Rosenbaum (Year 1)
Division of Nephrology
Supervisor: Drs. Adeera Levin and Paul Keown
Abstracts
Rosenbaum D, Kiaii M, Djurdjev O, Dorscheid D, Grant G, Levin A. Intensive care unit referral
patterns to nephrology. Abstract accepted for presentation at the CRRT conference March 2005
Publications
Halperin M, Rosenbaum D, Kamel KS. Approach to the patient with metabolic acidosis:
Emphasis on the ECF volume and the venous PCO2. Book chapter in press.
CIP Research Project
A strategy for reducing erythropoetin therapy in patients with
erythropoetin resistance. Study timeline: To commence in May/June.
Grants Applied for 2005-6
Kidney Foundation Fellowship
Currently on maternity leave
Page 113
Annual Report 2004
CONTINUING MEDICAL EDUCATION
PROGRAM
Dr. G.B. John Mancini
Professor & Director
New Initiatives/Developments
In 2004 Dr. G.B. John Mancini accepted the position of Director of the Program. The
Department was involved in several initiatives through the year. In February we co-sponsored,
with the Cardiovascular Society of Arizona, the “Southwestern Cardiology Symposium” held in
Phoenix. This was an excellent event and involved the participation of both Canadian and
American speakers.
Our “Medicine in the 21st Century” Conference was held June 10th – 12th at the Sutton Place
Hotel. Twenty-one UBC Faculty participated in the course which was presented to 105
attendees primarily from Canada and the United States. As in past years, we were pleased with
the attendance and quality of the course. The speakers were evaluated highly as was the course
content. It is our hope and intention to continue to offer this course on an annual basis and to
maintain the high quality as well as to continue increasing attendance. This annual event was
followed this year by a post-CME event in the form of an Alaskan Cruise on June 13 – 20. The
faculty consisted of Drs. Jerry Tenenbaum, Lucretia van den Berg, Najib Ayas and Hector
Baillie. The program and speakers were also highly evaluated by the attendees. We are
currently in the process of coordinating our 2005 program which is scheduled to be held June 2 –
4, 2005 at the Fairmont Hotel Vancouver.
In December 2004 we were involved with the Canadian Vascular Biology Working Group and
coordinated a meeting held in Whistler December 9 – 12. This meeting involved 20 participants
and the proceedings will again be published in the Canadian Journal of Cardiology.
In 2004 we began meeting with CME Divisional Program Directors/Division heads to begin to
work on development of further divisional events. We are also looking at development of a
Saturday morning series directed towards Family Practitioners and General Internists in the
community.
We would like to take this opportunity to thank the Faculty Members who have contributed to
the conferences in the past years and continue to work with the Department to help ensure
excellent ongoing CME programs.
Page 115
Annual Report 2004
GRADUATE STUDIES PROGRAM IN
EXPERIMENTAL MEDICINE
Dr. Vincent Duronio
Divisional Overview
Experimental Medicine is the UBC graduate studies program, within the Department of
Medicine, which was developed to train individuals seeking a career in biomedical research.
Students are enrolled in both MSc and PhD degree programs. Subspecialties within the
Experimental Medicine Program include Cancer Biology, Cardiology, Dermatology,
Gastroenterology, Haematology/Oncology, Immunology, Infectious Diseases, Molecular
Biology, Nephrology, Neurology, Pediatrics, Physiotherapy and Respiratory Medicine. A
substantial number of students in the program are under the supervision of faculty members
outside of the department. In 2004, 30 new students were admitted to the program. At the end of
2004, there were 117 students registered in the program, 53 for MSc degrees and 64 for PhD
degrees.
During 2004, a total of sixteen students graduated, seven at the May 2004 Convocation and nine
at the November 2004 Convocation. Student names and thesis titles are listed below (research
supervisor in parenthesis):
PhD Graduates
1.
Svetlana Dmitrienko, Gene Polymorphisms in Renal Transplantation, (Dr. Paul Keown)
2.
Ryan Hung, The Regulation of Apoptosis by Toxic Shock Syndrome Toxin-1 and
Associated Mutants, (Dr. Anthony Chow)
3.
Xiaomei Li, Selective Inhibition of Signal Transduction Pathways in Human CD4+ T
Lymphocyte, (Dr. Paul Keown)
4.
Muhammad Marwali, Role of Lipid Rafts in the Regulation of LFA-1, (Dr. Fumio Takei)
5.
Christopher Miller, The Antibacterial Role of Exogenous Nitrous Oxide Gas, (Dr. Jeremy
Road)
6.
Kenna Sleigh, Relations between Illness Perceptions, Coping, Social Support, and
Outcomes in the Chronic Fatigue Syndrome, (Dr. Grant Stiver)
Page 117
Annual Report 2004
MSc Graduates
1.
Kadria Alasaly, The Maternal Predisposition to the Syndrome of Pre-eclampsia, (Dr.
Keith Walley and Dr. Peter von Dadelszen)
2.
Mei Yieng Chin, Molecular Functions of the Tumour Suppressor p33ING2, (Dr. Gang
Li)
3.
Clare Gardiner, The Role of STAT-3 in Androgen-Dependent Prostate Cancer, (Dr.
Michael Cox)
4.
Anne-Lise Hestvik, Modulation of Host Protein Phosphorylation Upon Mycobacterial
Infection, (Dr. Yossef Av-Gay)
5.
Mohammed Khan, Mechanisms of Enteroaggregative Escherichia Coli flagellin-induced
IL-8 secretion from epithelial cells, (Dr. Theodore Steiner)
6.
Maryam Moussavi, Insight into the mechanisms by which apigenin, curcumin and
sulfasalazine induce apoptosis in colon cancer cells, (Dr. Bill Salh)
7.
Kuldip Ken Parhar, Interleukin 1B signaling in Intestinal Epithelial Cells, (Dr. Bill Salh)
8.
Amanda Rooyakkers, Absence of complement receptor 3 results in reduced binding and
ingestion of mycobacterium tuberculosis but has no significant effect on the induction of
reactive oxygen and nitrogen intermediates or on the survival of the bacteria in resident
and interferon-gamma activated macrophages, (Dr. Richard Stokes)
9.
Jennifer Slivinskas, Cost-effectiveness of Screening for Lung Cancer in A High Risk
Cohort Using Automated Sputum Cytometry, (Dr. Stephen Lam)
10.
Troy Sutton, Interventions for Prevention of Respiratory Syncytial Bronchiolitis and
Sequelae in Guinea Pigs, (Dr. Richard Hegele)
In 2004, 86 Experimental Medicine students received a total of $1,792,816 in funding, an
average of $20,847 per student. Research Supervisors provided $956,700 in Graduate Research
Assistantships. Other funding sources included CIHR ($299,700), the Michael Smith Foundation
($162,800), NSERC ($72,300), the Heart and Stroke Foundation ($41,000), and the UBC
Graduate Entrance Scholarship ($12,296).
There are 111 faculty members currently registered as Research Supervisors in the program.
Faculty members from other departments also participate as course lecturers, thesis committee
members, in research seminars and as examiners for internal examinations and theses defenses.
In the academic year 2004, the Experimental Medicine Program offered nine graduate courses.
These included: MEDI 501 (Molecular & Cellular Biology), MEDI 502 (Methodology), MEDI
530 (Gastroenterology) MEDI 535 (Journal Club), MEDI 548 (Directed Studies in Experimental
Page 118
Annual Report 2004
Medicine), MEDI 560 (Pulmonary Pathophysiology), MEDI 570 (Cardiology), MEDI 580
(Infectious Diseases) and MEDI 590 (Molecular Medicine).
The overall administration of the program is under the guidance of the Experimental Medicine
Committee. The committee is composed of representatives from each subspecialty and one
student representative. This committee meets four times per year to discuss policy and
procedures. Current members of the committee are: Dr. Anthony Chow (Infectious Diseases),
Dr. Vincent Duronio (Respiratory Medicine and Director), Dr. R. Keith Humphries
(Haematology/Oncology), Dr. Gang Li (Dermatology), Dr. Steve Pelech (Molecular Medicine),
Dr. Bill Salh (Gastroenterology), Dr. Andrew Sandford (Respiratory Medicine, iCapture Centre),
Dr. Yu Tian Wang (Neurology, Brain Research Centre), Ms. Alison Wallace (Student
Representative), Dr. Keith Walley (Critical Care), and Dr. Graydon Meneilly (ex-officio). The
Experimental Medicine Program’s daily administration is through the director and one secretary.
The Experimental Medicine Program continues to sponsor an annual Student Research Day. The
2004 event was held on November 12, at the Holiday Inn on Broadway. 16 students gave oral
presentations and 60 students participated in poster presentations. A total of $900 in cash prizes
was presented this year. The prizes this year went to:
Michael Rauh (MD/PhD, Supervisor: Dr. Gerry Krystal) - $300 Best Overall Presentation
Zabrina Brumme (PhD, Supervisor: Dr. Richard Harrigan) - $100 Best Oral Presentation
Poh Tan (PhD, Supervisor: Dr. Kelly McNagny) - $100 Best Oral Presentation
Sima Allahverdian (PhD, Supervisor: Dr. Delbert Dorscheid) - $100 Best Poster Presentation
Kyle Niessen (PhD, Supervisor: Dr. Aly Karsan) - $100 Best Poster Presentation
Benjamin Patchell (PhD, Supervisor: Dr. Delbert Dorscheid) - $100 Best Poster Presentation
Gina Rossi (PhD, Supervisor: Dr. Michael Cox) - $100 Best Poster Presentation
Financial support for Student Research Day was provided by GlaxoSmithKline Inc., Merck
Frosst Canada Inc., the Vancouver Hospital and Health Sciences Centre, Altana Pharma Inc., the
Canadian Society of Biochemistry, Molecular and Cellular Biology, AstraZeneca Canada Inc.,
Hoffman La-Roche, and Janssen-Ortho Inc.
The Experimental Medicine Program continued to offer travel grants to students who had already
used the travel grant provided by the Faculty of Graduate Studies.
The Experimental Medicine Office is located in Room S125, Koerner Pavilion, 2211 Wesbrook
Mall, UBC Campus. The office telephone number is 604-822-7215, the fax number is 604-8227897 and e-mail address is [email protected].
Page 119
Annual Report 2004
HIV/AIDS RESEARCH PROGRAM
Dr. Julio Montaner
Overview
The AIDS Research Program continues to refine the role of antiretroviral therapy for the
treatment of HIV infection. The main areas of research continue to be epidemiology, basic
science and clinical science. In the following report we summarize the program's activities and
areas of concern for the year 2004.
Epidemiological Research
The epidemiology group has again been very productive and continues to benefit from long-term
analyses emerging from the VanGuard Project, the VIDUS and CEDAR cohorts under the
leadership of Drs. Lampinen, Wood and Spittal, respectively. The Drug Treatment Program,
under the leadership of Dr. Robert Hogg, has emerged as a key contributor to our understanding
of the dynamics of the HIV epidemic as well as the effect of treatment. Several key papers,
some of them in highly respected international journals, were published demonstrating the
efficacy of antiretroviral therapy in terms of decreasing morbidity, mortality, and improving the
quality of life in HIV-infected individuals. Members of our team have received funding from the
Michael Smith Health Research Foundation and the Canadian Institutes of Health Research for
doctoral and post-doctoral training. These include Paula Braitstein, Tom Lampinen, Cari Miller,
Magda Piacenza, Amy Weber, Melanie Rusch and Laura Kuyper. Grant funding has also been
obtained by members of our group from the Michael Smith Health Research Foundation,
Canadian Institutes of Health Research, the Ontario HIV Treatment Network, and a number of
pharmaceutical companies.
Basic Science
The research laboratory based at the B.C. Centre for Excellence in HIV/AIDS has established
itself not only as a leading force in Canada, but also as a centre with considerable international
influence. During the year, the laboratory provided clinical services to the province of B.C. in
the areas of HIV drug resistance testing and pharmacokinetic measurement. The clinical
implications and predictors of HIV drug resistance continue to be investigated, both at the B.C.
Centre for Excellence and as part of international collaborations. The research laboratory
continues to develop new tools with clinical applications that may be employed in the near
future. These include tools for monitoring the side-effects and degree of adherence to
Page 121
Annual Report 2004
medications, as well as tracking variations in the HIV and human genomes which are associated
with response to HIV therapy, and virus pathogenicity. In addition to providing HIV drug
resistance testing as a clinical service to most of Canada and investigator driven trials, the
research lab has also received peer-reviewed funding for several studies from the Canadian
Institutes of Health Research, Michael Smith Health Research Foundation, and the Ontario HIV
Treatment Network. Finally, the novel testing applications in the laboratory have lead to the
Research Lab being used to provide testing support for three Phase III clinical trials from a major
pharmaceutical company.
In 2004, members of the lab published more than a dozen important research papers in peerreviewed journals including The Journal of Infectious Disease and AIDS.
Clinical Science
Members of the clinical science group are actively researching a range of issues essential to the
medical management of patients with HIV. Among the areas of focus are treatment of patients
with multidrug-resistant virus, pharmacokinetics of antiretrovirals, optimizing adherence to
antiretroviral therapy regimens, recognition and management of drug toxicities, management of
viral co-infections, and primary care initiatives.
Therapeutic strategies continue to evolve for patients who have experienced treatment failure on
a number of previous antiretroviral regimens. During 2004, a number of new agents with
promise for the treatment of multidrug-resistant HIV became available. These include enfuvirtide
(the first approved HIV fusion inhibitor, administered by subcutaneous injection) and the
investigational agents TMC125 and tipranavir. Enfuvirtide in particular has enabled the design of
effective salvage regimens which are more streamlined than the previous multiple drug salvage
regimens. The clinical group is evaluating novel mechanisms to optimize enfuvirtide
administration with the aim of maximizing patient acceptance and tolerance of this very useful
agent. Other strategies for optimizing salvage therapy, including simplifying complex salvage
regimens, are also being explored.
A number of studies being done by the clinical group in association with the B.C. Centre for
Excellence laboratory have focused on plasma concentrations of antiretroviral drugs, which are
increasingly being recognized as a critical factor in their effectiveness and toxicity. Complex
pharmacokinetic interactions between protease inhibitors, non-nucleoside reverse transcriptase
inhibitors, and other co-administered drugs can have clinically relevant effects on plasma drug
levels in HIV patients and are being studied by our group as well as others worldwide. For
example, intensive studies are underway at our centre examining pharmacokinetic interactions
between the investigational agents TMC125 and tipranavir, and other drugs with which they are
likely to be combined in salvage therapy regimens. In addition, drug level measurements
performed by our clinical and laboratory groups have identified that plasma levels are often low
for atazanavir, a new protease inhibitor that was approved for clinical use in 2004. Ongoing
studies are evaluating strategies for manipulating regimens to improve atazanavir levels and thus
optimize its effectiveness. The group’s capacity to conduct meaningful research into the
pharmacology and toxicology of antiretroviral drugs was greatly enhanced in September 2004
with the addition of Dr. Elizabeth Phillips to the clinical research team.
Page 122
Annual Report 2004
The issues surrounding adherence to antiretroviral drug regimens are a topic of active study by
two clinical psychologists on the team. A number of studies have been completed while others
are underway to systematically evaluate the factors associated with adherence, and to develop
effective intervention techniques with the goal of optimizing patients’ ability to take their
antiretrovirals.
Adverse effects of antiretroviral therapy continue to be a key focus of the clinical research
team’s efforts. Metabolic disorders such as dyslipidemia and mitochondrial toxicity of various
antiretroviral regimens are being intensively evaluated in two international, randomized clinical
trials spearheaded by the B.C. clinical research team, the SPRINT study (completed in 2004) and
the NRTI-sparing study (which is ongoing). Collaborative efforts with the Healthy Heart
Program are evaluating risk factors for cardiovascular disease in patients taking antiretrovirals
and developing novel strategies for preventing these complications of HIV therapy. Previous
work by our group which established an association between kidney toxicity and tenofovir, now
a widely-used antiretroviral agent, has been expanded with the identification of reduced
glomerular filtration rate (a measure of kidney function) as a factor which can be used to identify
patients at risk for this complication. As one strategy for reducing duration of exposure to
antiretrovirals and thereby deferring cumulative toxicities, as well as decreasing associated
health care costs, supervised treatment interruptions continue to be evaluated in terms of their
effects on short- and long-term outcomes. The clinical research team’s findings in all of these
areas were presented at major national and international conferences during 2004.
Co-infection with hepatitis B and C continues to have a major effect on the HIV-infected clinic
population. Ongoing research in this area is examining the effect of tenofovir on hepatitis B viral
load in individuals with HIV/hepatitis B co-infection, and mitochondrial toxicity in the liver
caused by HIV and hepatitis C treatment. In addition, a study is planned which will examine the
issue of suboptimal adherence to anti-hepatitis C treatment in HIV-positive patients.
In 2004, the John Ruedy Immunodeficiency Clinic (IDC) entered its second year as a primary
and specialty clinic for HIV infected patients. The clinical team includes individuals with
expertise in all areas of HIV care with specific emphasis on primary care, infectious diseases,
lipid disorders, anal dysplasia, neurology, dermatology, counseling and psychology, nephrology,
and clinical trial operations.
In the IDC, a large number of HIV-positive patients are monitored regularly. The clinic operates
5 days a week with after-hours on call coverage. A comprehensive team of family physicians,
nurses, social workers, nutritionist, pharmacist, and a substance use counselor is available to all
patients. A large database has been generated with information on primary care initiatives,
allowing a comprehensive assessment of the patient’s health status as well as immunizations, comorbidities, medications, substance use, and other factors of interest.
The clinic, in partnership with the Vancouver Coastal Health Authority and the UBC skill
enhancement program for Family Physicians, offers a 3-month post-graduate program for family
doctors. The aim of the program is to enhance skills in the care and treatment of patients with
HIV/AIDS. An Antiretroviral Outreach Program (ARV-ORO) was also established to help
inform, support and evaluate activities in Vancouver's Downtown Eastside.
Page 123
Annual Report 2004
Current Areas of Active Clinical Research
•
•
•
•
•
•
•
•
•
First-line antiretroviral therapy
Salvage therapy for patients with previous treatment failure and multiple drug-resistant HIV
Strategies for optimizing the use of investigational and newly available antiretroviral agents
Complications of antiretroviral therapy, including lipodystrophy, dyslipidemias,
cardiovascular disease, mitochondrial toxicity, peripheral neuropathy, hepatotoxicity,
nephrotoxicity, osteopenia/osteoporosis
Effect of treatment interruptions on long-term outcomes of HIV disease
Assessing and optimizing adherence to antiretroviral regimens and hepatitis C therapy
Pharmacokinetics of antiretroviral drugs, achieving optimal therapeutic drug levels, and drug
interactions
Treatment and complications of hepatitis B and C co-infections
Prevention and treatment of opportunistic infections
Page 124
Annual Report 2004
Students/Residents/Postdoctoral Research Fellows:
Student Name
Program Type
Supervisor
Dates
Braitstein, Paula
PhD, UBC
1999-2005
R. Hogg
Craib, Kevin
PhD, UBC
1997-2004
M. Schechter
Cuscheri, A.
PhD, UBC
2002-Present
M. Tyndall, R. Hogg
Rusch, Melanie
PhD, UBC
2002-Present
M. Tyndall
Miller, Cari
PhD, UBC
2001-Present
J Frankish et al.
Brumme, Zabrina
(Experimental
Medicine)
PhD, MSHRF, CIHR
2001-Present
R Harrigan, R. Hogg, J. Montaner
Lampinen, Tom
Post-Doc
2002-Present
R. Hogg
Edwards, J.
Environmental Health
2002-2004
Dr. Heacock, E Wood, MW Tyndall
Kulkarni, S.
Infectious Diseases Resident
2003-2004
V. Montessori
O’Connell, Jacqueline
Medical Student
2003-2004
E. Wood
Christie, Timothy
MSc
2003-Present
R. Hogg, J. Montaner
Ramirez Moreno,
Saby
Postdoctoral Research FellowHealth Professional
2004-Present
J. Montaner
Kretz, Patricia
CIHR Translational Research
in Infectious Diseases
2004
R. Hogg, E. Wood
Lloyd-Smith, Elisa
Epidemiology
2004
E. Wood, M. Tyndall
Collins, C.
CIHR Translational Research
in Infectious Diseases
2004
E. Wood
Kuyper, Laura
Medical Student
2004
E. Wood, R. Hogg, J. Montaner
Buchcar, Anna
2004
J. Montaner
Lester, Richard
2004
J. Montaner
Kristen Chen
Samir Malhotra
Ryan Cooper
Osama Al Enezi
Jenny Su
Mark Hull
Eliana Castillo
Residency
2004
J. Montaner
Page 125
Annual Report 2004
Erin Pepper
David Shu
Al Abdali
Elena Koundour
Gurpreet Hans
Abeer Al Shukairy
Florian Muller
Ibrahim Momenkhan
Ghassan Wali
Ana Luiza
Julie Stone
Melody Monro
Michael Buyliss
Harinder Dhaliwal
Gil Kimel
Roberta Halpenny
Dr. Mike Burns
Dr. Daphne Hart
Dr. Susan Ackland
Dr. Dave Forrest
Dr. Nikki Shaw
Dr. Danielle Rouleau
Dr. Tracey Morris
Dr. Claudia Vanzulli
Preceptorship
2004
Page 126
J. Montaner
S. Guillemi
Annual Report 2004
POSTGRADUATE EDUCATION PROGRAM
Dr. Iain Mackie
Clinical Professor & Director
(1997 - October 2004)
Dr. James Mark Roberts
Clinical Instructor & Director
(October 2004 - present)
New Initiatives/Developments
2004 proved to be an exciting year for the Internal Medical Residency Training Program. In
March 2004 the Chief Residents coordinated the “Resident Whistler Conference” over a two day
period. It is through the hard work and diligence of Chief Residents Carolyn Taylor, David
Wood, Monica Beaulieu and Andrew Robinson that this event was, for the second year, very
successful and well-attended.
In March 2004 the Chief Residents organized and hosted the Canadian Chief Medical Resident
Conference held at the Sutton Place Hotel in Vancouver. Over 35 Chief Residents from across
the country attended this 3-day event.
In April 2004 Vancouver was the host city for the Joint Canadian Internal Medicine Program
Directors (CAIMPD) & Canadian Internal Medicine Program Administrators (CAIMPA)
Meeting. Hazel Wilcox chaired the CAIMPA meeting.
In May 2004 we held the 20th Annual Resident Research Day where, once again, the calibre of
research presentations was superb. We welcomed adjudicators Dr. Kathryn Myers, Program
Director at Queen’s University; Dr. Frank Ervin, a community respirologist in Maple Ridge and
Dr. John Conly, Head of Medicine at the University of Calgary. Dr. Anita Palepu did an
excellent job as moderator for this event.
With respect to our resident numbers we received 3 additional PGY-1 positions from the MOH
bringing our currently MOH funding PGY-1 positions to 21. In 2004 several of our first year
residents transferred into other programs/disciplines leaving the Program with a shortage in
Page 127
Annual Report 2004
second year residents for the 2004/2005 academic year. We will receive 2 additional positions
for the 2005/2006 year and 1 PGY-2 position.
In September the program welcomed Sue Wong to the Postgraduate Administrative Team. Sue
is located in the Department of Medicine offices at St. Paul’s Hospital and liaises with the
Vancouver Hospital site.
In October 2004, Dr. Iain Mackie, Program Director for 7 years stepped down and the position
was restructured with the appointment of four New Program Directors. Dr. Mark Roberts,
Program Director, Dr. Roger Wong, Associate Program Director responsible for Curriculum
Development, Dr. Rose Hatala, Associate Program Director responsible for Evaluations &
Remediation, & Dr. Barry Kassen, Associate Program Director responsible for Community and
expansion into the distributed sites.
In November we received 296 Canadian PGY-1 applications for the upcoming academic year.
The interview process was reviewed and restructured and 130 interviews will be held on 3
different days in January rather than on each day throughout the month as in previous years.
Interviews will involve tours by our PGY-1 resident, question & answer session with the
Program Directors and Administrator and lunch to be followed by the actual interview. This will
allow for all applicants to get a better overview of our program as well as interact with many of
the Program Directors. This new process would not be possible without recruitment of many
faculty not directly associated with the Program as well as several senior residents. We would
like to take this opportunity to thank the faculty and residents who have given their time to help
with this process.
Challenges for the upcoming 2005 year will involve an Internal Review to be held in September
2005. Implementation of the Mini Clinical Examinations (Mini-CEX) during each resident
rotation. We also are looking forward to further development of the distributed sites during
expansion of the medical school. We look towards building a strong postgraduate team during
the next academic year with the aim to continue to develop and strengthen this program.
Page 128
Annual Report 2004
UNDERGRADUATE
EDUCATION PROGRAM
Dr. H. Grant Stiver
In the 2003-04 semester, the Undergraduate Program continues to be actively involved in the
bedside training of Second Year medical students prior to entering the Clinical Clerkship. In the
Third Year Clerkship, the National Board of Medical Examiners (NBME) Shelf Examination in
Medicine continues to be the written examination administered to Third Year clerks at the end of
their eight-week Clinical Teaching Unit (CTU) rotation in Internal Medicine. We are also in the
process of preparing pilot clerkship rotations in support of the Medical School Expansion and
researching ways in which academic materials can be delivered to distributed sites.
Second Year Bedside Clinical Skills: In the 2003-04 academic year, the Second year bedside
teaching sessions were again well received by both faculty and students. These sessions
continue to be one of the highest rated courses in the undergraduate curriculum. We have
continued with these sessions this current academic year where students are assigned a patient
and perform a complete and focused history and physical examination, reviewed at the bedside
by a clinician preceptor who also critiques the student’s write-up of the case. The duration of the
course this academic year remains the same as last, January to May, 2005.
Third Year Clerkship:
Evaluation of Academic Half-Day sessions: In September 2004, our Program will use the
WebEval on-line evaluation system for the evaluation of our academic half-day sessions and
Neurology Bedside Teaching sessions. This system sends electronic evaluation forms to
students to obtain feedback on their academic sessions. These reports will be made available to
faculty at the end of each academic year.
Written Examination at the End of the Third year Clerkship in Medicine: The National
Board of Medical Examiners Shelf Examination in Medicine continues to be administered to all
clinical clerks at the end of the 8-week Medicine clerkship. Advantages are the consistent
quality of the clinical case scenarios requiring not only a knowledge base but also some clinical
problem solving skills, as well as the opportunity to compare the performances of our students
with students at a similar stage of training across North America and assess deficiencies and
strengths of our curriculum. Our students are at or above the mean for North American 8-week
clerkships on the NBME exams. The performance of UBC first-time examinees of the NBME
shelf examination in Medicine (all clerkship rotations) during the 2003-04 academic year
resulted in a mean subject exam test score of 74.4 which is a bit higher than the mean for North
Page 129
Annual Report 2004
American medical schools who have an 8 week clerkship (73.9). The performance of students
beginning the clerkship at the end of Third Year generally increased compared with the
performance of the students beginning in September, reflecting the increased clinical experience
acquired throughout the year.
Medical School Expansion: In July 2004, the Undergraduate Program welcomed Dr. Janet
Kushner Kow as the Associate Director of Expansion and New Programs in the UBC
Department of Medicine. Dr. Kushner Kow is involved in planning pilot clerkship rotations in
Medicine in support of the Medical School Expansion. The Medical School Expansion Office
will run an integrated pilot clerkship rotation in Chilliwack, involving six Third Year UBC
medical students, from September 2004 to August 2005. Dr. Kushner Kow and members of the
Undergraduate Education Committee are also actively involved in researching ways in which
academic materials can be delivered to distributed sites.
Page 130
Annual Report 2004
PUBLICATIONS
Page 131
Annual Report 2004
ALLERGY/IMMUNOLOGY
Kanani, Dr. Amin S
Bowen T, Cicardi M, Farkas H, Bork K, Kreuz W, Zingale L, Varga L, Martinez-Saguer I,
Aygören-Pürsün E, Binkley K, Zuraw B, Davis A, Hebert J, Ritchie B, Burnham J, Castaldo A,
Menendez A, Nagy I, Harmat G, Bucher C, Lacuesta G, Issekutz A, Warrington R, Yang W,
Dean J, Kanani A, Stark D, McCusker C, Wagner E, Rivard G-E, Leith E, Tsai E, MacSween
M, Lyanga J, Serushago B, Leznoff A, Waserman S, de Serres J. Canadian 2003 International
Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema.
Journal of Allergy and Clinical Immunology 2004; 114, 3:638-644.
Schellenberg, Dr. Robert R
Robinson PJ, Schellenberg RR, Wakai Y, Road J, Pare P. Canine Trachealis Muscle
Shortening And Cartilage Mechanics. J Appl Physiol. Mar;96(3):1063-8. 2004.
Wong, Dr. HC George
Wong HCG. Potential adverse and allergic reactions to patent medicines containing prescription
drugs. Allergy Clin Immunol Int: J World Allergy Org, 2003; 15(3): 114-118.
Wong HCG. Mercury and Chinese herbal medicine. BC Med J 2004; 46(9):442.
CARDIOLOGY
Aymong, Dr. Eve D
Dangas G, Mehran R, Kobayashi Y, Lansky AJ, Mintz GS, Aymong E, Fahy M, Stone GW,
Leon MB. Short and long-term results after multivessel stenting in diabetics patients. JACC.
2004 Apr 21;43(8):1348-54.
Pellizzon GG, Grines CL, Cox DA, Stuckey T, Tcheng JE, Garcia E, Guagliumi G, Turco M,
Lansky AJ, Griffin JJ, Cohen DJ, Aymong E, Mehran R, O'Neill WW, Stone GW. Importance
of mitral regurgitation in patients undergoing percutaneous coronary intervention for acute
myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late
Angioplasty Complications (CADILLAC) trial. JACC. 2004 Apr 21;43(8):1368-74.
Halkin A, Grines CL, Cox DA, Garcia E, Mehran R, Tcheng JE, Griffin JJ, Guagliumi G,
Brodie B, Turco M, Rutherford B, Aymong ED, Lansky AJ, Stone GW. Impact of intravenous
ß-blockade prior to primary angioplasty on survival in patients undergoing mechanical
reperfusion therapy for acute myocardial infarction. JACC. 2004 May 19;43(10):1780-7.
Costantini CO, Stone GW, Mahran R, Aymong E, Grines CL, Cox DA, Stuckey T, Turco M,
Gersh BJ, Tcheng JE, Garcia E, Griffin JJ, Guagliumi G, Leon MB, Lansky AJ. Frequency,
correlates, and clinical implications of myocardial perfusion after primary angioplasty and
stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction. JACC.
2004 Jul 21;44(2)305-12.
Nikolsky E, Mehran R, Turcot D, Aymong ED, Mintz GS, Lasic Z, Lansky AJ, Tsounias E,
Moses JW, Stone GW, Leon MB, Dangas G. Impact of chronic kidney disease on prognosis of
patients with diabetes mellitus treated with percutaneous coronary intervention. American
Journal of Cardiology. 2004 Aug 1;94(3):300-5.
McLaughlin MG, Stone GW, Aymong E, Gardner G, Mehran R, Lansky AJ, Grines CL,
Tcheng JE, Cox DA, Stuckey T, Garcia E, Guagliumi G, Turco M, Josephson ME, Zimetbaum
P. Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications
trial. Prognostic utility of comparative methods for assessment ST-segment resolution after
primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device
Page 133
Annual Report 2004
Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. JACC. 2004 Sept
15;44(6):1215-23.
Nikolsky E, Mehran R, Halkin A, Aymong ED, Mintz GS, Lasic Z, Megoita M, Fahy M,
Krieger S, Moussa I, Moses JW, Stone GW, Leon MB, Pocock SJ, Dangas G. Vascular
complications associated with arteriotomy closure devices in patients undergoing percutaneous
coronary procedures: a meta-analysis. Journal of the American College of Cardiology. 2004 Sept
15;44(6):1200-9.
Dangas G, Aymong ED, Mehran R, Tcheng J, Grines CL, Cox DA, Garcia E, Griffin JJ,
Guagliumi G, Stuckey T, Lansky AJ, and Stone GW. Predictors of and outcomes of early
thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction
and usefulness of abciximab (the CADILLAC trial). American Journal of Cardiology. 2004 Oct
15;94(8):983-8.
Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ,
Moses JW, Stone GW, Leon MB, Dangas G. A simple risk score for prediction of
contrast-induced nephropathy after percutaneous coronary intervention. Journal of the American
College of Cardiology. 2004 Oct 6;44(7):1393-1399.
Nikolsky E, Mehran R, Aymong ED, Mintz GS, Lansky AJ, Lasic Z, Negoita M, Fahy M,
Pocock SJ, Na Y, Krieger S, Moses JW, Stone GW, Leon MB, Dangas G. Impact of anemia on
outcomes of patients undergoing percutaneous coronary interventions. American Journal of
Cardiology. 2004 Oct 15;94(8):1023-7.
Prasad A, Stone GW, Aymong E, Zimetbaum PJ, McLaughlin M, Mehran R, Garcia E, Tcheng
JE, Cox DA, Grines CL, Gersh BL. Impact of ST-Segment resolution following primary
angioplasty on outcomes after myocardial infarction in the elderly: An analysis from the
CADILLAC trial. American Heart Journal 2004;147(4):669-75.
Halkin A, Aymong ED, Cox DA, Mehran R, Lansky AJ, Fahy M, Weisz G, Garcia E, Tcheng
JE, Grines CL, Stone GW. Relation between late patency of the infarct-related artery, left
ventricular function, and clinical outcomes after primary percutaneous intervention for acute
myocardial infarction (CADILLAC trial). Am J Cardiol. 2004;93(3):349-53.
Nikolsky E, Mehran R, Mintz GS, Dangas GD, Lansky AJ, Aymong ED, Negoita M, Fahy M,
Moussa I, Roubin GS, Moses JW, Stone GW, Leon MB. Impact of symptomatic peripheral
arterial disease on one-year mortality in patients undergoing percutaneous coronary interventions.
Journal of Endovascular Therapies 2004;11:60-70.
Nikolsky E, Aymong E, Halkin A, Grines CL, Cox DA, Garcia E, Mehran R, Tcheng JE,
Griffin JJ, Guagliumi G, Stuckey T, Turco M, Cohen DA, Negoita M, Lansky AJ, Stone GW.
Impact of Anemia in Patients with Acute Myocardial Infarction Undergoing Primary
Percutaneous Coronary Intervention: Analysis from the CADILLAC Trial. Journal of the
American College of Cardiology. 2004 Aug 4;44(3):547-53.
Buller, Dr. Christopher E
Buller CE, Nogareda JG, Ramanathan K, Ricci DR, Djurdjev O, Tinckam KJ, Penn IM, Fox
RS, Stevens LA, Duncan JA, Levin A. The profile of cardiac patients with renal artery stenosis.
J Am Coll Cardiol. 2004;43:1606-13.
Segev A, Kassam S, Buller CE, Lau HK, Sparkes JD, Connelly PW, Seidelin PH, Natarajan
MK, Cohen EA, Strauss BH. Pre-procedural plasma levels of C-reactive protein and interleukin-6
do not predict late coronary angiographic restenosis after elective stenting. Eur Heart J. 2004;25:102935.
Webb JG, Pate GE, Humphries KH, Buller CE, Shalansky S, Al Shamari A, Sutander A,
Williams T, Fox RS, Levin A. A randomized controlled trial of intravenous N-acetylcysteine for
the prevention of contrast-induced nephropathy after cardiac catheterization: Lack of effect. Am
Heart J. 2004;148:422-9.
Page 134
Annual Report 2004
Pate GE, Lowe R, Kuchela A, Buller CE, Vaderah S, Carere RG, Ricci DR, Hamburger JN,
Webb JG. Procedural efficacy and complications of X-Sizer thrombectomy in de novo and stented
lesions. Catheter Cardiovasc Interv. 2004;63:177-82; discussion 183.
Armstrong PW, Bogaty P, Buller CE, Dorian P, O'Neill BJ. The 2004 ACC/AHA Guidelines:
a perspective and adaptation for Canada by the Canadian Cardiovascular Society Working Group.
Can J Cardiol. 2004;20:1075-9.
Bogaty P, Buller CE, Dorian P, O'Neill B J, Armstrong PW. Applying the new STEMI
guidelines: 1. Reperfusion in acute ST-segment elevation myocardial infarction. CMAJ.
2004;171:1039-41.
Dorian P, Bogaty P, Buller CE, O'Neill B J, Armstrong PW. Applying the new STEMI
guidelines: 2. Disturbances of cardiac rhythm after ST-segment elevation myocardial infarction.
CMAJ. 2004;171:1042-4.
Spargias K, Alexopoulos E, Kyrzopoulos S, Iacovis P, Greenwood DC, Manginas A, Voudris
V, Pavlides G, Buller CE, Kremastinos D, Cokkinos DV. Ascorbic acid prevents
contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary
angiography or intervention. Circulation. 2004;110:2837-42.
Madan M, Labinaz M, Cohen EA, Buller CE, Cantor WJ, Seidelin P, Ducas J, Carere RG,
Natarajan MK, Pieper KS, Hafley GE, O'Shea JC, Kitt MM, Califf RM, Tcheng JE. A
comparison of clinical outcomes between Canadian and American patients after non-urgent
coronary stenting. Can J Cardiol 2004 Nov;20(13):p1343-9.
Cairns, Dr. John A
Cairns JA. The Canadian Clinical Research Initiative: transforming Canadian clinical research
capacity. Clin Invest Med 2004; 25(6): 292-95.
Carere, Dr. Ronald G
Pate G, Carere R, Webb J. Damage to a covered stent by a thrombectomy device. Catheter
Cardiovasc Interv. 2004 Jan;61(1):107-110.
Madan M, Labinaz M, Cohen EA, Buller CE, Cantor WJ, Seidelin P, Ducas J, Carere RG,
Natarajan MK, Pieper KS, Hafley GE, O’Shea JC, Kitt MM, Califf RM, Tcheng JE. A
comparison of clinical outcomes between Canadian and American patients after non-urgent
coronary stenting. Can J Cardiol 2004 Nov;20(13):p1343-9.
Pate G, Webb J, Chugh S, Thompson C, Munt B, Carere R, Moss R. Percutaneous closure of a
complex mitral paravalvular leak using transesophageal echocardiographic guidance. Can J
Cardiol 2004;20:452-5.
Pate GE, Humphries KH, Izadnegahdar M, Gao M, Kiely M, Carere RG. Population rates of
invasive cardiac procedures in British Columbia, 1995-2001. Can J Cardiol 2004; 20(7)712-716.
Thompson CR, Humphries KH, Gao M, Galbraith D, Norris C, Carere RG, Knudtson ML,
Ghali WA. Revascularization use and survival outcomes after cardiac catheterization in British
Columbia and Alberta. Can J Cardiol 2004. Vol 20 No 14 Dec. p 1417-23.
Chan, Dr. Sammy
Ayyobi AF, McGladdery SH, Chan S, John Mancini GB, Hill JS, Frohlich JJ. Lecithin:
cholesterol acyltransferase (LCAT) deficiency and risk of vascular disease: 25 year follow-up.
Atherosclerosis. 2004;177(2):361-6.
Page 135
Annual Report 2004
Fung, Dr. Anthony
Sunderji R, Gin K, Shalansky K, Davies C, Schwartz L, Carter C, Chambers K, Fung A.
A randomized trial of patient self-managed versus physician-managed oral anticoagulation.
Canadian J of Cardiology 2004; 20: 1:1117-1123.
Sunderji R, Gin K, Shalansky K, Davies C, Schwartz L, Carter C, Chambers K, Fung A.
Clinical impact of point-of-care versus laboratory measurement of anticoagulation. American
Journal of Clinical Pathology 2005;123:184-8.
Gin, Dr. Kenneth G
Dokainish H, Abbey H, Gin K, Ramanathan K, Lee PK, Jue J. "Tissue Doppler Imaging of the
Right Ventricular Free Wall in the Diagnosis and Prognosis of RV Involvement in Acute Inferior
Wall Myocardial Infarction". Accepted for publication in the American Journal of Cardiology,
December 2004.
Sunderji R, Gin K et al. "A Randomized Trial of Patient Self-Managed versus
Physician-Managed Oral Anticoagulation". The Can J of Card 2004; 20:11:1117-23.
Wood D, Gin K. Cardo Case of the Month - Rate vs Rhythm, Perspectives in Cardiology,
March 2004, Vol 20 No. 3: 13-14.
Grewal J, Gin K. Troponin marks the spot! Perspectives in Cardiology, May 2004: 35-40.
Saw J, Levine A, Gin K. Coronary Artery Disease on Chronic Kidney Disease Patients:
Assessing the Evidence of Diagnosis, Screening and Revascularization. The Can J. of Card. 20:8
(June 2004) 807-813.
Christenson J, Innes G, McKnight D, Boychuk C, Grafstein E, Thompson C, Rosenberg F,
Anis AH, Gin K, Tilley J, Wong H, Singer J. Safety and Efficiency of Emergency Department
Assessment of Patients with Chest Discomfort, CMAJ, June 8, 2004;170(12).
Nogareda G, Gin K. Revascularization in CAD: Life-saving decisons. CardioCase of the Month.
Perspectives in Cardiology, August 2004.
Al-Shehri A, Gin K. All About Mild Aortic Stenosis. Consultant's Corner. The Canadian
Journal of CME, October 2004 16;10.
Sunderji R, Gin K. "Clinical Impact of point-of-care versus laboratory measurement of
anticoagulation" accepted for publication American Journal of Clinical Pathology, December
2004, 2005;123:184-188.
Christensen K, Innes G, McKnight D, Boyhuck C, Grafstein E, Thompson C, Rosenbert F,
Anis A, Gin K, Tilly J, Wong H, Singer J. "Safety and efficiency of emergency department
assessment of chest discomfort" CMAJ 2004;170:1803-1907.
Dzavik V, Sleeper LA, Picard M, Sanborn T, Lowe A, Gin K, Saucedo J, Webb JG, Menon V,
Slater J, Hockman JS. Outcome of patients age >= 75 years in the SHOCK trials. Do elderly
patients with acute myocardial infarction complicated by cardiogenic shock respond differently to
emergent revascularization? Am Heart J. June 2004.
Hamburger, Dr. Jaap N
Serruys PW, Degertekin M, Tanabe Kengo, Russell ME, Guiagliumi G, Webb J, Hamburger J,
Rutsch W, Kaiser C, Whitbourn R, Camenzind E, Meredith I, Reeves F, Nienaber C, Benit E,
Disco C, Koglin J, Columbo A. Vascular responses at proximal and distal edges of
paclitaxel-eluting stents: serial intravascular ultrasound analysis from the TAXUS II trial.
Circulation 2004; 109: 627-633.
Silbur S, Hamburger J, Grube E, Pfisterer M, Belardi J, Webb J, Zmudka K, Neinaber C,
Hauptman K, Rutsch W, Dawkins K, Drzewiecki J, Koglin J, Russell M, Columbo A. Direct
Page 136
Annual Report 2004
stenting with Taxus stents seems to be as safe and effective as with predilation: a posthoc
analysis of TAXUS II. Herz; 2004; 29: 171-180.
Heilbron, Dr. Brett G
Constantoyannis C, Heilbron B, Honey C. Electrocardiogram artifacts caused by deep brain
stimulation. Can. J. Neurol. Sci. 2004;31:343-346.
Humphries, Dr. Karin
LeLorier P, Humphries KH, Krahn A, Connolly SJ, Taljic M, Green M, Sheldon R, Dorian P,
Newman D, Kerr CR, Yee R, Skanes A, Klein GJ. Atrial Fibrillation compared to Atrial Flutter
- Is there a Difference in Outcomes? American Journal of Cardiology 2004;93(5):647-9.
Yeung-Lai-Wah JA, Qi A, McNeill E, Abel JG, Tung S, Humphries KH, Kerr CR. New-onset
Sustained Ventricular Tachycardia and Fibrillation Early After Cardiac Operations. Annals of
Thoracic Surgery 2004;77:2083-8.
Pilote L, Beck CA, Karp I, Alter DA, Austin PA, Cox J, Humphries KH, Jackevicius C,
Richard H, Tu JV. Secondary prevention after acute myocardial infarction in four Canadian
provinces, 1997-2000. Can J Cardiol 2004; 20(1):61-67.
Hassan A, Newman AM, Gong Y, Kennedy C, Humphries KH, Ghali WA, Hirsch GM. Use of
valve surgery in Canada. Can J Cardiol 2004; 20(2):149-154.
Pate GE, Humphries KH, Izadnegahdar M, Gao M, Kiely M, Carere RG. Population rates of
invasive cardiac procedures in British Columbia, 1995-2001. Can J Cardiol 2004; 20(7):712-716.
Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M, Ghali WA, Knudtson ML
for the APPROACH Investigators. The association between renal insufficiency, pharmacotherapy,
and outcomes in 6427 patients with heart failure and coronary artery disease. J Am Coll Cardiol
2004;44(8):1587-92.
Humphries KH, Jackevicius C, Gong Y, Svensen L, Cox J, Tu JV, Laupacis A. Atrial
Fibrillation/Flutter in Canada. Can J Cardiol 2004; 20(9):869-876.
Parkash, R Green MS, Kerr CR, Connolly SJ, Klein GJ, Sheldon R, Taljic M, Dorian P,
Humphries KH. The association of left atrial size and occurrence of atrial fibrillation: A
prospective cohort study from the Canadian Registry of Atrial Fibrillation. Am Heart J 2004;148:64954.
Humphries K.H., Kerr C.R., Steinbuch, M., Dorian, P. Limitations to antiarrhythmic drug use
in patients with atrial fibrillation. Can Med Assoc J. 2004;171(7):741-745.
Webb JG, Pate GE, Humphries KH, Shamari AA, Sutander A, Levin A, Shalansky S, Williams
T, Fox RS, Buller CE. A randomized controlled trial of intravenous N-acetylcysteine for the
prevention of contrast-induced nephropathy following cardiac catheterization. Am Heart J. 2004
Sep;148(3):422-9.
Thompson CR, Humphries KH, Gao M, Galbraith PD, Norris C, Carere RG, Knudtson ML,
Ghali WA. Revascularization use and Outcomes after Cardiac Catheterization in British
Columbia and Alberta. Can J Cardiol 2004;20(14):1417-1423.
Ignaszewski, Dr. Andrew P
Grewal J, Chandavimol M, Ignaszewski A. B-type natriuretic peptide: A new marker for
congestive heart failure, BC Medical Journal Vol 46 No.1 (48) Jan/Feb 2004.
Wiens L, Chandavimol M, Ignaszewski A. Randomized Trial of an Individualized Coronary
Risk Factor Intervention in Patients From Rural Communities Undergoing Percutaneous Coronary
Revascularization. J Cardiopulm Rehabil. 2004;24:259-63.
Shariff S, Straatman L, Allard M, Ignaszewski A. Novel associations of giant cell myocarditis:
Two case reports and a review of the literature. Can J. Cardiol Vol. 20 No. 5 April 2004.
Page 137
Annual Report 2004
Malek F., Ignaszewski, A. "Novel drugs for the treatment of advanced heart failure". Cor Vasa Journal of Czech Soc Cardiol 2004, 46(5):221-225.
Jue, Dr. John
Jue J, McDermid R, Abbey H, Dokainish H. The Relationship of Tissue Doppler to B-Type
Natriuretic Peptide Following Acute Myocardial Infarction. Can J Cardiol 2004;20
Suppl D:1D;468.
Kerr, Dr. Charles R
Humphries KH, Kerr CR, Steinbuch, M, Dorian, P. Limitations to antiarrhythmic drug use in
patients with atrial fibrillation. Can Med Assoc J. 2004;171(7):741-745.
Kerr CR, Connolly SJ, Abdollah H, et al. Canadian Trial of Physiological Pacing: Effects of
physiological pacing during long-term follow-up. Circulation 2004;109(3):357-62.
LeLorier P, Humphries KH, Krahn A, Connolly SJ, Taljic M, Green M, Sheldon R, Dorian P,
Newman D, Kerr CR, Yee R, Skanes A, Klein GJ. Atrial Fibrillation compared to Atrial Flutter
- Is there a Difference in Outcomes? American Journal of Cardiology 2004;93(5):647-9.
Parkash R, Green MS, Kerr CR, Connolly SJ, Klein GJ, Sheldon R, Taljic M, Dorian P,
Humphries KH. The association of left atrial size and occurrence of atrial fibrillation: A
prospective cohort study from the Canadian Registry of Atrial Fibrillation. Am Heart J 2004;148:64954.
Mancini, Dr. GB John
Mancini GBJ, Dahlof B, Diez J. Surrogate Markers for Cardiovascular Disease: Structural
Markers. Circulation. June 29, 2004 Vol 109; 25:IV 22-30.
Mancini GBJ, Editor, Advances in Vascular Biology, Can J Cardiol, Aug 2004;20 (supplement B).
Mancini GBJ. Reporting Measures of Endothelial Dysfunction Independent of Baseline Arterial
Diameter [Letter]. Am J Cardiol 2004;94:1222-1223.
Mancini GBJ, Schulzer M. Letter to the Editor re: Massel D. The number needed to harm: Is it
too optimistic? Can J Cardiol 2004;20(13):1375-76.
Mancini GBJ, Abbott D, Kamimura C, Yeoh E. Validation of a new ultrasound method for the
measurement of carotid artery intima medial thickness and plaque dimensions. Can J Cardiol
2004;20(13):1355-1359.
Ayyobi AF, McGladdery SH, Chan S, Mancini GBJ, Hill JS, Jiri JF. Lecithin: cholestrol
acyltransferase (LCAT) deficiency and risk of vascular disease: 25 year follow-up. Atherosclerosis
2004;177:361-66.
Munt, Dr. Bradley I
Kinnaird TD, Uzun O, Munt BI, Thompson CR, Yeung-Lai-Wah JA. Transesophageal
echocardiography to guide pulmonary vein mapping and ablation for atrial fibrillation. J Am Soc
Echocardiogr. 2004;17(7):769-74.
Munt B, Webb JG, Dang N, Fariabi S, Zarbatany D. Echocardiographic (cardiac ultrasound)
techniques for minimally invasive cardiac procedures. Proceedings from the materials and
processes for medical devices conference. ASM International 2004.
Cardiol 2004; 20: 452-5.
Page 138
Annual Report 2004
Webb J, Munt, B, Makkar R, Naqvi T, Dang N. A percutaneous stent-mounted valve for
treatment of aortic or pulmonary valve disease. Cathet Cardiovasc Interv; 2004: 63: 89-93.
Rabkin, Dr. Simon
Khan NA, McAlister FA, Campbell NR, Feldman RD, Rabkin SW, Mahon J, Lewanczuk R,
Zarnke KB, Hemmelgarn B, Lebel M, Levine M, Herbert C. Canadian Hypertension Education
Program. The 2004 Canadian recommendations for the management of hypertension: Part II-Therapy. Canadian Journal of Cardiology. 20(1):41-54, 2004 .
Kong JY, Rabkin SW. Reduction of Palmitate-induced Cardiac Apoptosis by Fenofibrate.
Molecular and Cellular Biochemistry 258 : 1-13, 2004.
Kong JY. Rabkin SW. Cytoskeletal actin degradation induced by lovastatin in cardiomyocytes
is mediated through caspase-2. Cell Biology International 28 :781-790, 2004.
Tsang MYC, Cowie SE, Rabkin SW. Palmitate increases nitric oxide synthase activity that is
involved in palmitate-induced cell death in cardiomyocytes. Nitric Oxide 10:11-19, 2004.
Ricci, Dr. Donald R
Buller CE, Nogareda JG, Ramanathan KR, Ricci DR, Djurdjev O, Tinckam KJ, Penn IM, Fox
RS, Stevens LA, Duncan JA, Levin A. The profile of cardiac patients with renal artery stenosis.
J Am Coll Cardiol 2004; 43:1606-13.
Saw, Dr. Jacqueline W
Saw J, Topol EJ. Lack of adverse clopidogrel - atorvastatin clinical interaction (letter). Am J
Cardiol 2004;93:669.
Saw J, Levin A, Gin K. Coronary artery disease in chronic kidney disease patients: Assessing
the evidence for diagnosis, screening and revascularization. Can J Cardiol 2004;20:807-13.
Saw J, Topol EJ, Steinhubl SR, Brennan D, Berger PB, Moliterno DJ, for the CREDO
Investigators. Long-term clopidogrel is particularly beneficial for patients requiring repeat
revascularization following percutaneous coronary intervention. Am J Cardiol 2004;94(5):623-5.
Saw J, Brennan D, Topol EJ, Steinhubl SR, Berger PB, Kereiakes DJ, Serebrauny VL.
Clopidogrel-Atorvastatin Interaction (reply). Circulation 2004;109:e230.
Saw J, Lincoff AM, Desmet W, Betriu A, Rutsch W, Wilcox RG, Kleiman NS, Wolski K,
Topol EJ for the REPLACE-2 Investigators. Lack of Clopidogrel Pretreatment Effect on the
Relative Efficacy of Bivalirudin with Provisional GPllb/llla Blockade Compared to Heparin with
Routine GPllb/llla Blockade. A REPLACE-2 Substudy. JACC 2004;44(6):1194-9.
Saw J, Gurm HS, Fathi RB, Bhatt DL, Abou-Chebl A, Bajzer C, Yadav JS. Effects of chronic
kidney disease on outcomes following carotid artery stenting. Am J Cardiol 2004;94(8):1093-6.
Saw J, Bhatt DL. The Evolving Role of Percutaneous Intervention in Coronary Artery Disease
with Coexistent Aortic Stenosis. J Inv Cardiol, 2004;16(12)692-3.
Saw J, Yadav JS, Haery C, Krieger DW, Abou-Chebl A. Intracranial middle cerebral artery
percutaneous intervention using a drug-eluting stent. Vascular Disease Management (Oct 2004).
Straatman, Dr. Lynn P
Shariff S, Straatman L, Allard M, Ignaszewski A. Novel associations of giant cell myocarditis:
Two case reports and a review of the literature. Can J. Cardiol Vol. 20 No. 5 April 2004.
Sedlak TL, Chandavimol M, Straatman L. Cardiac transplantation: a temporary solution for
Friedreich's ataxia-induced dilated cardiomyopathy. J Heart Lung Transplant 2004;23(11):1304-6.
Page 139
Annual Report 2004
Thompson, Dr. Christopher R
Christenson J, Innes G, McKnight D, Boychuk B, Grafstein E, Thompson CR, Rosenberg F,
Anis AH, Gin K, Tilley J, Wong H, Singer J. Safety and efficiency of emergency department
assessment of chest discomfort. CMAJ 2004;170:p1803-1807.
Echocardiogr. 2004;17(7):769-74.
Cardiol 2004;20:452-5.
Thompson CR, Humphries KH, Gao M, Galbraith D, Norris C, Carere RG, Knudtson ML,
Ghali WA. Revascularization use and survival outcomes after cardiac catheterization in British
Columbia and Alberta. Can J Cardiol 2004. Vol. 20 No. 14 Dec. p 1417-23.
Tung, Dr. Kei Kwong (Stanley)
Webb, Dr. John G
Pate G, Carere R, Webb J. Damage to a covered stent by a thrombectomy device. Catheter
Cardiovasc Interv. 2004 Jan;61(1):107-110.
complex perivalvular leak using transesophageal echocardiographic guidance. Can J Cardiol
2004; 20:452-5.
Pate G, Lowe R, Kuchela A, Buller CE, Vaderah S, Carere RG, Ricci DR, Hamburger JN,
Webb JG. Procedural efficacy and complications of X-Sizer thrombectomy in de novo and
stented lesions. Cathet Cardiovasc Interv 2004; 63: 177-82; discussion 183.
Webb J, Munt B, Makkar R, Naqvi T, Dang N. A percutaneous stent-mounted valve for
treatment of aortic or pulmonary valve disease. Cathet Cardiovasc Intervent; 2004: 63: 89-93.
Serruys PW, Degertekin M, Tanabe Kengo, Russell ME, Guiagliumi G, Webb J, Hamburger J,
Rutsch W, Kaiser C, Whitbourn R, Camenzind E, Meredith I, Reeves F, Nienaber C, Benit E,
Disco C, Koglin J, Columbo A. Vascular responses at proximal and distal edges of
paclitaxel-eluting stents: serial intravasuclar untlrasound analysis from the TAXUS II trial.
Circulation 2004; 109: 627-633.
McClure S, Webb J. Drug-eluting stents and saphenous vein graft intervention. J Invasive
Cardiol 2004; 16: 234-5.
Cotter G, Webb J, et al. Cardiac power is the strongest hemodynamic predictor of mortality in
cardiogenic shock: a report from the SHOCK Trial Registry. J Am Coll Cardiol 2004; 44: 340-8.
Webb JG, Pate G, Humphries KA, Buller CE, Al Shamari A, Sutander A, Shalansky S,
Williams T, Rebecca S, Fox RS, Levin A. A randomized controlled trial of intravenous
acetylcysteine for the prevention of contrast-induced nephropathy following cardiac
catheterization: Lack of effect. Am Heart J 2004; 148:422-9.
Silbur S, Hamburger J, Grube E, Pfisterer M, Belardi J, Webb J, Zmudka K, Neinaber C,
Hauptman K, Rutsch W, Dawkins K, Drzewiecki J, Koglin J, Russell M, Columbo A. Direct
stenting with Taxus stents seems to be as safe and effective as with predilation: a posthoc
analysis of TAXUS II. Herz; 2004; 29: 171-180.
Reifart N, Morice MC, Silber S, Benit E, Hauptmann KE, De Sousa E, Webb J, Kaul U, Chan
C, Thuesen L, Guagliumi G, Cobaught M, Dawkins K. The NUGGET study: Nir Ultra
gold-gilded equivalency trial. Cathet Cardiovasc Interv 2004; 62: 18-25.
Page 140
Annual Report 2004
Webb JG. How would you manage this case? J Invasive Cardiol 2004; 16: 199.
Munt B, Webb JG, Dang N, Fariabi S, Zarbatany D. Echocardiographic (cardiac ultrasound)
techniques for minimally invasive cardiac procedures. Proceedings from the materials and
processes for medical devices conference. ASM International 2004.
Yeung-Lai-Wah, Dr. John A
Echocardiogr. 2004;17(7):769-74.
CRITICAL CARE
Dodek, Dr. Peter M
Keenan SP, Dodek P, Chan K, Simon M, Hogg RS, Anis AH, Spinelli JJ, Tilley J, Norena M,
Wong H. ICU survivors have fewer hospital readmissions and readmission days than other
hospitalized patients in British Columbia. Critical Care Medicine 32: 391-398, 2004.
Griffith L, Cook D, Hanna S, Rocker G, Sjokvist P, Dodek P, Marshal J, Levy M, Varon J,
Finfer S, Jaeschke R, and Guyatt G for the Level of Care Investigators and the Canadian Critical
Care Trials Group. Clinician discomfort with life support plans for mechanically ventilated
patients. Intensive Care Medicine 30:1783-1790, 2004.
Dodek P. Diabetes and other comorbidities were associated with a poor outcome in the severe
acute respiratory syndrome [Comment]. ACPJ Club. 2004 Jan-Feb; 140:19.
Meade MO, Jacka MJ, Cook DJ, Dodek P, Griffith L, Guyatt GH for the Canadian Critical Care
Trials Group. A Survey of Interventions for the Prevention and Treatment of Acute Respiratory
Distress Syndrome. Critical Care Medicine 32:946-954, 2004.
Thompson W, Dodek PM, Norena M, Dodek J. Computerized physician order entry of
diagnostic tests in an ICU is associated with improved timeliness of service. Critical Care
Medicine. 32:1306-1309, 2004.
Dodek PM, Heyland DK, Rocker GM, Cook DJ. Translating family satisfaction data into quality
improvement. Critical Care Medicine, 32: 1922-1927, 2004.
Rocker G, Cook D, Sjokvist P, Weaver B, Finfer S, McDonald E, Marshall J, Kirby A, Levy
M, Dodek P, Heyland D, Guyatt G, for the Level of Care Study Investigators & the Canadian
Critical Care Trials Group. Clinician Predictions of Intensive Care Unit Mortality. Critical Care
Medicine. 32:1149-1154, 2004.
Dodek PM, Cook DJ, Keenan S, Heyland DK, Brun-Buisson C, Hall R, Jacka M, Foster D,
Hand L, Mehta N, Muscedere J for the Canadian Critical Care Trials Group. Evidence based
clinical practice guideline for the prevention of ventilator-associated pneumonia. Annals of
Internal Medicine, 141: 305-313, 2004.
Sinuff T, Cook DJ, Rocker GM, Griffith LE, Walter SD, Fisher MM, Dodek PM, Sjokvist P,
McDonald E, Marshall JC, Kraus PA, Levy MM, Lazar NM, Guyatt GH for the Level of Care
Study Investigators and the Canadian Critical Care Trials Group. DNR directives are established
early in mechanically ventilated intensive care unit patients. Canadian Journal of Anesthesia. 51:
1034-1041, 2004.
Page 141
Annual Report 2004
Dorscheid, Dr. Delbert R
Davani EY, Dorscheid DR, Lee CH, Van Breemen C, Walley KR. Novel regulatory mechanism
of cardiomyocyte contractility involving ICAM-1 and the cytoskeleton. Am J Physiol Heart
Circ Physiol. 2004 Apr 15. [Epub ahead of print]
Undevia NS, Dorscheid DR, Marroquin BA, Gugliotta WL, Tse R, White SR. Smad and
p38-MAPK Signaling Mediates Apoptotic Effects of Transforming Growth Factor-{beta}1
(TGF-{beta}1) in Human Airway Epithelial Cells. Am J Physiol Lung Cell Mol Physiol. 2004
May 7. [Epub ahead of print]
Keenan, Dr. Sean P
Keenan SP, Chan K, Simon M, Levy AR, Hogg R, Spinelli J, Craib K, Dodek P. ICU
Survivors have fewer hospital readmissions and readmission days than other hospitalized
patients. Crit Care Med 2004: 32:391-398.
Sinuff T, Keenan SP. A clinical practice guideline for the use of noninvasive positive pressure
ventilation in COPD patients with acute respiratory failure. J Crit Care 2004; 19:82-91.
Dodek PM, Keenan SP, Cook DJ, et al. Evidence based clinical practice guideline for the
prevention of ventilator-associated pneumonia. Ann Intern Med 2004; 141:305-313
Keenan SP, Sinuff T, Cook DJ, Hill N. Does noninvasive positive pressure ventilation improve
outcome in acute hypoxemic respiratory failure? A systematic review. Crit Care Med 2004;
32:2516-2523.
Ronco, Dr. Juan J
Chittock DR, Dhingra VK, Ronco JJ, Russell JA, Forrest D, Tweeddale MG, Fenwick JC.
Severity of illness and the risk of death associated with pulmonary artery catheter use. Crit Care
Med 2004; 32(4):911-915.
Russell, Dr. James A
Russell JA, Naviickis RJ, Wilkes MW. Albumin vs. crystalloid for pump priming in cardiac
surgery: Meta-analysis of controlled trials. J Cardiothoracic Vasc Anesth 2004; 18(4): 429-437.
Kinasewtiz G, Yan B, Basson, Comp, Russell JA, Cariou, Um, Utterback, Laterre, Dhainaut.
Universal changes in biomarkers of coagulation and inflammation occur in patients with severe
sepsis, regardless of causative organism. Crit Care 2004; 8(2): R 82 - R 90.
Groshaus H, Manocha S, Walley KR, Russell JA. Mechanisms of beta-receptor stimulation and
clearance of pulmonary edema. Critical Care 2004; 8: 234-242.
Chittock D, Dhingra V, Ronco J, Russell JA, Forrest D, Tweedale M, Fenwick J. Severity of
illness and risk of death associated with pulmonary artery catheter use. Crit Care Med 2004; 32:
911-915.
Fuchisawa A, van Eeden S, Magee LA, Whalen B, Leung PCK, Russell JA, Walley KR, von
Dadelszen P. Neutrophil apoptosis in preeclampsia, do steroids confound the relationship? J
Obs Gyn Res 2004; 30 (5): 342-348.
Von Dadelszen P, Magee LA, Devarakonda RM, Hamilton T, Ainsworth LM, Yin R, Kuzeljivic
B, Norena M, Walley KR, Gruslin A, Redman CWG, Moutquin J-M, Lee SK, Russell JA.
The prediction of adverse maternal outcomes in pre-eclampsia. J Obstet Gynecol Can 2004; 26
(10): 871-880.
McIntyre LA, Fergusson DA, Hebert PC for the Transfusion Requirements in Critical Care
Investigators. Is a restrictive transfusion strategy safe in resuscitated multiple trauma victims? J
Trauma 2004;57(3):563-568.
Page 142
Annual Report 2004
Walley, Dr. Keith R
Groshaus HE, Manocha S, Walley KR, Russell JA. Mechanisms of beta-receptor
stimulation-induced improvement of acute lung injury and pulmonary edema. Crit Care 8(4):234-42,
2004.
Davani EY, Dorscheid DR, Lee CH, Van Breemen C, Walley KR. Novel regulatory mechanism
of cardiomyocyte contractility involving ICAM-1 and the cytoskeleton. Am J Physiol Heart
Circ Physiol. 287(3):H1013-22, 2004.
Dadelszen P. Neutrophil apoptosis in pre-eclampsia, do steroids compound the relationship. J
Obstet Gynaecol Res. 30(5), 342-348, 2004.
von Dadelszen P, Magee LA, Devarakonda RM, Hamilton T, Ainsworth LM, Yin R, Kuzeljvic
B, Norena M, Walley KR, Gruslin A, Redman CWG, Moutquin J-M, Lee SK, Russell JA. The
prediction of adverse maternal outcomes in pre-eclampsia. J Obstet Gynaecol Can. 26(10):871-80,
2004.
Tebbutt SJ, He JQ, Burkett KM, Ruan J, Opushnyev IV, Tripp BW, Zeznik JA, Abara CO,
Nelson CC, Walley KR. Microarray genotyping resource to determine population stratification
in genetic association studies of complex disease. Bio Techniques 37:977-985, 2004.
Holmes CL, Walley KR. Vasopressin in the ICU. Curr Opin Crit Care. 10(6):442-448, 2004.
DERMATOLOGY
Cowan, Dr. Bryce J
Cowan B, Zhou B, Gauldie J, Rabinovitch M. Different Mechanisms Underlie Elafin and
Alpha1-Proteinase Inhibitor Repression of IL-1ß Stimulated Fibronectin Synthesis in Cultured
Porcine Coronary Artery Smooth Muscle Cells. Circulation Research 2004. (Accepted pending
revisions).
Dutz, Dr. Jan P
Schutze-Redelmeir MP, Kong S, Bally MB, DUTZ J. Antennapedia transduction sequence
promotes anti tumour immunity to epicutaneously administered CTL episodes. Vaccine 2004;
7;22(15-16):1985-91.
Klimuk SK, Semple SC, Aslanian S, DUTZ JP. CpG adjuvants promote the generation of CTL
to epicutaneously administered peptide or protein antigen application of CpG, J Invest Dermatol
2004; 122(4):1042-9.
Lee I-F, Qin H, Trudeau J, DUTZ JP, Tan R. Regulation of autoimmune diabetes by complete
Freund's adjuvant is mediated by natural killer cells. J Immunol 2004; 172(2):937-42.
Albrecht J, Berlin JA, Braverman IM, Callen JP, Costner MI, DUTZ J, Fivenson D, Franks AG,
Jorizzo JL, Lee LA, McCauliffe DP, Sontheimer RD, Werth VP. Dermatology position paper on
the revision of the 1982 ACR criteria for systemic lupus erythematosus. Lupus 2004;13(11):839-49.
Qin H, Trudeau JD, Reid GS, Lee IF, DUTZ JP, Santamaria P, Verchere CB, Tan R. Progression
of spontaneous autoimmune diabetes is associated with a switch in the killing mechanism used
by autoreactive CTL. Int Immunol 2004 Nov;16(11):1657-62.
Ho, Dr. Vincent
Ho V. The use of ciclosporin in psoriasis: A clinical review. Brit J Dermatol 2004;150 (Suppl
67):1-10.
Griffiths CEM, Dubertret L, Ellis C, Finlay A, Finzi AF, Ho VC et al. Ciclosporin in
psoriasis: Clinical practice. An international consensus statement. Brit J Dermatol 2004;150
(Suppl 67): 1-13.
Page 143
Annual Report 2004
Li, Dr. Gang
Campos EI, Xiao H, Li G. Generation of a polyclonal antibody specifically against the
p33ING1b tumor suppressor. J Immunoassay & Immunochem 2004; 25:71-80.
Campos EI, Martinka M, Mitchell DL, Dai DL, Li G. Mutations of the ING1 tumor suppressor
gene detected in human melanoma abrogate nuclear excision repair. Int J Oncol 2004; 25:73-80.
Bush JA, Li G. Current advances in metastatic melanoma treatment: Bcl-2 antisense therapy.
Hospital Pharmacy Europe 2004; 14:38-39.
Dai DL, Martinka M, Bush JA, Li G. Reduced Apaf-1 expression in human cutaneous
melanoma. Br J Cancer 2004; 91:1089-1095.
Campos EI, Chin MY, Kuo WH, Li G. Biological functions of the ING family tumor
suppressors. Cel. Mol Life Sci 2004; 61:42597-2613.
Ng KP, Campos EI, Martinka M, Li G. XAF1 expression is significantly reduced in human
malignant melanoma. J Invest Dermatol 2004; 123:1127-1134, 2004.
Jia W, Bu X, Philips D, Yan H, Liu G, Chen X, Bush JA, Li G. Rh2, a compound extracted
from ginseng, hypersensitizes multidrug-resistant tumor cells to chemotherapy. Can J Physiol
Pharmacol 2004; 82: 431-437.
Lui, Dr. Harvey
Tang L, Cao L, Sundberg JP, LUI H, Shapiro J. Restoration of hair growth in mice with an
alopecia areata-like disease using topical anthralin. Exp Dermatol 2004; 13:5-10.
Hamzavi I, Jain H, McLean D, Shapiro J, Zeng H, LUI, H. Parametric modeling of narrowband
UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index.
Arch Dermatol 2004; 140(6):677-83.
Huang H, Zheng W, Xie S, Chen R, Zeng H, McLean DI, LUI H. Laser-induced
autofluorescence microscopy of normal and tumor human colonic tissue. Int J Oncol 2004; 24:59-64.
Huang Z, LUI H, Chen XK, Alajlan A, McLean DI, Zeng H. Raman spectroscopy of in vivo
cutaneous melanin. J Biomed Optics 2004; 9:1198-1205.
Kragballe K, Noerrelund KL, LUI H, Ortonne JP, Wozel G, Uurasmaa T, Fleming C, Lopez
Estebaranz JL, Hanssen LI, Persson LM. Efficacy of once-daily treatment regimens with
calcipotriol ointment in psoriasis vulgaris. Brit J Dermatol 2004;150:1167-1173.
LUI H, Langley R et al. Incorporating biologics into the treatment of psoriasis. J Cutan Med
Surg 2004;8-13.
Gupta AK, Langley R, Poulin Y, LUI H et al. Pathogenesis of psoriasis and current challenges.
J Cutan Med Surg 2004; 3-7.
McLean, Dr. David I
Huang Z, Zheng W, Xie S, Rong C, Zeng H, McLean D, Lui H. Laser-induced autofluorescence
microscopy of normal and tumor human colonic tissue. Int J Oncol 2004; 24:59-64.
Rivers, Dr. Jason K
Rivers JK. Is there more than one road to melanoma? Lancet 2004;363:728-730.
de Gannes GC, Ip JL, Martinka M, Crawford RI, Rivers JK. Early detection of skin cancer by
family physicians: A pilot project. J Cutan Med Surg 2004;Mar 25.
Rivers JK. Topical 3% diclofenac in 2.5% hyaluronan gel for the treatment of actinic keratoses.
Skin Therapy Lett 2004;9:1-3.
Shapiro, Dr. Jerry
Tang L, Cao L, Sundberg J, Lui H, Shapiro J. Restoration of hair growth in mice with an
alopecia areata like disease using topical anthralin. Exper Dermatol 2004; 13(1):5-10.
Page 144
Annual Report 2004
Tan E, Martinka M, Ball N, Shapiro J. Primary cicatricial alopecias - a clinico-pathologic
review of 112 cases. J Am Acad Dermatol 2004; 50:25-32.
Hamzavi I, Jain H, McLean D, Shapiro J, Zeng H, LUI, H. Parametric modeling of narrowband
UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index.
Arch Dermatol 2004; 140(6):677-83.
Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D et al. Alopecia areata
investigational assessment guidelines-Part II. J Am Acad Dermatol 2004; 51(3):440-7.
Ross EK, Shapiro J. A practical approach to nonscarring alopecia: Male pattern hair loss.
Contemporary Dermatol 2004; 2(1).
Ross EK, Shapiro J. A practical approach to nonscarring alopecia: Female pattern hair loss and
telogen effluvium. Contemporary Dermatol 2004; 2(2).
ENDOCRINOLOGY
Fung, Dr. Michelle A
Fung M, Tildesley H, Gill S. New treatments and treatment philosophy for type 1 diabetes.
British Columbia Medical Journal 2004;46(9):451-456.
Fung M, Thompson D, Warnock G. Pancreatic islet transplantation: A review. British
Columbia Medical Journal 2004;46(9):457-460.
Prior, Dr. Jerilynn C
Papaioannou A, Joseph L, Ioannidis G, Berger C, Anastassiades T, Brown JP, Hanley DA,
Hopman W, Josse RG, Kirkland S, Murray TM, Olszynski W, Pickard L, Prior JC, Siminoski
K, Adachi JD, CaMOS Research Group. Risk Factors Associated with Incident Clinical
Vertebral and Non-Vertebral Fractures in Postmenopausal Women: The Canadian Multicentre
Osteoporosis Study (CaMOS). Osteoporosis International. On-Line Oct 2004.
Hitchcock CL, Prior JC. A critical woman-centred review of Is Menstruation Obsolete? By
Coutinho and Segal. Women and Therapy 2004:27:195-203.
Hitchcock CL and Prior JC. Evidence about extending the duration of oral contraceptive use to
suppress menstruation. Women's Health Issues. 2004 Vol 14/6 pp201-211.
Tildesley, Dr. Hugh D
Fung M, Tildesley H & Gill S. New Treatments and Treatment Philosophy for Type 1
Diabetes. BC Medical Journal. Vol. 46, No. 9, November 2004, pp. 451-456.
Thommasen HV, McArthur A, Tierney M, Nast S & Tildesley H. Do Rural Patients Benefit
From Visits to an Urban Diabetes Teaching Centre? BC Medical Journal. Vol. 46, No. 9,
November 2004, pp. 467-471.
Tildesley H. Long-Term Experience in Out-Patient Treatment of Type 1 Diabetes: Results of
934 Patients Up To 10 Years. (Accepted for Publication - Canadian Journal of Diabetes) 2004.
GASTROENTEROLOGY
Byrne, Dr. Michael F
Gerke H, White R, Byrne MF, Stiffier H, Mitchell RM, Hurwitz HI, Morse MA, Branch MS,
Jowell PS, Czito B, Clary B, Pappas TN, Tyler DS, Baillie J. Complications of
pancreaticoduodenectomy after neoadjuvant chemoradiation in patients with and without
preoperative biliary drainage. Dig Liver Dis. 2004;36:412-418.
Page 145
Annual Report 2004
Byrne MF, Mitchell RM, Gerke H, Goller S, Stiffler HL, Golioto M, Branch MS, Jowell PS,
Baillie J. The need for caution with topical anesthesia during endoscopic procedures, as liberal
use may result in methemoglobinemia. J Clin Gastroenterol. 2004;38:225-229.
Byrne MF, Gerke H, Mitchell RM, Stiffler HL, McGrath K, Branch MS, Baillie J, Jowell PS.
Yield of endoscopic ultrasound-guided fine-needle aspiration of bile duct lesions. Endoscopy.
2004;36:715-719.
Byrne MF, Power DG, Keeling AN, Kay E, Murray FE, Patchett SE. Combined terminal
ileoscopy and biopsy is superior to small bowel follow-through in detecting terminal ileal
pathology. Dig Liver Dis. 2004 Feb;36(2):147-52.
Sheehan KM, Byrne MF, Murray FE. The seroprevalence of Helicobacter pylori in an Irish
university student population. J Infect. 2004 Apr;48(3):283-4.
Corcoran PA, Byrne MF. Is the host responsible? -- the role of the immune system in
Helicobacter pylori infection. Med Hypotheses. 2004;62(1):95-6.
Gerke H, Byrne MF, Xie HB, Paulson EK, Tyler DS, Baillie J, Jowell PS. A wolf in sheep's
clothing: a non-functioning islet cell tumor of the pancreas masquerading as a microcystic (serous
cystic) adenoma. Jop. 2004;5:225-230.
Gerke H, Byrne MF, Stiffler HL, Obando JV, Mitchell RM, Jowell PS, Branch MS, Baillie J.
Outcome of endoscopic minor papillotomy in patients with symptomatic pancreas divisum. Jop.
2004;5:122-131.
Sheehan KM, Cahill RA, McGreal G, Steele C, Byrne MF, Kirwan WO, Kay EW, Fitzgerald
DJ, Redmond HP, Murray FE. Cyclooxygenase-2 expression in primary human colorectal
cancers and bone marrow micrometastases. Dig Liver Dis. 2004;36:392-397.
Sheehan KM, O'Connell F, O'Grady A, Conroy RM, Leader MB, Byrne MF, Murray FE, Kay
EW. The relationship between cyclooxygenase-2 expression and characteristics of malignant
transformation in human colorectal adenomas. Eur J Gastroenterol Hepatol. 2004;16:619-625.
Chatur, Dr. Nazira
Chatur, N. Your Liver: What is it and What Happens when it Fails. MSJ VIVA. 2004.
Yoshida EM, Ramji A, Chatur N, Davis JE, Owen DA. Regression of cirrhosis associated with
Be (Hbe) antigen-negative chronic hepatitis infection with prolonged lamivudine therapy. Eur J
Gastroenterol Hepatol. 2004;16:355-358.
Enns, Dr. Robert A
Enns RA, Barkun AN, Gerdes H. Electronic endoscopic information systems: what is out there?
Gastrointest Endosc Clin N Am. 2004;14:745-754, x.
Bressler B, Lo C, Pluta K, Amar J, Whittaker S, Chaun H, Halparin L and Enns R.
Prospective Evaluation Of Screening Colonoscopy: Who Is Being Screened? Gastrointest
Endosc. 2004;60:921-926.
Barkun A, Sabbah S, Enns R, Armstrong D, Gregor J, Fedorak RN, Rahme E, Toubouti Y,
Martel M, Chiba N, Fallone CA. The Canadian Registry on Nonvariceal Upper Gastrointestinal
Bleeding and Endoscopy (RUGBE): Endoscopic hemostasis and proton pump inhibition are
associated with improved outcomes in a real-life setting. Am J Gastroenterol. 2004;99:1238-1246.
Panaccione R, Fedorak RN, Aumais G, Bernstein C, Bitton A, Croitoru K, Enns R, Feagan B,
Fishman M, Gelly A, Greenberg G, Griffiths A, Marshall JK, Rasul I, Sadowski D, Seidman E,
Steinhart H, Sutherland L, Walli E, Wild G, Williams N, Zachos M. Canadian Association of
Gastroenterology Clinical Practice Guidelines: The Use of Infliximab in Crohn’s Disease. Can J
Gastroenterol. 2004;18:503-508.
Sandborn WJ, Feagan BG, Radford-Smith G, Kovacs A, Enns R, Innes A, Patel J. CDP571, a
humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's
disease: a randomised, double blind, placebo controlled trial. Gut. 2004;53:1485-1493.
Page 146
Annual Report 2004
Enns R. Capsule endoscopy: new technology that is here to stay. Can J Gastroenterol.
2004;18:545-546.
Enns R, Go K, Chang H, Pluta K. Capsule endoscopy: a single-centre experience with the first
226 capsules. Can J Gastroenterol. 2004;18:555-558.
Enns R, Andrews CN, Fishman M, Hahn M, Atkinson K, Kwan P, Levy A. Description of
prescribing practices in patients with upper gastrointestinal bleeding receiving intravenous proton
pump inhibitors: a multicentre evaluation. Can J Gastroenterol. 2004;18:567-571.
Enns R. Less acid + less bleeding = better outcomes and more money! Can J Gastroenterol.
2004;18:747-748; discussion 748.
Fishman, Dr. Martin J
Enns R, Andrews CN, Fishman M, et al. Description of prescribing practices in patients with
upper gastrointestinal bleeding receiving intravenous proton pump inhibitors: a multicentre
evaluation. Can J Gastro 2004; 18:567-71.
Panaccione R, Fedorak RN, Aumais G, Bernstein CN, Bitton A, Croitoru K, Enns R, Feagan
B, Fishman M, Greenberg G, Griffiths A, Marshall JK, Rasul I, Sadowski D, Seidman E,
Steinhart H, Sutherland L, Walli E, Wild G, Zachos M. Canadian Association of
Gastroenterology Clinical Practice Guidelines: the use of infliximab in Crohn’s disease. Can J Gastro
2004; 18:503-8.
Barkun A, Fallone CA, Chiba N, Fishman M, Flook N, Martin J, Rostom A, Taylor A. A
Canadian clinical practice algorithm for the management of patients with nonvariceal upper
gastrointestinal bleeding. Can J Gastro 2004; 18: 605-9.
Freeman, Dr. Hugh J
Freeman HJ. Strongly positive tissue transglutaminase antibody assays without celiac disease.
Can J Gastroenterol. 2004 Jan;18(1):25-8.
Freeman HJ. Lymphoproliferative and intestinal malignancies in 214 patients with
biopsy-defined celiac disease. J Clin Gastroenterol 2004; 38: 429-434.
Freeman HJ. Collagenous colitis as the presenting feature of biopsy-defined celiac disease. J Clin
Gastroenterol 2004; 38: 664-668.
Freeman HJ. Long-term prognosis of early-onset Crohn's disease diagnosed in childhood or
adolescence. Canad J Gastroenterol 2004; 18: 661-665.
Freeman HJ. Risk of gastrointestinal malignancies and mechanisms of cancer development with
obesity and its treatment. Ballaire's Best Practice and Research, Clinical Gastroenterology 2004;
18: 1167-1175.
Freeman HJ. Primary biliary cirrhosis in genetically-identical twins. Gastroenterology 2004;
127: 1645.
Freeman HJ. Comparison of longstanding pediatric-onset to adult-onset Crohn’s disease. J
Pediatr Gastroenterol Nutr 2004; 39: 183-186.
Freeman HJ, Davis JE, Myers DM. Complete histologic resolution of collagenous sprue.
Canad J Gastroenterol 2004; 18: 333-336.
Freeman HJ, Davis JE, Prest ME, Lawson EJ. Granulomatous bronchiolitis and necrobiotic
pulmonary nodules in Crohn’s disease. Canad J Gastroenterol 2004; 18: 687-690.
Freeman HJ. Anti-neoplastic effects of 5-aminosalicylates and potential cancer preventive role in
inflammatory bowel disease. Canad J Gastroenterol 2004; 18: 407-408.
Freeman HJ, Hailey J. Longstanding pediatric-onset Crohn’s disease. Pediatric Notes 2004; 28: 1.
Halparin, Dr. Lawrence
Bressler B, Lo C, Amar J, Whittaker S, Chaun H, Halparin L, Enns R. Prospective evaluation
of screening colonoscopy: who is being screened? Gastrointest Endosc. 2004;60:921-926.
Page 147
Annual Report 2004
Kwan, Dr. Peter W
Enns R, Andrews CN, Fishman M, Hahn M, Atkinson K, Kwan P, Levy A. Description of
prescribing practices in patients with upper gastrointestinal bleeding receiving intravenous proton
pump inhibitors: a multicentre evaluation. Can J Gastroenterol. 2004;18:567-571.
Ramji, Dr. Alnoor
Heathcote J, Ramji A. When to treat patients with chronic hepatitis C. Curr Gastroenterol Rep.
2004 Aug;6(4):261-3.
Yoshida EM, Ramji A, Chatur N, Davis JE, Owen DA. Regression of cirrhosis associated with
hepatitis B e (Hbe) antigen-negative chronic hepatitis B infection with prolonged lamivudine
therapy. Eur J Gastroenterol Hepatol. 2004 Mar;16(3):355-358.
Salh, Dr. Baljinder Singh
Gomez-Munoz A, Kong JY, Salh B, Steinbrecher UP. Ceramide-1-phosphate blocks apoptosis
through inhibition of acid sphingomyelinase in macrophages. J Lipid Res. 2004 Jan;45(1):99-105.
Epub 2003 Oct 01.
Wong VK, Yoshida EM, Ryan AG, Ho SG, Salh B. Advanced colon cancer before the age of 20
years: a case for extension of the current colonoscopy surveillance guidelines in hereditary
nonpolyposis colorectal cancer syndrome. Can J Gastroenterol. 2004;18:319-320.
Steinbrecher, Dr. Urs P
Gomez-Munoz A, Kong JY, Salh B, Steinbrecher UP. Ceramide-1-phosphate blocks apoptosis
through inhibition of acid sphingomyelinase in macrophages. J Lipid Res. 2004 Jan;45(1):99-105.
Cowie SE, Yoshida EM, Ryan AG, Chung SW, Buczkowski AK, Ho SG, Erb SR, Steinbrecher
UP, Scudamore CH. Hepatic abscesses after liver transplantation secondary to traumatic
intrahepatic bile duct injuries in a cadaveric allograft donor. Transpl Int. 2004;17:379-383.
Steinbrecher UP, Gomez-Munoz A, Duronio V. Acid sphingomyelinase in macrophage
apoptosis. Curr Opin Lipidol. 2004;15:531-537.
Telford, Dr. Jennifer J
Telford JJ, Saltzman JR, Kuntz KM, Syngal S. The impact of preoperative staging and
chemoradiation versus postoperative chemoradiation on outcome in patients with rectal cancer. A
decision analysis. Journal of the National Cancer Institute 2004;96:191-201.
Telford JJ, Carr-Locke DL, Baron TH, Tringali A, Parsons WG, Gabbrielli A, Costamagna G.
Palliation of patients with malignant gastric outlet obstruction with the enteral Wallstent:
outcomes from a multicenter study. Gastrointest Endosc. 2004;60:916-920.
Gelrud A, Sheth S, Banerjee S, Weed D, Shea J, Chuttani R, Howell DA, Telford JJ,
Carr-Locke DL, Regan MM, Ellis L, Durie PR, Freedman SD. Analysis of cystic fibrosis gener
product (CFTR) function in patients with pancreas divisum and recurrent acute pancreatitis. Am
J Gastroenterol. 2004;99:1557-1562.
Yoshida, Dr. Eric M
Yoshida EM, Ramji A, Chatur N, Davis JE, Owen DA. Regression of Cirrhosis Associated
with HBe Antigen Negative Chronic Hepatitis B with Prolonged Lamivudine Therapy.
European Journal of Gastroenterology & Hepatology 2004; 16: 355-58.
Cowie SE, Yoshida EM, Ryan AG, Chung SW, Buczkowski AK, Erb SR, Ho SGF,
Steinbrecher UP, Scudamore CH. Hepatic Abscesses Post-Liver Transplant Secondary to
Traumatic Bile Duct Injuries in a Liver Allograft Donor. Transplant International, 2004;17:379-83.
Warburton DE, Sheel AW, Hodges AN, Stewart IB, Yoshida EM, Levy RD, McKenzie DC.
Effects of upper extremity exercise training on peak aerobic and anaerobic fitness in patients after
Page 148
Annual Report 2004
transplantation. Am J Cardiol. 2004 Apr 1;93(7):939-43.
Tremlett HL, Yoshida EM, Oger J. Liver injury associated with the beta-interferons for MS: a
comparison between the three products. Neurology. 2004 Feb 24;62(4):628-31.
Kang A, Gray JR, McGuire TM, Amar JN, Owen DA, Yoshida EM, Salh B. Celiac Sprue and
Ulcerative Colitis in South Asian Females. Indian Journal of Gastroenterology 2004;23:24-25.
Wong VK, Yoshida EM, Salh B. Advanced Colon Cancer Before the Age of 20 Years: A Case
for Extension of the Current Colonoscopy Surveillance Guidelines in Hereditary Non-Polyposis
Colorectal Cancer Syndrome (HNPCC). Canadian Journal of Gastroenterology 2004; 18: 319-20.
Yoshida EM, Devonshire V, Prout AJE. Remission of Multiple Sclerosis Post-Liver
Transplantation. Canadian Journal of Neurological Sciences 2004; 31: 539-41.
Cheung J, Scudamore CH, Yoshida EM. Management of Polycystic Liver Disease. Canadian
Journal of Gastroenterology 2004;18: 666-670.
GENERAL INTERNAL MEDICINE
Hatala, Dr. Rose
Wyer PC, Keitz S, Hatala R, et al. Tips for learning and teaching evidence-based medicine:
introduction to the series. CMAJ. 2004; 171: 347-348.
Barratt A, Wyer PC, Hatala R, et al. Tips for learners of evidence-based medicine: 1. Relative
risk reduction, absolute risk reduction and number needed to treat. CMAJ. 2004; 171: 353-358.
Holmes, Dr. Cheryl L
Holmes CL, Landry DW, Granton JT. Science review: Vasopressin and the cardiovascular
system part 2 - Clinical physiology. Crit Care Forum 2004 8 (1); 15-23.
Holmes CL, Walley KR. Vasopressin in the ICU. Current Opinion in Critical Care 2004 Dec;
10(6): 442-8.
Khan, Dr. Nadia A
Khan NA, McAlister FA, Campbell NRC, Feldman RD, Mahon J, Lewanczuk R, Rabkin SW,
Zarnke KB, Hemmelgarn B, Lebel M, Levine M, Herbert C, for the Canadian Hypertension
Education Program. The 2004 Canadian Recommendations for the Management of Hypertension:
Therapy 2004. Canadian Journal of Cardiology; 20(1):41-54.
Wardman D, Khan N. Antidepressant medication use among First Nations people within British
Columbia 2004 (accepted).
Wardman D, Khan N. Smoking Cessation Pharmacotherapy Use Among First Nations People in
BC. 2004. Nicotine and tobacco research (accepted).
Wardman D, Khan N. Smoking attributable mortality among First Nations people within
British Columbia. 2004. International circumpolar health journal (accepted).
Zarnke KB, Hemmelgarn B, Campbell NRC, Feldman RD, McKay DW, McAlister FA, Khan
N, Schiffrin EL, Myers MG, Bolli P, Honos G, Lebel M, Levine M. The 2004 Canadian
Hypertension Education Program (CHEP) recommendations for the management of hypertension:
Part 1. Blood pressure measurement, diagnosis, and assessment of risk. 2004 Canadian Journal
of Cardiology 20(1):31-40.
Feldman R, on behalf of the Canadian Hypertension Education Program. What's new in the 2004
hypertension guidelines? Perspectives in Cardiology. 2004.
Magee, Dr. Laura A
Caetano M, Ornstein M, von Dadelszen P, Hannah ME, Logan AG, Gruslin A, Willan A,
Magee LA. A survey of Canadian practitioners regarding the diagnosis and evaluation of the
Page 149
Annual Report 2004
hypertensive disorders of pregnanacy. Hypertens Pregn 2004;23(2):197-209.
Gutzin S, Kozer E, Magee L, Feig D, Koren G. The safety of oral hypoglycemic agents in the
first trimester of pregnancy: a meta-analysis. Can J Clin Pharmacol 2004;10(4):179-183.
Caetano M, Ornstein M, von Dadelszen P, Hannah ME, Logan AG, Gruslin A, Willan A,
Magee LA. A survey of Canadian practitioners regarding the management of the hypertensive
disorders of pregnanacy. Hypertens Pregn 2004;23(1):61-74.
Waterman EJ, Magee LA, Lim KI, Skoll A, Rurak D, von Dadelszen P. Commonly used oral
antihypertensives do not alter fetal or neonatal heart rate characteristics: a systematic review.
Hypertens Pregn 2004;23(2):155-169.
Magee LA, Abdullah S. The safety of antihypertensives therapy in pregnancy. Expert Opin Drug
Saf 2004;3:25-38.
Allen VM, Joseph KS, Murphy KE, Magee LA, Ohlsson A. The effect of hypertensive disorders
in pregnancy on small for gestational age and stillbirth: a population based study. BioMed
Central Pregnancy and Childbirth 2004;4:17-24 (www.biomedcentral.com/1471-2393/4/17).
Fuchisawa A, Magee LA, Whalen B, Leung PCK, Russell JA, Walley KR, van Eeden S, von
Dadelszen P. Neutrophil apoptosis in preeclampsia, do steroids confound the relationship? J
Obstet Gynaecol Res 2004;30(5):342-348.
von Dadelszen P, Magee LA, Devarakonda RM, Hamilton T, Ainsworth LM, Yin R, Norena M,
Walley FR, Gruslin A, Redman CWG, Moutquin J-M, Lee SK, Russell JA. The prediction of
adverse maternal outcomes in preeclampsia. JOGC 2004;26(10):871-880.
Magee LA, von Dadelszen P. Treatment of hypertension in pregnancy. Can J Clin Pharm
2004;11(2):199-201.
Coté, AM, Opatrny, L, Keyes RD, Nulman I, Magee LA. The practicalities of managing seizures
in pregnancy: a review. Fet Mat Med Rev 2004;15(2):181-204.
Palepu, Dr. Anita
Chan ACH, Palepu A, Guh D, Sun H, Anis AH. Injection drug use and leaving a specialized
HIV/AIDS ward against medical advice. JAIDS 2004; 35 (1): 56-9.
Kerr T, Palepu A, Barnes G, Hogg R, Montaner JSG, Tyndall M, Wood E. Psychosocial
Determinants of Adherence To Highly Active Antiretrovial Therapy Among Injection Drug
Users. Antiviral Therapy 2004; 9(3): 407-14.
Palepu A, Horton NB, Meli S, Samet JH. Uptake and adherence to highly active antiretroviral
therapy among HIV-infected people with alcohol and other substance use problems: the impact of
substance abuse treatment. Addiction 2004; 99(3): 361-8.
Samet JH, Horton NJ, Meli S, Freedberg KA, Palepu A. Alcohol consumption and antiretroviral
adherence among HIV-infected persons with alcohol problems. Alcoholism: Clinical and
Experimental Medicine 2004; 28(4): 572-7.
Wood E, Hogg RS, Bonner S, Kerr T, Li K, Palepu A, Guillemi S, Schechter MT, Montaner
JSG. Staging for antiretroviral therapy among HIV-infected injection drug users. Journal of the
American Medical Association 2004; 292(10): 1175-7 (research letter).
Marra CA, Marra F, Cox VC, Palepu A, Fitzgerald JM. Factors Influencing Quality of Life in
Patients with Active Tuberculosis. Health and Quality of Life Outcomes 2004; 2(1): 58.
Palepu A, Tyndall MW, Chan K, Wood E, Montaner JSG, Hogg RS. Initiating highly active
therapy and continuity of HIV care: The impact of incarceration and prison release on adherence
and HIV treatment outcomes. Antiviral Therapy 2004; 9: 713-719.
Braitstein P, Palepu A, Dieterick D, Benhamou Y, Poynard T, Montaner JSG. Special
Considerations in the Initiation and Management of Antiretroviral Therapy Among HIV and
Hepatitis C Co-Infected Individuals. AIDS 2004; 18: 2221-34.
Page 150
Annual Report 2004
Wright, Dr. James (Jim) M
Mattu GS, Heran BS, Wright JM. Accuracy of the BpTRU TM, an automated electronic blood
pressure device. Blood Pressure Monit 2004;9:47-52.
Mattu GS, Heran BS, Wright JM. Comparison of the automated non-invasive oscillometric
blood pressure monitor (BpTRU TM) with the auscultatory mercury sphygmomanometer in the
paediatric population. Blood Pressure Monit 2004;9:39-45.
Herbert CP, Wright JM, Wakefield J, Maclure M, Dormuth C, Brett-MacLean P, Legare J,
Premi J. Better Prescribing Project: a randomized controlled trial of the impact of case-based
educational modules and personal prescribing feedback on prescribing for hypertension in primary
care. Family Practice 2004;21:575-581.
Dormuth CR, Maclure M, Bassett K, Jauca C, Whiteside C, Wright JM. Periodic letters on
evidence-based drug therapy improves prescribing: a randomized trial. Can Med Assoc J.
2004;171:1057-1061.
GERIATRIC MEDICINE
Beattie, Dr. Lynn
Beattie BL & Feldman H. "Treatment Efficacy in Alzheimer Disease (TRED) conference",
BCMJ, September 2004; 46:7, 344-347 (2004).
Beattie BL & Feldman H. "The New Era of Treatable Alzheimer Disase: Ending a dark age in
British Columbia", BCMJ, September 2004; 46:7, 332-333 (2004).
Lee, Dr. Philip E
Wong RYM and Lee PE. Teaching physicians geriatric principles: a randomized control trial on
academic detailing plus printed materials versus printed materials only. J Gerontology Series
A-Biological Sciences & Medical Sciences, 59(10):1036-40, 2004 Oct.
Lee PE, Gill SG, Freedman M, Bronskill S, Hillmer M, Rochon P. Atypical Neuroleptic
Therapy in the Treatment of Behavioural and Psychological Symptoms of Dementia: Systematic
Review. BMJ 2004; 329(7457):75.
Madden, Dr. Kenneth M
Madden KM, Levy W, Jacobson A, Caldwell J, Stratton J. The effect of aging on
phenylephrine-responsiveness in normal human subjects. Journal of the American Aging
Association, 26:3-10, 2004.
Menezes, Dr. Janice A
A Lo, S Shalansky, J Menezes. "Comparison of the Completeness of Prescription Medication
Histories for Hospitalized Geriatric Patients Documented by Different Health Care Professionals";
Can J Hosp Pharm Vol 57(1): pp32-38, February 2004.
Wong, Dr. Roger Y
Wong RYM, Lee PE. Teaching physicians geriatric principles: a randomized control trial on
academic detailing plus printed materials versus printed materials only. Jour of Geron Med Sci
2004; 59A(10): 1036-1040.
Page 151
Annual Report 2004
HEMATOLOGY
Ballem, Dr. Penny J
Stephenson MD, Ballem PJ, Tsang P, Purkiss S, Ensworth S, Houlihan E, Ensom MH.
Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial
comparing low molecular weight heparin to unfractionated heparin. J Obstet Gynaecol Can 26(8):
729-734, 2004.
Barnett, Dr. Michael J
Toze CL, Barnett MJ, Connors JM, Gascoyne RD, Voss NJ, Nantel SH, Nevill TJ, Shepherd
JD, Sutherland HJ, Lavoie JC, Forest DL, Song KW & Hogge DE. Long-term disease-free
survival of patients with advanced follicular lymphoma after allogeneic bone marrow
transplantation. Br J Haematol 127: 311-321, 2004.
Bredeson C, Leger C, Couban S, Simpson D, Huebsch L, Walker I, Shore T, Howson-Jan K,
Panzarella T, Messner H, Barnett M & Lipton J. An evaluation of the donor experience in the
Canadian multicenter randomized trial of bone marrow versus peripheral blood allografting. Biol
Blood Marrow Transplant 10:405-414, 2004.
Smith M, Barnett M, Bassan R, Gatta G, Tondini C, Kern W. Adult acute myeloid leukaemia.
Crit Rev Oncol Hematol 50:197-222, 2004.
Benny, Dr. Barrett W
Seftel MD, Growe GH, Petraszko T, Benny WB, Le A, Lee CY, Spinelli JJ, Sutherland HJ,
Tsang P & Hogge DE. Universal prestorage leukoreduction in Canada decreases platelet
alloimmunization and refractoriness. Blood 103(1):333-9, 2004.
Eaves, Dr. Allen C
Chalandon Y, Jiang X, Loutet S, Eaves AC & Eaves CJ. Growth autonomy and lineage
switching in BCR-ABL-transduced human cord blood cells depend on different functional
domains of BCR-ABL. Leukemia 18: 1006-1012, 2004.
Jiang X, Zhao Y, Chan WY, Vercauteren S, Pang E, Kennedy S, Nicolini F, Eaves A & Eaves
C. Deregulated expression in Ph+ human leukemias of AHI-1, a gene activated by insertional
mutagenesis in mouse models of leukemia. Blood 103: 3897-3904, 2004.
Thanopoulou E, Cashman J, Kakagianne T, Eaves A, Zoumbos N & Eaves C. Engraftment of
NOD/SCID-ß2 microglobulin null mice with multilineage neoplastic cells from patients with
myelodysplastic syndrome. Blood 103: 4285-4293, 2004.
Forrest, Dr. Donna L
Khoury H, Dalal BI, Nantel SH, Horsman DE, Lavoie JC, Shepherd JD, Hogge DE, Toze CL,
Song KW, Forrest DL, Sutheralnd HJ, Nevill TJ. Correlation between karyotype and
quantitative immunophenotype in acute myelogenous leukemia with t(8;21). Mod Pathol 17(10):
1211-6, 2004.
Cournoyer D, Toffelmire EB, Wells GA, Barber DL, Barrett BJ, Delage R, Forrest DL, Gagnon
RF, Harvey EA, Laneuville P, Patterson BJ, Poon MC, Posen GA, Messner HA; Canadian
PRCA Focus Group. Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment
with recombinant erythropoietic products: recommendations for minimization of risk. J Am Soc
Nephrol 15(10): 2728-34, 2004.
Kuruvilla J, Forrest DL, Lavoie JC, Nantel SH, Shepherd JD, Song KW, Sutherland HJ, Toze
CL, Hogge DE & Nevill TJ. Characteristics and outcome of patients developing endocarditis
following hematopoietic stem cell transplantation. Bone Marrow Transplant 34(11): 969-973, 2004.
JD, Sutherland HJ, Lavoie JC, Forrest DL, Song KW, Hogge DE. Long-term disease-free
Page 152
Annual Report 2004
transplantation. Br J Haematol 127(3): 311-21, 2004.
Galbraith, Dr. Paul
Lester R, Li CH, Phillips P, Shenkier TN, Gascoyne RD, Galbraith PF, Vickars LM, Leitch
HA. Improved Outcome of Human Immunodeficiency Virus-Associated -Plasmablastic
Lymphoma of the Oral Cavity in the Era of Highly Active Antiretroviral Therapy: A Report of
Two Cases. Leukemia & Lymphoma 45(9): 1881-1885, 2004.
Hogge, Dr. Donna
Tsang P, Hogge DE. Universal prestorage leukoreduction in Canada decreases platelet
Song KW, Forrest DL, Sutherland HJ, Nevill TJ. Correlation between karyotype and
quantitative immunophenotype in acute myelogenous leukemia with t(8;21). Mod Pathol
17(10):1211-1216, 2004.
Hogge DE, Feuring-Buske M, Gerhard B & Frankel AE. The efficacy of diphtheria-growth factor
fusion proteins is enhanced by co-administration of cytosine arabinoside in an immunodeficient
mouse model of human acute myeloid leukemia. Leuk Res 28: 1221-1226, 2004.
Nicolini FE, Cashman JD, Hogge DE, Humphries RK & Eaves CJ. NOD/SCID mice engineered
to express human IL-3, GM-CSF and Steel Factor constitutively mobilize engrafted human
progenitors and compromise human stem cell regeneration. Leukemia 18: 341-347, 2004.
Urieto JO, Liu T, Black JH, Cohen KA, Hall PD, Willingham MC, Pennell LK, Hogge DE,
Kreitman RJ & Frankel AE. Expression and purification of the recombinant diphtheria fusion
toxin DT388IL3 for phase I clinical trials. Protein Expr Purif 33: 123-133, 2004.
Humphries, Dr. Richard Keith
Nicolini FE, Cashman JD, Hogge DE, Humphries RK & Eaves CJ. NOD/SCID mice engineered
to express human IL-3, GM-CSF, and Steel Factor constitutively mobilize engrafted human
progenitors and compromise human stem cell regeneration. Leukemia 18: 341-347, 2004.
Pineault N, Abramovich C, Ohta H & Humphries RK. Differential and common leukemogenic
potentials of multiple NUP98-Hox fusion proteins alone or with Meis1. Mol Cell Biol 24:
1907-1917, 2004.
Gurevich RM, Aplan PD & Humphries RK. NUP98-Topoisomerase I acute myeloid
leukemia-associated fusion has potent leukemogenic activities independent of an engineered
catalytic site mutation. Blood 104: 1127-1136, 2004.
Oh I-H, Fabry ME, Humphries RK, Pawliuk R, Leboulch P, Hoffman R, Nagel R & Eaves C.
Expression of an anti-sickling b-globin in human erythroblasts derived from
retrovirally-transduced primitive normal and sickle cell disease hematopoietic cells. Exp Hematol
32: 461-469, 2004.
Rawat VPS, Cusan M, Deshpande A, Hiddemann W, Quintanilla-Martinez L, Humphries RK,
Bohlander SK, Feuring-Buske M & Buske C. Ectopic expression of the homeobox gene Cdx2 is
Page 153
Annual Report 2004
the transforming event in a mouse model of t(12;13)(p13;q12) acute myeloid leukemia. Proc
Natl Acad Sci USA 101: 817-822, 2004.
Beslu N, Krosl J, Laurin M, Mayotte N, Humphries RK & Sauvageau G. Molecular interactions
involved in HOXB4-induced activation of HSC self-renewal. Blood 104: 2307-2314, 2004.
Imren S, Fabry ME, Westerman KA, Pawliuk P, Tang P, Rosten PM, Nagel RL, Leboulch P,
Eaves CJ & Humphries RK. High-level ß-globin expression and preferred intragenic integration
after lentiviral transduction of human cord blood stem cells. J Clin Invest 114: 953-962, 2004.
Milsom MD, Woolford LB, Margison GP, Humphries RK & Fairbairn LJ. Enhanced in vivo
selection of bone marrow cells by retroviral-mediated coexpression of mutant 06
methylguanine-DNA-methytransferase and HOXB4. Mol Ther 10: 862-873, 2004.
Sauvageau G, Iscove NN & Humphries RK. In vitro and in vivo expansion of hematopoietic
stem cells. Oncogene 23: 7223-7232, 2004.
Lansdorp, Dr. Peter M
Baross A, Schertzer M, Zuyderduyn SD, Jones SJM, Marra MA & Lansdorp PM. The effect of
telomerase (hTERT) and Ataxia Telangiectasia Mutated (ATM) on gene expression profiles in
human fibroblasts. Genes Chromosomes Cancer 39:298-310, 2004.
Cheung I, Schertzer M, Baross A, Rose AM, Lansdorp PM & Baird DM. Strain-specific
telomere length revealed by single telomere length analysis in Caenorhabditis elegans. Nucleic
Acids Res 32: 3383-3391, 2004.
Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM,
Rimsza LM, Grogan TM, Miller TP, LeBlanc M, Greiner TC, Weisenburger DD, Lynch JC,
Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Connors JM, Lansdorp PM,
Ouyang Q, Lister TA, Davies AJ, Norton AJ, Muller-Hermelink HK, Ott G, Campo E,
Montserrat E, Wilson WH, Jaffe ES, Simon R, Yang L, Powell J, Zhao H, Goldschmidt N,
Chiorazzi M & Staudt LM. Prediction of survival in follicular lymphoma based on molecular
features of tumor-infiltrating immune cells. N Engl J Med 351: 2159-2169, 2004.
Ding H, Schertzer M, Wu X, Gersteinsen M, Selig S, Kammori M, Pourvali R, Poon S, Vulto
I, Chavez E, Tam PPL, Nagy A & Lansdorp PM. Regulation of murine telomere length by Rtel:
An essential gene encoding a helicase-like protein. Cell 117: 873-886, 2004.
Shepherd BE, Guttorp P, Lansdorp PM & Abkowitz JL. Estimating human hematopoietic stem
cell kinetics using granulocyte telomere lengths. Exp Hematol 32: 1040-1050, 2004.
Ochsenbein AF, Riddell SR, Brown M, Corey L, Baerlocher GM, Lansdorp PM, Greenberg PD.
CD27 expression promotes long-term survival of functional effector-memory CD8+ cytotoxic T
lymphocytes in HIV-infected patients. J Exp Med 200(11):1407-1417, 2004.
Lavoie, Dr. Julye C
1211-6, 2004.
Page 154
Annual Report 2004
Leger, Dr. Chantal S
Leger CS, Nevill T. Hematopoietic stem cell transplantation: A primer for the primary care
physician. Review article. Canadian Medical Association Journal 170:1569-1577, 2004.
Bredeson C, Leger C, Couban S, Simpson D, Heubsch L, Walker I, Shore T, Howson-Jan K,
Panzarella T, Messner H, Barnett M, Lipton J. An Evaluation of the Donor Experience in the
Canadian Multicentre Randomized Trial of Bone Marrow versus Peripheral Allografting.
Biology of Blood and Marrow Transplantation 10:405-414, 2004.
Leitch, Dr. Heather A
Leenman EE, Panzer-Grumayer ER, Fischer S, Leitch HA, Horsman DE, Lion T, Gadner H,
Ambros PF, Lestou VS. Rapid determination of EBV latent or lytic infection in single human
cells using in situ hybridization. Modern Pathology 17:1564-72, 2004.
Lester R, CH Li, P Phillips, TN Shenkier, RD Gascoyne, PF Galbraith, LM Vickars, HA
Leitch. Improved Outcome of Human Immunodeficiency, Virus-Associated Plasmablastic
Lymphoma of the Oral Cavity in the Era of Highly Active Antiretroviral Therapy: A report of
two cases. Leukemia & Lymphoma 45(9): 1881-5, 2004.
Mangel J, HA Leitch, JM Connors, R Buckstein, K Imrie, D Spaner, NL Berinstein. Intensive
Chemotherapy and Autologous Stem Cell Transplantation plus Rituximab is Superior to
Conventional Chemotherapy for Newly Diagnosed Advance Stage Mantle Cell Lymphoma: A
Matched-Pair Analysis. Annals of Oncology 15: 283-90, 2004.
Li, Dr. Charles H
Nantel, Dr. Stephen H
1211-6, 2004.
Nevill, Dr. Thomas J
Song KW, Forrest DL, Sutherland HJ & Nevill TJ. Correlation between karyotype and
quantitative immunophenotype in acute myelogenous leukemia with t(8;21). Mod Pathol 17:
1211-1216, 2004.
Leger D & Nevill TJ. Hematopoietic stem cell transplantation: a primer for the primary care
physician. CMAJ 170: 1569-1577, 2004.
Page 155
Annual Report 2004
Petraszko, Dr. Tanya R
Schrader, Dr. John W
Ward KR, Zhang K-X, Somasiri A, Roskelley C, & Schrader JW. Expression of activated
M-Ras in a murine mammary epithelial cell line induces epithelial-mesenchymal transition and
tumorigenesis. Oncogene 23(6): 1187-1196, 2004.
Grill, Brock, Wilson, Gary M, Zhang K-X, Wang B, Doyonnas R, Quadroni M, Schrader JW.
Activation/division of lymphocytes results in increased levels of cytoplasmic
activation/proliferation-associated protein-1: prototype of a new family of proteins. J. Immunol
172(4): 2389-2400, 2004.
Zhang K-X, Ward KR & Schrader JW. Multiple aspects of the phenotype of mammary epithelial
cells transformed by expression of activated M-Ras depends on an autocrine mechanism
mediated by hepatocyte growth factor/scatter factor. Molecular Cancer Research 2(4): 242-255, 2004.
Ehrhardt A, David M, Ehrhardt GRA & Schrader JW. Distinct mechanisms determine the
patterns of differential activation of H-Ras, K-Ras 4B and M-Ras by receptors for growth factors
or antigen. Mol Cell Biol 24(14): 6311-6323, 2004.
McLean G, Schrader JW & Junker A. Biased Immunoglobulin G (IgG) subclass production in a
case of hyper-IgM syndrome. Clinical and Diagnostic Lab Immunology 11(6): 1192-1193, 2004.
Ward KR, Zhang K-X, Somasiri AM, Roskelley CD & Schrader JW. Expression of activated
M-Ras in a murine mammary epithelial cell line induces epithelial-mesenchymal transition and
tumorigenesis. Oncogene 23(54): 8858, 2004.
Shepherd, Dr. John D
1211-6, 2004.
Smith, Dr. Clayton A
Smith C. Stem Cells and Transplantation. Cancer Control 11:75-77, 2004.
Elwood N, Jiang XR, Chiu CP, Lebkowski J & Smith C. Enhanced long term survival but no
increased replicative capacity following retroviral transduction of cord blood CD34+ cells with
hTERT. Hematologica 89: 377-378, 2004.
Gasparetto M, Sebti S, Bhalla K and Smith C. Identification of small molecules that enhance
anti-CD20 mediated apoptosis and cell cycle effects in non-Hodgkin’s lymphoma cells using
automated flow cytometric screening. J Immunologic Methods 292: 59-71, 2004.
Page 156
Annual Report 2004
Song, Dr. Kevin W
quantitative immunophenotype in acute myelogenous leukemia with t(8;21). Mod Pathol
17(10):1211-1216, 2004.
following hematopoietic stem cel transplantation. Bone Marrow Transplant 34(11): 969-973, 2004.
Mollee P, Gupta V, Song K, Reddy V, Califaretti N, Tsang R, Crump M, Keating A.
Long-term Outcome After Intensive Therapy with Etoposide, Melphalan, Total Body Irradiation
and Autotransplant for Acute Myeloid Leukemia. Bone Marrow Transplantation 33(12):
1201-1208, 2004.
Song KW, Rifkind J, Al-Beirouti B, Yee K, McCrae J, Messner HA, Keating A & Lipton JH.
Short Communication: Subdural hematomas during CML therapy with imatinib mesylate.
Leukemia and Lymphoma 45(8): 1633-1636, 2004.
Sutherland, Dr. Heather J
Tsang P, Hogge DE. Universal prestorage leukoreduction in Canada decreases platelet
1211-6, 2004.
Vercauteren SM, Sutherland HJ. Constitutively active Notch4 promotes early human
hematopoietic progenitor cell maintenance while inhibiting differentiation and causes lymphoid
abnormalities in vivo. Blood 105(8): 2315-2322, 2004.
Toze, Dr. Cynthia L
transplantation. Br J Haematol 127: 311-21, 2004.
quantitative immunophenotype in acute myelogenous leukemia with t(8;21). Mod Pathol 17:
1211-6, 2004.
Page 157
Annual Report 2004
following hematopoietic stem cell transplantation. Bone Marrow Transplant 34: 969-973, 2004.
Tsang, Dr. Peter W
Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial
comparing low molecular weight heparin to unfractionated heparin. J Obstet Gynaecol Can 26(8):
729-734, 2004.
Vickars, Dr. Linda M
INFECTIOUS DISEASES
Av-Gay, Dr. Yossef Y
Movahedzadeh, F., Smith, D.A., Norman, R.A., Dinadayala, P., Murray-Rust, J., Russell,
D.G., Kendall, S., Rison, S., M.S.B., M., Bancroft, G.J., MacDonald, N., Daffe, M., Av-Gay,
Y., and Stoker, N.G. (2004). The Mycobacterium tuberculosis ino1 gene is essential for growth
and virulence. Molecular Microbiology. 51:1003-1014.
Wiens, T. Redelmeier, T. and Av-Gay, Y. (2004). Development of a Liposome Formulation of
Ethambutol. Anti microbial agents and Chemotherapy. 48(5):1887-1888.
Rawat, M., Uppal, M., Newton, G.L., and Av-Gay, Y. (2004) Targeted Mutagenesis of the
Mycobacterium smegmatis mca Gene Encoding a Mycothiol Dependent Detoxification Protein.
J. Bacteriol. 186:6050-6058.
Pick, N., Cameron, S., Arad, D., and Av-Gay, Y. (2004). Screening of Compounds Toxicity
against Human Macrophages-THP-1 by Flow Cytometry. Biological Procedures Online. 6:220-225.
Bowie, Dr. William R
Sifton E, Stephen C, Bowie WR, Wetzstein M. Evaluating our capacity to measure animal
antimicrobial use in British Columbia. Canadian Veterinary Journal 2004; 45: 309-311.
Hutchinson J, Patrick DM, Marra F, Ng H, Bowie WR, Heule L, Muscat M, Monnet DL.
Measurement of antibiotic consumption: a practical guide to the use of the Anatomic Therapeutic
Chemical classification and Defined Daily Dose system methodology in Canada. Can J Infect
Dis 2004; 15: 29-35.
Patrick DM, Marra F, Hutchinson J, Monnet DL, Ng H, Bowie WR. Per capita antibiotic
consumption: how does a North American jurisdiction compare with Europe? Clin Infect Dis
2004; 39: 11-17.
Brunham, Dr. Robert C
Babiuk S, Skowronski DM, De Serres G, HayGlass K, Brunham RC, Babiuk L. Aggregate
content influences the Th1/Th2 immune response to influenza vaccine: Evidence from a mouse
model. J Med Virol. 2004 Jan;72(1):138-42.
Page 158
Annual Report 2004
Hirst M, Astell CR, Griffin M, Coughlin S, Moksa M, Zeng T, Smailus D, Holt RA, Jones S,
Marra M, Petric M, Krajden M, Lawrence D, Mak A, Chow R, Skowronski D, Tweed A, Goh
SH, Brunham RC, Robinson J, Bowes V, Byrne SK, Paetzel M. A novel avian influenza H7N3
mutant strain associated with pathogenicity in domestic chickens. Emerg Infect Dis 2004 Dec;
10(12):2192-2195.
Cherkasov AR, Sui SJ, Brunham RC, Jones SJ. Structural characterization of genomes by large
scale sequence-structure threading: application of reliability analysis in structural genomics.
BMC Bioinformatics. 2004 Jul 26; 5(1):101.
Finlay BB, See RH, Brunham RC. Science and society: Rapid response research to emerging
infectious diseases: Lessons from SARS. Nat Rev Microbiol 2004 July, 2(7):602-607.
Pourbohloul B, Brunham RC. Network Models and Transmission of Sexually Transmitted
Disease. Sex Transm Dis. 2004 June, 31(6):388-390.
Luo M, Cohen CR, Narayansingh MJ, Pan S, Mckinnon L, Brunham RC, Plummer F.
Identification of a Novel HLA-DQA1 Null allele, DQA1*0403N, from an East Africa Woman.
Tissue Antigens 2004: 63: 609-611.
Ness RB, Brunham RC, Shen C, Bass DC. Associations among human leukocyte antigen
(HLA) class II DQ variants, bacterial STDs, endometritis, and fertility among women with
clinical PID. Sex Transm Dis. 2004 May; 31(5):301-4.
Slutsky AS, Jha P, Aslanyan G, Bergeron MG, Brown D, Brunham RC, D’Alessandro D,
Hunkin J, Kain K, Kopelow J, McGeer A, Nagelkerke N, Plummer FA. Health and economic
benefits of an accelerated program of research to combat global infectious diseases. Global IDEA
Scientific Advisory Committee. CMAJ 2004 Nov 9; 171(10):1203-1208.
Cherkasov, Dr. Artem
A.R. Cherkasov, S.J.M. Jones. Structural characterization of genomes by large scale
sequence-structure threading. BMC Bioinformatics, 5, 37 (2004).
M. Hsing, J. Bellenson, C. Chansky, A. Cherkasov. Semantic Modelling of Cell Signalling
Network within BioCAD Simulation Environment. BMC Bioinformatics, 5, 156, (2004).
A. Cherkasov, S.J. Ho Sui, R.C. Brunham, S.J.M. Jones. Structural Characterization of
Genomes by Large Scale Sequence-structure Threading: Application of Reliability Analysis in
Structural Genomics. BMC Bioinformatics, 5, 101 (2004).
A.R. Cherkasov, S.J.M. Jones. An Approach to Large Scale Identification of Non-obvious
Structural Similarities Between Proteins. BMC Bioinformatics, 5, 61 (2004).
A. Cherkasov, B. Jankovic. Application of "Inductive QSAR Descriptors for Quantification of
Antibacterial Activity of Cationic Polypeptides. Molecules, 9, 1034-1052 (2004).
Chow, Dr. Anthony W
Kalyan S, Chow AW: Human peripheral T cells potentiate the early pro-inflammatory cytokine
response to staphylococcal toxic shock syndrome toxin-1. J Infect Dis 189:1892-1896, 2004.
Hung RWY, Chow AW: Dissecting the end game: clinical relevance, molecular mechanisms,
and laboratory assessment of apoptosis. Clin Invest Med 27:324-344, 2004.
Grigg, Dr. Michael
M.A. Miller, M.E. Grigg, C. Kreuder, E.R. James, A.C. Melli, P.R. Crosbie, D.A. Jessup,
J.C. Boothroyd, D. Brownstein, and P.A. Conrad. (2004) An unusual genotype of Toxoplasma
gondii is common in Californian Sea Otters (Enhydra lutris nereis) and is associated with high
mortality. Intl. J. Parasitol. 34:297-303.
C.G. Jung*, C.Y.F. Lee*, and M.E. Grigg. (2004) The SRS superfamily of Toxoplasma gondii
surface proteins. Intl. J. Parasitol. 34:285-296. *joint first-authors
Page 159
Annual Report 2004
N. Rachinel, D. Buzoni-Gatel, C. Dutta, F.J.D. Mennechet, S. Luangsay, L.A. Minns, M.E.
Grigg, S. Tomavo, J.C. Boothroyd, and L.H. Kasper. (2004) The induction of acute ileitis by a
single microbial antigen of Toxoplasma gondii. J. Immunol. 173:2725-2735.
Hmama, Dr. Zakaria
Lee JS, Hmama Z, Mui A, Reiner NE. Stable gene silencing in human monocytic cell lines
using lentiviral-delivered small intereference RNA. Silencing of the p110alpha isoform of
phosphoinositide 3-kinase reveals differential regulation of adherence induced by 1alpha, 25
dihydroxycholecalciferol and bacterial lipopolysacharide. J Biol Chem, 279:9379-88, 2004.
Hmama Z, Sendide K, Talal A, Garcia R, Dobos K, Reiner NE. Quantitative analysis of
phagolysosome fusion in intact cells: inhibition by mycobacterial lipoarabinomannan and rescue
by an 1alpha, 25-dihydroxyvitamin D3-phosphoinositide 3-kinase pathway. J Cell Sci,
117:2131-2140, 2004.
Sendide K, Deghmane AE, Reyrat, JM, Talal A, Hmama Z. Mycobacterium bovis BCG urease
attenuates major histocompatibility complex class II trafficking to the macrophage cell surface.
Infec Immun, 72:4200-9, 2004.
Noubir S, Hmama Z, Reiner NE. Dual receptors and distinct pathways mediate interleukin-1
receptor-associated kinase degradation in response to lipopolysaccharide. Involvement of
CD14/TLR4, CR3, and phosphatidylinositol 3-kinase. J Biol Chem, 279:25189-95, 2004.
Montaner, Dr. Julio S
Wood E, Montaner JSG, Braitstein P, Schechter M, O'Shaughnessy MV, Hogg R. Elevated
rates of antiretroviral therapy discontinuation among injection drug users: Implications for drug
police and public health. International Journal of Drug Policy. 2004; 15: 133-138.
Wood E, Hogg RS, Yip C, Harrigan PR, O'Shaughnessy MV, Montaner JSG. The impact of
adherence on CD4 cell count responses among HIV-infected patients. JAIDS 2004;35(3):261-268.
Wood E, Montaner JSG, Yip B, Tydall M, Schechter MT, O'Shaughnessy MV, Hogg RS.
Adherence to antiretroviral therapy and CD4+ T cell count responses among HIV-infected
injection drug users. Antiviral Therapy 2004;9(2):229-235.
Miller C, Wood E, Spittal P, Li K, Frankish J, Braitstein P, Montaner JSG, Schechter MT.
The future face of co-infection: Prevalence and incidence of HIV and hepatitis C co-infection
among young injection drug users. JAIDS 2004;1;36(2):743-749.
Alexander CS, Montaner JSG, Asselin JJ, Ting L, McNabb K, Harris M, Guillemi S, Harrigan
PR. Simplification of therapeutic drug monitoring for twice-daily regimens of lopinavir/ritonavir
for HIV infection. Ther Drug Monit 2004;26(5):516-523.
Braitstein P, Palepu A, Dieterich D, Benhamou Y, Montaner JSG. Special considerations in the
initiation and management of antiretroviral therapy in individuals coinfected with HIV and
hepatitis C. AIDS 2004;18(17):2221-2234.
Harrigan PR, Brumme ZL, Dong WWY, Yip B, Wynhoven B, Hoffman NG, Swanstrom R,
Jensen MA, Mullins JI, Hogg RS, Montaner JSG. Clinical and immunological impact of HIV
envelope V3 sequence variation after starting initial triple antiretroviral therapy. AIDS 2004;
18(4):F1-9.
Kerr T, Palepu A, Barnes G, Walsh J, Hogg R, Montaner J, Tyndall M, Wood E.
Psychosocial determinants of adherence to highly active antiretroviral therapy among injection
drug users in Vancouver. Antiviral Therapy 2004; 9:407-414.
King MS, Bernstein BM, Walmsley SL, Sherer R, Feinberg J, Sanne I, Cernohous P, Montaner
JSG, Brun SC, Sun E. Baseline HIV-1 RNA Level and CD4 Cell Count Predict Time to Loss
of Virologic Response to Nelfinavir, but Not Lopinavir/Ritonavir, in Antiretroviral
Therapy–Naive Patients. J Infect Dis 2004;190:280-284.
Page 160
Annual Report 2004
Kuyper LM, Hogg RS, Montaner JSG, Schechter MT, Wood E. The cost of inaction on HIV
transmission among injection drug users and the potential for effective interventions. J Urban
Health 2004;81(4):655-660.
Kuyper L, Wood E, Montaner JSG, Yip B, O‚Connell J, O‚Shaughnessy MV, Hogg RS.
Gender differences in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence
among HIV-infected patients in a population-based cohort. JAIDS 2004;37(4):1470-76.
Loutfy MR, Raboud JM, Walmsley SL, Saskin R, Montaner JS, Hogg RS, CA Thompson CA,
Harrigan PR. Predictive value of HIV-1 protease genotype and virtual phenotype on the
virological response to lopinavir/ritonavir-containing salvage regimens. Antiviral Therapy 2004;
9:595-602.
Miller CL, Schechter MT, Wood E, Spittal PM, Li K, Laliberte N, Montaner JSG, Hogg RS.
The potential health and economic impact of implementing a medically prescribed heroin
program among Canadian injection drug users. Intern J Drug Policy 2004;15:259-263.
Normén L, Frohlich J, Montaner J, Harris M, Elliott T, Bondy G. Combination Therapy With
Fenofibrate and Rosiglitazone Paradoxically Lowers Serum HDL Cholesterol. Diabetes Care
2004;27:2241-2242.
Palepu A, Tyndall MW, Chan K, Wood E, Montaner JS, Hogg RS. Initiating highly active
therapy and continuation of HIV care: The impact of incarceration and prison release on adherence
and HIV treatment outcomes. Antiviral Therapy 2004;9:713-719.
Press N, Montaner JSG, Bondy G. Resolution of diabetes after initiation of antiretroviral therapy
in two human immunodeficiency virus-infected patients. Case Report. Endocrine Practice
2004;10(3):199-202.
Recsky MA, Brumme ZL, Chan KJ, Wynhoven B, Yip B, Dong WWY, Heath KV, Montaner
JSG, Levy AR, Hogg RS, Harrigan PR. Antiretroviral resistance among HIV-infected persons
who have died in British Columbia, in the era of modern antiretroviral therapy. J Infect Dis 2004;
190:285-92.
Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A,
Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H Jr., Passe S, De Pamphilis J, Diff F,
Schrenk UM, Dieterich DT. APRICOT Study Group. Peginterferon alfa-2a plus ribavirin for
chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351(5):422-423.
Wood E, Spittal PM, Small W, Kerr T, Li K, Hogg RS, Tyndall MW, Montaner JS, Schechter
MT. Displacement of Canada’s largest public illicit drug market in response to a police
crackdown. Can Med Assoc J 2004;170(10):1551-1556.
Wood E, Kerr T, Small W, Li K, Marsh DC, Montaner JS, Tyndall MW. Changes in public
order after the opening of a medically supervised safer injecting facility for illicit injection drug
users. Can Med Assoc J 2004;171(7):731-4.
Wood E, Hogg RS, Bonner S, Kerr T, Li K, Palepu A, Guillemi S, Schechter MT, Montaner
JSG. Staging for antiretroviral therapy among HIV-infected drug users. JAMA 2004;292(10):
1175-1177.
Wood E, Tyndall M, Spittal P, Li K, Hogg R, Montaner J, O'Shaughnessy, M, Schechter M.
Inability to access addiction treatment and risk of HIV infection among injection drug users
JAIDS 2004;36:750-754.
Wood E, Hogg RS, Yip B, Harrigan PR, Montaner JS. CD4+ T-Cell gain with nonnucleoside
or protease inhibitors: Convenience may not always be the most convenient. JAIDS
2004;36(2):760-761.
Wood E, Kerr T, Montaner JS, Strathdee SA, Wodak A, Hankins CA, Schechter MT, Tyndall
MW. Rationale for evaluating North America’s first medically supervised safer-injecting facility.
Lancet Infect Dis 2004;4(5):301-306.
Page 161
Annual Report 2004
Wood E, Li K, Miller C, Hogg RS, Montaner JSG, Schechter MT, Kerr T. Baseline
self-perceived risk of HIV infection independently predicts the rate of HIV seroconversion in a
prospective cohort of injection drug users. Int J Epidemiol 2004; November 23.
Yeni PG, Hammer SM, Hursch MS, Saag MS, Schechter M, Carpenter CCJ, Fischl MA, Gatell
JM, Gazzard BG, Jacobsen DM, Katzenstein DA, Montaner JSG, Richman DD, Schooley RT,
Thompson MA, Vella S, Volberding PA. Treatment for adult HIV infection. 2004
Recommendations of the International AIDS Society-USA Panel. JAMA 2004;292(2):251-65.
Montessori, Dr. Valentina C
Montessori V, Press N, Harris M, Montaner JSG. Adverse effects of antiretroviral therapy for
human immunodeficiency virus infection. CMAJ 2004;170(2):229-238.
Phillips, Dr. Elizabeth J
Tang P, Louie M, Richardson SE, Smieja M, Simor AE, Jamieson F, Fearon M, Poutanen SM,
Mazzulli T, Tellier R, Mahony J, Loeb M, Petrich A, Chernesky M, McGeer A, Low DE,
Phillips E, Jones S, Bastien N, Li Y, Dick D, Grolla A, Fernando L, Henry B, Rachlis AR,
Matukas LM, Rose DB, Lovinsky R, Walmsley S, Gold WL, Krajden S, and the Ontario
Laboratory Working Group for the Rapid Diagnosis of Emerging Infections. Interpretation of
diagnostic laboratory tests for severe acute respiratory syndrome: the Toronto experience.
Fast-tracked article. Early release, published at www.cmaj.ca on Dec. 2, 2003. Subject to revision.
CMAJ JAN. 6, 2004: 170(1).
Martin AM, Nolan D, Gaudieri S, Almeida CA, Nolan R, James I, Carvalho F, Phillips E,
Christiansen FT, Purcell AW, McCluskey J, Mallal S. Predisposition to abacavir
hypersensitivity conferred by HLA-B*5701 and ahaplotypic Hsp70-Hom variant. Proc Natl Acad
Sci U S A. 2004 Mar 23;101(12):4180-5.
Tailor SAN, Simor AE, Cornish W, Phillips E, Knowles S, Rachlis A. Analysis of
spontaneous reports of hypoglycemia and hyperglycemia associated with marketed systemic
fluoroquinolones made to the Canadian adverse drug reaction monitoring program. Can J Hosp
Pharm 2004;57(1):12-17.
Knowles SR, Phillips EJ, Wong G, Shear NH. Valdecoxib-induced hypersensitivity syndrome:
A report of two cases. J Am Acad Dermatology 2004;51(6):28-29.
Van Heeswijk RPG, Khaliq Y, Gallicano KD, Bourbeau M, Seguin I, Phillips EJ, Cameron
DW. The pharmacokinetics of nelfinavir and M8 during pregnancy and postpartum. Clinical
Pharmacology & Therapeutics 2004;76(6):588-97.
Martin AM, Nolan D, Gaudieri S, Phillips E, Mallal S. Pharmacogenetics of Antiretroviral
Therapy: genetic variation of response and toxicity. Pharmacogenomics 2004;5(6):643-55.
Phillips, Dr. Peter
HA. Improved outcome of human immunodeficiency virus-associated plasmablastic lymphoma
of the oral cavity in the era of highly active antiretroviral therapy: a report of two cases.
Leukemia and Lymphoma 2004;45(9):1881-1885.
Lalonde R, Boivin G, Deschênes J, Hodge WG, Hopkins J, Klein A, Lindley J, Phillips P,
Shafran S, Walmsley S. Canadian consensus guidelines for the management of cytomegalovirus
disease in HIV/AIDS. Can J Infect Dis Med Microbiol Nov/Dec 2004;15(6):327-335.
Press, Dr. Natasha M
Montessori V. Press N. Harris M. Akagi L. Montaner JS. Adverse effects of antiretroviral therapy
for HIV infection. CMAJ 170(2):229-38, 2004 Jan 20.
Page 162
Annual Report 2004
Press NM, Montaner JSG, Bondy G. Resolution of diabetes after initiation of antiretroviral
therapy in two human immunodeficiency virus-infected patients. Endocrine Practice 10(3):
199-202, 2004 May/June.
Reiner, Dr. Neil E
Lee JSI, Reiner NE. Stable gene silencing in human monocytic cell lines using
lentiviral-delivered siRNA:silencing of the p110alpha insoform of phosphoinositide 3-kinase
reveals differential regulation of adherence induced by 1alpha, 25-dihydroxyvitamin D3 and
bacterial lipopolysaccharide. J. Biol. Chem. 2004; 279:9379-9388.
Hmama Z, Sendide K, Talal A, Garcia R, Dobos K, Reiner NE. Quantitative analysis of
phagosome maturation in intact cells: inhibition by mycobacterial lipoarabinomannan and rescue
by 1alpha, 25-dihydroxyvitamin D3/Phosphatidylindositol 3-Kinase Pathway. J. Cell Sci. 2004;
117:2131-2140.
Noubir, S., Z Hmama and NE Reiner. Dual receptors and distinct pathways mediate IRAK
degradation in response to lipopolysaccharide: involvement of CD14/TLR4, CR3 and
phosphatidylinositol 3-kinase, J. Biol. Chem. 279(24):25189-95.
Farajnia, S, MH Alimohammadian, NE Reiner, M Karim, S Ajdari and F Mahboudi (2004)
Molecular characterization of a novel class I nuclease from Leishmania major amastigote, Int J
Parasitol. 34(8):899-908.
Rekart, Dr. Michael L
Stajduhar KI, Poffenroth L, Wong E, Archibald CP, Sutherland D, Rehart M. Missed
Opportunities: Injection drug use and HIV/AIDS in Victoria, Canada. International Journal of
Drug Policy. International Journal of Drug Policy 2004; 15(2004), 171-181.
Steiner, Dr. Theodore S
Khan MA, Kang J, Steiner TS. Enteroaggregative Escherichia coli flagellin-induced interleukin-8
secretion requires Toll-like receptor 5-dependent p38 MAP kinase activation. Immunology.
2004 Aug;112 (4):651-60.
Stiver, Dr. H Grant
Stiver HG. The treatment and prospects for control of an influenza pandemic. Expert Rev Vaccines
2004 3;35-41.
Tyndall, Dr. Mark W
Bruneau J, Brogley S, Tyndall MW, Lamothe F, Franco E. Intensity of drug injection as a
determinant of sustained injection cessation among chronic drug users: the interface with social
factors and service utilization. Addiction 2004; 99(6):727-37.
Wood E, Montaner JSG, Yip B, Tyndall M, Schechter MT, O'Shaughnessy MV, Hogg RS.
Adherence to antiretroviral terapy and CD4 T-cell count responses among HIV-infected injection
drug users. Antiviral Ther. 2004; 9(2):229-35.
Kerr T, Wood E, Grafstein E, Ishida T, Shannon K, Lai C, Montaner J, Tyndall MW. High
rates of primary care and emergency department use among injection drug users in Vancouver. J
Public Health 2004; Nov 25; [Epub ahead of print].
Wood E, Kerr T, Lloyd-Smith E, Buchner C, Marsh D, Montaner JSG, Tyndall MW.
Methodology for evaluating Insite: Canada’s first medically supervised safer injection facility for
injection drug users. Harm Reduct J 2004; 1(1):9.
antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on
adherence and HIV treatment outcomes. Antivir Ther 2004; 9(5):713-9.
Page 163
Annual Report 2004
Wood E, Kerr T, Small W, Li K, Marsh D, Montaner JSG, Tyndall MW. Changes in public
users. CMAJ 2004; 171 (7):731-4.
Fischer B, Brissette S, Brochu S, Bruneau J, el-Guebaly N, Noel L, Rehm J, Tyndall MW,
Wild C, Mun P, Haydon E, Baliunas D. Determinants of overdose incidents among illicit
opioid users in 5 Canadian cities. CMAJ. 2004; 171(3):235-9.
Kerr T, Palepu A, Barness G, Walsh J, Hogg R, Montaner J, Tyndall MW, Wood E.
Psychosocial determinants of adherence to highly active antiretroviral therapy among injection
drug users in Vancouver. Antivir Ther. 2004; 9(3):407-14.
Wood E, Spittal PM, Small W, Kerr T, Li K, Hogg RS, Tyndall MW, Montaner J, Schechter
M. Displacement of Canada’s largest public illicit drug market in response to a police
crackdown. CMAJ. 2004; 170 (10):1551-6.
Wood E, Kerr T, Montaner J, Strathdee S, Wodak A, Hankins C, Schechter M, Tyndall MW.
Rationale for evaluating North America's first medically supervised safer-injecting facility. Lancet
Infect Dis. 2004; 4(5):301-6.
Wood, Dr. Evan
Spittal P, Small W, Wood E, Laliberte N, Johnson C, Schechter M. How otherwise well
meaning exchange agents can contribute to limited sterile syringe availability in Vancouver,
Canada. International Journal of Drug Policy 2004;15:36-45.
Wood E, Hogg RS, Yip B, Harrigan RP, O'Shaughnessy MV, Montaner JS. The impact of
adherence on CD4 cell count responses among HIV-infected patients. J Acquir Immune Defic
Syndr 2004; 35(3):261-268.
Wood E, Montaner J, Braitstein P, Schechter M, O’Shaughnessy MV, Hogg R. Elevated rates
of antiretroviral therapy discontinuation among injection drug users: Implications for drug policy
and public health. International Journal of Drug Policy 2004; 15: 133-138.
Wood E, Spittal P, Small, W. Li, K. Kerr T, Tyndall M, Hogg R, Montaner J, Schechter M.
Displacement of Canada’s largest public illicit drug market in response to a police crackdown.
CMAJ. 2004 May 11;170(10):1551-6.
Wood E, Kerr T. Montaner JS, Strathdee S, Kerr T, Wodak A, Spittal P, Hankins C, Schechter
MT, Tyndall M. Rationale For Evaluating North America’s First Medically Supervised Safer
Injecting Facility. Lancet Infectious Diseases. 2004 May;4(5):301-6.
Wood E, Montaner JS, Yip B, Tyndall M, Schechter MT, O'Shaughnessy MV, Hogg RS.
Adherence to Antiretroviral Therapy and CD4+ T Cell Count Responses among HIV-Infected
Injection Drug Users. Antiviral Therapy. 2004 Apr;9(2):229-35.
Wood E, Tyndall M, Spittal P, Li K, Hogg R, Montaner J, O'Shaughnessy M, Schechter M.
Inability to access addiction treatment and risk of HIV infection among injection drug users J
Acquir Immune Defic Syndr. 2004;36:750–754.
Miller C, Wood E, Spittal P, Li K, Frankish J, Braitstein P, Montaner JS, Schechter MT. The
Future Face of Co-Infection: Prevalence and Incidence of HIV and Hepatitis C Co-infection
Among Young Injection Drug Users. J Acquir Immune Defic Syndr 2004. Jun 1;36(2):743-749.
Kerr T, Palepu A, Barnes G, Hogg RS, Montaner JS, Tyndall M, Wood E. Psychosocial
determinants of adherence to highly active antiretroviral therapy among HIV-infected injection
drug users. Antiviral Ther. 2004 Jun;9(3):407-14.
Wood E, Hogg RS, Yip B, Harrigan PR, Montaner JS. CD4+ T-Cell Gain With Nonnucleoside
or Protease Inhibitors: Convenience May Not Always Be The Most Convenient. J Acquir
Immune Defic Syndr. 2004 Jun 1;36(2):760-761.
therapy and continuation of HIV care: The impact of incarceration and prison release on adherence
Page 164
Annual Report 2004
and HIV treatment outcomes. Antivir Ther. 2004 Oct;9(5):713-9.
Kuyper L, Hogg R, Montaner J, Schechter MT, Wood E. The cost of inaction on
HIV-transmission among injection drug users and the potential of effective interventions. J Urban
Health. 2004 Dec;81(4):655-60.
Wood E, Hogg RS, Yip B, Harrigan RP, Montaner JS. Using baseline CD4 cell count and
plasma HIV RNA to guide the initiation of highly active antiretroviral therapy. Revista de
Investigacion Clinica. 2004 (56):232-236.
Kerr T, Suwannawong P, Kaplan K, Wood E. The Global Fund to Fight AIDS, Tuberculosis, and
Malaria: funding for unpopular public-health programmes. The Lancet. 2004 Vol 364 pg 12-13.
Wood E, Kerr T, Small W, Li K, Marsh D, Montaner JS, Tyndall MW. Changes in public
users. CMAJ. 2004 Sep 28;171(7):731-4.
Kuyper L, Wood E, Montaner JS, Yip B, O’Connell J, O’Shaughnessy MV, Hogg RS. Gender
differences in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence among
HIV-infected patients in a population-based cohort. J Acquir Immune Defic Syndr. 2004 Dec
1;37(4):1470-1476.
Wood E, Hogg RS, Bonner S, Kerr T, Li K, Spittal PM, Guillemi S, Schechter MT, Montaner
JS. Staging for antiretroviral therapy among HIV-infected injection drug users. JAMA. 2004
Sep 8;292(10):1175-7.
Kerr T, Oleson M, Wood E. Harm-reduction activism: a case study of an unsanctioned user-run
safe injection site. Can HIV/AIDS Law Rev. 9(2):13-19.
Wood E, Hogg RS, Yip B, Harrigan PR, Montaner JS. Earlier initiation of HAART does not
protect against the deleterious effects of non-adherence. AIDS. 2004; 18(18):12-14.
Kerr T, Wodak A, Elliott R, Montaner JS, Wood E. Opioid substitution and HIV/AIDS
treatment and prevention. Lancet. 2004 Nov 27;364(9449):1918-9.
Kerr T, Wood E, Grafstein E, Ishida T, Shannon K, Lai C, Montaner J, Tyndall MW. High
rates of primary care and emergency department use among injection drug users in Vancouver. J
Public Health. 2004 Nov 25.
Kuyper LM, Lampinen TM, Li K, Spittal PM, Hogg RS, Schechter MT, Wood E. Factors
associated with sex trade involvement among male participants in a prospective study of
injection drug users. Sex Transm Infect. 2004 Dec;80(6):531-5.
Wood E, Kerr T, Buchner C, Marsh D, Montaner JS, Tyndall MW. Methodology for
evaluating Insite: Canada’s first medically supervised safer injection facility for injection drug
users. Harm Reduction Journal. 2004 Nov 09;1(1):9.
MEDICAL ONCOLOGY
Chi, Dr. Kim N
Chi KN, Gleave ME. Antisense approaches in prostate cancer. Expert Opinion on Biologic
Therapy. 4(6):927-936, 2004.
Connors, Dr. Joseph M
Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink
HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH,
Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC. Confirmation of the molecular
classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue
microarray. Blood 2004;103:275-82.
Au WY, Horsman DE, Gascoyne RD, Viswanatha DS, Klasa RJ, Connors JM. The spectrum of
lymphoma with 8q24 aberrations: A clinical, pathological and cytogenetic study of 87
Page 165
Annual Report 2004
consecutive cases. Leuk Lymph 2004;45:519-28.
Mangel J, Leitch HA, Connors JM, Buckstein R, Imrie K, Spaner D, Crump M, Pennell N,
Boudreau A, Berinstein NL. Intensive chemotherapy and autologous stem-cell transplantation
plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage
mantle-cell lymphoma: a matched pair analysis. Ann Oncol 2004;15:283-290.
Hoglund M, Sehn L, Connors JM, Gascoyne RD, Siebert R, Sall T, Mitelman F, Horsman DE.
Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular
lymphomas. Gene Chrom Cancer 2004;39:195-204.
Henderson LJ, Okamoto I, Lestou VS, Ludkovski O, Robichaud M, Chhanabhai M, Gascoyne
RD, Klasa RJ, Connors JM, Marra MA, Horsman DE, Lam WL. Delineation of a minimal
region of deletion at 6q16.3 in follicular lymphoma and construction of a bacterial artificial
chromosome contig spanning a 6-megabase region of 6q16-q21. Genes Chromosomes Cancer
2004;40:60-5.
Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM,
Rimsza LM, Grogan TM, Miller TP, Leblanc M, Greiner TC, Weisenburger DD, Lynch JC,
Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Connors JM, Lansdorp PM,
Ouyang Q, Lister TA, Davies AJ, Norton AJ, Muller-Hermelink HK, Ott G, Campo E,
Montserrat E, Wilson WH, Jaffe ES, Simon R, Yang L, Powell J, Zhao H, Goldschmidt N,
Chiorazzi M, Staudt LM. Prediction of survival in follicular lymphoma based on molecular
features of tumor-infiltrating immune cells. N Engl J Med 2004;351:2159-2169.
Iqbal J, Sanger WG, Horsman DE, Rosenwald A, Pickering DL, Dave B, Dave S, Xiao L, Cao
K, Zhu Q, Sherman S, Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Ott G,
Muller-Hermelink HK, Delabie J, Braziel RM, Jaffe ES, Campo E, Lynch JC, Connors JM,
Vose JM, Armitage JO, Grogan TM, Staudt LM, Chan WC. BCL2 translocation defines a
unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J
Pathol 2004;165:159-166.
Gill, Dr. Sharlene
Sinicrope FA, Gill S. Role of Cyclooxygenase-2 in Colorectal Cancer, Cancer and Metastasis
Reviews, 2004 Jan; 23:63-75
Gill S, Goldberg RM. First-line Treatment Strategies to Improve Survival in patients with
Advanced Colorectal Cancer, Drugs, 2004;64(1):27-44.
Gill S, Loprinzi C, Sargent D, Haller D, Benedetti J, Shepherd L, LaBianca R, Francini G and
Goldberg RM. A Pooled Analysis of 5-FU Based Adjuvant Therapy for Stage II and III Colon
Cancer: Who Benefits and by How Much? Journal of Clinical Oncology, 2004 May;
22:1797-1806. [Accompanied by Editorial, Epub ahead of print]
Goldberg RM, Gill S. Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as
chemotherapy for metastatic colorectal cancer. Cancer Chemother Pharmacol. 2004;54 Suppl
1:S57-64.
Hoskins, Dr. Paul J
Law JKY, Ho JK, Hoskins PJ, Erb SR, Steinbrecher UP, Yoshida EM. Fatal reactivation of
hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen negative. Hepatitis
B core antibody positive patient: implications for future prophylaxis recommendations.
(Accepted by Leukemia and Lymphoma 2004).
Melosky, Dr. Barbara L
Cottrell W, Graham W, Growe G, Jordan J, Levin A, Lordan T, Martino F, Martin J, Melosky
B, Meuser J, Moore-Orr R, Nguyen A, Ramen-Wilms L, Stewart J, Strobart K, Rosser W,
Wazny L. "Guidelines for the Management of Anemia". Anemia Review Panel, 1st Edition, 2004.
Page 166
Annual Report 2004
Murray, Dr. Robert Nevin C
Laskin J, Erridge S, Coldman A, D’yachkova J, Speers C, Westeel V, Hislop G, Olivotto I,
Murray N. Population-based outcomes for small cell lung cancer: impact of standard
management policies in British Columbia. Lung Cancer 43: 7-14, 2004.
Murray N, Salgia R, Fossella F. Targeted molecules in small cell lung cancer. Semin Oncol
31(suppl 1):106-111, 2004.
Murray N. Meeting Report: 10th World Conference of Lung Cancer August 10-14, 2003,
Vancouver Canada. Lung Cancer 44, 133-138, 2004.
Savage, Dr. Kerry J
Savage KJ, Chhanabhi M, Gascoyne RG, Connors JC. Characterization of peripheral T-cell
Lymphomas in single North American institution by the WHO classification. Annals of
Oncology. 2004;15:1467-1475.
Shenkier, Dr. Tamara N
Shenkier TN, Levine M, Olivotto I. Treatment of Locally Advanced Breast Cancer, Reply to
Letter to the Editor. Canadian Medical Association Journal, August 2004; 171: 221-222;
10.1503/cmaj.1040848.
Shenkier TN, Weir L, Levine M, Olivotto I, Whelan T, Reyno L for the steering Committee on
clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical practice
guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or
locally advanced breast cancer. CMAJ 2004; 170(6):983-94.
Lester R, Li C, Galbraith P, Vickers L, Leitch H, Phillips P, Shenkier T, Gascoyne R.
Improved outcome of human immunodeficiency virus-associated plasmablastic lymphoma of the
oral cavity in the era of highly active antiretroviral therapy: A report of two cases. Leuk
Lymphoma 2004: 45(9):1881-5.
Swenerton, Dr. Kenneth D
Dark GG, Calvert AH, Grimshaw R, Poole C, Swenerton K, Kaye S, Coleman R, Jayson G, Le
T, Ellard S, Trudeau M, Vasey P, Hamilton M, Cameron T, Barrett E, Walsh W, McIntosh L
and Eisenhauer E. Randomised trial of two intravenous schedules of the liposomal topoisomerase
I inhibitor, OSI-211, in women with relapsed epithelial ovarian cancer (accepted by J Clin Oncol).
Le LH, Swenerton KD, Elit L, Provencher DM, Stuart GCE, Le T, Lee U, Rogers A, Pond GR,
Hu H and Oza AM. Phase II multicentre open-label study of carboplatin and pegylated
liposomal doxorubicin in uterine and cervical malignancies (accepted by Int J Gyn Cancer).
NEPHROLOGY
Duncan, Dr. John A
Buller CE, Nogareda JG, Ramanthan K, Ricci DR, Djurdjev O, Tinckam KJ, Penn IM, Fox
RS, Stevens LA, Duncan JA, Levin A. Renal Artery Stenosis in a Cardiac Population at Risk.
Journal of the American College of Cardiology, 43(9):1606-13, 2004.
Gill, Dr. John S
M. Tonelli, B. Hemmelgarn, B. Manns, G. Pylypchuk, C. Bohm, K. Yeates, S. Gourishankar,
J.S. Gill. Death and Renal Transplantation Among Aboriginal People Undergoing Dialysis.
CMAJ. 2004 Sep 14;171(6):577-82.
Gill JS, Tonelli M, Mix C and Pereira BJG. Why do preemptive transplant recipients have an
allograft survival advantage? Transplantation. 2004 78(6):873-879.
Page 167
Annual Report 2004
Gill JS. Challenges from bias when estimating change of renal allograft funciton, authors reply.
Kidney International 2004 66:463-4.
Gill JS, Tonelli M, Mix C, Johnson N and Pereira BJG. The Effect Of Maintenance
Immunosuppression On Kidney Allograft Function. Kidney International 2004 65:692-9.
Keown, Dr. Paul A
Whiting JF, Kiberd B, Kalo Z, Keown P, Roels L, Kjerulf M. The cost-effectiveness of organ
donation: evaluating investment into donor action and other donor activities. Am. J. Transplant
2004. 4 (4):569-73.
Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving
calcineurin inhibitors. Am. J. Transplant 2004. 4(4): 583-95.
Keown PA. Composite outcomes in renal transplantation. Transplant Proc. 2004 36(2
Suppl):35S-39S.
Johnston A, Belitsky P, Drewe J, Frei U, Horvath, J, Hoyer P, Helderman H, Oellerich M,
Pollard S, Riad H, Rigotti P, Keown P, Nashan B. Potential clinical implications of
substitution of generic cyclosporine formulations for cyclosporine microemulsion (Neoral®) in
transplant recipients. Eur J Clin Pharmacol. 2004. 60(6): 389-95.
De la Rosa R, Harris M, Uyeda L, Goodison K, Keown P, Montaner JS. Life-threatening
reaction after first dose of abacavir in an HIV-I-infected patient. Aids. 2004. 18 (3): 578-9.
Keown PA, Kiberd B, Balshaw R, Khorasheh S, Marra C, Belitsky P, Kalo Z for The Canadian
Neoral Study Group. An economic model of two-hour post-dose cyclosporine monitoring in
renal transplantation. Pharmacoeconomics. 2004; 22(10):621-32.
Levin, Dr. Adeera
Levin A. "Cardiac Disease in Chronic Kdiney Disease: Current Understandings and
Opportunities for Change". Blood Purification. Jan 2004; 22(1):21-7.
Stevens L & Levin A. "Translating Research Findings of Chronic Kidney Disease Management
to Clinical Practice Challenges and Opportunities". Advances in Renal Replacement Therapy.
Jan 2004; 11(1)66-75.
Roger SD, McMahon LP, Clarkson A, Disney A, Harris D, Healy C, Kerr P, Lynn K, Parnham
A, Pascoe R, Voss D, Walker R & Levin A. "Impact of Early and Late Intervention with
Epoetin Alpha on Left Ventricular Mass in Chronic Kidney Disease". JASN. Jan 2004; 15(1),
148-156.
Roger S, McMahon L, Clarkson A, Disny A, Harris D, Hawley C, Healy H, Kerr P, Kelvin L,
Parnham A, Pascoe R, Voss D, Walker R & Levin A. "Effects of Early and Late Intervention
with Epoetin Alpha on Left Ventricular Mass Among Patients with Chronic Kidney Disease
(stage 3 or 4): Results of a Randomized Clinical Trial" JASN. Jan 2004; 15(1):148-56.
Stevens L, Djurdjev O, Cardew S, Cameron EC, Levin A. "Calcium, Phosphate and Parathyroid
Hormone Levels in Combination and as a Function of Dialysis Duration Predict Mortality:
Evidence for the Complexity of the Association Between Mineral Metabolism and Outcomes".
JASN. Mar 2004; 15(3), 770-779.
Buller C, Nogareda JG, Ramanathan K, Ricci DR, Djurdjev O, Tinckam K, Penn IM, Fox RS,
Stevens L, Duncan J & Levin A. "The Profile of Cardiac Patients with Renal Artery Stenosis".
JACC. May 5 2004. 43(9):1606-13.
McMahon LP, Roger SD & Levin A. "The Development, Prevention and Potential Reversal of
Left Ventricular Hypertropy in Chronic Kidney Disease". JASN. June 2004; 15(6); 1640-1647.
Saw J, Levin A & Gin K. "Coronary artery disease in chronic kidney disease patients: Assessing
the evidence for diagnosis, screening and revascularization". Can J Cardiol. June 2004 Vol 20,
No 8. 807-13.
Page 168
Annual Report 2004
Stigant CE, Djurdjev O & Levin A. "C-Reactive Protein Levels in Patients on Maintenance
Hemodialysis: Reliability and Reflection on the Utility of Single Measurements". Journal
International Urology and Nephrology. Accepted August 2004.
Webb JG, Pate GE, Humphries KH, Buller CE, Shalansky S, Al-Shamari A, Sustandar A,
Williams T, Fox RS & Levin A. "A Randomized Controlled Trial of Intravenous
N-Acetylcysteine for the Prevention of Contrast-Induced Nephropathy Following Cardiac
Catheterization: Lack of Effect". AHJ Sept 2004; 148(3), 422-429.
Johnson CA, Levey AS, Coresh J, Levin A, Lau J & Eknoyan G. "Clinical Practice Guidelines
for Chronic Kidney Disease in Adults: Part II. Glomerular Filtration Rate, Proteinuria and Other
Markers". Am Fam Physician. Sept 15 2004. 70(6):1091-7.
Johnson CA, Levey A, Coresh J, Levin A, Lau J & Eknoyan G. "Clincial Practice Guidelines
for Chronic Kidney Disease in Adults: Part I. Definition, Disease Stages, Evaluation, Treatment
and Risk Factors". Am Fam Physician. Sept 1 2004. 70(5):869-76.
Shalansky S, Levin A, Pate G & Webb J. "N-Acetylcysteine for Prevention of
Radiocontrast-Induced Nephrotoxicity: The Importance of Dose and Route of Administration".
Heart Journal. Sept 2004.
MacRae JM, Ahmed A, Johnson N, Levin A & Kiaii M. "Central Vein Stenosis: A Common
Problem in Hemodialysis Patients". ASAIO accepted with revisions, Oct 2004.
Eknoyan G, Lameire N, Barsoum R, Eckardt KU, Levin A, Levin N, Locatelli F, MacLeod A,
Vanholder R, Walker R & Wang H. "The Burden of Kidney Disease: Improving Global
Outcomes". Kidney Int. Oct 2004. 66(4): 1310-4.
Curtis, Bryan M, Ravani, Pietro, Malberti F, Kennett F, Taylor P, Djurdjev O & Levin A.
"The Short and Long Term Impact of Multi-Disciplinary Clinics in Addition to Standard
Nephrology Care on Patient Outcomes". NDT. Dec 2004.
Kasiske B, Cosio FG, Beto J, Bolton K, Chavers BM, Grimm R Jr, Levin A, Masri B, Purekh
R, Wanner C, Wheeler DC & Wilson PWF. "Clinical practice guidelines for managing
dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in
Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease
Outcomes Quality Initiative". AmJT 2004; 4(Suppl. 7):13-53.
Wong, Dr. Norman L
Sonntag M, MH Wang, and NLM Wong. Endothelin up regulates the expression of vasopressin
V2 mRNA in the inner meduilary collection duct of the rat. Metabolism 53: 1177-1183, 2004.
NEUROLOGY
Barton, Dr. Jason J
Barton JJS. The symptomatic IV nerve palsy. Neuro-ophthalmology, 2004; 28: 171-8.
Manoach DS, Lindgren KA, Barton JJS. Deficient saccadic inhibition in Asperger's disorder and
the social-emotional processing disorder. J Neurol Neurosurg Psychiatry 2004; 75: 1719-26.
Barton JJS, Cherkasova MV, Hefter R, Cox TA, O’Connor M, Manoach DS. Are patients with
social developmental disorders prosopagnosic? Perceptual heterogeneity in the Asperger and
socio-emotional processing disorders. Brain 2004; 127: 1706-16.
Ramchandran RS, Manoach DS, Cherkasova MV, Lindgren KS, Barton JJS. The relation of
saccadic peak velocity to latency: evidence for a new prosaccadic abnormality in schizophrenia.
Exp Brain Res 2004; 159: 99-107.
Barton JJS. ‘Retinal diplopia’ associated with macular wrinkling. Neurology 2004; 63: 925-27.
Barton JJS, Cherkasova M, Press DZ, Intriligator J, O'Connor M. Perceptual function in
prosopagnosia. Perception 2004; 33: 939-56.
Page 169
Annual Report 2004
Barton JJS, Cherkasova MV, Hefter R. The covert priming effect of faces in prosopagnosia.
Neurology 2004; 63: 2062-8.
Barton JJS. Is MRI diagnostic for Susac syndrome? Journal Watch Neurology 2004: 6(6):46.
Barton JJS. Aspects of internuclear ophthalmoplegia in stroke. Journal Watch Neurology 2004:
6(10): 76.
Briemberg, Dr. Hannah
Briemberg HR, Amato AA. Transthyretin amyloidosis presenting with multifocal
mononeuropathies. Muscle Nerve. 2004;29(2):318-22.
Greenberg SA, Briemberg HR. A neurological and hematological syndrome associated with zinc
excess and copper deficiency. J Neurol 2004;251:111-114.
Chapman, Dr. Kristine M
Benatar M, Chapman KM, Rutkove SB. Repetitive Nerve Stimulation for the Evaluation of
Peripheral Nerve Hyperexcitability. Journal of the Neurological Sciences. 2004 Jun
15:221(1-2):47-52.
Devonshire, Dr. Virginia A
Yoshida EM, Devonshire VA, Prout AJ. Remission of multiple sclerosis post-liver transplantation.
Can J Neurol Sci. 2004 Nov;31(4):539-41.
Doudet, Dr. Doris J
Neto P, Doudet DJ, Cumming P. "Gradients of dopamine D1 and D2/3 binding sites in the
basal ganglia of pig and monkey measured by PET" Neurolmage 22:1076-1083 (2004).
Endres CJ, DeJesus OT, Uno H, Doudet DJ, Nickles RJ, Holden JE "Time profile of cerebral
[18F]6-fluoro-L-dopa metabolites in non-human primate: Implications for the kinetics of
therapeutic L-dopa" Frontiers in Bioscience 9:505-512 (2004).
Doudet D.J., Allen R., Honey C., Schweikert A., Cornfeldt M. "In vivo evaluation of retinal
pigment epithelial cell transplant by PET " Exp. Neurol. 189:361-368 (2004).
Strome E.M., Jivan S., Doudet D.J. "Quantitative in vitro phosphor imaging using [3H] and
[18F] radioligands: effects of chronic desipramine treatment on serotonin 5HT2 receptors" J.
Neurosci. Methods 141:143-154 (2004).
Feldman, Dr. Howard H
Spacey SD, Green GJ, Pastore M, McGuillivray B, Fleming J, Gambetti P, Feldman H. Fatal
Familial Insomnia: The First Account in a Family of Chinese Descent Archives of Neurology.
2004 Jan; 61(1): 122-125.
McKeith IM, Mintzer J., Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, Dickson D, Dubois
B, Duda J, Feldman H, Gauthier S, Halliday G, Lawlor B, Lippa C, Lopez O, Machado J,
O’Brien J, Playfer J, Reid W. Dementia with Lewy Bodies. Lancet Neurology. 2004 Jan; 3(1):
19-28.
Mackenzie IRA and Feldman H. Extrapyramidal features in patients with motor neuron disease
and dementia; a clinicopathological correlative study. Acta Neuropathologica (Berl). 2004 Apr;
107(4): 336-340.
Tabet N and Feldman H. Naproxen for treatment of Alzheimer's Disease. The Cochrane Library
Systematic Reviews. (3) 2004.
Mackenzie IRA and Feldman H. Neuronal intranuclear inclusions distinguish familial
FTD-MND type from sporadic cases. Demend Geriatr Cogn Disord. 2004; 17(4): 333-6.
Feldman H, Scheltens P, Scarpini E, Herrmann N, Mesenbrink P, Mancione L, Tekin S, Lane R
and Ferris S. Behavioral symptoms in mild cognitive impairment: Findings from the InDDEx
Study. Neurology. 2004 (62); 1199-1201.
Page 170
Annual Report 2004
Peters KR, Graf P, Hayden S, and Feldman H. Neuropsychological Characterization of
Cognitively-Impaired-Not-Demented (CIND) Individuals: Clinical Comparison Data. The
Clinical Neuropsychologist. 2004; 18(2): 208-28.
Erkinjuntti T, Roman G, Gauthier S, Feldman H and Rockwood K. Emerging Therapies for
Vascular Dementia and Vascular Cognitive Impairment. Stroke. 2004 Apr; 35(4): 1010-1017.
Hsiung GY, Sadovnick AD, and Feldman, H. Apolipoprotein E genotype as a risk factor for
cognitive decline and dementia: data from the Canadian Study on Health and Aging (CSHA).
Canadian Medical Association Journal. 2004 Oct 12; 171(8): 863-7.
Feldman H, Gauthier SG, Hecker J, Vellas B, Hux M, Xu Y, Schwam E, Shah S and Mastey V.
An Economic Evaluation of Donepezil in Moderate to Severe AD. Neurology. 2004 Aug 24;
63(4): 644-50.
Mackenzie IRA and Feldman H. Neurofilament inclusion body disease with early onset
frontotemporal dementia and primary lateral sclerosis. Clinical Neuropathology. 2004 Jul-Aug;
23(4): 183-93.
Voisin T, Reynish E, Portet F, Feldman H and Vellas B. What are the treatment options for
patients with severe Alzheimer’s disease? CNS Drugs. 2004; 18(9): 575-83.
Hallam, Dr. Bradley J
Rosen HJ, Narvaez JM, Wyss-Coray C, Hallam BJ, Kramer JH, Johnson JK, & Miller BL
(2004). Neuropsychological and functional measures of severity in Alzheimer disease,
frontotemporal dementia, and semantic dementia. Alzheimer Disease and Associated
Disorders, 18(4), 202-7.
Hsiung, Dr. Ging-Yuek R
Hsiung G, Sadovnick D, Feldman H. Apolipoprotein E e4 genotype as a risk factor for cognitive
decline and dementia: data from the Canadian Study on Health and Aging (CSHA) Canadian
Medical Association Journal, 2004 Oct 12;171(8):863-7.
Hsiung G, Kaplan B, Petryshen T, Lu S, Field LL. A dyslexia susceptibility locus (DYX7)
linked to dopamine D4 receptor (DRD4) region on chromosome 11p15.5 Am J Medical
Genetics/Neuropsychiatric Genetics 2004 Feb 15;125B(1):112-9.
Johnston, Dr. Dean C
Johnston DCC and Hill MD. The patient with transient cerebral ischemia: a golden opportunity
for stroke prevention. Can. Med. Assoc. J.170:1134-1137 Mar 2004.
Horner RD, Oddone EZ, Granbow S, Johnston DCC, Stechuchak S. Who Doesn't Receive
Carotid Endarterectomy When Appropriate? Journal of Vascular Surgery 39:1 161-168
January 2004.
Keyes, Dr. Robert D
Cote, A.M., Opatrny, L., Keyes, R.D., Nulman, I., and Magee, L.A., "The Practicalities of
Managing Seizures in Pregnancy: A Review", in Fetal and Maternal Medicine Review 2004:
15:2 181-204.
Krieger, Dr. Charles
Murphy, B., Krieger, C. and Hoffer, A. (2004) Chronically implanted epineural electrodes for
repeated assessment of nerve conduction velocity and compound action potential amplitude in
rodents. J. Neurosci. Methods. 132: 25-33.
Li, S., Wang, X., Klee, C.B., and Krieger, C. (2004) Overexpressed mutant G93A superoxide
dismutase protects calcineurin from inactivation. Brain Res. 125: 156-161.
Page 171
Annual Report 2004
Lee, Dr. Chong S
Lee CS, Schulzer, M, de la Fuente-Fernández R, Mak E, Kuramoto L, Sossi V,
Ruth TJ, Calne DB, Stoessl AJ (2004). Lack of regional selectivity during the progression of
Parkinson’s disease: Implications for pathogenesis. Arch. Neurol. 61: 1920-1925.
McKeown, Dr. Martin J
McKeown MJ, Hanlon CA. A re-sampling / region of interest (ROI) method for discriminating
patterns of activity in fMRI data, Journal of Neuroscience Methods 135 (2004) 137-147.
R. Liao, M.J. McKeown, and J.L. Krolik, "Isolation and Minimization of Effects of Motion on
fMRI Data Using Multiple Reference Images", Second IEEE International Symposium on
Biomedical Imaging, Feb, 2004.
R. Liao, M.J. McKeown, and J.L. Krolik, "Motion-Corrected Independent Component
Analysis for Robust Functional Magnetic Resonance Imaging", The IEEE International
Conference on Acoustics, Speech, and Signal Processing, May, 2004.
Huettel SA, McKeown MJ, Song AW, Hart S, Spencer DD, Allison T, McCarthy G. Linking
hemodynamic and electrophysiological measures of brain activity: Evidence from functional MRI
and intracranial field potentials Cerebral Cortex, February 2004; 14:165-173.
Oger, Dr. Joel
Tremlett H, J Oger. Elevated aminotransferases during treatment with IFNB for MS: actions and
outcomes. Multiple Sclerosis 2004;10:298-301.
Reder AT, J Oger. Anti-myelin oligodendrocyte glycoprotein antibodies in multiple sclerosis.
Neurology 2004;62:1922-1923.
Tremlett H, J Porciuncula, E Gibbs, J Oger. Binding antibody positive MS patients treated with
interferon beta-1b are less likely to develop elevated liver enzymes. Journal of Applied
Therapeutic Research 2004;5(1):12-16.
Tremlett HKL, J Porciuncula, J Oger. Treatment with beta-interferon prior to glatiramer acetate
diminishes the serum IgG response in multiple sclerosis patients. Journal of Applied Therapeutic
Research 2004;5(2):12-16.
Tremlett H, J Oger. Hepatic injury, liver monitoring and the beta-interferons for multiple
sclerosis. J Neurol. 2004 Nov;251(11):1297-303.
Oger J, A Al-Araji. Multiple Sclerosis. Early Intervention is essential to delaying disease
progression. Parkhurst Exchange, July 2004. 67-73.
Phillips JT, Rice G, Frohman E, Vande Gaer L, Scott T, Haas J, Eggenberger E, Freedman MS,
Stuart W, Cunha L, Jacobs L, Oger J, Arnold D, Murray TJ, DiBiase M, Jethwa V, Goelz S. A
multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled
syringe (liquid) formulation of Avonex in patients with multiple sclerosis. Clin Ther. 2004
Apr;26(4):511-21.
Laule C, Vavasour IM, Moore GR, Oger J, Li DK, Paty DW, MacKay AL. Water content and
myelin water fraction in multiple sclerosis. A T2 relaxation study. J Neurol. 2004
Mar;251(3):284-93.
Tremlett HL, Yoshida EM, Oger J. Liver injury associated with the beta-interferons for MS: a
comparison between the three products. Neurology. 2004 Feb 24;62(4):628-31. Review.
Summary for patients in: Neurology. 2004 Feb 24;62(4):E8-9.
Tremlett HL, Yoshida E, Oger J. Liver injury associated with the IFNBs for MS: a comparison
between IFNB-1b(sc), IFNB-1a (sc) and IFNB-1a (im) Neurology 2004;63 1142-1143.
Pelech, Dr. Steven
Zhang L, Pelech S & Uitto VJ. Bacterial GroEL-like heat shock protein 60 proetcts epithelial
cells from stress-induced death through activation of ERK and inhibition of caspase-3. Exp. Cell.
Page 172
Annual Report 2004
Res. 292:231-240 (2004).
Zhang L, Pelech S & Uitto VJ. Long-term effect of heat shock protein 60 from Actinobacillus
actinomycetemcomitans on epithelial cell viability and mitogen-activated protein kinases. Infect.
Immun. 72:38-45 (2004).
Tudan C, Kacson J, Higo TT, Hampong M, Pelech S & Burt H. Calcium pyrophosphate
dihydrate crystal-induced neutrophil activation and repression of TNF-alpha induced apoptosis is
mediated by the p38 MAP kinase. Cell Signalling. 16:211-221 (2004).
Zhang H, Xiaoqing Shi X, Hampong M, Paddon H, Dai W & Pelech S. Polo-like kinase
regulation of centrosomes is mediated through Serine 4 phosphorylation of B23/nucleophosmin.
J. Biol. Chem. 279:35726-35734 (2004).
Wong AST, Roskelley CD, Pelech S, Miller D, Leung PCK & Auersperg N. Progressive
changes in Met-dependent signaling in a human ovarian surface epithelial model of malignant
transformation. Exp. Cell. Res. 299:248-256 (2004).
Pelech SL. Tracking cell signalling protein expression and phosphorylation by innovative
proteomic solutions. Curr. Pharm. Biotech. 5, 69-77 (2004).
Prout, Dr. Alister
Yoshida, E.M., Devonshire, V.A., Prout, A.J.E., "Remission of Multiple Sclerosis Post-Liver
Transplantation" Can. J. Neurol. Sci., 2004;31(4):539.
Spacey, Dr. Sian
Spacey SD, Szczwgielski BI, Selby K, Hukin J, Snutch TP. A novel mutation in the frataxin
gene is associated with a novel presentation of Friedreich’s Ataxia. Canadian Journal of
Neurological Sciences 2004 vol 31 (3): 383-386.
Spacey SD, Hildebrand ME, Materek LA, Bird TD, Snutch TP. Functional implications of a
novel EA2 missense mutation in the P/Q-type calcium channel. Annals of Neurology 2004
Aug;56(2):213-20.
Spacey SD, Green GJ, Berry K, Fleming J, Peterson RB, McGillivray, Gambetti PL, Feldman
H. Fatal Familial Insomnia: the first account in a family of Chinese descent. Archives of
Neurology 2004 Jan;61(1):122-5.
Stoessl, Dr. A Jon
Zimprich A, Muller-Myhsok B, Farrer M, Leitner P, Sharma M, Hulihan M, Lockhart P,
Strongosky A, Kachergus J, Calne DB, Stoessl AJ, Uitti RJ, Pfeiffer RF, Trenkwalder C,
Hormann N, Ott E, Wenzel K, Asmus F, Hardy J, Wszolek Z, Gasser T (2004). The
PARK8-locus in autosomal-dominant parkinsonism: confirmation of linkage and further
delineation of the disease containing interval. Am. J. Human Genetics 74:11-19.
Zamburlini M, Camborde M-L, de la Fuente-Fernandez R, Stoessl AJ, Ruth TJ, Sossi V
(2004). Impact of the spatial normalization template and realignment procedure on the SPM
analysis of 11C-raclopride PET studies. IEEE Trans Nucl. Sci. 51: 205-211.
Hedrich K, Meyer E-M, Schule B, Kock N, de Carvalho Aguiar P, Wiegers K, Koelman JH,
Garrels J, Durr R, Liu L, Schwinger E, Ozelius LJ, Landwehrmeyer B, Stoessl AJ, Tijssen MA,
Klein C (2004). Myoclonus-dystonia: detection of novel, recurrent, and de novo SCGE
mutations. Neurology 62: 1229-1231.
de la Fuente-Fernandez R, Schulzer M, Mak E, Calne DB, Stoessl AJ (2004). Presynaptic
mechanisms of motor fluctuations in Parkinson's Disease: a probabilistic model. Brain 127:
888-899.
de la Fuente-Fernandez R, Schulzer M, Stoessl AJ (2004). Placebo mechanisms and reward
circuitry: Clues from Parkinson's disease. Biological Psychiatry 56: 67-71.
Page 173
Annual Report 2004
Wszolek ZK, Pfeiffer RF, Tsuboi Y, Uitti RJ, McComb RD, Stoessl AJ, Strongosky AA,
Zimprich A, Müller-Myhsok B, Farrer MJ, Gasser T, Calne DB, Dennis W. Dickson (2004).
Autosomal dominant Parkinsonism associated with variable synuclein and tau pathology.
Neurology 62: 1619-1622.
Furtado S, Payami H, Lockhart PJ, Hanson M, Nutt JG, Singleton A, Singleton A, Bower J,
Uitti RJ, Bird T, de la Fuente-Fernandez R, Tsuboi Y, KKKlimek ML, Suchowersky O, Hardy
J, Calne DB, Wszolek ZK, Farrer M, Gwinn-Hardy K, Stoessl AJ (2004). Profile of families
with parkinsonism-predominant spinocerebellar ataxia type 2 (SCA2). Movement Disorders
19: 622-629.
Kumar A, Calne S, Schulzer M, Mak E, Wszolek ZK, Netten C, Tsui JKC, Stoessl AJ, Calne
DB (2004). Clustering of Parkinson's Disease: Shared cause or coincidence? Arch. Neurol. 61:
1057-1060.
Sossi V, de la Fuente-Fernandez R, Holden JE, Schulzer M, Ruth TJ, Stoessl AJ (2004).
Changes of dopamine turnover in the progression of Parkinson’s disease as measured by PET:
their relationship to disease compensatory mechanisms. J. Cerebral Blood Flow Metab.
24: 869-876.
Lee CS, Schulzer, M, de la Fuente-Fernández R, Mak E, Kuramoto L, Sossi V, Ruth TJ, Calne
DB, Stoessl AJ (2004). Lack of regional selectivity during the progression of Parkinson disease:
Implications for pathogenesis. Arch. Neurol. 61: 1920-1925.
Constantoyannis C, Kumar A, Stoessl AJ, Honey CR (2004). Tremor induced by thalamic deep
brain stimulation in patients with complex regional facial pain. Movement Disorders 19: 933-936.
de la Fuente-Fernandez R, Sossi V, Huang Z, Furtado S, Lu J-Q, Calne DB, Ruth TJ, Stoessl
AJ (2004). Levodopa-induced changes in synaptic dopamine levels increase with progression of
Parkinson's disease: implications for dyskinesias. Brain 127: 2747-2754.
Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M,
Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F,
Muller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T (2004).
Mutations in LRRK2 cause autosomal dominant Parkinsonism with pleomorphic pathology.
Neuron 44: 601-607.
Oliveira JR, Spiteri E, Sobrido MJ, Hopfer S, Klepper J, Voit T, Gilbert J, Wszolek ZK, Calne
DB, Stoessl AJ, Hutton M, Manyam BV, Boller F, Baquero M, Geschwind DH (2004). Genetic
heterogeneity in familial idiopathic basal ganglia calcification (Fahr disease). Neurology. 2004;
63:2165-7.
Teal, Dr. Phillip A
Teal PA. Recent clinical trials with antiplatelet therapy: implications in stroke prevention.
Cerebrovascular Diseases. 2004;17 Suppl 3:6-10.
Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and Thrombolytic
Therapy for Ischemic Stroke. Chest 2004;126:483S-512S.
Thiessen, Dr. Brian A
Dalmau J, Graus F, Villarejo A, Posner JB, Blumenthal D, Thiessen B, Saiz A, Meneses P,
Rosenfeld MR. Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004:127(8):1831-44.
Traboulsee, Dr. Anthony
Traboulsee A. MRI: Role in optimizing treatment. Journal of Neurology. 2004, 251 Suppl 5:36-41.
Tremlett, Dr. Helen L
Tremlett HL, Yoshida E, Oger J: Liver injury associated with the IFNBs for MS: a comparison
between IFNB-1b(sc), IFNB-1a (sc) and IFNB-1a (im); Neurology 2004;62:628-631.
Page 174
Annual Report 2004
Tremlett HL, Oger J: Elevated aminotransferases during treatment with Beta-Interferon for
Multiple Sclerosis: actions and outcomes; Multiple Sclerosis 2004; 10: 298-301.
Tremlett HL, Porciuncula J, Oger J: Treatment with beta-interferon prior to glatiramer acetate
diminishes the serum IgG response in multiple sclerosis patients; Journal of Applied Therapeutic
Research 2004; 5(1): 12-16.
Tremlett HL, Oger J: Hepatic injury, liver monitoring and the beta-interferons for Multiple
Sclerosis (Review); Journal of Neurology 2004;251:1297-1303.
Tremlett HL, Yoshida E, Oger J. Liver injury associated with the IFNBs for MS: a comparison
between IFNB-1b(sc), IFNB-1a (sc) and IFNB-1a (im) Neurology 2004;63 1142-1143.
Tsui, Dr. Joseph K
Kumar A, Calne S, Schulzer M, Mak E, Wszolek ZK, Netten C, Tsui JKC, Stoessl AJ, Calne
DB (2004). Clustering of Parkinson's Disease: Shared cause or coincidence? Arch. Neurol. 61:
1057-1060.
Wang, Dr. Yu Tian
Ahmadian G, W Ju, LD Liu, A Dunah, M Wyszynski, M Sheng, and YT Wang, Tyrosine
phosphorylation of GluR2 is required for regulated AMPA receptor endocytosis and LTD,
EMBO J, 23:1040-1050, 2004.
Persad V, CT Wong, MA Cortez, YT Wang and OC Snead III, Hormonal regulation of atypical
absence seizures, Ann Neurol, 55:353-361, 2004.
Liu L, TP Wong, MF Pozza, K Lingenhoehl, Y Wang, M Sheng, YP Auberson, YT Wang,
Subtypes of NMDA receptors govern the direction of hippocampal synaptic plasticity, Science,
304:1021-1024, 2004.
Wang Y, W Ju, KH Kuo, S Fam, L Liu, S D’Souza, C Taghibiglou, M Salter, CY Seow, YT
Wang, a--amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor endocytosis is essential
for N-methyl-D-aspartate-induced apoptosis, J. Biol. Chem. 279:41267-41270, 2004.
Wong TP, L Liu, M Sheng and YT Wang, Response to Comment on "Role of NMDA
Receptor Subtypes in Governing the Direction of Hippocampal Synaptic Plasticity", Science,
305:1912, 2004.
Prange O, TP Wong, K Gerrow, YT Wang, and A El-Husseini, A balance between excitatory
and inhibitory synapses is controlled by PSD-95 and neuroligin, PNAS, 101: 13915-13920, 2004.
Dong H, YY Xiang, N Farchi, W Ju, Y Wu, L Chen, Y Wang, B Hochner, B Yang, H Soreq,
WY Lu, Excessive expression of acetylcholinesterase impairs glutamatergic synaptogenesis in
hippocampal neurons, J. Neurosci. 24:8950-60, 2004.
Collingridge GL, JTR Isaac and YT Wang, Receptor trafficking and synaptic plasticity, Nature
Neuroscience Rev. 5:952-962, 2004.
Wu Y, S Ali, G Ahmadian, CC Liu, YT Wang, KM Gibson, AR Calver, J Francis, MN Pangalos,
and Snead OC, III. Gamma-hydroxybutyric acid (GHB) and gamma-aminobutyric acid
B receptor (GABABR) binding sites are distinctive from one another: molecular evidence.
Neuropharmacol. 47:1146-56, 2004.
Woolfenden, Dr. Andrew R
The IMS Study Investigators. Combined intravenous and intra-arterial recanalization for acute
ischemic stroke: the Interventional Management of Stroke (IMS) Study. Stroke 2004;35:904-11.
Berlis A, Lutsep H, Barnwell S, Norbash A, Wechsler L, Jungreis CA, Woolfenden AR,
Redekop G, Hartmann M, Schumacher M. Mechanical thrombolysis in acute ischemic stroke
with endovascular photoacoustic recanalization. Stroke 2004;35:1112-6.
Page 175
Annual Report 2004
LaMonte MP, Nash ML, Wang DZ, Woolfenden AR, Schultz J, Hursting MJ, Brown PM.
Argatroban Anticoagulation in Patients with Acute Ischemic Stroke (ARGIS-1): A Randomized,
Placebo-Controlled Study. Stroke 2004;35:1677-82.
PHYSICAL MEDICINE & REHABILITATION
Anton, Dr. Hubert A
Anton HA, Townson AF. Drug Therapy for Autonomic Dysreflexia (letter). CMAJ 170, No. 8,
1210, 2004.
Dawson, Dr. Andrew S
Eng JJ, Dawson AS, Chu K. (2004). Submaximal exercise in individuals with stroke: test-retest
and concurrent validity with maximal oxygen consumption. Archives of Physical Medicine and
Rehabilitation, 85, 113-118.
Eng, Dr. Janice J
McCrea PH, Eng JJ, Willms R (2004). Phenol reduces hypertonia and enhances strength: A
longitudinal case study. Neurorehabilitation and Neural Repair, 18, 112-6.
Underwood HA, Tokuno CD, Eng JJ (2004). A comparison of two prosthetic feet on the
multi-joint and multi-plane kinetic gait compensations in individuals with a unilateral
trans-tibial amputation. Clinical Biomechanics, 19, 609-616.
Chu KS, Eng JJ, Dawson AS, Harris JE, Ozkaplan A, Gylfadóttir S (2004). Water-based
exercise for cardiovascular fitness in people with chronic stroke: A randomized controlled trial.
Archives of Physical Medicine and Rehabilitation, 85:870-874.
Liu-Ambrose T, Khan KM, Eng JJ, Janssen PA, Lord SR, McKay HA (2004). Resistance and
agility training reduce fall risk in women aged 75 to 85 with low bone mass: A 6-month
randomized, controlled trial. Journal of the American Geriatrics Society, 52, 657-665.
Kim CM, Eng JJ, Whittaker M (2004). Level walking and ambulatory capacity in persons with
incomplete spinal cord injury: relationship with muscle strength. Spinal Cord, 42:156-162.
Donnelly C, Eng JJ, Hall J, Giachino R, Alford L, Northon K, Wilkinson S, Kerr DS (2004).
Client-centred assessment and the identification of meaningful treatment goals for individuals
with a spinal cord injury. Spinal Cord, 42:302-307.
Inkster LM, Eng JJ (2004). Postural control during a sit-to-stand task in individuals with mild
Parkinson's disease. Experimental Brain Research, 154:33-8.
Eng JJ, Dawson AS, Chu K. (2004). Submaximal exercise in individuals with stroke: test-retest
and concurrent validity with maximal oxygen consumption. Archives of Physical Medicine and
Rehabilitation, 85, 113-118.
Underwood, Dr. Heather A
Underwood, HA, CD Tokuno & JJ Eng. A comparison of two prosthetic feet on the multi-joint
and multi-plane kinetic gait compensation in individuals with a unilateral trans-tibial
amputation. Clinical Biomechanics, 19, p. 609-616, 2004.
Yassi, Dr. Annalee
Ostry AS, Tomlin KM, Cvitkovich Y, Ratner PA, Park I, Tate R, Yassi A. Choosing a model
of care for alternate level care patients: Caregivers' perspectives with respect to staff injury.
Canadian Journal of Nursing Research. 2004; 36(4): 142-157.
Spiegel JM, Barceló C, Loucks E, Bonet M, Aldama A, Yassi A. What the Cuban context
provides health researchers: Assessing the feasibility of a longitudinal multi-methods study of
the impact of housing improvements on health in Havana, Cuba. Journal of Public Health.
Page 176
Annual Report 2004
2004;26(1):95-100.
Spiegel JM, Yassi A. Lessons from the margins of globalization: Appreciating the Cuban health
paradox. Journal of Public Health Policy. 2004;25(1):96-121.
Yassi A, Cohen M, Cvitkovich Y, Park I, Ratner PA, Ostry AS, Village J, Pollack N. Factors
associated with staff injuries in intermediate care facilities in British Columbia, Canada. Nursing
Research. 2004;53(2):87-98.
RESPIRATORY MEDICINE
Ayas, Dr. Najib T
Patel SR, Ayas NT, Malhotra MR, White DP, Speizer FE, Stampfer MJ, Hu FB. A Prospective
Study of Sleep Duration and Mortality Risk in Women. Sleep 2004; 27:440-4.
Patel SR, Karmapolitis D, Ayas NT, Hess D, Kacmarek R, Thompson BT, Wain J, Malhotra
A. The Utility of Open Lung Biopsy in Patients with the Acute Respiratory Distress
Syndrome:The Experience of a Large Teaching Hospital. Chest 2004; 195:197-202.
Pittman SD, Pillar G, Ayas NT, Suraiya S, Malhotra A, White DP. Can Obstructive Sleep
Apnea be Diagnosed in the Home Using a Wrist-mounted Device with Automated Analysis of
Peripheral Arterial Tonometry, Pulse Oximetry, and Actigraphy? Sleep 2004; 27:923-33.
Ayas NT, Patel SR, Malhotra A, Schulzer M, Malhotra M, Jung D, Fleetham J, White DP.
Auto-Titrating Versus Standard Continuous Positive Airway Pressure for the Treatment of
Obstructive Sleep Apnea: Results of a Meta-analysis. Sleep 2004; 27:249-253.
Bai, Dr. Tony R
Catherine Lemiere, Tony R Bai, Allan Becker et al. Adult Asthma Guidelines update 2003. Can
Resp J 2004, 11 (suppl A): 9A-18A.
Bai TR. Mucus plugging in asthma [letter]. Am J Med 2004; 116(1): 67.
Lynd LD, Sandford AJ, Kelly EM, Pare PD, Bai TR, Fitzgerald JM, Anis AH. Reconcilable
Differences: A Cross-sectional Study of the Relationship Between Socioeconomic Status and the
Magnitude of Short-Acting {beta}-Agonist Use in Asthma. Chest. 126(4):1161-1168. 2004.
Raghu G et al, for the Idiopathic Pulmonary Fibrosis Study Group*. A placebo-controlled trial
of INF gamma in patients with IPF. New Eng J Med 2004; 350:125-33.
Zheng X, Zhou D, Seow CY and Bai TR. Cardiotrophin-1 alters airway smooth muscle
structure and mechanical properties in airway explants. Am J Physiol Lung Cell Mol Physiol.
2004 Dec;287(6):L1165-71. Epub 2004 Jul 23.
Bai TR. Role of airway smooth muscle dysfunction in asthma. Journal of Asthma, Allergy and
Clinical Immunology 2004. 24 [Suppl II]: S82-97.
Bai TR. New approach to asthma management by adjustable dosing. Journal of Asthma, Allergy
and Clinical Immunology 2004. 24 [Suppl II]: S121-131.
Bai TR, Bates JH, Brusasco V, Camoretti-Mercado B, Chitano P, Deng LH, Dowell M, Fabry
B, Ford LE, Fredberg JJ, Gerthoffer WT, Gilbert SH, Gunst SJ, Hai CM, Halayko AJ, Hirst SJ,
James AL, Janssen LJ, Jones KA, King GG, Lakser OJ, Lambert RK, Lauzon AM, Lutchen
KR, Maksym GN, Meiss RA, Mijailovich SM, Mitchell HW, Mitchell RW, Mitzner W,
Murphy TM, Pare PD, Schellenberg RR, Seow CY, Sieck GC, Smith PG, Smolensky AV,
Solway J, Stephens NL, Stewart AG, Tang DD, Wang L. On the terminology for describing the
length-force relationship and its changes in airway smooth muscle. J Appl Physiol. Dec;97(6):
2029-34. 004.
Page 177
Annual Report 2004
Cook, Dr. Victoria J
Hernandez-Garduno E, Cook VJ, Kunimoto D, Elwood RK, Black WA and FitzGerald JM.
Transmission of tuberculosis from smear-negative patients: a molecular epidemiology study.
Thorax 2004;59:286-290.
Cook VJ, Manfreda J and Hershfield ES. The Epidemiology and Bacteriology of Tuberculous
Lymphadenitis in Manitoba (1990 to 2000). Canadian Respir J 2004;11(4):279-286.
CY Turenne, L Thibert, K Williams, TV Burdz, VJ Cook, JN Wolfe, DW Cockcroft and A
Kabani. Mycobacterium saskatchewanense sp. nov., a novel slowly growing scotochromogenic
species from human clinical isolates related to Mycobacterium interjectum and
Accuprobe-positive for Mycobacterium avium complex. Int J Syst Evol Microbiol 2004;
54:659-667.
Turenne CY, Cook VJ, Pauls RJ, Burdz TV, Wolfe JN, Thibert L and Kabani A.
Mycobacterium parascrofulaceum sp. nov., a novel slowly growing, scotochromogenic clinical
isolate related to Mycobacterium simiae. Int J Syst Evol Microbiol, 2004 Sep; 54 (Pt 5):1543-51.
Elwood RK, Hernandez-Garduno E, and Cook VJ. Risk of tuberculosis in children from smear
negative source cases. Int J Tuberc Lung Dis, Journal 2005;9(1):1-7.
Cook VJ, Hernandez-Garduno E, Kunimoto D, Hershfield ES, Fanning A, Hoeppner VH,
Elwood RK, FitzGerald JM and the Canadian Molecular Epidemiology of Tuberculosis Study
Group. Influence of BCG Vaccination on Tuberculosis Transmission in Aboriginal Communities
of Western Canada (1995-1997). Canadian Respiratory Journal, Accepted October 2004.
Elwood, Dr. Richard K
Marra F, Cox VC, FitzGerald JM, Moadebi S, Elwood RK. Successful treatment of
multidrug-resistant tuberculosis following drug-induced hepatic necrosis requiring liver
transplant. Int J Tuberc Lung Dis 2004 8(7):905-909.
FitzGerald, Dr. J Mark
FitzGerald JM, Menzies D. Missed TB. Commentary. April 2004. AHRQ Web M & M.
http://webmm.ahrq.gov/cases.aspx?1c=56.
FitzGerald JM, Becker A, Sears MR, et al. A randomized controlled trial of doubling the dose of
inhaled corticosteroids versus placebo in acute asthma exacerbations. Thorax, 2004;59:550-556.
Sobolev B. FitzGerald JM, Mercer D. Drawing policy conclusions from uncontrolled studies.
CMAJ 2004;170:317-318.
Dragicevic S, Schuurman N, FitzGerald JM. The utility of exploratory spatial data analysis in
the study of tuberculosis incidences in an urban Canadian population. Cartographia 2004;39:29-39.
Hernandez Garduno E, Cook V, Kunimoto D, Elwood RK, Black WA, FitzGerald JM.
Transmission of tuberculosis from smear negative patients: a molecular epidemiology study.
Thorax 2004 ;59:286-290.
Lynd LD, Guh DP, Pare PD, Bai TR, FitzGerald JM & Anis AH. The relationship between
proximate and contextual measures of socioeconomic status and asthma control. Chest 2004;
2004; 126:1161-1688.
Aaron S, Vandemheen K, Fergusson D, FitzGerald JM, et al. The Canadian Optimal Therapy of
COPD trial: design, organization and patient recruitment. Can Respir J 2004;11:581-585.
Lemiere C, Bai T, Becker A, et al. Adult asthma guidelines consensus. Update 2003. Can
Respir J 2004;11;9A-18A.
Yassi Annalee, Bryce J on behalf of the Working group. Protecting the faces of health care
workers: knowledge gaps and research priorities for effective protection against occupationally
acquired respiratory infectious disease. A report for the Change Foundation Ontario. 2004.
Baker RG, Norton PG, Flintoft V, et al (Member of the study group). The Canadian Adverse
Events Study: the incidence of adverse events among hospital patients in Canada. Can Med
Page 178
Annual Report 2004
Assoc J 2004;170:1678-86.
Jasmer RM, Bozeman L, Schwartzman K, Cave DM, Saukkonen JJ, Metchook B, Khan A,
Burman WJ and the Tuberculosis Trials Consortium. Recurrent tuberculosis in the United
States and Canada. Relapse or reinfection? Amer J Respir Crit Care Med 2004;1360-1366.
FitzGerald JM, Olsson P, Michils A. Adjustable maintenance dosing with
budesonide/formoterol in a single inhaler-efficacy and safety. Int J Clinical Practice.
2004;58:18-25.
Cook V, FitzGerald JM. The role of corticosteroids in pericardial TB. N Eng J Med
2004;351:1804-1805.
Fleetham, Dr. John A
Tsuiki S., Lowe A.A., Almeida F.R. and Fleetham J.A. Effects of an anteriorly-titrated
mandibular position on airway size and obstructive sleep apnea severity. Am J Orthod, 125(5):
548-55, 2004.
Tsuiki S., Lowe A.A., Almeida F.R., Kawahata N., Fleetham J.A. Effects of mandibular
advancement on airway curvature and obstructive sleep apnea severity. European Respiratory
Journal, 23(2):263-8, 2004.
Hussain S.F., Love L., Burt H., Fleetham J.A. A randomized trial of auto-titrating CPAP and
fixed CPAP in the treatment of obstructive sleep apnea-hypopnea. Respiratory Medicine
98:330-333, 2004.
Fleetham JA. Sleep disorders breathing awoken. Thorax, 59:5-6, 2004.
Ayas NT, Patel SR, Malhotra A, Schulzer M, Malhotra M, Jung D, Fleetham J, White DP.
Auto-titrating vs. standard continuous positive airway pressure for the treatment of obstructive
sleep apnea: Results of a meta-analysis. Sleep 27:(2):249-53, 2004.
Fleetham J. (Series Editor) Obstructive sleep apnea/hypopnea syndrome. Thorax, 2004-2005.
Levy, Dr. Robert D
Levine SM, Maurer JR, Barbers RG, Cohen NM, Conte JV, Kotloff RM, Levy RD, Meyer KC,
Singer LG. A survey of clinical practice of lung transplantation in North America. Chest 2004;
125: 1224-1238.
Warburton DER, Sheel AW, Hodges ANH, Stewart IB, Yoshida E, Levy RD, McKenzie DC.
The effects of upper extremity exercise training on peak aerobic and anaerobic fitness in patients
after transplantation. Am J Cardiol 2004; 93: 939-43.
Man, Dr. SF Paul
Szkotak AJ, Man SFP, and Duszyk M. The role of basolateral CI- channels in human airway
epithelial anion secretion. Am J Respire Cell Mol Biol 2003;29:710-720.
Sin DD and Man SFP. Inhaled Corticosteriods in the Long-Term Management of Patients with
Chronic Obstructive Pulmonary Disease. Drugs and Aging 2003;20(12):867-880.
Sin DD, Svenson LW, Cowie RL, and Man SFP. Can Universal Access to Health Care
Eliminate Health Inequities between Children of Poor and Non-Poor Families? A case study of
childhood asthma in Alberta. Chest 2003;124:51-56.
Sin, Sharpe. Cowie, MAN, on behalf of the ASTHMA Executive Committee. Spirometric
Findings Among school aged First Nations Children on a reserve. A Pilot Study. Cdn
Respiratory Journal 2004;11(1):45-48.
Sin D, Spier S, Svenson L, Schopflocher D, Senthilselvan A, Cowie R, Man SFP. The
Relationship between Birth Weight and Childhood Asthma. Arch Pediatr Adolesc Med. 2004;
158: 60-64.
Sharpe H, Sin D, Andrews E, Cowie R, Man SFP. Alberta Strategy To Help Manage Asthma
(ASTHMA): A Provincial Initiative to Improve Outcomes for Individuals with Asthma.
Page 179
Annual Report 2004
Healthcare Quarterly. 2004;7: 55-60.
Sin D, Man J, Sharpe H, Gan W, Man SFP. Pharmacological Management to Reduce
Exacerbations in Adults with Asthma -- A Systematic Review and Meta-Analysis. JAMA.
2004;292 (3): 367-376.
Gan W, Man SFP, Senthilselvan A, Sin D. Association between COPD and Systemic
Inflammation: A Systematic Review and Meta-Analysis. Thorax. 2004;59: 574-580.
Sin D, Lacy P, York E, Man SFP. Effects of Fluticasone on Systemic Markers of Inflammation
in COPD. Am J Respir Crit Care Med. 2004; 170: 760-765.
Saude E, Lacy P, Musat-Marcu S, Mayes D, Bagu J, Man SFP, Sykes B, Moqbel R. NMR
Analysis of Neutrophil Activation in Sputum Samples from Patients with Cystic Fibrosis.
Magn. Reson. Med. 2004;52:807.
Sin D, Jones R, Mannino R, Man SFP. Forced Expiratory Volume in 1 Second and Physical
Activity Participation in the General Population. Am. Journ. Med. 2004;117:270-3.
Sin D, Bell N, Man SFP. Effects of Increased Primary Care Access on Process of Care and
Health Outcomes among Patients with Asthma who Frequent Emergency Departments. Am.
Journ. Med. 2004; 117: 479-483.
Sin D, Johnson M, Gan W, Man SFP. Combination Therapy of Inhaled Corticosteroids and
Long Acting ß2-Adrenergics In Management of Patients with Chronic Obstructive Pulmonary
Disease. Curr. Pharma. Design. 2004; 10: 1-14.
Pare, Dr. Peter D
Robinson PJ, Schellenberg RR, Wakai Y, Road J, Paré PD. Canine trachealie muscle
shortening and cartilage mechanics. J Appl Physiol., 2004;96:1063-8.
de Jong PA, Nakano Y, Lequin MH, Mayo JR, Woods R, Paré PD, Tiddens HA. Progressive
damage on high resolution computed tomography despite stable lung function in cystic fibrosis.
Eur Respir J, 2004;23:93-7.
Road, Dr. Jeremy
Meehan CF, Ford TW, Road JD, Donga R, Saywell SA, Anissimova NP, Kirkwood PA. The
rosto-caudal distribution of motoneurones and the variation in ventral horn area within a segment
of the feline thoracic spinal cord. The Journal of Comparative Neurology, 472:281-291, 2004.
Richards JC, McKenzie DC, Warburton DER, Road JD, Sheel AW. Prevalence of
exercise-induced arterial hypoxaemia in healthy women. Med Sci Sports Exerc 36(9):1514-1521,
2004.
O'Donnell DE,Aaron S, Bourbeau, Road J, et al. State of the Art Compendium: Canadian
Thoracic Society recommendations for the management of chronic obstructive pulmonary disease.
11 Suppl B:7B-59B, 2004.
Ryan, Dr. Francis (Frank) C
Ryan CF, Flint J, Müller NL. Idiopathic diffuse pulmonary ossification. Thorax 2004; 59: 1004.
Sandford, Dr. Andrew J
Sandford AJ, Chan HW, Wong GWK, Lai CKW, Chan-Yeung M. Association study of 11
candidate genetic polymorphisms for asthma/atopy in Chinese schoolchildren from Hong Kong.
Int. J. Tuberc. Lung Dis. 2004; 8: 519-527.
Lynd LD, Sandford AJ, Kelly EM, Paré PD, Bai TR, FitzGerald JM, Anis AH. Reconcilable
differences - a cross-sectional study of the relationship between socioeconomic status and the
magnitude of short-acting beta-agonist use in asthma. Chest. 2004; 126:1161-8.
He J-Q, Connett JE, Anthonisen NR, Paré PD, Sandford AJ. Glutathione S-transferase variants
and their interaction with smoking on lung function. Am. J. Respir. Crit. Care Med. 2004; 170:
388-94.
Page 180
Annual Report 2004
Zhang X, Zhang W, Qiu D, Sandford A, Tan WC. The E237G polymorphism of the high
affinity immunoglobulin E receptor beta chain and asthma. Ann. Allergy Asthma Immunol.
2004; 93:499-503.
Tebbutt, Dr. Scott J
Tebbutt, S.J., Burkett, K.M., He, J-Q, Ruan, J., Opushnyev, I.V., Tripp, B.W., Zeznik, J.A.,
Abara, C.O., Nelson, C.C., Walley, K.R. A microarray genotyping resource to determine
population stratification in genetic association studies of complex disease. BioTechniques
37:977-985 (2004).
Van Eeden, Dr. Stephan F
Goto Y, Hogg JC, Whalen B, Shih CH, Ishii H, van Eeden SF. Monocyte recruitment into the
lungs in pneumococcal pneumonia. Am J Respir Cell Mol Biol. 2004. 30:620-626.
Goto Y, Hogg JC, Shih CH, Ishii H, Vincent R, van Eeden SF. Exposure to ambient particles
accelerates monocyte release from the bone marrow in atherosclerotic rabbits. Am J Physiol
Lung Cell Mol Physiol. 2004 287(1):L79-85.
Ishii H, Fujii T, Hogg JC, Hayashi S, Mukae H, Vincent R, van Eeden SF. The contribution
of IL-1{beta} and TNF-{alpha} to the initiation of the peripheral lung response to atmospheric
particulates (PM10). Am J Physiol Lung Cell Mol Physiol. 287(1):L176-83, 2004.
Dalelszen P. Neutrophil apoptosis in pre-eclampsia, do steroids compound the relationship. J
Obstet Gynaecol Res. 30(5):342-8, 2004.
Goto Y, Ishii H, Hogg JC, Shih CH, Yatera K, Vincent R, van Eeden SF. Particulate matter air
pollution stimulates monocyte release from the bone marrow. Am J Respir Crit Care Med.
15;170(8):891-7, 2004.
Ward, Dr. Helen
Dimich-Ward H, Guernsey JR, Pickett W, Rennie D, Hartling L, Brison RJ. Gender differences
in the occurrence of farm-related injuries. Occup Environ Med, 2004; 61(1):52-6.
Becker A, Watson W, Ferguson A, Dimich-Ward H & Chan-Yeung M. The Canadian asthma
primary prevention study: outcomes at 2 years of age. Journal of Allergy & Clinical
Immunology. 2004; 113(4):650-6.
Manfreda J, Sears MR, Becklake MR, Chan-Yeung, Dimich-Ward H, Siersted HC, Ernst P,
Sweet L, Van Til L, Bowie DM & Anthonisen NR. Geographic and gender variability in the
prevalence of bronchial responsiveness in Canada. Chest 2004; 125(5):1657-64.
Camp PG, Dimich-Ward H & Kennedy SM. Women and occupational lung disease: sex
differences and gender influences on research and disease outcomes. Clinics in Chest Medicine
2004; 25(2):269-79.
Dimich-Ward H, Wymer ML & Chan-Yeung M. Respiratory Health Survey of Respiratory
Therapists. Chest 2004; 126:1048-53.
Wilson, Dr. Jennifer M
Wilson JM. Why am I coughing up blood? The Canadian Journal of CME 16(4) March 2004
114-119.
RHEUMATOLOGY
Chalmers, Dr. Andrew
Backman CL, Kennedy SM, Chalmers A, Singer J. Participation in paid and unpaid work by
adults with rheumatoid arthritis. J Rheumatol. 2004;31:47-56.
Page 181
Annual Report 2004
Cibere J, Bellamy N, Thorne A, McGorm K, Esdaile JM, Chalmers A, Hunag S, Peloso P,
Shojania K, Singer J, Wong H, Kopec J. Reliability of the Knee Examination in Osteoarthritis:
Effect of Standardization. Arthritis Rheum 2004;50(2):458-68.
Lacaille D, Sheps S, Spinelli JJ, Chalmers A, Esdaile JM. Identification of modifiable
work-related factors that influence the risk of work disability in rheumatoid arthritis. Arthritis
Rheum 2004;51:843-52.
Marra CA, Esdaile JM, Guh D, Kopec JA, Brazier JE, Koehler BE, Chalmers A, Anis AH. A
comparison of four indirect methods of assessing utility values in rheumatoid arthritis. Med Care
2004;42:1125-31.
Cibere, Dr. Jolanda
Prlic HM, Lehman AJ, Cibere J, Esdaile JM. Identification and evaluation of an ayurvedic
medicine approach to the treatment of inflammatory arthritis. Clin Exp Rheumatol 2004;
21:747-52.
Cibere J, Bellamy N, Thorne A, McGorm K, Esdaile JM, Chalmers A, Huang S, Peloso P,
Shojania K, Singer J, Wong H, Kopec J. Reliability of the Knee Examination in Osteoarthritis:
Effect of Standardization. Arthritis Rheum 2004; 50:458-68.
Cibere J, Kopec JA, Thorne A, Singer J, Canvin J, Robinson DB, Pope J, Hong P, Grant E,
Esdaile JM. Randomized double-blind placebo-controlled glucosamine discontinuation trial in
knee osteoarthritis. Arthritis Care Res 2004;51:738-45.
Ensworth, Dr. Stephanie G
Miettunen PM, Ortiz-Alvarez O, Petty RE, Cimaz R, Malleson PN, Cabral DA, Ensworth S,
Tucker LB. Gender and ethnic origin have no effect on long-term outcome of childhood onset
systemic lupus erythematosus. J. Rheumatol 2004;31:1650-4.
Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: A randomized pilot trial
comparing low molecular weight heparin to unfractionated heparin. J Obstet Gynaecol Can 2004;
26:729-34.
Esdaile, Dr. John M
Prlic H, Lehman A, Cibere J, Sodhi V, Varma S, Sukamaran T, Esdaile JM. Identification and
evaluation of an Ayurvedic medicine approach to the treatment of inflammatory arthritis.
Rheumatol 2004;21:747-752.
Kopec JA, Sayre EC, Esdaile JM. Predictors of back pain in a general population cohort. Spine
2004;29:70-7.
Cibere J, Bellamy N, Thorne A, McGorm K, Esdaile JM, Chalmers, A, Huang S, Peloso P,
Shojania K, Singer J, Wong H, Kopec J. Reliability of the knee examination in osteoarthritis:
Effect of standardization. Arthritis Rheum 2004;50:458-468.
Cibere J, Kopec JA, Thorne A, Singer J, Kopec J, Canvin J, Robinson DB, Pope J, Hong P,
Grant E, Esdaile JM. Randomized double-blind placebo-controlled glucosamine discontinuation
trial in knee osteoarthritis. Arthritis Rheum 2004;51:738-45.
Rheum 2004;51:843-52.
Clarke AE, Penrod J, St. Pierre Y, Petri MA, Manzi S, Isenberg DA, Gordon C, Senecal JL,
Fortin PR, Sutcliffe N, Goulet JR, Choquette D, Grodzicky T, Esdaile JM. The systemic lupus
erythematosus Tri-Nation Study: Absence of a link between health resource use and health
outcome. Rheumatology 2004;43:1016-24.
Page 182
Annual Report 2004
2004;42:1125-31.
Marra CA, Lynd LD, Esdaile JM, Kopec J, Anis AH. The impact of low family income on
self-reported health outcomes in patients with rheumatoid arthritis within a publicly funded
health-care environment. Rheumatology 2004;43:1390-7.
Gillies, Dr. Jean H
Bent H, Goligher EC, Kopec J, Gillies JH. Computer-administered BATH ankylosing
spondylitis and Quebec Scale outcome measures for low back pain: Agreement with traditional
paper formats. J Rheumatol 2004;31:1435.
Goligher EC, Ratzlaff CR, Gillies JH. External rotation of hip during stance phase of gait:
Grading system validation and reliability study. J Rheumatol 2004;31:1434.
Goligher EC, Ratzlaff CR, Wong AD, Gillies JH. An association between gait and passive range
of motion of hip internal rotation: Implications for early diagnosis of hip osteoarthritis. J
Rheumatol 2004;31:1434.
Klinkhoff, Dr. Alice V
Gladman DD, Cook RJ, Schentag C, Feletar M, Inman R, Hitchon C, Karsh J, Klinkhoff AV,
Maksymowych WP, Mosher DP, Nair B, Stone MA. The clinical assessment of patients with
psoriatic arthritis: Results of a reliability study of the spondyloarthritis research consortium of
Canada. J Rheumatol 2004;31:1126-31.
Klinkhoff A. Biological agents for rheumatoid arthritis: Targeting both physical function and
structural damage. Drugs 2004;64:1267-83.
Koehler, Dr. Barry
2004;42:1125-31.
Lacaille, Dr. Diane
Rheum 2004;51:843-52.
Gignac MAM, Badley EM, Lacaille D, Cott CC, Adam P, Aslam AH. Managing arthritis and
employment: Making arthritis-related work changes as a means of adaptation. Arthritis Rheum
2004;51:909-16.
Shojania, Dr. Kamran
Cibere J, Bellamy N, Thorne A, McGorm K, Esdaile JM, Chalmers A, Huang S, Peloso P,
Shojania K, Singer J, Wong H, Kopec J. Reliability of the knee examination in osteoarthritis:
Effect of standardization. Arthritis Rheum 2004;50(2):458-68.
Wade, Dr. John P
Neustadt D, Wade J, Gimbel J, Bell M, Caldwell J. Clinical effects of intra-articular high
molecular weight hyaluronan (Orthovisc) in osteoarthritis of the knee. Arthritis Rheum 2004;
50:S144.
Page 183
Annual Report 2004
GRANTS AND RESEARCH AWARDS
Page 185
Annual Report 2004
AWARDS BY DIVISION FOR 2004-2005
Division
Researcher
Type
SPONSOR
04/05
Allergy/Immunology
Stark
Clinical Trial
Aventis Behring Canada Inc.
$
Allergy/Immunology
Allergy/Immunology
Allergy/Immunology
Stark
Wong
Wong
Clinical Trial
Grant
Grant
$
$
$
Cardiology
Aymong
Grant
Cardiology
Aymong
Clinical Trial
Bayer Inc.
VCHRI: Interdisciplinary Grant
VCHRI: VGH & UBC Hospital
Fdn In it for Life (Operating)
MSFHR: Institutional
Infrastructure Support Program
INS002031
The Medicines Company
$
Cardiology
Bernstein
Clinical Trial
Sanofi-Synthelabo Canada Inc.
$
Cardiology
Bernstein
Clinical Trial
Pfizer Canada Inc.
$
Cardiology
Bernstein
Grant
Cardiology
Cardiology
Bernstein
Bernstein
Clinical Trial
Clinical Trial
Various pharmaceutical
$
companies
CIHR: Health Research Institutes $
Vasogen Inc.
$
Cardiology
Bernstein
Clinical Trial
Vasogen Inc.
$
Cardiology
Bernstein
Clinical Trial
$
Cardiology
Cardiology
Cardiology
Bernstein
Bernstein
Bernstein
Clinical Trial
Clinical Trial
Clinical Trial
Hamilton Health Sciences
Corporation
MRC: Clinical Trials
National Institutes of Health
Eli Lilly Canada Inc.
$
$
$
Cardiology
Bernstein
Clinical Trial
Pfizer Canada Inc.
$
Cardiology
Cardiology
Cardiology
Bernstein
Bernstein
Bernstein
Grant
Clinical Trial
Clinical Trial
Knoll Pharmaceuticals
Merck Frosst Canada Inc.
$
$
$
Cardiology
Buller
Clinical Trial
Canadian Vigour Centre
$
$
Page 187
TITLE
7,813.00 A phase 2/3 open-label, prospective, randomized, actively-controlled, multicentre
study of the pharmacokinetics, efficacy, safety and tolerability of immune globulin
subcutaneous (human), CE1200 in subjects with primary immune deficiency
5,172.00 IVIG-C %10 Rapid Infusion Trial in Primary Immune Deficient Patients
9,550.00 Measurement Properties of a Novel Walk Test in a Frail Elderly Population
35,376.00 Functional Performance in the Frail Elderly Population
2,700.00 Prognosis of patients with prior coronary artery bypass grafting including
saphenous vein grafts who present for cardiac catheterization
7,699.00 The ACUITY Trial: A randomized comparison of Angiomas(bivalirudin)versus
Lovenox/Clexane(enoxaparin) in patients undergoing early invasive management
for acute coronary syndromes without ST-segment elevation
2,118.00 AMADEUS 64720: Multicenter Randomized Open-Label Assessor-Blind NonInferiority Study Comparing the Efficacy & Safety of Once-Weekly Subcutaneous
Idraparinux (SanOrg34006) with Adjusted-Dose Oral Vitamin-K Antagonists in
the Prevention of…
1,309.00 A2581087 (ACTFAST): Achieve Cholesterol Targets Fast with Atorvastatin
Stratified Titration. Multicentre 12 Wk Treatment Single Step Titration OpenLabel Study Assessing the % of Dyslipidemic High-Risk Patients Achieving Low
Density Lipo...
71,911.00 Cardiology Research
1,000.00 AF-CHF: Atrial Fibrillation and congestive Heart Failure
3,780.00 Protocol 0202 (ACCLAIM): Multicenter Randomized Double-Blind Parallel Group
Placebo-Controlled Study to Assess the Effects of Immune Modulation Therapy
(IMT) on Mortality and Morbidity in Patients with Chronic Heart Failure
12,820.00 Protocol 0101: Multicenter Randomized Double-Blind Parallel Group Placebo
Controlled Study of Efficacy & Safety of Immune Modulation Therapy in
Improving Walking Distance in Patients with Intermittent Claudication Secondary
to PAD
11,154.00 ONTARGET: Ongoing Telmisartan Alone and in Combination with Ramipril
Global Endpoint Trial
9,466.00 Heart Outcomes Prevention Trial (HOPE)
39,877.00 STICH: Surgical Treatment for Ischemic Heart Failure
30,991.00 Ruth Study, Raloxifene Hydrochloride or placebo in postmenopausal women at
risk for major cardiovascular events
35,593.00 IMAGINE - Ischemia Management with Accupril post bypass graft via inhibition of
converting enzyme (IMAGINE): An evaluation of the effect of 12 to approximately
24 months treatment with Quinapril 40 mg QD post CABG surgery Ismetic events
60,000.00 Magnesium use in the prevention of atrial arrhythmias after cardiac surgery
10,159.00 PEACE - Prevention of Events with Angiotensin Converting Enzyme Inhibition
9,600.00 804-00: Randomized Double-Blind Placebo-Controlled Multicentre Study to
Evaluate Efficacy Safety & Tolerability of Ezetimibe 10mg or Placebo Coadministered with Existing Atorvastatin 10mg or 20mg in Attaining LDL
Cholesterol Target Levels…
3,900.00 Protocol CVC1002: The WEST Study: Which Early ST Elevation Myocardial
Infarction Therapy
Annual Report 2004
Cardiology
Buller
Clinical Trial
Takeda Global Research and
Development
$
Cardiology
Buller
Clinical Trial
Arginox Pharmaceuticals, Inc.
$
Cardiology
Cardiology
Buller
Buller
Clinical Trial
Clinical Trial
evYsio Medical Devices ULC
$
Canadian Heart Research Centre $
Cardiology
Buller
Clinical Trial
NIH (US): Research Grant
$
Cardiology
Buller
Clinical Trial
Organon Canada Ltd.
$
Cardiology
Buller
Clinical Trial
Heart and Stroke Foundation of
Ontario
$
Cardiology
Buller
Clinical Trial
$
Cardiology
Carere
Agreement
National Heart, Lung and Blood
Institute
Cardiology
Carere
Grant
Cardiology
Cardiology
Chan
Chan
Grant
Clinical Trial
Cardiology
Fung
Grant
Cardiology
Fung
Clinical Trial
Vancouver Coastal Health
Authority
Genentech Canada Inc.
Cardiology
Fung
Clinical Trial
Cardiology
Fung
Clinical Trial
$
Cardiology
Fung
Clinical Trial
Aventis Pharma Inc.
$
Cardiology
Fung
Clinical Trial
Velocimed, Inc.
$
Cardiology
Fung
Clinical Trial
Amersham Life Sciences Inc.
$
St Lukes-Roosevelt Institute For
Health Sciences
H&SFBC: Research
PPD Development
$
$
$
$
$
$
Page 188
12,577.00 01-01-TL-OPI-516 - PERISCOPE: Double-Blind Randomized ComparatorControlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the
Effects of Pioglitazone HCL vs Glimepiride on the Rate of Progression of
Coronary Atherosclerotic Disease
13,801.00 ARG-101-061503 SHOCK 2: Randomized Double-Blind Placebo-Controlled
Dose-Ranging Study of Nitric Oxide Synthase Inhibition with Ng Monomethyl-LArginine (L-NMMA) in Pts with Cardiogenic Shock Complicating Acute
Myocardial Infarction…
1,500.00 Evaluation of a Novel Guidewire Exchange Catheter
1,500.00 PO2855 (SPIRE): Safety Pharmacokinetics and Pharmacodynamics of Integrilin
in Patients with Acute Coronary Syndromes and Renal Insufficiency
5,051.00 Total Occlusion Study of Canada-2 (TOSCA-2) An Angiographic Substudy of the
Occluded Artery Trial (OAT)
3,150.00 Protocol ASPIRE Pilot: Randomized Blinded Pilot Trial of Fondaparinux Sodium
(Arixtra) vs Unfractioned Heparin in Addition to Standard Therapy in a Broad
Range of Patients Undergoing Percutaneous Coronary Intervention
43,200.00 The STREAM Study: Stent Restenosis and Metabolism: An Open-Label
Randomized Trial of Subcutaneous Insulin vs Control in Patients with Type II
Diabetes Undergoing Percutaneous Coronary Intervention with Stent
3,002.00 OAT: Occluded Artery Trial - Total Occlusion Study of Canada 2 (TOSCA 2)
Substudy
3,383.00 Clinical outcomes utilizing revascularization and aggressive drug evaluation
(COURAGE) Trial
34,050.00 Open Artery Trial (OAT II)
60,000.00 Aging, cardiac risk factors, endothelial function and endothelial progenitor cells
64,584.00 A phase II randomized, double-blind, placebo-controlled, multi-center brachial
artery ultrasound study of ETC-588 in patients with stable atherosclerosis
233,897.00 Interventional cardiology research -clinical research coordinators positions
1,110.00 A Phase II, Randomized, Open-Label, Multicenter, International, Angiographic
Trial of the Efficacy of TNK-tPA Compared with Accelerated Activase Alteplase
rt-PA in Acute Myocardial Infarction (TIMI 10B)
1,445.00 Protocol CHRC 248: Canadian Registry of Acute Coronary Syndrome Patients:
ACS Registry 2
6,700.00 Protocol EFC 3197 (OASIS 5): International Randomized Double-Blind Study
Evaluating the Efficacy & Safety of Fondaparinux vs Enoxaparin in the Acute
Treatment of Unstable Angina/Non ST-Segment Elevation MI Acute Coronary
Syndromes
150,000.00 XRP4563/4001 STEEPLE: International Phase 2/3 Stratified Randomized OpenLabel Parallel-Group Clinical Trial to Evaluate the Safety and Efficacy of a Single
Intravenous Bolus of Enoxaparin vs Intravenous Unfractionated Heparin in
Patient...
27,812.00 Protocol 0231-001 (The Proximal Trial) Proximal Protection During Saphenous
Vein Graft Intervention Using the Proxis Embolic Protection System: A
Randomized Prospective Multicentre Clinical Trial
6,686.00 VIS-P4-007: 2 Stage, Prospective Randomized Double-Blind Study of the Effects
of an Isosmolar Contrast Medium Visipaque 320 (iodixanol) vs Optiray 320
(ioversol) on Serum Creatinine Concentrations in Subjects with Elevated Serum
Creatin...
Annual Report 2004
Cardiology
Gin
Clinical Trial
$
Cardiology
Gin
Clinical Trial
AstraZeneca Canada Inc
$
Cardiology
Gin
Clinical Trial
Procter & Gamble, Canada
$
Cardiology
Gin
Clinical Trial
Atherogenics, Inc.
$
Cardiology
Hamburger
Clinical Trial
Atherogenics, Inc.
$
Cardiology
Hamburger
Clinical Trial
Boston Scientific Corporation
$
Cardiology
Hamburger
Clinical Trial
Kerberos Proximal Solutions, Inc
$
Cardiology
Humphries
Grant
$
Cardiology
Humphries
Grant
$
80,000.00 Secondary prevention - the gap between evidence and practice
Cardiology
Cardiology
Humphries
Humphries
Grant
Grant
Cardiology
Humphries
Grant
Cardiology
Humphries
Grant
Cardiology
Ignaszewski
Clinical Trial
CIHR: Operating Grant MOP
57884
MSFHR: Career Investigator
Program C1-SCH-67(01-2)
H&SFBC: Research
INS002031
NCE/Stem Cell Network:
Research
Research Student Award
Novartis Pharmaceuticals
Canada Inc
10,181.00 Protocol EFC4912 (ACTIVE): Atrial Fibrillation Clopidogrel Trial with Irbesartan
for Prevention of Vascular Events
1,203.00 Protocol DISCOVERY: Direct Statin Comparison of LDL-C Values: An Evaluation
of Rosuvastatin Therapy
46,350.00 PREMIER Study: Multicentre Randomized Double-Blind Parallel-Group PlaceboControlled Study of a 200 mg Oral Dose of PG-116800 Given Twice Daily for 90
Days to Patients Following Acute Myocardial Infarction with Post-Treatment
Follow-up
8,739.00 AGI-1067-042 ARISE: Multicenter Double-Blind Randomized Placebo-Controlled
Trial to Study the Reduction of Vascular Inflammation & Coronary
Atherosclerosis with AGI-1067 a V-Protectant Reduces Cardiovascular Events in
Patients with Coronary…
29,638.00 Safety and efficacy of AGI-1067 as an agent to prevent post angioplasty
restenosis and coronary atherosclerosis progression (CART II)
30,174.00 TAXUS II: Randomized, Double-Blind, Controlled Study of the Safety and
Performance of the NIRx Paclitaxel-Coated Conformer Coronary Stent
29,502.00 Multicenter Prospective Non-Randomized Study to Evaluate Safety &
Performance of the Rinspiraton Catheter in Conjunction with an Approved Distal
Protection Filter in Patients Undergoing Primary PCI for the Treatment of AMI
25,356.00 Secondary prevention - the gap between evidence and practice
Cardiology
Ignaszewski
Clinical Trial
Amgen, Inc.
$
Cardiology
Ignaszewski
Clinical Trial
Parke-Davis Pharmaceuticals
$
Cardiology
Jue
Clinical Trial
Pfizer Canada Inc.
$
Cardiology
Cardiology
Cardiology
Jue
Jue
Jue
Contract
Clinical Trial
Clinical Trial
Various Sources
$
Aventis Pharmaceuticals Inc.
$
Cardiology
Jue
Grant
Canadian Institutes of Health
Research
$
$
190,859.00 Magnesium for the prevention of atrial arrhythmias after cardiac surgery
3,600.00 BC cardiovascular outcomes research team
$
396,846.00 HOXB4 target-genes specifying hematopoietic stem cell self-renewal
$
20,000.00 Characterization of the role of MEIS1 in hematopoiesis
$
1,500.00 A Six-month, Multicenter, Randomized, Open-label Study of the Safety,
Tolerability and Efficacy of Two Neoral(R) Doses in addition to Certican (TM) and
Steroids in de novo Heart Transplant Recipients
7,550.00 A double-blind, randomized, placebo-controlled, multicentre study to assess the
impact of subcutaneous (SC) Darbepoetin Alfa treatment on exercise tolerance in
subjects with symptomatic congestive heart failure (CHF) and anemia
94,146.00 The effect of LDL-cholesterol lowering beyond currently recommended minimum
targets on coronary heart disease (CHD) recurrence in patients with pre-existing
CHD
1,934.00 A2581087 (ACTFAST): Achieve Cholesterol Targets Fast with Atorvastatin
Stratified Titration. Multicentre 12 Wk Treatment Single Step Titration OpenLabel Study Assessing the % of Dyslipidemic High-Risk Patients Achieving Low
Density Lipo...
26,045.00 Echo Research Account
375.00 Protocol CHRC 011: Interact 1 Year Follow-Up Study
26,210.00 The Synergy Trial: A Prospective, Randomized, Open-Label, Multicentre Study in
Patients Presenting with Acute Coronary Syndromes (ACS)
15,779.00 Protocol DC-452-003: ASTRONOMER - The Effect of Cholesterol Lowering on
Progression of Aortic Stenosis in Patients with Mild to Moderate Aortic Stenosis
$
Page 189
Annual Report 2004
Cardiology
Cardiology
Jue
Kerr
Clinical Trial
Clinical Trial
Guidant Corporation
Various US Companies
$
$
Cardiology
Cardiology
Kerr
Kerr
Clinical Trial
Grant
Guidant Corporation
Montreal Heart Institute
$
$
Cardiology
Kerr
Clinical Trial
Procter & Gamble, Canada
$
Cardiology
Cardiology
Cardiology
Kiess
Mancini
Mancini
Grant
Grant
Contract
$
$
$
Cardiology
Mancini
Grant
Cardiology
Penn
Grant
Cardiology
Rabkin
Clinical Trial
Cardiology
Ricci
Clinical Trial
King Pharma
Various Sources
Canadian Vigour Centre,
University of Alberta
VCHRI: Scholar Award (Fellow:
Lacaille, Diane)
INS002031
Various Pharmaceutical
Companies
Cardiology
Straatman
Clinical Trial
Canada Inc
$
Cardiology
Thompson
Clinical Trial
Novo-Nordisk
$
Cardiology
Cardiology
Cardiology
Cardiology
Cardiology
Thompson
Tung
Tung
Webb
Webb
Grant
Clinical Trial
Clinical Trial
Grant
Clinical Trial
$
$
$
$
$
Cardiology
Webb
Clinical Trial
CIHR: Health Research Institutes
Medtronic (USA)
St. Jude Medical Inc.
Various Sources
Hoffmann-La Roche Ltd
(Canada)
Sanofi-Synthelabo Recherche
Cardiology
Webb
Clinical Trial
PercuSurge Inc.
$
Cardiology
Webb
Clinical Trial
$
Cardiology
Webb
Clinical Trial
$
Cardiology
Webb
Clinical Trial
$
$
$
$
$
$
Page 190
1,600.00 CAFÉ: Canadian Atrial Fibrillation Evaluation Study
137.00 SHOCK - Should we emergently revascularize occluded coronaries for
cardiogenis shock: an international randomized trial of emergently PTCA/CABG
800.00 Insignia I ULTRA SR Pacemaker Trial
1,200.00 Atrial Fibrillation and Congestive Heart Failure (AF-CHF) - A multicentre study
evaluating the value of a therapeutic strategy to restore and maintain sinus
rhythm in patients with atrial fibrillation and congestive heart failure versus…
5,456.00 A multi-centre, six-month, double-blind, placebo-controlled, parallel-group design
clinical study to assess the efficacy and safety of a daily oral dose of 125mg of
Azimilide Dihydrochloride for the prophylactic treatment of atrial fibrillation…
4,218.00 (VISION 304) Vasodilator Induced Stress in Concordance with Adenosine
397,816.00 Carotid studies
26,000.00 The WEST Study: Which Early ST Evaluation Myocardial Infarction Therapy?
10,000.00 Preventing work loss from inflammatory arthritis: program development and pilot
testing
3,600.00 Study to assess associated risk factors for premature atherosclerosis and
coronary artery disease in people of South Asian descent (STAAR)
280.00 Clinical Trials
38,388.00 Protocol H7T-MC-TAAH (JUMBO-TIMI 26): Double-Blind, Randomized,
Multicenter, Dose-Ranging Trial of CS-747 Compared with Clopidogrel in
Subjects Undergoing Percutaneous Coronary Intervention - Joint Utilization of
Medications to Block Plate...
8,499.00 A 12-month, multicentre, randomized, adaptive design, open-label study to
evaluate the benefit of C-2 hour monitoring of Neoral(R) on safety and efficacy
outcomes in de novo cardiac transplant recipients receiving basilixmab induction
3,979.00 A randomized, parallel-group, open-label, multinational trial comparing the safety
and efficacy of insulin aspart (NovoRapid) versus human insulin (Actrapid) used
in a multiple injection regimen, in the treatment of pregnant women with…
58,513.00 To reduce IDDM in type 1 diabetes in the genetically at risk TRIGR
2,300.00 SAVE PACe - Search AV Extension for Promoting Atrioventricular Conduction
3,668.00 Sensitivity and Specificity of Morphology Discrimination: A Prospective Study
6,300.00 various sources
51,325.00 WEST: Which Early ST Elevation Myocardial Infarction Therapy?
11,000.00 An international randomized double-blind study evaluating the efficacy and safety
of Fondapainux versus Enoxaparin in the acute treatment of unstable angina/non
ST-segment elevation MI acure coronary syndromes (OASIS - 5)
61,988.00 Enhanced myocardial efficacy and recovery by aspiration of liberalized debris
(EMERALD) P02-0040
6,000.00 An international, randomized study evaluating the efficacy and safety of
fondaparinux sodium versus control therapy and glucose insulin-potassium
infusion versus control in a broad range of patients with ST segment elevation
acute myocardial…
19,226.00 SYMBIOT III: A prospective randomized trial evaluating the Symbiot III covered
stent system in saphenous vein grafts
4,268.00 TAXUS II: A double-blind, controlled, study of the safety and performance of the
NIRx(TM) Paclitaxel-coated conformer coronary stent
Annual Report 2004
Cardiology
Cardiology
Webb
Webb
Clinical Trial
Clinical Trial
Cardiva Medical, Inc
Arginox Pharmaceuticals, Inc.
$
$
Cardiology
Webb
Clinical Trial
VELOCIMED, INC
$
Cardiology
Cardiology
Cardiology
Cardiology
Cardiology
Webb
Webb
Webb
Webb
Webb
Clinical Trial
Clinical Trial
Clinical Trial
Grant
Clinical Trial
Kerberos Proximal Solutions, Inc.
Kerberos Proximal Solutions, Inc.
Edwards Lifesciences
Cardiva Medical, Inc.
Edwards Lifesciences
$
$
$
$
$
Cardiology
Webb
Clinical Trial
Cardiology
Yeung
Clinical Trial
Medtronic (USA)
$
Critical Care
Chittock
Grant
VHHSC: VGH/UBC Fdn Special
Opportunities Research Fund
$
Critical Care
Chittock
Clinical Trial
CIHR
$
Critical Care
Chittock
Clinical Trial
$
Critical Care
Chittock
Clinical Trial
CIHR: Randomized Controlled
Trials (Clinical Trials)
Society of Critical Care Medicine
Critical Care
Critical Care
Dhingra
Dhingra
Grant
Clinical Trial
Critical Care
Dodek
Grant
Critical Care
Dodek
Grant
Critical Care
Dorscheid
Grant
Critical Care
Critical Care
Dorscheid
Dorscheid
Grant
Grant
Critical Care
Dorscheid
Grant
Critical Care
Fenwick
Critical Care
Fenwick
$
$
Canadian Intensive Care Fdn &
University of Ottawa
HC/CIHR: Research Project
$
$
$
Clinical Trial
CIHR: Operating Grant MOP62778
Program C1-SCH-31 (01-2)
BC Lung: Project Grant
MSFHR: Matching Establishment
Grant CI-SCH-31(01-2)
(Fellow: Dorscheid, Delbert)
Clinical Trial
Chiron Corporation
$
$
2,968.00 Clinical study of the VasoStasis Vascular Closure System (VCS)
24,543.00 SHOCK-2 Trial-A randomised, double-blind, placebo-controlled, dose-ranging
study of Nitrous Oxide Synthase inhibition with Ng-Monomethyl_L-Arginine (LNMMA) in patients with cardiogenic shock complicating acute myocardial
infarction…
20,921.00 Proximal Protection during Saphenous Vein Graft Intervention using the Proxis
TM Embolic Protection System: A Randomized, Prospective, Multicenter, Clinical
Trial (PROXIMAL)
10,523.00 RINSE: RINspiration of Saphenous vein graft Emboli trial
28,146.00 Canadian EMI Registry
4,022.00 Coronary Artery Bypass & Ischemic Mitral Regurgitation (Edwards Mitral Valve)
53,186.00 Clinical Study of the VasoStasis Vascular Closure System II
1,706.00 Edwards LifeScience Percutaneous Mitral Annulopasty Repair System: A Phase
I Feasibility, Non-Randomized, Multi-Center, Prospective, Consecutive Registry.
A Percutaneous Interventional Treatment of Mitral Regurgitation
3,563.00 EVEREST II: A Study of the Evalve Cardiovascular Valve Repair System (CVRS)
Endovascular Valve Edge-to-Edge
28,187.00 Medtronic EMPIRIC Study - Evaluation of EMPIRIC Programming to Improve
Patient Management
34,345.00 The Vancouver Interaction and Calmness Scale in Mechanically Ventilated
Patients: A Prospective Randomized Controlled Trial of the Effect of Measuring
Sedation and Agitation on the Duration of Mechanical Ventilation
17,200.00 (VAP) A Randomized Trial of Empiric Broad Spectrum Antibiotics and Invasive
Diagnostic Techniques in the Setting of Ventilator Associated Pneumonia
1,400.00 VASST: Randomized Controlled Trial of Vasopressin vs. Norepinephrine in
Septic Shock
2,150.00 VICS: Effect of Measuring Sedation and Agitation on Duration of Mechanical
Ventilation
15,000.00 Survival using glucose algorithm regulation (SUGAR) trial
5,000.00 (FINESS) Fluids in Early Severe Sepsis Retrospective Review
$
2,150.00 Improving the quality and end of life care in Canada: Understanding the
perspectives of seriously ill patients and their caregivers
50,758.00 Geographic variation in outcomes of critical care in BC: The role of ICU
organizational factors
37,500.00 Airway epithelial injury as a result of corticosteroid-induced apoptosis
$
$
27,000.00 Airway epithelial damage, viral infection and excessvie apoptosis
$
$
30,223.00 Protocol F1K-MC-EVBR: Randomized Double-Blind Placebo-Controlled Trial of
Prophylactic Heparin in Patients with Severe Sepsis & Higher Disease Severity
Who Are Undergoing Treatment with Drotrecogin Alfa (Activated)
13,383.00 Protocol TFP008: Phase 3 Multicenter Randomized Placebo-Controlled DoubleBlind Three-Arm Study to Evaluate the Safety & Efficacy of Tifacogin
(recombinant tissue factor pathway inhibitor) Administration in Subjects with
Severe Community...
Page 191
Annual Report 2004
Critical Care
Fenwick
Clinical Trial
Altana Pharma, Inc.
$
Critical Care
Fenwick
Clinical Trial
$
Critical Care
Fenwick
Clinical Trial
GlaxoSmithKline Inc.
$
Critical Care
Fenwick
Clinical Trial
Novo-Nordisk
$
Critical Care
Fenwick
Clinical Trial
Novo-Nordisk
$
Critical Care
Henderson
Grant
$
Critical Care
Ronco
Clinical Trial
VCHRI: Mentored Clinical
Scientist
Critical Care
Critical Care
Ronco
Ronco
Clinical Trial
Grant
Critical Care
Ronco
Clinical Trial
Critical Care
Ronco
Grant
VGH/UBC Foundation Special
Opportunities Research Fund
$
Critical Care
Russell
Grant
$
Critical Care
Critical Care
Russell
Russell
Contract
Clinical Trial
MSFHR: Junior Graduate
Studentship Award ST-JGS
222(03-1) CLIN (Fellow:
Sutherland, Ainsley)
Eli Lilly and Company, US
Critical Care
Russell
Grant
Critical Care
Critical Care
Tsang
Walley
Grant
Grant
Critical Care
Walley
Grant
Critical Care
Walley
Grant
Critical Care
Walley
Grant
$
Fujisawa Canada Inc.
$
Cdn Diabetes Assoc.: Charles H. $
Best Fund/Grant-in-Aid
Mallinckrodt Medical, Inc.
$
$
$
MSFHR: Postdoctoral Trainee
Fellowship (Fellow: Manocha,
Sanjay)
Studentship Award (Fellow:
Shaw, David)
Heart & Stroke Fdn of BC
MSFHR: Distinguished Scholar
Award CI-DSH-73(02-1)
Heart & Stroke Fdn Cda:
Research Fellowship - Bateman,
Ryon
$
9,287.00 BY2001-M1-007 (VALID Study): Venticute (rSP-C Surfactant) in Patients with
Pneumonia or Aspiration of Gastric Contents Leading to Intubation Mechanical
Ventilation and Severe Oxygenation Impairment
14,369.00 Protocol F1K-MC-EVCL: Efficacy and Safety of Drotrecogin Alfa (Activated) in
Adult Patients with Early Stage Severe Sepsis
2,500.00 EMD20001: Prospective Randomized Double-Blind Placebo-Controlled Dose
Ranging Multicenter Study of the Safety and Efficacy of Three Days Continuous
Intravenous Infusion of GR270733 in the Treatment of Suspected or Confirmed
Gram-Negative Ss
8,012.00 F7CBI-1600: Randomized Double-Blind Placebo-Controlled Multicenter Dose
Escalation Study to Evaluate the Safety and Preliminary Efficacy of
Recombinant Factor VIIa (novoSevenNiaStase) in Subjects with Brain
Contusions
8,157.00 F7CBI-1587: Multicenter Observational Study to Evaluate the Incidence and
Magnitude of Hemorrhagic Progression of Cerebral Contusions and the
Identification of Important Safety Issues Following Traumatic Brain Injury
50,000.00 Salary: Survival using glucose algorithm regulation (SUGAR) trial
8,000.00 LOVS: A randomized trial of a Lung Open Ventilation Strategy in Acute Lung
Injury (MRC #78042)
11,000.00 MYC-001: Canadian ICU Infection Survey
67,500.00 Survival using glucose algorithm regulation (SUGAR) trial
4,500.00 Puritan Bennett Model 840 Ventilator System with Proportional Assist Ventilation
field Evaluation Protocol
27,010.00 Treatment of Catheter Related Bloodstream Infection Caused by Coagulase
Negative Staphylococcus; Removal of Catheter Followed by Two Days
Compared with Seven Days of Vancomycin
2,292.00 Genetic Determinants of the Host Response to Infection in Critically III Adults
with Systemic Inflammatory Response Syndrome
10,500.00 A randomized trial of a lung open ventilation strategy in acute lung injury
33,445.00 Efficacy and safety of Drotrecogin Alfa (activated) in adult patients with early
stage severe sepsis
39,000.00 Clinical Outcomes of Acute Lung Injury: Role of Cytokine Gene Polymorphisms
as Predictors
$
$
30,000.00 Endothelins and the mechanism of hypoxemia in acute pulmonary embolism
625.00 Clinical outcomes of cardiac surgery are influenced by genetics of inflammatory
mediators
$
190,000.00 Genetic determinants of cognitive dysfunction following cardiopulmonary bypass
surgery
120,000.00 Translating mechanistic understanding of the systemic inflammatory response
syndrome (SIRS) to clinical practice via genomics
38,000.00 Mechanism of myocardial dysfunction in sepsis
$
$
Page 192
Annual Report 2004
Critical Care
Walley
Grant
Critical Care
Walley
Grant
Critical Care
Walley
Grant
Critical Care
Walley
Contract
Critical Care
Critical Care
Walley
Walley
Grant
Grant
Dermatology
Dutz
Grant
Dermatology
Dutz
Grant
Dermatology
Dutz
Grant
Dermatology
Dutz
Grant
Dermatology
Dermatology
Dutz
Dutz
Grant
Grant
Dermatology
Ho
Dermatology
MSFHR:Establishment Grant C1DSH-73(02-1)
Fellowship ST-PDF 147(03-1)BM
(Fellow: Bateman, Ryon)
Sirius Genomics Inc.
$
$
$
$
Clinical Trial
H&SFBC: Research
57774
National Alopecia Areata Fdn
(US)
CIHR: Operating Grant MOP 67186
CIHR/Strategic: Request for
Applications NSM-66117 in
collaboration with: Institute of
Musculoskeletal Health and
Arthritis (CIHR)
JDFI: Research 5-2004-223
BCRICWH: Investigatorship
Award
Abbott Laboratories
$
Ho
Clinical Trial
Centocor Inc.
$
Dermatology
Ho
Clinical Trial
Canada Inc
$
Dermatology
Ho
Clinical Trial
Canada Inc
$
Dermatology
Ho
Clinical Trial
$
Dermatology
Ho
Clinical Trial
$
Dermatology
Ho
Clinical Trial
Abbott Laboratories, Limited
(Canada)
$
$
$
$
$
37,500.00 Translating mechanistic understanding of the systemic inflammatory response
syndrome (SIRS) to clinical practice via genomics
7,125.00 Mechanism of myocardial dysfunction in sepsis
109,661.00 Myocardial Dysfunction Induced by ICAM-1 binding
91,520.00 CRA: Association of the influence of inflammatory mediator polymorphisms with
outcomes in systemic inflammatory response syndrome (SIRS) and multiple
organ system failure (MOSF)
83,000.00 Mechanism of Myocardial Dysfunction during Sepsis
80,952.00 Influence of polymorphisms in coagulation pathway in inflammatory mediator
genes on phenotype post-cardiopulmonary bypass surgery
40,896.00 Screening for cytoxic T lymphocyte epitopes in alopecia areata
114,332.00 Modifying islet antigen presentation to treat diabetes
$
63,979.00 Chemo-immunotherapy and CTL priming to treat malignant melanoma
$
59,956.00 RFA: New Discoveries - High Risk Grant: Tolerance induction by skin
immunization
$
$
58,848.00 Treating diabetes using the skin to induce tolerance
80,682.00 BCRICWH: Investigatorship Award - Jan Dutz
Page 193
8,467.00 Protocol M02-529: Phase II Multicenter Extension Study of the Safety & Efficacy
of Adalimumab (D2E7) in Subjects with Moderate to Severe Chronic Plaque
Psoriasis
130,193.00 C0168T44: Phase III Multicenter Randomized Double-Blind Placebo-Controlled
Trial Evaluating the Efficacy and Safety
3,000.00 CASM981C2442: 12 Week Multicenter Study Consisting of a 6 Week DoubleBlind Randomized Vehicle Controlled Parallel Group Phase Followed by a 6
Week Open Label Phase to Assess the Safety & Efficacy of Elidel Cream 1% in
Mild to Moderate ....
1,690.00 Extension 1 to ASM981 C201: A Safety Extension Study of Patients Treated in a
12 Week Randomized Double-Blind Placebo-Controlled Multicenter ParallelGroup Dose-Finding Core Study to Determine the Dose-Response Safety &
Tolerability of 3 ..
5,600.00 FG-506-06-33: Long-Term Non-Comparative Study to Evaluate the Safety and
Efficacy of Tacrolimus Ointment in Pediatric Patients
28,250.00 FG-506-06-32: Randomized Multicentre Double-Blind Pharmacokinetic Study of
Tacrolimus Ointment (0.03%) in Pediatric Patients (aged 3 months to 24 months)
with Atopic Dermatitis Following First and Repeated Once Daily or Twice Daily
.....
4,388.00 Protocol M03-658: Multicenter Open-Label Continuation Study in Moderate to
Severe Chronic Plaque Psoriasis Subjects Who Completed a Preceding
Psoriasis Clinical Study with Adalimumab
Annual Report 2004
Dermatology
Ho
Clinical Trial
Fujisawa Healthcare Inc.
$
Dermatology
Ho
Clinical Trial
Canada Inc
$
Dermatology
Ho
Clinical Trial
(Canada)
$
Dermatology
Li
Grant
NCIC: Research Grant 01424
$
Dermatology
Li
Grant
$
Dermatology
Li
Grant
MSFHR: Doctoral Trainee
Research Award STPHD63020
(Fellow: Eric Campos)
NCIC: Research Grant 014029
Dermatology
Li
Grant
Dermatology
Li
Grant
Dermatology
Li
Grant
Dermatology
Lui
Dermatology
$
129,912.00 Enhancement of melanoma chemosensitivity by adenoviral delivery of PUMA
and Apaf-1
9,375.00 Mechanisms of the novel tumour suppressor p331NG1 in UV-induced apoptosis
of melanoma cells
2,292.00 Enhancement of melanoma chemosensitivity by adenoviral delivery of PUMA
$
88,539.00 Role of p33ing1 in repair of uv-damaged dna
Clinical Trial
CIHR: Operating Grant DOP
62280
Studentship Award ST-JGS
31(03-1)BM
NCIC/CCS: Research Scientist
012443
Biogen Idec, Inc.
$
Lui
Clinical Trial
$
Dermatology
Lui
Clinical Trial
QLT PhotoTherapeutics Inc.
$
Dermatology
McElwee
Grant
$
Dermatology
Prendiville
Clinical Trial
Dean of Medicine: Spring Start
Up Funds
Canada Inc
22,297.00 Protocol C-733: An Open-Label Multicentre Study to Evaluate the Safety &
Tolerability of Repeat Courses of Intramuscular Administration of Alefacept (LFA3/IgG1 Fusion Protein) in Patients with Chronic Plaque Psoriasis
67,792.00 Protocol FG 03-0-171: Phase 3 Long-Term Open-Label study to Evaluate the
Safety of Once Daily 0.3% Tacrolimus Gel in the Treatment of Psoriasis
10,095.00 Protocol VFI MBCC 02: A Randomized, Placebo-Controlled, Masked,
Multicentre, Phase III Study of Photodynamic Therapy with Verteporfin for
Injection (VFI) for the Treatment of Multiple Basal Cell Carcinoma
60,000.00 Mechanisms of hair disease
Dermatology
Rivers
Clinical Trial
Canada Inc
$
Dermatology
Shapiro
Clinical Trial
Isotechnika, Inc.
$
Dermatology
Shapiro
Clinical Trial
Leo Laboratories Canada Ltd
$
Dermatology
Shapiro
Clinical Trial
QLT PhotoTherapeutics Inc.
$
Dermatology
Dermatology
Zhou
Zhou
Grant
Grant
VCHRI: Scholar Award
$
Cdn Dermatology Fdn: Research $
$
44,793.00 Protocol FG 03-0-166: Phase 3 Randomized Double-Blind Study Comparing
Twice Daily Tacrolimus Cream 0.03% vs Cream Vehicle in the Treatment of Mild
to Moderate Atopic Dermatitis in Pediatric Subjects
33,579.00 CASM981C2315: 26-week Randomized Multicenter Parallel-Group Double-Blind
Vehicle-Controlled Study to Evaluate the Incidence of Atopic Dermatitis Flares
When ASM981 (pimecrolimus) Cream 1% is Used at the First Signs and/or
Symptoms of Atopic…
791.00 Protocol M02-528: Phase 2 Multicentre Study of the Safety and Efficacy of
Adalimumab (D2E7) in Subjects with Moderate to Severe Chronic Plaque
Psoriasis
123,264.00 Functional role of p33ING1 phosphorylation in cellular stress response to DNA
damage
2,500.00 Functional role of p33ING1 phosphorylation in cellular stress response to DNA
damage
$
$
Page 194
4,000.00 A 5-year, multicenter, open-label, parallel group, randomized study to
demonstrate the short and long-term safety of Elidel (pimecrolimus, ASM981)
cream 1% in the treatment of mild to moderate atopic dermatitis in infant (3-<12
mths of age)
39,615.00 CASM981M2301: 6 Week Randomized Multicenter Double-Blind PlaceboControlled Parallel Group Study to Investigate the Efficacy & Safety of Elidel
Cream 1% in Patients With Mild to Moderate Chronic Hand Dermatitis Followed
by a 6 Week Open ...
16,080.00 ISA04-03: Phase III Randomized Multicentre Double-Blind Placebo-Controlled
Study of ISA247 in Plaque Psoriasis Patients
41,270.00 Protocol MBL 0401 INT: Calcipotriol Plus Betamethasone Dipropionate Gel in
Scalp Psoriasis
75,441.00 Protocol T0074 AGA 002: Phase II Treatment Optimization Study of
Photodynamic Therapy for Androgenetic Alopecia with Topical QLT0074
30,000.00 Molecular Pathogenesis of Sezary Syndrome - Gene Signatures of Sezary Cells
50,000.00 Endothelin-3 in malignant melanoma
Annual Report 2004
Clinical Trial
Grant
National Rosacea Society:
Research Grant
Hoechst-Roussel
Pharmaceuticals, US
$
Elliott
Elliott
Clinical Trial
Grant
$
$
Endocrinology
Elliott
Clinical Trial
Boehringer Ingelheim (Canada)
Ltd.
$
Endocrinology
Elliott
Clinical Trial
Bristol-Myers Squibb Company
(Cda)
$
Endocrinology
Elliott
Clinical Trial
Canada Inc
$
Endocrinology
Kreisman
Agreement
Endocrinology
Prior
Grant
NIH (US): Research Grant 5R01- $
DK058356-03, PO Q643711310
in collaboration with: University of
Minnesota
CIHR/Rx&D: Research Program $
Endocrinology
Endocrinology
Prior
Prior
Grant
Grant
Vancouver Foundation
$
$
Endocrinology
Endocrinology
Prior
Prior
Grant
Grant
$
$
Endocrinology
Prior
Grant
Endocrinology
Sadar
Grant
Endocrinology
Sadar
Grant
Endocrinology
Endocrinology
Gastroenterology
Sadar
Sadar
Anderson
Grant
Grant
Clinical Trial
Various Sources
Donations for Health Science
Research
INS002031
CIHR: Doctoral Research Awards
JMO 58977 In collaboration with:
Canadian Prostate Cancer
Research Initiative (Fellow:
Quayle, Steven)
Research Award 75(02-1)BM
(Fellow: Quayle, Steven)
Health Canada
Health Canada
Elan Pharmaceuticals Inc.
Dermatology
Zhou
Grant
Endocrinology
Dawson
Clinical Trial
Endocrinology
Elliott
Endocrinology
Endocrinology
$
$
47,953.00 Molecular Disease Markers
1,370.00 HOPE Study: Heart Outcomes Prevention Evaluation
10,000.00 Protocol H80-MC-GWAP: Safety & Efficacy of Exenatide in Patients with Type 2
Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin
221,754.00 Action to control Cardiovascular Risks in Diabetes (ACCORD) Trial
9,945.00 Post-operative Glycemic Control in Surgical Patients (POGS) - A Feasibility
Study to Determine the Frequency of Hypoglycemia when Principles of Intensive
Insulin Therapy are Applied to Post-Operative Surgical Patients
23,777.00 502.397 (AMADEO): Prospective Randomized Double-Blind Double-Dummy
Forced-Titration Multicentre Parallel-Group 1 Yr Treatment Trial to Compare
Micardis (telmisartan) 80mg vs Cozaar (Losartan) 100mg in Hypertensive Type 2
Diabetic Patients with..
8,453.00 CV131169: Irbesartan vs Placebo in Combination with Standard Cardiovascular
Protection ACE-1 Therapy with Ramipril for the Treatment of Albuminuria in
Hypertensive Subjects at Elevated Cardiovascular Risk
27,369.00 NAVIGATOR: Multinational Randomized Double-Blind Placebo-Controlled
Forced-Titration 2x2 Factorial Design Study of the Efficacy & Safety of Long
Term Administration of Nateglinide & Valsartan in the Prevention of Diabetes &
Cardiovascular..
519.00 Diabetes Therapy to Improve BMI and Pulmonary Function in CF Subjects with
Abnormal Glucose Tolerance
38,800.00 (CAMOS) Canadian multicentre osteoporosis study - a cross sectional and
prospective observational study of bone density, bone strength and fracture risk
13,564.00 Young women and osteoporosis: building our knowledge and resources
8,574.00 Community Pharmacists' Knowledge about Progesterone: Knowledge
Translation within the Vancouver Coastal Health Authority
5,877.00 Centre for Menstrual Cycle and Ovulation Research (CEMCOR)
3,687.00 Exercise, Reproduction and Health Research Fund
$
3,600.00 Validation of perimenopause experiences project (PEP) tool using interpersonal
comparisons
$
1,000.00 Identification of new targets for the treatment of androgen-independent prostate
cancer
$
2,500.00 Identification of new targets for the treatment of androgen-independent prostate
cancer
$
$
$
100,000.00 Androgen independence
103,000.00 Potential new therapy for androgen independent
11,322.00 Protocol ELN100226-CD351: Phase III Multicenter Open-Label Long-Term Study
of the Safety Tolerability & Efficacy of Intravenous Antegren (Natalizumab) in
Crohn's Disease Subjects who have Previously Participated in Studies CD251
Page 195
Annual Report 2004
CD301 CD303
Gastroenterology
Anderson
Clinical Trial
Bristol-Myers Squibb
Pharmaceutical Group (Cda)
$
Gastroenterology
Anderson
Clinical Trial
(Cda)
$
Gastroenterology
Anderson
Clinical Trial
Schering Canada Inc.
$
Gastroenterology
Anderson
Clinical Trial
Centocor Inc.
$
Gastroenterology
Anderson
Clinical Trial
Bristol-Myers Squibb
Pharmaceutical Group (Cda)
$
Gastroenterology
Anderson
Clinical Trial
Protein Design Labs, Inc.
$
Gastroenterology
Anderson
Clinical Trial
Protein Design Labs, Inc.
$
Gastroenterology
Anderson
Clinical Trial
(Cda)
$
Gastroenterology
Anderson
Clinical Trial
Tillotts Pharma AG
$
Gastroenterology
Enns
Clinical Trial
Abbott Laboratories
$
Gastroenterology
Enns
Clinical Trial
Abbott Laboratories
$
Gastroenterology
Enns
Clinical Trial
$
Gastroenterology
Enns
Clinical Trial
$
Gastroenterology
Enns
Grant
$
Gastroenterology
Enns
Grant
Parexel International Corporation $
Page 196
11,300.00 Protocol AI463-026: A Phase 3 Study of the Comparison of Entecavir to
Lamivudine in Chronic Hepatitis B Subjects with Incomplete Response to Current
Lamivudine Therapy
10,000.00 A1463-022: Phase III study of the safety and antiviral activity of entecavir vs
lamivudine in adults with chronic hepatitis B infection who are positive for
hepatitis B E antigen
47,907.00 Protocol No. P02370: PEG-Intron Plus Rebetol for the Treatment of Subjects with
Chronic Hepatitis C who Failed to Respond to Previous Combination Therapy
(Any alpha Interferon Treatment in Combination with Ribavirin)
11,141.00 Protocol C0168T37 (ACT 1): Randomized Placebo-Controlled Double-Blind Trial
to Evaluate the Safety and Efficacy of Infliximab in Patients with Active Ulcerative
Colitis
11,440.00 Protocol AI463-901: A Preliminary Assessment of Safety and Antiviral Activity of
Open-Label Entecavir Plus Lamivudine Therapy in Subjects with Chronic
Hepatitis B Who Have Viremia on Monotherapy in Other Entecavir Trials
70,631.00 Protocol DAC-1008: Phase II Randomized Double-Blind Placebo-Controlled
Multicenter Dose-Ranging Study of Intravenous Daclizumab in Patients with
Moderate to Severe Ulcerative Colitis
3,944.00 ZAF-707: Phase II, Double-Blind, Placebo-Controlled Study to Determine the
Safety and Efficacy of a Humanized Anti-Interferon-y Monoclonal Antibody
(HuZAF) Administered to Patients with Moderate to Severe Crohn's Disease
161.00 Protocol AI463049: Long-term Assessment of Treatment Outcomes with
Entecavir & Lamivudine for Chronic Hepatitis B Infection in Patients Who Have
Enrolled in Phase III Entecavir Trials
2,578.00 Protocol TP0308: EPIC-2 Phase III Randomized Placebo-Controlled DoubleBlind Parallel Group Multicentre Study to Assess the Efficacy & Safety of
Omega-3 Free Fatty Acids (Epanova) for the Maintenance of Symptomatic
Remission in Subjects
4,660.00 (M04-690) A multi-Centre, Open-label Study of the Human Anti-TNF Monoclonal
Adalimumab in Subjects with Crohn's Disease
131,956.00 A multi-center, randomised, double-blind, placebo-controlled study of the Human
Anti-TNF Monoclonal Antibody Adalimumab for the Induction of clinical remission
in subjects with Crohn's disease. Clinical Study Protocol M02-403
11,432.00 A 4-week,randomised,double-blind,multicentre,dose-finding phase IIb study with
AZD0865 25,50,75mg and esomeprazole 20mg,given orally once daily for the
treatment of GERD without erosive esophagitis according to the LA classification
in adults…
9,370.00 A randomized, double-blind, multicentre dose-finding, phase IIb study for up to 8
weeks' treatment with AZD0865 25, 50, 75mg and esomeprazole 40mg, given
orally once daily for the healing of erosive esophagitis in adult subjects with
GERD…
295,945.00 A Phase III Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability,
and Efficacy of Intravenous Antegren (natalizumab) in Crohn's Disease Subjects
Who Have Previously Participated in Studies CD251, CD301,CD303, CD306
(Substudy)
18,245.00 A Study of the Efficacy and Safety of Teduglutide in Subjects with Parenteral
Nutrition Dependent Short Bowel Syndrome (CI 0600-004)
Annual Report 2004
Gastroenterology
Enns
Clinical Trial
Otsuka America Pharmaceutical
Inc.
$
Gastroenterology
Enns
Clinical Trial
Tillotts Pharma AG
$
Gastroenterology
Enns
Clinical Trial
Altana Pharma, Inc.
$
Gastroenterology
Enns
Clinical Trial
Altana Pharma, Inc.
$
Gastroenterology
Enns
Clinical Trial
NDO Surgical, Inc
$
Gastroenterology
Enns
Clinical Trial
Celltech Research Ltd.
$
Gastroenterology
Enns
Clinical Trial
Abbott Laboratories
$
Gastroenterology
Enns
Clinical Trial
Abbott Laboratories
$
Gastroenterology
Gray
Clinical Trial
$
Gastroenterology
Gray
Clinical Trial
$
Gastroenterology
Gray
Clinical Trial
Canada Inc
$
Gastroenterology
Gray
Clinical Trial
Canada Inc
$
Gastroenterology
Gray
Clinical Trial
Canada Inc
$
Gastroenterology
Gray
Clinical Trial
Janssen-Ortho Inc.
$
Page 197
17,820.00 A prospective, randomized, double-blinded placebo (sham)-controlled study to
evaluate the safety and effectiveness of the Adacolumn Apheresis system for the
treatment of moderate to severe ulcerative colitis (512-04-205)
16,123.00 A phase III randomized, placebo-controlled, double-blind, parallel group, multicentre study to assess the efficacy and safety of Omega-3 free fatty acids
(Epanova(TM)) for the maintenance of symptomatic remission in subjects with
Crohn's Disease
7,350.00 (M04-691) A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled Study
of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of
Clinical Remission in Subjects with Moderate to Severe Crohn's Disease Who
Have Lost Response…
3,745.00 Healing of patients suffering from gastroesophageal reflux esophagitis grade A-D
according to Los Angeles classification after treatment with pantoprazolemagnesium dihydrate 80mg od in comparison to pantoprazole-sodium
sesquihydrate 40mg
39,167.00 Study of the NDO endoscopic plication system for the treatment of symptomatic
gastroesophageal reflux disease
7,284.00 A phase III multi-national, multi-centre, double-blind, placebo-controlled, parallelgroup, 26-week study to assess the maintenance of clinical response to
humanised anti-TNF PEG conjugate, CDP870 400mg sc, (dosed 4-weekly from
weeks 8 to 24)
34,761.00 A multi-center, randomised, double-blind, placebo-controlled study of the Human
Anti-TNF Monoclonal Antibody Adalimumab for the Maintenance of clinical
remission in subjects with Crohn's disease. Clinical Study Protocol M02-0433
239,301.00 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the
Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and
Maintenance of Clinical Remission in subjects with Crohn's Disease
12,655.00 D9770C00012: Randomized Double-Blind Multicentre Dose-Finding Phase IIb
Study for up to 8 Weeks Treatment with AZD0865 25,50,75mg and
Esomeprazole 40mg Given Orally Once Daily for the Healing of Erosive
Esophagitis in Adult Subjects with...
10,124.00 D9770C00011: 4 Week Randomized Double-Blind Multicentre Dose-Finding
Phase IIb Study With AZD0865 25, 50, 75mg & Esomeprazole 20mg Given
Orally Once Daily for the Treatment of GERD Without Erosive Esophagitis
According to the LA Classification…
3,000.00 CHTF919G2203: 6 Week Randomized Double-Blind Double-Dummy PlaceboControlled Multicenter Study to Assess the Effect of Tegaserod 2mg tid and 6mg
tid on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic
Gastropathy
3,175.00 CHTF919A2417: 4 Week Multicenter Double-Blind Placebo-Controlled
Randomized Parallel-Group Clinical Study to Evaluate the Efficacy of Tegaserod
in Relieving the Symptoms of Female Patients with IBS Excluding Those With
Predominant Diarrhea...
3,750.00 CHTF919E2309: Randomized Double-Blind Placebo-Controlled Multicenter
Evaluation of the Efficacy and Safety of Tegaserod (6mg bid) Administered Orally
for 12 Weeks in Male Patients With Chronic Constipation
6,875.00 RAB-GRD-3001: Randomized Controlled Parallel-Group Open-Label Study to
Evaluate Different Dosing Regimens of Rabeprazole in Controlling Nocturnal
Heartburn Symptoms in Patients with Gastroesophageal Reflux Disease
Annual Report 2004
Gastroenterology
Kwan
Clinical Trial
Idenix Pharmaceuticals, Inc.
$
Gastroenterology
Kwan
Clinical Trial
Idenix Pharmaceuticals, Inc.
$
Gastroenterology
Gastroenterology
Gastroenterology
Lam
Steinbrecher
Steinbrecher
Clinical Trial
Grant
Grant
$
$
$
Gastroenterology
Steinbrecher
Grant
Gastroenterology
Gastroenterology
Steinbrecher
Tai
Grant
Grant
Gastroenterology
Gastroenterology
Tai
Tai
Grant
Grant
Broncus Technologies, Inc.
CIHR: Operating Grant
Geraldine Dow Ferry Endowment
Fund
Canadian Liver Fdn : Summer
Studentship Program Fellow:
Parhar, Kuljit
Donation
CAG/CIHR: New Operating Grant
in Gastroenterology
Various Sources
CSIR: Research Grant
$
$
Gastroenterology
Yoshida
Clinical Trial
Micrologix Biotech Inc
$
Gastroenterology
Yoshida
Clinical Trial
Hoffmann-La Roche
$
Gastroenterology
Yoshida
Clinical Trial
Gilead Sciences
$
Gastroenterology
Yoshida
Clinical Trial
Human Genome Sciences, Inc.
$
Gastroenterology
Yoshida
Clinical Trial
Ortho Biotech
$
Gastroenterology
Yoshida
Clinical Trial
(Canada)
$
General Internal Med.
Birmingham
Grant
$
Hatala
Grant
Magee
Grant
Magee
Grant
Magee
Grant
Palepu
Grant
INS002031
RCPSC: Medical Education
Research Grant
MSFHR: Scholar Award CI-SCH57(02-1)
Grant C1-SCH-57(02-1)
Grant C1-SCH-57(02-1)
MSFHR: Senior Scholar Award
CI-SSH-083(03-1)POPN
$
$
$
$
4,214.00 NV-02B-010: Phase IIb Extension Study of LdT (Telbivudine) Lamivudine or LdT
plus Lamivudine in Subjects with Chronic Hepatitis B Who Have Completed
Study NV-02B-003
1,957.00 Protocol NV-02B-007: Randomized Double-Blind Trial of LdT (Telbivudine) vs
Lamivudine in Adults with Compensated Chronic Hepatitis B
7,504.00 Feasibility Study of the Broncus Alair System for the treatment of asthma
98,276.00 Pathogenesis of atherosclerosis
75,000.00 Endowment for inflammatory bowel disease research and education
4,000.00 Modulation of survival pathways in Kupffer cells by oxidized LDL
500.00 Clinical Research in Chronic Liver Diseases
40,000.00 Genome-wide analysis revels a novel gene involved in chemotherapy resistance
in colorectal cancers
37,688.00 Laboratory start-up fund
25,000.00 Dissecting chemotherapy resistance in colorectal cancer using a genome-wide
approach
15,000.00 HCV-04-001: Phase II Randomized Dose-Ranging Open-Label Multicentre Study
to Evaluate the Safety and Efficacy of Celgosivir for 12 Weeks in Patients with
Chronic Hepatitis C Infection
1,300.00 An extension Protocol to Evaluate the Long-term Effects of Treatment with
Peginterferon Alpha-2a (PEG-IFN) or Roferon A for Patients with Chronic
Hepatitis C in Original Studies NV15495, NV15496 and NV 15497
3,309.00 Protocol GS-01-550: Phase 3b Open-Label Program of Adefovir Dipivoxil in the
Treatment of Patients with Lamivudine-Resistant Chronic Hepatitis B Who Have
Limited Treatment Options
65,088.00 ALFR-HC-03CA: Double Injection Dose-Ranging Study to Evaluate the Safety,
Tolerability, Pharmacodynamics and Pharmacokinetics of Albuferon
(Recombinant Human Albumin-Interferon alfa fusion protein) in Interferon Alfa
Naive Subjects with Chronic…
8,250.00 HEPC-AN-2: Prospective Study to Evaluate the Hemoglobin Levels of Hepatitis
C Virus Infected Patients Receiving Treatment with Combination
Ribavirin/Interferon or Ribavirin/Pegylated Interferon
8,900.00 BV16209 A Multicenter Open Label Expanded Access Program of Pegintereron
alfa-2a (ro 25-8310) Monotherapy and Combination Therapy with Ribavirin
(Ro20-9963) in Patients with Chronic Hepatitis C
3,600.00 Prevalence and Mortality from eating disorders
$
21,350.00 Evaluation of a modified mini-clinical evaluation exercise as a high stakes
assessment of clinical competence
80,000.00 CHIPS (control of hypertension in pregnancy study): a pilot trial
$
$
$
66,250.00 Health research of vulnerable urban populations
Page 198
Annual Report 2004
Palepu
Grant
Palepu
Grant
Palepu
Grant
Studney
Clinical Trial
Studney
$
24,000.00 Social determinants and HIV: a community-based intervention in injection drug
users (IDUs)
$
61,635.00 Development of a Quality of Life Instrument for Homeless Persons and Street
Youth
1,000.00 Social Determinants and HIV: an evaluation of a community-based intervention in
injection drug users (research allowance)
Clinical Trial
CIHR: New Investigator Award
(CIHR Scholarship)
# HNI-50103
CIHR: Operating Grant HPI66923
(CIHR Scholarship)
# HNI-50103
CHARISMA
Aventis Pharma Inc
$
Van Eeden
Van Eeden
Grant
Grant
H&SFBC: Research
BC Lung: Project Grant 869231
$
$
Magee
Grant
$
Geriatric Medicine
Adler
Grant
Geriatric Medicine
Geriatric Medicine
Adler
Beattie
Grant
Grant
Geriatric Medicine
Beattie
Agreement
Geriatric Medicine
Meneilly
Grant
Hematology
Hogge
Grant
Hematology
Hogge
Clinical Trial
Sunnybrook Health Science
Centre
BCMSF: Research Grant
BCM03-0128
Various Sources
MSFHR Health Research
Network Proposal Development
Award IN-NTC-008-045
CIHR: Operating Grant MOP57686 in collaboration with
University Health Network
Cdn Diabetes Assoc.: Charles H.
Best Fund/Grant-in-Aid
CIHR: Operating Grant IC1 70245
Janssen-Ortho Inc.
Hematology
Hogge
Clinical Trial
Antigenics, Inc.
$
Hematology
Humphries
Grant
$
Hematology
Humphries
Grant
Hematology
Humphries
Grant
Hematology
Lansdorp
Grant
Hematology
Lansdorp
Grant
Fellowship STPDF 163021
(Fellow: Hirose, Koichi)
Research
Research Student Award Argiropoulos, Bob
CFI Infrastructure Operating
Fund 3857
CFI Infrastructure Operating
Fund 3857
$
$
$
3,670.00 Protocol EFC4505: CHARISMA - Clopidogrel for High Atherothrombotic Risk and
Ischemic Stabilization, Management and Avoidance
1,000.00 HOE 901/3502: Open-Label, Multicentre, Randomized Study to Assess an Early
Insulization Strategy with Insulin Glargine vs a Standard Oral Strategy in the
Management of Type 2 Diabetes
60,000.00 Air pollution induced atherogenesis
10,000.00 Development of an in vitro method for the controlled delivery of one or more
particles to a single human lung cell: measurement of cytokine expression at the
per cell per particle level
12,100.00 Control of hypertension in pregnancy - pilot study
$
$
47,755.00 Access to health services: The experience of newer, older immigrants to Greater
Vancouver
25,000.00 Research support: Addressing the root causes of genocide
24,600.00 BC's aging network research program (BCANRP)
$
14,400.00 Canadian Alzheimer's disease quality of life study
$
74,737.00 Diabetes in the Elderly
$
45,836.00 Optimization of the use of diptheria toxin-growth factor fusion proteins for
treatment of acute leukemia
2,088.00 Protocol R115777-INT-21: Open-Label Phase 2 Study of the Farnesyl
Transferase Inhibitor Zarnestra (R115777) as Postconsolidation Therapy for
Acute Myeloid Leukemia (AML) in Subjects 60 Years and Older
3,864.00 C-300-01 CML: Phase II Study of AG-858 Plus Gleevec in Patients with Chronic
Myelogenous Leukemia (CML) in Chronic Phase who are Cytogenetically
Positive After Treatment with Gleevec
11,000.00 Molecular mechanisms linking Hox transcription factors to leukemia
$
$
$
396,846.00 HOXB4 target-genes specifying hematopoietic stem cell self-renewal
20,000.00 Characterization of the role of MEIS1 in hematopoiesis
$
5,000.00 CFI Infrastructure Operating Funds - Stem Cell Centre - Operations
$
67,000.00 CFI Infrastructure Operating Funds - Stem Cell Centre - Operations
Page 199
Annual Report 2004
Hematology
Lansdorp
Grant
Hematology
Lansdorp
Grant
Hematology
Lansdorp
Grant
Hematology
Lansdorp
Grant
Hematology
Lavoie
Grant
Hematology
Nevill
Grant
Hematology
Schrader
Grant
Hematology
Schrader
Grant
Hematology
Schrader
Grant
Hematology
Shepherd
Clinical Trial
Hematology
Smith
Clinical Trial
AnorMed Inc.
$
Hematology
Smith
Grant
$
Hematology
Song
Grant
Canada Research Chair: Tier II
(CIHR) 950-01-2053
National Cancer Institute of
Canada
Hematology
Vickars
Clinical Trial
Bristol-Myers Squibb, US
(Princeton)
$
Hematology
Vickars
Grant
Heart and Stroke Foundation of
B.C. & Yukon
$
Hematology
Vickars
Clinical Trial
Bayer Inc.
$
Hematology
Vickars
Grant
$
38075
CIHR: Canadian Graduate
Scholarships - Doctoral Award
CGD 65038 (Fellow: Cheung,
Iris)
Research Award STPHD067021
(Fellow: Cheung, Iris)
Research Student Award (Fellow:
Greenwood, Matthew)
INS002031
National Cancer Institute of
Canada
Canada Research Chair Tier I
(CIHR)
NCE/Protein Engineering:
Research
Canada Inc
$
113,500.00 Replicative Shortening of Telomeres in Human Cells
$
5,000.00 Molecular mechanism of genome stability and telomere shortening in dog-1
mutants
$
2,000.00 Molecular mechanisms of genomic instability and telomere shortening in Dog-1
mutants
$
20,000.00 The effect of artificial Telomere Elongation using lentiviral based transduction of
hTERT in Human hematopoietic stem cells
$
2,250.00 Risks and outcomes of invasive Aspergillus infections in allogenic stem cell
transplant recipients and high risk hematological malignancies
$
$
15,612.00 Phase III Study of Concurrent Tretionoin and Chemotherapy With/Without
Arsenic Trioxide (As203) (NSC#706363) as Initial Consolidation Therapy
Followed by Maintenance Therapy with Intermittent Tretinoin vs Intermittent
Tretinoin and Mercaptopu..
200,000.00 Canada Research Chair - John Schrader
$
135,280.00 Molecular characterization of the M-Ras pathway
$
40,000.00 Pence P3 Deg4 - Titratable reversible protein silncing (TRPS) technology via
cellular missorting
2,406.00 A phase III study of ST1571-106 versus Interferon-a (IFN-A) combined with
Cytarabine (Ara-C0 in patients with newly diagnosed previously untreated
Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in
chronic phase (CML-CP)
7,700.00 AMD3100-C201: Treatment with AMD3100 in Non-Hodgkin's Lymphoma and
Multiple Myeloma Patients to Increase the Number of Peripheral Blood Stem
Cells When Given a Mobilizing Regimen of G-CSF
100,000.00 Canada Research Chair in cell therapies for Dr. Clayton Smith
$
$
Page 200
9,000.00 Randomized Phase III Study of Thalidomide and Prednisone as Maintenance
Therapy Following Autologous Stem Cell Transplant in Patients with Multiple
Myeloma
1,500.00 Protocol CV185-010: A Phase 2 Randomized, Double-blinded (BMS-562247 and
enoxaparin), Active-Controlled (Enoxaparin and Warfarin), Parallel-arm, DoseResponse Study of the Oral Factor Xa Inhibitor BMS-562247 In Subjects
Undergoing Elective Total
1,256.00 REVERSE (REcurrent VEnous thrombolembolism Risk Stratification Evaluation)
A study to develop a clinical prediction rule to predict low recurrence risk in
patients with idiopathic venous thromboembolism
95,077.00 Oral direct factor Xa inhibitor BAY 59-7939 in the prevention of VTE in patients
undergoing total knee replacement.ODIXa-knee-a randomised, controlled,
double-blind, double-dummy phase IIb dose-ranging trial
4,000.00 Exclaim study - A double blind, placebo controlled, parallel, multi center study on
extended VTE Prophylaxis in acutely ill medical patients with prolonged
immobilization
Annual Report 2004
Hematology
Vickars
Clinical Trial
$
Hematology
Vickars
Grant
Canadian Apheresis Group
$
Hematology
Vickars
Clinical Trial
$
Hematology
Vickars
Clinical Trial
Ltd.
$
Hematology
Vickars
Clinical Trial
Organon Inc
$
Infectious Diseases
Av-Gay
Grant
$
Infectious Diseases
Av-Gay
Grant
JBH - 47862 (CIHR Scholarship)
BC Lung/CIHR Investigator
Infectious Diseases
Infectious Diseases
Av-Gay
Av-Gay
Grant
Grant
Various Sources
MND Diagnostics Ltd
$
$
Infectious Diseases
Infectious Diseases
Av-Gay
Av-Gay
Grant
Grant
$
$
Infectious Diseases
Av-Gay
Grant
Infectious Diseases
Infectious Diseases
Av-Gay
Av-Gay
Grant
Grant
Infectious Diseases
Av-Gay
Contract
NCE/Canadian Bacterial:
Research
VGH & UBC Hospital Fdn
Research Phase III
Nanobac Pharmaceuticals Inc
$
Infectious Diseases
Infectious Diseases
Av-Gay
Brunham
Grant
Grant
TB Vets; VH Foundation
Aventis Pasteur
$
$
Infectious Diseases
Infectious Diseases
Brunham
Brunham
Grant
Grant
Aventis Pasteur
NIH/U. Washington
$
$
Infectious Diseases
Infectious Diseases
Brunham
Brunham
Grant
Grant
CIHR
TIGR/NIH
$
$
Infectious Diseases
Cherkasov
Grant
$
Infectious Diseases
Infectious Diseases
Cherkasov
Cherkasov
Grant
Grant
Infectious Diseases
Chow
Grant
Dean of Medicine - Faculty Start
Up funds
VHHSC: Scholar Award
Studentship Award (Hsing,
Michael)
$
$
$
$
8,346.00 An open-label, parallel-group, multi-center study to evaluate the efficacy and
safety of enoxaparin versus unfractionated heparin in the prevention of venous
thromboembolism in patients following acute ischemic stroke
600.00 A comparison of solvent detergent vs cryosupernatant plasma in TTP and viral
surveillance in apheresis
69,003.00 The Van Gogh-DVT trial, a multicenter, international, randomized, open-label,
assessor-blind, non-inferiority study comparing the efficacy and safety of once
weekly subcutaneous SanOrg34006 with the combination of(LMW) Heparin and
vitamin K and…
1,500.00 A Phase III Randomized, Parallel-Group, Double-Blind, Active Controlled Study
to Investigate the Efficacy and Safety of Two Different Dose Regimens (75mg
Day 1 Followed by 150mg Day 2 - Completion, and 110mg Day 1 Followed by
220mg Day 2…
5,089.00 The VanGogh extension trial, a multicenter, international, randomized, doubleblind study comparing the efficacy and safety of once-weekly subcutaneous
SanOrg34006 with placebo in the long-term prevention of symptomatic venous
thromboembolism
25,000.00 Molecular Analysis of Mycobacterium Tuberculosis Cell Signaling Elements
(Salary)
25,000.00 Molecular Analysis of Mycobacterium Tuberculosis Cell Signaling Elements
(Salary).
1,000.00 Role of Cholesterol in Tuberculosis Infection
16,103.00 Cloning and examination of Rhinovirus and SARS 3C protease as a diagnostic
tool for viral infections
30,000.00 Mycothiol dependent isoniazid resistance in Mycobacterium tuberculosis
33,302.00 Agilent 2100 Bioanalyzer (Equipment)
47,549.00 Molecular analysis of Mycobacterium tuberculosis protein kinases and
phosphatases
61,294.00 TB Research - Various Sources
90,500.00 Phase III: Mycobacterium tuberculosis protein kinases and phosphatases as
novel drug targets
162,108.00 Biochemical characterization of calcified particles originated from human and
bovine area
8,706.00 TB research support
100,000.00 Investigate protective efficacy & immunogenicity in mice of Serovar D Pal antigen
- Chlamydia trachomatis vaccine
37,500.00 DNA vaccine for Chlamydia trachomatis
98,000.00 Chlamydia and gonococcal infection: Immunobiology in the female reproductive
tract
121,470.00 Immunology of Chlamydia trachomatis infection
135,000.00 Comparative genomics of the Chlamydiaceae family of obligate intracellular
parasites
9,700.00 In Silico Discovery of Novel Antibiotic Candidates
$
$
30,000.00 Bioinformatics study of microbial pathogens
1,458.00 Modelling and simulating intra-cellular signalling systems in response to
pathogen invasions by semantic networks
$
41,653.00 Multi-task gel documentation system (Equipment)
Page 201
Annual Report 2004
Infectious Diseases
Chow
Grant
Infectious Diseases
Infectious Diseases
Chow
Chow
Grant
Grant
Infectious Diseases
Chow
Grant
Infectious Diseases
Chow
Grant
Infectious Diseases
Chow
Grant
Infectious Diseases
Chow
Grant
Infectious Diseases
Infectious Diseases
Infectious Diseases
Infectious Diseases
Chow
Chow
Chow
Chow
Grant
Grant
Grant
Grant
Infectious Diseases
Chow
Grant
Infectious Diseases
Chow
Grant
Infectious Diseases
Chow
Grant
Infectious Diseases
Grigg
Grant
Infectious Diseases
Grigg
Grant
Infectious Diseases
Infectious Diseases
Grigg
Grigg
Grant
Grant
Infectious Diseases
Grigg
Grant
Infectious Diseases
Infectious Diseases
Grigg
Harrigan
Grant
Grant
Infectious Diseases
Harrigan
Grant
Research
NCE/Canadian Bacterial
Research
CIHR: Operating Grant MT-7630
CIHR/Strategic Training:
Strategic Training Program Grant
STI-63299 in collaboration with:
Institute of Infection and
Immunity (CIHR)
VCHRI
MRC: MD/PhD Studentship: Lee,
Jimmy
MRC: MD/PhD Studentship:
Rauh, Michael
Yong, Paul
CIHR: MD/PhD: Coburn, Bryan
CIHR: MD/PhD: Brunham, Liam
CIHR: MD/PhD: Tan, Clara
MSFHR: Senior Graduate
Studentship Award: Kalyan,
Shirin
CIHR: MD/PhD Program
Studentship: Heine, Heather
CIHR: MD/PhD Program
Studentship: Joe, Aaron
Sheldon, Claire
CIHR: Operating Grant MOP64388 in collaboration with:
Immunity (CIHR)
(CIHR Scholarship) MSH-69170
(Fellow: Grigg, Michael,
Infectious Diseases - Med, Van
Coastal Health Research Inst.)
VHHSC: Scholar Award
CIHR: Proof of Principle PPP67408
CFI: New Opportunities 9147
Research Award (STPHD 60021)
- Brumme, Zabrina
CIHR: Doctoral Research
Awards (CGD-65030) - Brumme,
Zabrina
$
$
$
$
$
98,020.00 Phase III: D4: Diagnosis of Intracellular Pathogens in Community-Acquired
Pneumonia HSP60 Gene Sequences
98,278.00 Pathogenesis of Staphylococcal Toxic Shock Syndrome
310,500.00 UBC Training program for translational research in infectious diseases
10,000.00 Pilot Project: Heat shock protein 60 in staphylococcal pathogenesis: a new
paradigm
1,000.00 Phagosome biogenesis
$
1,000.00 Cytokine-mediated signal transduction in leukemia
$
1,000.00 Chromosomal abnormalities in reproduction failure and development
$
$
$
$
1,000.00
1,000.00
1,000.00
2,291.00
$
1,000.00 Myocardial regeneration with hematopoietic stem cells
$
1,000.00 Molecular determinants of stem cell trafficking
$
1,000.00 Neuronal pH: Regulation in health and disease
The pathogenic of salmonella infection
Identification and validation of genes modulating LDL cholesterol in humans
The regulation of transcription factors by integrin linked kinase in cancer cells
Role of yo T cells and HMG-1 in staphylococcal toxic shock syndrome
$
92,816.00 Toxoplasma Surface Antigens and Immunity
$
43,875.00 Toxoplasma Surface Antigens and Immunity
$
$
30,000.00 Molecular Basis of Toxoplasma Pathogenesis
36,500.00 Molecular basis of Toxoplasma Pathogenesis
$
87,487.00 Role of T regs in Toxoplasma pathogenesis. Co applicant M. Levings
$
$
$
Page 202
260,000.00 Laboratory of Molecular Imaging and Parasite Pharmacogenomics
2,000.00 Factors impeding the success of HIV antiretroviral therapy today: genetic
variation, viral evolution and drug resistance, and cellular reservoirs of HIV
5,000.00 An investigation into challenges faced in antiretroviral (anti-HIV) therapy today:
human and viral genetic variation, HIV antiviral resistance and the existence of
viral reservoirs
Annual Report 2004
Infectious Diseases
Hmama
Grant
MSFHR: Matching Establishment $
Grant CI-SCH-26(01-2)
Infectious Diseases
Hmama
Grant
$
Infectious Diseases
Hmama
Grant
$
Infectious Diseases
Hmama
Grant
CIHR: Postdoctoral Fellowship
MFE-70513 (Fellow: Deghmane,
Ala-Eddine)
Infectious Diseases
Hmama
Grant
Infectious Diseases
Hmama
Grant
Infectious Diseases
Infectious Diseases
Hmama
Montaner
Grant
Clinical Trial
Infectious Diseases
Montaner
Clinical Trial
Infectious Diseases
Montaner
Infectious Diseases
$
(CIHR Scholarship)
TB Vets; VH Foundation
CIHR/Rx&D: Research Program
- Clinical Trials
DCT-48206
(Canada)
$
$
Grant
Ontario HIV Treatment Network
$
Montaner
Clinical Trial
(Canada)
$
Infectious Diseases
Montaner
Clinical Trial
(Cda)
$
Infectious Diseases
Montaner
Clinical Trial
Janssen-Ortho Inc.
$
Infectious Diseases
Montaner
Grant
(Canada)
$
Infectious Diseases
Montaner
Clinical Trial
Serono Inc.
$
Infectious Diseases
Montaner
Grant
$
Infectious Diseases
Infectious Diseases
Montaner
Montessori
Clinical Trial
Clinical Trial
Ltd.
Tibotec Pharmaceuticals Ltd
Pfizer Canada Inc.
Infectious Diseases
Nandan
Grant
Infectious Diseases
Phillips
Grant
38005
Canadian Dermatology
Association
$
$
14,583.00 Molecular study of interaction between Mycobacterium tuberculosis and the
macrophage endosomal compartment: an approach to identify mycobacterial
virulence factors
30,000.00 Alteration of the macrophagic endosomal compartment by Mycobacteria. Role of
the surface glycolipid lipoarabinomannan and the mycobacterial urease
35,000.00 Identification and characterization of a mycobacterial secreted protein that
interact with the actin binding protein coronin-1/TACO in human macrophages
45,000.00 Molecular study of interaction between Mycobacterium tuberculosis and the
macrophage endosomal compartment: an approach to identify mycobacterial
virulence factors.
58,500.00 Cell signaling regulating mycobacterial-macrophage interactions
$
87,168.00 Identification of mycobacterial factors that inhibit phagosome maturation in
human macrophages
70,000.00 TB research support
2,274.00 An Open Label, Randomized Study to Evaluate the Antiretroviral Effect,
Tolerability, Safety and Pharmacokinetics of Squinavir SGC/Ritonavir QD vs.
Indinavir/Norvir BID in HIV Infected Patients
375.00 An extension protocol to evaluate the long-term effects of treatment with
Peginterferon Alfa-2a (PEG-IFN) or Interferon (IFN) based therapies for patients
with chronic hepatitis C (Protocol NV15908B)
450.00 Non-invasive assessment of atherosclerosis and its determinants in HIV-infected
people
3,240.00 A phase III open-label, randomized, active-controlled study assessing the
efficacy and safety of T-20/Ro 29/9800 (HIV-1 fusion inhibitor) in combination
with an optimized background regimen, versus optimized background regimen
alone, in patients…
3,300.00 A study to compare long-term safety and tolerability of Stavudine (d4T) extended
release (ER) versus conventional (immediate release, IR) formulations, each in
combination with Lamivudine (3TC) and Efavirenz (EFV) in subjects who have…
4,145.00 A Phase II Randomized, Controlled, Partially Blinded, 48-Week Trial to
Investigate Dose-Response of TMC114/RTV in 3-Class-Experienced, Multi PIExperienced HIV-1 Infected Subjects (TMC114-C213)
5,000.00 A randomized controlled trial of once-daily tenofovir, 3TC and lopinavir/r versus
remaining on the same regimen in HIV-infected patients virologically suppressed
on their first PI-containing HAART regimen
18,784.00 A phase III, multi-center, randomized, double-blind, placebo-controlled, parallel
group study of the safety and efficacy of serostim (mammalian cell-derived
recombinant human growth hormone, r-hGH) in the treatment and maintenance
of Human Immuno…
75,000.00 Ritonavir-boosted Tipranavir and Lopinavir: A Preliminary Pharmacokinetic
Evaluation
78,625.00 Protocols TMC125-C203 and TMC125-C209
43,938.00 Alanine Aminotransferase Elevations and Ishak-Knodell Scores in HIV/Hep C
Co-Infected Patients
82,162.00 Molecular Mechanism of Leishmania Pathogenesis
$
20,000.00 Abacavir hypersensitivity reaction: Investigations of immunopathogenesis
$
$
$
Page 203
Annual Report 2004
Infectious Diseases
Reiner
Grant
Infectious Diseases
Reiner
Grant
Infectious Diseases
Reiner
Grant
Infectious Diseases
Reiner
Grant
Infectious Diseases
Reiner
Grant
Infectious Diseases
Infectious Diseases
Infectious Diseases
Rekart
Steiner
Steiner
Grant
Grant
Grant
Infectious Diseases
Steiner
Grant
Infectious Diseases
Steiner
Grant
Infectious Diseases
Infectious Diseases
Infectious Diseases
Infectious Diseases
Infectious Diseases
Tyndall
Tyndall
Tyndall
Tyndall
Wood
Grant
Grant
Grant
Grant
Grant
Infectious Diseases
Wood
Grant
Medical Oncology
Chi
Agreement
Medical Oncology
Chi
Grant
VPR Research Development
Fund
UBC/PWIAS: Exploratory
Workshop Grants
CIHR: Proof of Principle PPP67408
MSFHR Fdn 57(02-1)BM:
Doctoral Trainee Research
Award - Lee, Jimmy
CIDA
VHHSC Scholar Award
MSH 69156
CFI: Infrastructure Operating
Fund 4453
CIHR: Operating Grant MOP64355 in collaboration with:
Immunity (CIHR)
BC Centre for Excellence in HIV
CIHR
VCHA
VCHA
NIH (US): Research Grant (2R01-DA011591-04A1)
CIHR: Operating Grant (HHP67262)
US Army DAMD17-02-0226,
PC011011 In collaboration with
OncoGenex
Ontario Clinical Oncology Group
Nephrology
Chiu
Clinical Trial
$
Nephrology
Duncan
Clinical Trial
$
Nephrology
Duncan
Clinical Trial
Ortho Biotech
$
Nephrology
Nephrology
Duncan
Jastrzebski
Clinical Trial
Clinical Trial
Merck & Co., Inc.
(Canada)
$
$
$
$
7,500.00 Research support for workshop entitled Network science, implications for biology
and medicine
16,500.00 Network Science: Implications for Biology and Medicine
$
100,000.00 Identification of therapeutic leads for hospital acquired infections
$
123,147.00 Monocyte Cell Regulation
$
2,000.00 Role of distinct P13-kinase isoforms in regulating phagocytosis and phagosome
maturation
$
$
$
855,988.00 STI/HIV/AIDS prevention and care in southern Vietnam
50,000.00 Mechanisms of Innate Immune Signalling by Enteroaggregative E. coli Flagellin
43,875.00 Mechanisms of Innate Immune Signalling by Enteroaggregative E. coli Flagellin
$
$
835.00 CFI Infrastructure Operating Fund
96,648.00 Mechanisms of innate immune signaling by enteroaggregative Escherichia coli
flagellin
$
$
$
$
$
125,157.00
45,030.00
200,000.00
490,000.00
566,301.00
$
158,355.00 The Vancouver injection drug user's study: A programme of study of HIV and
Hepatitis C and other harms related to injection drug use
377,720.00 A Phase 1/11 study of combination neoadjuvant hormone therapy and weekly
OGX-011 (Clusterin Antisense Oligonucleotide) prior to radical prostatectomy in
patients with prostate cancer
32,000.00 EPO-CAN-29 Randomized Trial of Epoetin Alfa in Men with Hormone Refractory
Prostate Cancer and Anemia
41,341.00 A double-blind, randomised, dose-ranging, multi-centre, phase IIIb study to
evaluate the efficacy and safety of high doses of candesartan cilexetil (Atacand)
on the reduction of proteinuria in the treatment of subjects with hypertension
and...
8,720.00 4522IL/0096 (AURORA): Study to Evaluate the Use of Rosuvastatin in Subjects
On Regular Haemodialysis: An Assessment of Survival & Cardiovascular Events:
Double-Blind Randomized Multicentre Phase IIIb Parallel-Group Study to
Compare the ....
55,523.00 Protocol EPO-IMU-401: An Active Safety Surveillance Plan to Prospectively
Monitor the Incidence of Pure Red Cell Aplasia (PRCA) in Patients Receiving
Epoetin-Alfa Therapy
37,839.00 SHARP: Study of Heart and Renal Protection
16,088.00 BA17283: Randomized Controlled Open-Label Multicentre Parallel-Group Study
to Demonstrate the Efficacy & Safety of RO-0503821 when Administered
Intravenously for the Maintenance Treatment of Anemia in Patients with Chronic
Kidney Disease...
$
$
Page 204
Salary support for Dr. Mark Tyndall
Role of injection drug use and hepatitis C infection on tolerability of HAART
Community health and safety evaluation project
Scientific evaluation of the supervised injection site (SESIS)
Evaluating the natural history of injection drug use
Annual Report 2004
Nephrology
Jastrzebski
Clinical Trial
(Canada)
$
Nephrology
Jung
Clinical Trial
AstraZeneca UK Limited
$
Nephrology
Landsberg
Grant
$
Nephrology
Landsberg
Grant
$
44,400.00 The humoral immune response in kidney allograft rejection
Nephrology
Levin
Grant
$
55,000.00 The value of cardiac specific troponin in predicting cardiac outcomes in an
asymptomatic chronic kidney disease population
Nephrology
Levin
Grant
$
7,500.00 The value of cardiac specific troponin in predicting cardiac outcomes in an
asymptomatic chronic kidney disease population
Nephrology
Levin
Clinical Trial
INS002031
Kidney Foundation: Biomedical
Scholarship
CIHR: Postdoctoral Fellowship
MFE-63502 in collaboration with:
Institute of Circulatory &
Respiratory Health (CIHR)
(Fellow: Khan, Nadia)
MSFHR:Postdoctoral Trainee
Fellowship STPDF240021
(Fellow: Khan, Nadia)
Janssen-Ortho Inc.
4,200.00 BA16736B: An Open-Label Randomized Multicentre Parallel-Group Study to
Demonstrate Correction of Anemia Using Intravenous Injections of RO0503821
in Patients with Chronic Kidney Disease who are on Dialysis
22,477.00 A study to evaluate the use of rosuvastatin in subjects on regular hemodialysis:
An assessment of survival and cardiovascular events (AURORA)(4522IL-0096);
a double-blind, randomised, multicentre, phaseIIIb, parallel-group study to
compare the…
3,600.00 Living anonymous donation clinical pilot study
$
Nephrology
Nephrology
Levin
Levin
Grant
Grant
Various Sources
Kidney Foundation of Canada
$
$
Nephrology
Levin
Clinical Trial
Hoffmann-La Roche
$
Nephrology
Levin
Clinical Trial
Merck Frosst Canada Inc.
$
Nephrology
Nephrology
Levin
Levin
Clinical Trial
Clinical Trial
University of Oxford
Johnson & Johnson
$
$
Nephrology
Quamme
Grant
$
Nephrology
Quamme
Grant
Nephrology
Wong
Grant
Nephrology
Yeung
Clinical Trial
CIHR: Operating Grant # MOP53288
Kidney Fdn: Biomedical
Research Grant
Canadian Apoptosis Research
Foundation (NEW)
Medtronic (USA)
Neurology
Barton
Grant
Neurology
Barton
Grant
Neurology
Barton
Grant
Neurology
Barton
Grant
CFI: Canada Research Chairs
Infrastructure Fund 202111
CI-SSH-035(03-1) CLIN
Canada Research Chair Tier II
(CIHR) 950-202111
NIMH Grant
76,790.00 IICT: A study of the interaction of Vascular Reactivity and Program Hemoglobin
in End Stage Diabetic Dialysis Patients
88,651.00 NERC
12,500.00 Care prior to dialysis: A multicentre prospective cohort study in renal insufficiency
to assess the impact of elements of care on patient outcomes (CREDA)
4,200.00 An Open Label, Randomized, Multicentre, Parallel Group Study To Demonstrate
Correction Of Anemia Using Subcutaneous Injections Of RO0503821 In Patients
With Chronic Kidney Disease Who Are Not On Dialysis
240,000.00 A Randomized Control Trial Comparing Combined Cardiology, Kidney and
Diabetic Care Clinic CCKDC to Current Therapy Received In Multiple Clinics:
Improving Care and Resource Utilization
1,320,107.00 Study of Heart and Renal Protection (SHARP)
104,235.00 An Active Safety Surveillance Plan to Prospectively Monitor the Incidence of
Pure Red Cell Aplasia (PRCA) in Patients Receiving Epoetin Alfa Therapy
166,250.00 Studies of Renal Magnesium Transport
$
50,000.00 Characterization of MagT, a Novel Family of Renal Magnesium Transporters
$
25,000.00 Accelerated neuronal aging caused by transient exposure to toxin.
$
$
$
$
$
Page 205
28,187.00 Medtronic EMPIRIC Study - Evaluation of EMPIRIC Programming to Improve
Patient Management
239,956.00 The UBC neuropsychology laboratory for investigation of human visual
processing and ocular motor control
8,750.00 Neuropsychology of vision and eye movements
58,333.00 Canada Research Chair for Dr. Jason Barton in Neuropsychology of vision and
eye movements
330,000.00 National Institute of Mental Health, 1R01 MH069898: "Perceptual encoding and
imagery in prosopagnosia"
Annual Report 2004
Neurology
Neurology
Calne
Calne
Grant
Grant
Various sources 16-017292-7
MRC: Operating Grant
$
$
267,520.00 Movement Disorder Clinic
58,324.00 Studies on the natural history and etiology of sporadic Parkinson's disease
Neurology
Neurology
Calne
Chapman
Grant
Clinical Trial
MRC: Group Grant MGC 36035 $
Wyeth-Ayerst Canada Inc
$
24,358.00 DDMP Core A: Biomedical Mathematical Core
86,681.00 Protocol 0912A2-212-NA: Multicenter Randomized Double-Blind PlaceboControlled Study of 3 Fixed Doses of EAA-090 in Adult Outpatients with
Neuropathic Pain Associated with Diabetic Neuropathy
Neurology
Devonshire
Grant
37,052.00 MS COSTAR Data Entry for the Genetic Susceptibility to MS Study
Neurology
Doudet
Contract
Research
Schering Ag
$
Neurology
Doudet
Grant
Titan Pharmaceuticals Inc.
$
Neurology
Doudet
Grant
MRC: Group Grant MOP-14535
$
Neurology
Doudet
Grant
$
Neurology
Doudet
Agreement
$
Neurology
Doudet
Grant
$
Neurology
Eisen
Clinical Trial
Neurology
Eisen
Clinical Trial
Studentship Award ST-SGS
128(03-1)BM (Fellow: Strome,
Elissa)
Companies LTS 3069,
EFC 2491(in collab. with Sanofi
Canada Inc. & Quintiles Canada
Inc.)
Aventis Pharma Inc.
RP54274/CA1.401
Neurology
Eisen
Grant
Feldman
Grant
Neurology
Feldman
Grant
Neurology
Feldman
Grant
Neurology
Feldman
Clinical Trial
Pfizer Canada Inc. A2581078
$
Neurology
Feldman
Contract
Pfizer Canada Inc.
$
Neurology
Feldman
Grant
$
Neurology
Feldman
Clinical Trial
Fellowship, 117(02-01) BM
(Fellow: Hsiung, Ging-Yuek)
Janssen-Ortho Inc.
$
Research
CIHR: Institute of Aging (Pilot
Project Grant)
Companies
Companies
108,905.00 Evaluation of three preparations of Spheramine in a rodent model of Parkinson's
Disease
75,720.00 In vivo PET study of the effects of striatal implantation of Retinal Pigment
Epithelial Cells in a primate model of Parkinson's Disease
52,258.00 DDMP Project 10: In vivo study of the effects of manipulations on the
dopaminergic synapse by PET
41,927.00 Stereological assessment of the survival of human retinal pigmented epithelial
cells implanted in a rodent model of Parkinson's disease
18,183.00 Effects of striatal implantation of RPE cells in a rodent model of Parkinson's
Disease
2,292.00 The effects of electroconvulsive therapy in an animal model of Parkinson's
disease: mechanisms of a potential adjunct treatment
$
22,800.00 Clinical Trials
$
64,524.00 A Canadian Multicentre Phase IV Comparative Study of the Effect of Riluzole 50
mg Bid on the Survival of ALS Subjects Compared to Historical Controls - the
CARE STUDY
50.00 General Neurology Research
$
$
$
$
$
Page 206
50,000.00 Preventing Alzheimer disease and other dementias: The development of a
statistical framework for the design of randomized controlled trials
195,000.00 ACCORD II - A longer term Assessment of cognitive Impairment and Dementia
Syndromes with an Evaluation of Treatment Effectiveness
76,400.00 ACCORD II - Transfer Master Account - A longer term Assessment of cognitive
Impairment and Dementia Syndromes with an Evaluation of Treatment
Effectiveness
52,357.00 A2581078 The LEADe Study: 80-week Randomized Multicenter Parallel-Group
Double-Blind Study of the Efficacy & Safety of Atorvastatin 80mg +
Acetylcholinesterase Inhibitor vs an Acetylcholinesterase Inhibitor Alone in the
Treatment of Mild …
15,332.00 Economic Modelling Agreement: To develop a Canadian Economic Model
assessing the impact of AD Treatment - Accord Database
9,750.00 Susceptibility genes and environment risk factors for Alzheimer's disease
585.00 Multi-National Follow-Up Audit of Admission to Supported Accommodation for
Annual Report 2004
Patients Who Participated in Clinical Trials of Galantamine
Neurology
Feldman
Clinical Trial
University of California, San
Diego
$
Neurology
Feldman
Clinical Trial
Janssen-Ortho Inc.
$
Neurology
Feldman
Clinical Trial
$
Neurology
Feldman
Clinical Trial
$
Neurology
Gibson
Clinical Trial
$
Neurology
Gibson
Clinical Trial
$
Neurology
Gibson
Clinical Trial
Bayer Corp
$
Neurology
Hashimoto
Clinical Trial
Biogen Idec, Inc.
$
Neurology
Johnston
Clinical Trial
$
Neurology
Jones
Clinical Trial
Pfizer Canada Inc.
$
Neurology
Jones
Clinical Trial
Pfizer Canada Inc.
$
Neurology
Jones
Clinical Trial
UCB Pharma
$
Neurology
Jones
Clinical Trial
Pfizer Canada Inc.
$
Neurology
Jones
Clinical Trial
UCB Pharma
$
Neurology
Kastrukoff
Contract
Chemokine Therapeutics Corp
$
Neurology
Kastrukoff
Grant
$
Neurology
Kim
Grant
Neurology
Krieger
Clinical Trial
Research
Canadian Myelin Research
Initiative
Canada Inc
13,369.00 A randomized double blind, placebo controlled trial to evaluate the safety &
efficacy of vitamin E and Donepezil HC1 (Aricept) to delay clinical progression
from mild cognitive impairment (MCI) to Alzheimer's disease
4,485.00 AGAL-COG-3002: Phase 3b - An Analysis of Mortality in Subjects Who
Participated in Three Studies of Galantamine in Mild Cognitive Impairment
6,000.00 LTS5283: Long-Term Safety Extension of Phase II Study EFC5286 of SR57667B
in Patients with Mild-to-Moderate Alzheimer's Disease
135,901.00 Protocol EFC 5286: Phase II Multicentre Multinational Randomized Double-Blind
Placebo-Controlled Efficacy, Safety and Tolerability Study of SR57667B in
Patients with Mild to Moderate Alzheimer's Disease
22,608.00 Protocol B7A-MC-MBCW: LY333531 Treatment for Symptomatic Peripheral
Neuropathy in Patients with Diabetes
13,494.00 Protocol B7A-MC-MBBR: LY333531 Treatment of Peripheral Neuropathy in
Patients with Diabetes: A Phase 3 Pivotal Clinical Trial
13,292.00 Protocol 100538: Multicentre Randomized Double-Blind Placebo-Controlled
Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C) 10%
Treatment in Subjects with Chronic Inflammatory Demyelinating Polyneuropathy
8,090.00 C-850 CHAMPIONS: Controlled High Risk AVONEX Multiple Sclerosis
Prevention Study in Ongoing Neurological Surveillance
6,972.00 Clopidogrel for high atherothrombotic risk and ischemic stabilization,
management and avoidance (CHARISMA)
2,178.00 Protocol 1008-114-141: Pregabalin Open-Label Add-On Trial: An Open-Label
Multicentre Follow-On Study to Determine Long-Term Safety and Efficacy in
Patients with Partial Seizures
6,825.00 Protocol 1008-164: Pregabalin BID Open-Label, Add-On Trial: A Follow-On
Study To Determine Long-Term Safety and Efficacy in Patients with Partial
Seizures
9,807.00 N01057: double-blind, multicenter, randomized, placebo-controlled study to
evaluate the efficacy & safety of adjunctive treatment with 3000 mg/day (pediatric
target dose of 60mg/kg/day) oral levetiracetam (LEV) (166, 250,and 500 mg
tablets)
6,630.00 Protocol 1008-112-141: Pregabalin BID Add-On Trial: A Randomized, DoubleBlind, Parallel-Group, Placebo and Lamotrigine-Controlled, Multicenter Study in
Patients with Partial Seizures
1,081.00 N167: Open-Label, Multicenter, Follow-up Study to Evaluate the Safety and
Efficacy of Levetiracetam (LEV) (oral tablets of 166, 250 or 500 mg bid) at
Individualized Doses Up To a Maximum or 4000 mg/day (or 80 mg/kg/day for
Children & Adolescents…
7,554.00 Determination of Peripheral Blood Mobilization of Committed Progenitors or
Colony Forming Cells Following Administration of Compounds in Female Balb/c
Mice
200.00 Virology Research
$
25,762.00 Immortalized human neural stem cells genetically modified for brain repair
$
62,349.00 Protocol CTCH346A 2211: A Randomized, Double-Blind, Placebo-Controlled,
Stratified Parallel-Group, Multicentre, Dose-Ranging Study Evaluating Four Oral
Doses of TCH346 (1.0, 2.5, 7.5 and 15 mg) Administered Once Daily in Patients
Page 207
Annual Report 2004
with ALS
Neurology
Lee
Grant
Neurology
Lee
Grant
Neurology
Lee
Clinical Trial
Neurology
Lee
Grant
Neurology
Neurology
Li
Li
Contract
Grant
Neurology
Martzke
Grant
Neurology
McKeown
Grant
Neurology
McKeown
Agreement
Neurology
Oger
Clinical Trial
Neurology
Oger
Agreement
Berlex Canada Inc
$
Neurology
Oger
Clinical Trial
Biogen, Inc C-1801
$
Neurology
Oger
Grant
$
Neurology
Oger
Clinical Trial
MSSC: Career Development
Award (Fellow: Tremlett, Helen)
Biogen Inc.
$
Neurology
Oger
Clinical Trial
Berlex Canada Inc
$
Neurology
Oger
Grant
Fellowship ST-PDF 262(03-1)
CLIN (Fellow: Tremlett, Helen)
$
Neurology
Oger
Clinical Trial
Neurocrine Biosciences Ltd. NBI- $
5788-0201
Pacific Parkinson's Research
Institute
69382
Eisai Co. Ltd. In collaboration
with: Pharmaceutical Research
Associates, Inc.
CI-SSH-038(03-1)BIOM
Various Sources
Research
Whitaker Fdn: Biomedical
Engineering Research Grant RG04-0004 in collaboration with:
University of North Carolina at
Chapel Hill Duke University
National Parkinson Foundation,
US
Canada Inc.
$
60,000.00 Mechanisms of levodopa-induced dyskinesia: Role of dopaminergic denervation
$
58,229.00 Neural mechanisms underlying response changes to levidopa in Parkinson's
disease
25,449.00 E2020-E044-316: 24 Week Multicentre Randomized Double-Blind PlaceboControlled Study of the Efficacy tolerability & Safety of Donepezil (ARicept) in
Parkinson's Disease Patients with Dementia
75,000.00 Studies on rational treatment of Parkinson's disease
$
$
$
$
$
$
$
$
Page 208
598,871.00 MS/MRI operating funds - admin office
2,358.00 Health Science Research Donations
9,912.00 Neurobehavioral outcome following implantation of bilateral subthalmic nucleus
stimulators in Parkinson's Disease
65,406.00 Information as a measure of motor function after stroke: Effect of dynamic visual
perturbations
57,271.00 Designation as a National Parkinson Foundation, Centre of Excellence
144,460.00 Protocol CFTY720D2201: Double-Blind Randomized Placebo-Controlled
Parallel-Group Multicenter Study Evaluating Safety Tolerability & Effect on MRI
Lesion Parameters of FTY720 vs Placebo in Patients with Relapsing Multiple
Sclerosis
55,000.00 Interferon-beta influence on MxA Protein Levels in Multiple Sclerosis Patients
with Seroconverted Neutralizing Antibody Status
54,785.00 C-1801: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group,
Multicentre Study to Determine the Safety and Efficacy of Natalizumab in
Subjects with Relapsing-Remitting Multiple Sclerosis
50,000.00 The impact of beta-interferon therapy on multiple sclerosis: effectiveness and
toxicity
47,209.00 Protocol C-862: Multicentre Prospective and Retrospective Long-Term
Observational Study of Avonex and Rebif to Determine the Efficacy Tolerability
and Safety in Subjects with Relapsing Multiple Sclerosis
32,266.00 306440 BEYOND Study: International Randomized Multicenter Phase 3b Study
in Patients with Relapsing-Remitting Multiple Sclerosis Comparing Over a
Treatment Period of 104 Weeks: Double-Blinded Safety Tolerability and Efficacy
of Betaseron/B
29,667.00 Aminotransferase abnormalities and Multiple Sclerosis
24,530.00 Protocol NBI-5788-0201: Randomized Double-Blind Placebo-Controlled Study to
Evaluate the Safety, Tolerability and Efficacy of NBI-5788 in Patients with
Relapsing-Remitting Multiple Sclerosis
Annual Report 2004
Neurology
Oger
Clinical Trial
Biogen Inc C-867
$
Neurology
Oger
Clinical Trial
Aventis Pharma Inc. HMR
1726/2002
$
Neurology
Oger
Clinical Trial
Berlex Canada Inc. 304747
$
Neurology
Neurology
Oger
Oger
Grant
Clinical Trial
Donation
Teva Neuroscience, GP
$
$
Neurology
Oger
Grant
$
Neurology
Pelech
Grant
Neurology
Neurology
Ruth
Ruth
Grant
Grant
Neurology
Ruth
Grant
Neurology
Ruth
Grant
Neurology
Ruth
Grant
Research
MRC: Operating Grant MOP
38062
MRC: Group Grant MGC 36035
Fund 5034
MRC: Multi-User Maintenance
Grant
MRC: Group Grant MT - 14535
Neurology
Ruth
Grant
Neurology
Spacey
Grant
Neurology
Neurology
Spacey
Spacey
Grant
Grant
Neurology
Stoessl
Grant
Neurology
Stoessl
Agreement
Neurology
Stoessl
Clinical Trial
Fund 5034
National Ataxia Foundation
VCHRI: Mentored Clinical
Scientist
Canada Research Chair Tier I
(CIHR)
US National Parkinson Fdn:
Research
Sanofi-Synthelabo Canada Inc
Neurology
Neurology
Stoessl
Stoessl
Grant
Clinical Trial
CIHR MGP 15126
Amgen, Inc 20020168-901
$
$
Neurology
Stoessl
Grant
Parkinson Society Canada
$
12,768.00 Protocol C-867: Multicentre Open-Label Immunogenicity and Safety Study of a
Serum-Free Pre-Formulated Solution of Avonex (Interferon beta 1a)
Administered Intramuscularly to Patients with Relapsing/Remitting Multiple
Sclerosis
27,658.00 Protocol HMR 1726D/2002: Extension of Protocol HRM 1726D/2002, A Phase II
Study of the Safety & Efficacy of Teriflunomide (HMR 1726) in Multiple Sclerosis
with Relapses
7,640.00 304747: Double-Blind Placebo-Controlled Randomized Parallel Group
Multicenter Phase 3 Study to Evaluate the Safety Tolerability and Efficacy of 8
MIU Interferon Beta-1b (Betaseron) in Patients with a First Demyelinating Event
Suggestive of MS
6,398.00 Neuro-Immunology Research
2,807.00 GA-O&I/001: Pharmacogenomics of Glatiramer Acetate: Study of the Genetic
Basis of Responsiveness to Glatiramer Acetate in Multiple Sclerosis Patients
2,760.00 Myasthenia Gravis Research
$
107,531.00 Protein kinase pathways in seastar oocyte cell cycle control
$
$
258,184.00 DDMP Core B: Positron Emission Tomography
76,314.00 Development of radiotracers based on oligonculeotides labelling
$
$
$
46,360.00 CFI Infrastructure Operating Funds - Functional Imaging in Basic Biomedical
Research Operations
14,340.00 MRC: Multi-User Maintenance Grant MR-11806
$
12,915.00 DDMP Project 10: In vivo study of the effects of manipulations on the
depaminergic synapse by PET
5,000.00 CFI Infrastructure Operating Funds - Functional Imaging in Basic Biomedical
Research - Centre Share
50,000.00 In it for Life: Mentored Clinician Scientist Salary - Paroxysmal neurological
disease: the role of the human P/Q type calcium channel
34,710.00 The role of the human P/Q-type calcium channel in the pathogenesis of ataxia
10,000.00 Research: Paroxysmal neurological disease: The role of the human P/Q type
calcium channel
200,000.00 Canada Research Chair - A. Jon Stoessl
$
138,375.00 National Parkinson Foundation, Centre of Excellence
$
135,750.00 Protocol ACT5288: Phase II Randomized Multicentre Multinational Double-Blind
Placebo-Controlled Study of the Effect of SR57667B on Dopaminergic NigroStriatal Function Assessed by 18F-Dopa PET Imaging in Outpatients with Early
Pakinson's Disease
127,761.00 Studies on fluctuations in response to dopaminergic therapy
90,000.00 GDNF 20020168: PET Scanning in Association with a Multicentre Randomized
Double-Blind Placebo-Controlled Parallel-Group Trial of Liatermin (rmetHuGDNF) Administered by Bilateral Intraputaminal (Ipu) Infusion of Subjects
with Idiopathic…
45,000.00 Neuroimaging investigation of early markers for nigrostrialal cell damage in
patients with a high genetic risk of developing Parkinson's disease
$
$
$
$
Page 209
Annual Report 2004
Neurology
Stoessl
Clinical Trial
Ltd
$
Neurology
Neurology
Stoessl
Stoessl
Grant
Clinical Trial
$
$
Neurology
Stoessl
Clinical Trial
MRC: Group Grant MT-14751
Smithkline Beecham
Pharmaceuticals (Canada)
101468/170
Kyowa Pharmaceutical, Inc in
collaboration with: Lineberry
Research Associates
Neurology
Stoessl
Clinical Trial
Kyowa Pharmaceutical, Inc 6002- $
US-005 in collaboration with:
Lineberry Research Associates
Neurology
Neurology
Neurology
Stoessl
Stoessl
Teal
Grant
Grant
Clinical Trial
CIHR MGP 15126
CIHR MOP-15127
Ltd.
$
$
$
Neurology
Teal
Clinical Trial
$
Neurology
Teal
Clinical Trial
Aventis Pharma Inc.
$
Neurology
Teal
Clinical Trial
$
Neurology
Teal
Clinical Trial
ONO Pharma USA, Inc
$
Neurology
Teal
Clinical Trial
Bayer Inc.
$
Neurology
Teal
Clinical Trial
$
Neurology
Teal
Clinical Trial
Wake Forest University - School
of Medicine
$
Neurology
Traboulsee
Clinical Trial
Teva Neuroscience, GP 9014
$
Neurology
Neurology
Tremlett
Tsui
Grant
Clinical Trial
MSSC: Research Grant
AN072-401CD
$
$
$
Page 210
31,923.00 SCEPTRE - 1198.100: Fourteen Week Placebo-Controlled Dose-Response
Efficacy & Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study
for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor)
28,383.00 DDMP Project 11: Pharmacological studies in experimental models of dyskinesia
25,698.00 A non-interventional follow-up study to observe the long term outcome of
Parkinson's Disease in patients who completed study SK & F 101468/056 or
study SK&F 101468/125 (STUDY 101468/170)
16,537.00 6002-US-018: A 12 Week, Double-Blind, Placebo-Controlled, Randomized,
Multicenter Study of the Efficacy or 40mg/day KW-6002 as Treatment for
Parkinsons's Disease in Patients with Motor Response Complications on
Levodopa/Carbidopa Therapy
13,169.00 6002-US-005: A 12 Week, Double-Blind, Placebo-Controlled, Randomized,
Multicenter Study of the Efficacy or 40mg/day KW-6002 as Treatment for
Parkinsons's Disease in Patients with Motor Response Complications on
Levodopa/Carbidopa Therapy
323,354.00 Degenerative Disorders of the Motor Pathways
58,324.00 The natural history of sporadic and inherited Parkinson's disease
11,635.00 9.159 PROFESS: Prevention Regimen for Effectively Avoiding Second Strokes:
A Double-Blind Active and Placebo Controlled Study of Aggrenox vs Clopidogrel
and Aspirin with and without Micardis
64,000.00 Protocol SA-NXY-0007: Double-Blind Randomized Placebo-Controlled ParallelGroup Multicenter Phase IIb/III Study to Assess the Efficacy & Safety of
Intravenous NXY-059 in Acute Ischemic Stroke
7,800.00 IRP4563H/4001 - PREVAIL: An Open Label Randomized Parallel-Group
Multicenter Study to Evaluate the Efficacy & Safety of Enoxaparin vs
Unfractionated Heparin in the Prevention of Venous Thromboembolism in
Patients Following Acute Ischemic ..
26,057.00 Protocol EFC4505: (CHARISMA) Clopidogrel for High Atherothrombotic Risk and
Ischemic Stabilization, Management and Avoidance
51,535.00 2506/INT0104: Randomized, Double-Blind, Placebo-Controlled, Multi-Centre
Study of the Effects of ONO-2506 IV Infusion on the Amelioration of Neurological
Damage and Improvement of Stroke Assessment Scale Scores in Patients with
Acute Ischemic Stroke
170,799.00 RECT: A randomized, double-blind, placebo-controlled trial to evaluate the
efficacy, safety, tolerability, and pharmacokinetic/pharmacodynamic effects of a
targeted exposure of intravenous repinotan in patients with acute ischemic stroke
5,000.00 Vitamin Intervention for Stroke Prevention
19,749.00 Protocol C0116T41 AbESTT-II: Abciximab (ReoPro) in Acute Ischemic Stroke: A
Phase III Multinational Multicentre Randomized Double-Blind Placebo-Controlled
Trial
46,591.00 Protocol GA 9014: Multicentered Randomized Double-Blind Placebo-Controlled
Parallel Study Assessing the Add-On Effect of Minocycline in RelapsingRemitting Multiple Sclerosis (RR-MS) Subjects Treated with Glatiramer Acetate
(GA)
32,160.00 The Impact of Beta-interferon Therapy on MS: Effectiveness and Toxicity
11,688.00 An Open Label Safety and Immunogenecity Study of MYOBLOC (NEUROBLOC;
BOTULINIM TOXIN TYPE B) Injectable Solution in Patients with Cervical
Dystonia.
Annual Report 2004
3,600.00 Occupational Risk Factors in Parkinson's Disease
$
2,124.00 191622-064-01: An Observational Study of the Prevalence of Migraine and Other
Primary Headache Disorders and Headache Attributed to Craniocervical
Dystonia in a Population of Subjects with Cervical Dystonia
600.00 AMPAR trafficking in models of cerebral ischemia
Tsui
Grant
Neurology
Tsui
Clinical Trial
Neurology
Wang
Grant
Neurology
Wong
Clinical Trial
CIHR: Doctoral Research Awards $
DD5 61947 In Collaboration With:
Institute of Circulatory &
Fellow: Liu, Yitao
ONO Pharma USA, Inc
$
Neurology
Woolfenden
Clinical Trial
Novo-Nordisk
$
Neurology
Physical Medicine &
Rehabilitation
Woolfenden
Dhawan
Clinical Trial
Clinical Trial
Allergan Inc
$
$
Physical Medicine &
Rehabilitation
Respiratory
Van Rijn
Grant
Abboud
Grant
Respiratory
Abboud
Agreement
$
Authority
$
Research
Workers' Compensation Board of $
British Columbia
Respiratory
Ayas
Grant
Respiratory
Ayas
Grant
Respiratory
Ayas
Clinical Trial
Respironics Inc
$
Respiratory
Ayas
Grant
$
Respiratory
Respiratory
Ayas
Ayas
Grant
Grant
$
$
21,750.00 The societal consequences of sleep apnea
33,750.00 The public health impact of obstructive sleep apnea hypopnea
Respiratory
Ayas
Grant
$
25,000.00 Investigation of the diagnosis and treatment of sleep disordered breathing
Respiratory
Respiratory
Ayas
Bai
Grant
Grant
$
$
25,000.00 Investigation of the diagnosis and treatment of sleep disordered breathing
81,302.00 Modulation of airway function by neurotrophic cytokines
Respiratory
Bai
Grant
INS002031
BCLA
MSFHR: Scholar Award CI-SCH060(03-1) HSR
(CIHR Scholarship)
JBH-56261
UBC Killam Fellowship
18,464.00 Evaluation of Electronically Recorded Occupational Peak Flow Monitoring and
Weekly Occupational Change in Spirometry as Substitutes for Inhalation
Challenge Testing in Red Cedar Asthma
50,000.00 The Impact of CPAP Therapy for Obstructive Sleep Apnea Hypopnea on
Cardiovascular Risk Factors: A Randomised Crossover Trial
37,500.00 MSFHR/WCB Scholar Award: The public health impact of obstructive sleep
apnea hypopnea. A focus on work productivity, occupational injuries and motor
vehicle crashes
12,632.00 IICT: REMStar Auto with C-Flex: In Laboratory Performance vs Conventionally
Titrated CPAP Therapy: Performances and Preferences
3,600.00 The public health and safety impacts of obstructive sleep apnea
INS002031
Allergan Inc.
$
Neurology
VCHRI: VGH & UBC Hospital
$
Fdn In it for Life (Operating)
MSFHR: Establishment Grant CI- $
SCH-060(03-1) HSR
$
Page 211
13,801.00 A randomized, double-blind, placebo-controlled, parallel group, multi-center study
of the effects of ONO-2505 intravenous on the improvement of strokes and
improvement in the stroke assessment scales scores in patients with acute
ishcemic s
35,979.00 Protocol F7ICH-1371: Randomized Double-Blind Placebo-Controlled Multicentre
Parallel Groups Study to Evaluate the Efficacy and Safety of Activated
Recombinant Factor VII (Niastas/NovoSeven) in Acute Intracerebral
Haemorrhage
28,119.00 Warfarin Aspirin symptomatic intractranial disease (WASID) study
2,537.00 Protocol 191622-056: Multicenter Open-Label Study of the Safety of Repeated
Doses of Botox (Botulinum Toxin Type A) Purified Neurotoxin Complex for the
Treatment of Focal Upper Limb Poststroke Spasticity
104,101.00 Salary: Research Nurse
70.00 Donations
3,000.00 UBC Killam Memorial Faculty Research Fellowship
Annual Report 2004
Respiratory
Bai
Clinical Trial
Intermune Pharmaceuticals, Inc.
$
Respiratory
Bai
Clinical Trial
$
Respiratory
Cook
Grant
$
Respiratory
Respiratory
Duronio
Duronio
Grant
Grant
Respiratory
Duronio
Grant
Respiratory
Duronio
Grant
Research Institute
CIHR Operating Grant
Fellowship ST-PDF 164()3-1)BM
(Fellow: Germain, Marc)
Studentship Award ST-SGS
125(03-1)BM: (Fellow: Scott,
Alexander)
70(CI-2001)
Respiratory
Fitzgerald
Grant
Respiratory
Fitzgerald
Clinical Trial
Respiratory
Fitzgerald
Contract
Respiratory
Fitzgerald
Clinical Trial
Respiratory
Respiratory
Fitzgerald
Fitzgerald
Grant
Grant
Respiratory
Fitzgerald
Contract
Respiratory
Respiratory
Fitzgerald
Fitzgerald
Grant
Agreement
Respiratory
Fitzgerald
Contract
Respiratory
Fitzgerald
Clinical Trial
Respiratory
Fitzgerald
Clinical Trial
Healthshares Holdings, Inc. in
collaboration with: Vancouver
Coastal Health Authority
Merck Frosst Canada & Co.
Centers for Disease Control and
Prevention 200-2001-00094,
Task #1
Canada Inc.
CIHR/BC Lung Assn.:
Investigator JBC-56221
Centers for Disease Control and
Prevention 200-200100094/0013, Modification #3
GlaxoSmithKline
Trials (Clinical Trials) in
collaboration with: Ottawa Health
Research Institute
Centers for Disease Control &
Prevention 200-2001-00094,
Task Order 0009
GlaxoSmithkline Inc
Ltd. 205.259
$
$
$
4,760.00 An open-label study of the safety of subcutaneous recombinant interferon
gamma-1b (IFN-y1b) in patients with idiopathic pulmonary fibrosis. GIPF-006
4,692.00 An open-label study of the safety and efficacy of subcutaneous recombinant
interferon gamma-1b (IFN-y1b) in patients with idiopathic pulmonary fibrosis
40,000.00 Implementation & Evaluation of Strategies to Control
119,354.00 Cytokine regulated signalling pathways in inflammatory cells
29,250.00 Analysis of nuclear and cytoplasmic Mcl-1 protein complexes
2,500.00 The roles of apoptosis and IGF-1 in tendinoisis of the rotator cuff
$
100,000.00 Key Signalling Pathways Controlling Survival and Death of Hemopoietic Cells
$
121,975.00 Initiative for the Study and Implementation of Systems (ISIS)
$
$
$
$
$
$
$
$
8,900.00 005-00 Double-Blind Randomized Placebo-Controlled Multicentre Parallel-Group
Dose-Ranging Study of L-000883191 in Patients with COPD
67,219.00 CDC Tuberculosis Epidemiology Study Group
50,119.00 Protocol CQAB149A2208: Randomized Double-Blind Placebo-Controlled 4
Period Incomplete Block Cross-Over Multicenter Multiple Dose (7 days) DoseRanging Study Followed by a Single Day's Treatment with Formoterol 12ug bid
to Assess the Efficacy…
42,000.00 Bringing evidence to the patient
34,611.00 Task 13: Factors associated with acceptance of adherence to toxicity from
treatment for Latent Tuberculosis Infection (TLTBI) and pilot study of TLBI
effectiveness
30,000.00 Risk factors for LOS and re admission for COPD exacerbations
27,350.00 Optimal Therapy of COPD to Prevent Exacerbations and Improve Quality of Life:
A Randomized Double-Blind Placebo-Controlled Trial
$
13,441.00 Enhanced surveillance to identify missed opportunities for TB prevention in
foreign-born populations in the United States and Canada
$
12,500.00 Can Advair and Flovent Reduce Systemic Inflammation Related to COPD? A
Multicentre Randomized Controlled Trial
12,161.00 SAFE: Spiriva Assessment of FEV1. The Effect of Inhaled Tiotopium Bromide
(18 mcg Once Daily) on the Change in FEV1 and Symptoms During Long-Term
Treatment in Patients with COPD. A I yr Parallel Group Double-Blind
Randomized Placebo Controlled Study
$
Page 212
Annual Report 2004
Respiratory
Fitzgerald
Clinical Trial
GlaxoSmithkline SAM40056
$
Respiratory
Fitzgerald
Clinical Trial
Altana Pharma, Inc.
$
Respiratory
Fitzgerald
Clinical Trial
Merck Frosst Canada & Co.
$
Respiratory
Fitzgerald
Clinical Trial
GlaxoSmithkline Inc.
$
Respiratory
Fitzgerald
Grant
$
Respiratory
Fitzgerald
Clinical Trial
Authority
D5890L00004
Respiratory
Fitzgerald
Grant
Respiratory
Fleetham
Grant
Respiratory
Fleetham
Grant
Respiratory
Fleetham
Grant
Respiratory
Respiratory
Fleetham
Khalil
Respiratory
Respiratory
$
Clinical Trial
Contract
MSFHR: Scholar Award CI-DSH059(03-1) CLIN
MSFHR: Research Unit
Authority
Companies
Various Sources
iCell Therapeutics Inc
$
$
Khalil
Khalil
Grant
Grant
Various Sources
VHHSC Scientist Award
$
$
Respiratory
Respiratory
Respiratory
Respiratory
Lam
Lam
Lam
Lam
Clinical Trial
Clinical Trial
Clinical Trial
Clinical Trial
NCI - USA
NIH - USA
NIH - USA
Genome Canada
$
$
$
$
Respiratory
Lam
Clinical Trial
NCI - USA
$
Respiratory
Respiratory
Lam
Lam
Clinical Trial
Clinical Trial
NCI - USA
BC Lung Association
$
$
Respiratory
Lam
Clinical Trial
Genome Canada
$
Respiratory
Respiratory
Respiratory
Lam
Lam
Levy
Clinical Trial
Clinical Trial
Clinical Trial
Vancouver Hospital Foundation
NIH - USA
Encysive, L.P. in collaboration
with: Research Point
$
$
$
$
$
11,550.00 Protocol SAM40056: Randomized Double-Blind Double-Dummy Parallel Group
Study of a Standard Dosing Regimen with Salmeterol/Fluticasone Combination
50/250ug bid (via the Diskhaler inhaler) vs a Symptom-Driven Variable Dosing
Regimen with F….
7,075.00 Protocol BY9020/M1-134 STAR: Comparison of Ciclesonide (640 ug/day) and
Fluticasone Propionate (750 ug/day) in moderate to Severe Asthma Patients
Well Controlled Under High Doses of inhaled Corticosteroids
8,900.00 005-00:Double-Blind Randomized Placebo-Controlled Multicenter Parallel-Group
Dose-Ranging Study of L-000883191 in Patients with COPD
5,125.00 Protocol SAS40068: PACE-IMT 24 Week Multicentre Randomized Double-Blind
Parallel Group Trial to Compare the Efficacy & Tolerability of
Salmeterol/Fluticasone Propionate Diskus Combination (Advair) 50/100 mcg bid
with Fluticasone Propionate
1,980.00 Salary: Clinical Trials Research Coordinator
1,500.00 Comparison of Symbicort Single Inhaler Therapy (Symbicort 200 Turbuhaler 1
Inhalation bid plus as needed) and Conventional Best Practice for the Treatment
of Persistent Asthma in Adolescents and Adults: 26 Week Randomized Ope...
139,000.00 Respiratory Sleep Disorders Research Unit
$
65,000.00 Sleep Disorders Program Fellowship
$
9,500.00 Respiratory Division Education Fund
Page 213
2,000.00 UBC Vancouver Hospital Respiratory Faculty Development Fund
10,000.00 CRA: Transforming growth factor beta 1 regulation of vascular smooth muscle
proliferation and fibrosis
9,304.00 Transforming growth factor beta regulation of pulmonary fibrosis
60,000.00 Transforming Growth Factor Beta Regulation of Pulmonary Fibrosis and Airway
Remodeling
1,366,127.00 A Phase II Trial of ACAPHA in Former Smokers with IEN
592,524.00 Chemoprevention of Lung Cancer
54,824.00 EDRN: Novel Reagents and New Biomarkers in Lung Cancer
4,200,000.00 Cancer Genomics: A multi-disciplinary approach to the large scale, highthroughput identification of genes involved in early stage cancers
30,909.00 Phase I Study of the Safety and Potential Efficacy of MyoInositol as a Lung
Cancer Chemopreventive Agent
11,917.00 UTSW SPORE in Lung Cancer
25,000.00 Novel Xenograft Models of Early Stage Human Lung Cancer and Preneoplastic
Lesions
2,250,000.00 Application of Pharmacogenomics for the Rational Chemotherapy of Lung
Cancer
50,000.00 Detection of Early Lung Cancer by Serum Protein Expression Profiling
397,497.00 Optical Systems for In Vivo Molecular Imaging of Cancer
33,792.00 Protocol FPH03 STRIDE III: Long-Term Open-label Study to Evaluate the Safety
of Sitaxsentan Sodium Treatment in Patients with Pulmonary Arterial
Hypertension
Annual Report 2004
25,000.00 Early detection of bronchiolitis obliterans following lung transplantation with high
resolution CT scan imaging
$
17,812.00 Protocol FPH06: Double-Blind Safety and Efficacy Study of Sitaxsentan Sodium
Treatment in Patients With Pulmonary Arterial Hypertension Who Have Failed
Bosentan Therapy
2,314.00 An 18-week randomized, double-blind, placebo-controlled, multicenter study
designed to compare treatment with Ariflo (cilomilast) to that with placebo for
changes in ventilatory mechanics and function (both at rest and during exercise)
as well
9,666.00 A double-blind, randomized, placebo-controlled, multicenter study to assess the
efficacy, safety and tolerability of bosentan in patients with idiopathic pulmonary
fibrosis
218,352.00 Relationship between cardiovascular risks and systemic inflammation in chronic
obstructive pulmonary disease
2,813.00 A1481142: Multicentre Multinational Long-Term Extension Study to Assess the
Safety & Tolerance of Subject Optimised Treatment Regimens of Oral Sildenafil
for Pulmonary Arterial Hypertension in Subjects Who Have Completed Study
A1481140
8,500.00 An int'l multicentre double blind randomized parallel placebo controlled
comparison of the safety and efficacy of chronic subcutaneous UT-15 plus
conventional therapy to conv. therapy in patients with pulmonary hypertension: A
12-week study
673,725.00 Inflammatory Gene Hapiotypes and Susceptibility to Cardiac, Vascular and
Pulmonary Disease
273,507.00 IMPACT: Integrated and mentored pulmonary and cardiovascular training
Levy
Grant
Respiratory
Levy
Clinical Trial
Respiratory
Levy
Clinical Trial
$
Respiratory
Levy
Clinical Trial
Actelion Pharmaceuticals
Canada Inc
$
Respiratory
Man
Grant
$
Respiratory
Ostrow
Clinical Trial
Pfizer Canada Inc.
$
Respiratory
Ostrow
Clinical Trial
United Therapeutics Corporation
$
Respiratory
Pare
Grant
Respiratory
Pare
Grant
Respiratory
Pare
Grant
CIHR: Operating Grant GEI$
53960
CIHR/Strategic Training:
$
Strategic Training Program Grant
STR-63308 in collaboration with:
Heart & Stroke Foundation of
Canada, Institute of Circulatory &
MSFHR: Distinguished Scholar
$
Award 60(CI-2001):
Respiratory
Pare
Agreement
Respiratory
Pare
Grant
Respiratory
Pare
Grant
Respiratory
Pare
Grant
Respiratory
Pare
Grant
Respiratory
Pare
Grant
BC Lung Assn.: Dr. Stefan
Grzybowski Fellowship (Fellow:
De Jong, Pim)
Encysive, L.P. in collaboration
with: Research Point
$
Respiratory
Ontario Genomics Institute in
collaboration with: Genome
British Columbia
MR : Operating Grant MOP
37924
American Thoracic Society, Inc
Parker B. Francis Fellowship in
Pulmonary Research (Fellow:
Mahmudi-Azer, Salahaddin)
Heart/Stroke Fdn Cda/CIHR:
Strategic Training Initiatives PG03-0191
BC Lung: Investigator in
collaboration with: St. Paul's
Hospital (Fellow: Sin, Don)
120,000.00 Molecular and Genetic Mechanisms of Obstructive Lung Disease
$
95,041.00 Mapping and isolation of genes influencing severity of disease in cystic fibrosis
$
67,766.00 Human airway smooth muscle function and bronchial hyperresponsiveness
$
64,360.00 Molecular mechanisms and genetic determinants of mediator mobilization and
release from neutrophil azurophilic granules as it relates to COPD
52,000.00 Mediator mobilization and release from neutrophil azurophillic granules in
association with Asthma and COPD
$
$
36,968.00 IMPACT: Integrated and mentored pulmonary and cardiovascular training
$
32,500.00 BC Lung Association/St. Paul's Hospital Investigator Award
Page 214
Annual Report 2004
Respiratory
Pare
Grant
Clinical Trial
Fellowship STPDF 167021
(Fellow: Mahmudi-Azer,
Salahadding)
CIHR/PMRF: Fellowship Awards
MFE-63469 Fellow: Camp,
Patricia
Research Award
# 54(02-1)BM: Despina
FRANGOLIAS (Res/Travel)
Research Award, STPHD
129021 (Fellow: Wallace, Alison)
Altana Pharma, Inc
Respiratory
Pare
Grant
Respiratory
Pare
Grant
Respiratory
Pare
Grant
Respiratory
Road
$
Respiratory
Road
Clinical Trial
Glaxo Smithkline
$
Respiratory
Road
Clinical Trial
Ltd
$
Respiratory
Road
Clinical Trial
$
Respiratory
Road
Clinical Trial
Altana Pharma, Inc
$
Respiratory
Road
Clinical Trial
$
Respiratory
Ryan
Agreement
ONO Pharma USA, Inc CTAONO-6126-POI011 in
collaboration with: PharmaNet,
LLC
Companies
Respiratory
Sandford
Grant
Respiratory
Sandford
Grant
Respiratory
Sandford
Grant
Respiratory
Respiratory
Sandford
Sin
Grant
Grant
Canada Research Chair: Tier II
(CIHR) 950-01-2053
MSFHR: Scholar Award C1SCH-26(02-01)
CCFF: Research
Canada Research Chair Tier II
(CIHR) 950-202044
$
11,000.00 Mediator mobilization and release from neutrophil azurophillic granules in
association with Asthma and COPD
$
5,000.00 Gender differences in chronic obstructive pulmonary disease
$
2,500.00 Contribution of Genes other than CFTR Gene to Disease Severity in Cystic
Fibrosis
$
2,500.00 Role of alveolar macrophage proteinase genetic polymorphisms in the
development of emphysema
$
$
$
$
$
$
Page 215
99,993.00 Protocol BY217/M2-118: Effect of 500 ug Roflumilast on Exercise Tolerance and
Respiratory Reserve in Patients With Chronic Obstructive Pulmonary Disease. A
12 Weeks Double-Blind Study with Roflumilast Once Daily vs Placebo
46,693.00 Protocol 207499/180: 18 week Randomized Double-Blind Placebo-Controlled
Multicenter Study Designed to Compare Treatment with Ariflo (Cilomilast) to That
With Placebo For Changes in Ventilatory Mechanics & Function (both at rest and
during….
9,730.00 Protocol 205.252: Randomized Double-Blind Double-Dummy Placebo and
Active-Controlled Parallel Group Efficacy & Safety Comparison of 12 Week
Treatment of 2 Doses (5ug(w actuations of 2.5ug) and 10ug (2 actuations of 5ug)
of Tiotropium…
7,160.00 Protocol DC-039-0003: A Study in Canadian COPD Patients to Evaluate the
Nature Treatment & Impact of COPD Exacerbation in Patients Who are Likely to
Benefit From Treatment With Symbicort (budesonide/formoterol) Turbuhaler. An
Open-Label…
4,670.00 BY217/M2-121: HERO Study: 24 Week Double Blind Randomized Study to
Investigate the Effect of 500 ug Roflumilast Tablets Once Daily vs Placebo on
Parameters Indicative of Hyperinlation in Patients with Chronic Obstructive
Pulmonary Disease
29,019.00 Four-week Double-blind Placebo-controlled Exploratory Evaluation of the Safety
and Efficacy of ONO-6126 in Patients with Chronic Obstructive Pulmonary
Disease (COPD)
28,125.00 Randomized Study to Compare Polysomnography with Overnight Home
Oximetry and Auto-CPAP for Diagnosis and Nasal CPAP Titration in Patients
with a High Probability of Obstructive Sleep Apnea
100,000.00 Canada Research Chair - Dr. Andrew Sandford
15,000.00 Genetic modifiers of pulmonary disease severity in cystic fibrosis
105,244.00 The role of macrophage protease polymorphisms in the development of
emphysema
90,000.00 Genetic Modifiers of Pulmonary Disease Severity in Cystic Fibrosis
75,000.00 Canada Research Chair in Chronic Obstructive Pulmonary Disease for Dr. Don
Sin
Annual Report 2004
Respiratory
Sin
Grant
Respiratory
Sin
Grant
Respiratory
Sin
Grant
Respiratory
Sin
Grant
(CIHR Scholarship) MSH-46814
CFI: Canada Research Chairs
Infrastructure Fund
Trials (Clinical Trials) MCT 52684
CIHR
Respiratory
Sin
Clinical Trial
$
Respiratory
Tebbutt
Grant
$
Respiratory
Respiratory
Ward
Ward
Grant
Grant
Respiratory
Wilcox
Clinical Trial
BC Lung: Project Grant 7568GR0001
CIHR/BC Lung Assn. Investigator
40941
Respiratory
Wilcox
Clinical Trial
Boehringer Ingelheim
Pharmaceuticals Inc.
$
Respiratory
Wilcox
Clinical Trial
Boehringer Ingelheim
Pharmaceuticals Inc.
$
Rheumatology
Anis
CAN
$
Rheumatology
Anis
CAN
$
Rheumatology
Badii
WCB
$
Rheumatology
Blocka
Clinical Trial
Hoffmann-La Roche
$
Rheumatology
Chalmers
Clinical Trial
Alexion
$
Rheumatology
Chalmers
Clinical Trial
Bristol-Meyers Squibb
$
Rheumatology
Rheumatology
Cibere
Cibere
Grant
Grant
$
$
Rheumatology
Cibere
Grant
Rheumatology
Cibere
Grant
TAS
CIHR: Clinician Scientist MC269188
CIHR: Clinician Scientist MC269188
CIHR
$
$
$
$
14,625.00 The Impact of Integrated Care on the Process of Care and Health Outcomes of
Patients with COPD
295,766.00 The effects of systematic inflammation in chronic obstructive pulmonary disease
(COPD)
174,443.00 Effects of Nocturnal Noninvasive Mechanical Ventilation on the Health Status of
COPD Patients
220,000.00 Interdisciplinary capacity enhancement: Briding excellence in respiratory disease
and gender studies (ICEBERGS)
423,347.00 IICT: Can Advair and Flovent reduce systemic inflammation related to COPD? A
multi-center randomized controlled Trial
17,000.00
$
$
42,000.00 Occupational health risks in the Health Care industry
40,950.00 Occupational health risks in the Health Care industry
$
13,213.00 A randomized, double-blind, placebo-controlled, phase 3 study of the safety and
efficacy of Interferon Gamma-1b in patients with idiopathic pulmonary fibrosis.
(The INSPIRE Trial: INternational study of Survival outcomes in IPF with
InteRfEron)
2,427.00 Spriva Assessment of FEV1 (SAFE) The effect of inhaled tiotropium bromide
(18mcg once daily) on the change in FEV1 during long-term treatment in patients
with COPD. A one-year parallel group, double-blind, randomised, placebocontrolled study
27,488.00 A Randomized, Double-Blind, Placebo-Controlled study to investigate the
Efficacy and Safety of 24 weeks of oral treatment with BIIL 284 in Adult
(75mg,150mg) and Pediatric (75mg) Cystic Fibrosis Patients
9,030.00 Sensitivity to change and responsiveness of different indirect utility measures:
the Health Utilities Index, the SF36, the EuroQoL, and a disease-specific
measure, the RA QoL questionnaire, in pts with RA
15,687.00 The effect of user fees on prescription drug utilization: Analysis of a longitudinal
cohort of patients with rheumatoid arthritis
88,003.00 Prospective randomised double-blind controlled trial of selective nerve root
blockade in patients with acute or subacute sciatica
9,402.00 A Randomized, Placebo-controlled, Double-Blind, Multicentre Study to Evaluate
the Safety and Efficacy of Rituximab in Combination with Methotrexate in
Patients with Active Rheumatoid Arthritis who have had an Inadequate Response
to anti-TNFα Therapies
8,747.00 Extension Study of h5G1.1-mAb in Rheumatoid Arthritis Patients Receiving
Methotrexate or Leflunomide Who Participated In Study C01-004
30,000.00 A Phase III, Multi-Centre, Randomized, Double-Blind, Placebo-Controlled Study
to Evaluate the Safety and Tolerability of BMS-188667 Administered
Intravenously to Subjects with Active Rheumatoid Arthritis With or Without
Medical Co-Morbidities Receiving Disease Modifying Anti-rheumatic Drugs
(DMARDs) and/or Biologics Approved for RA
80,000.00 Development of a model for the MRI Progression of Knee Osteoarthritis
43,875.00 Development of a Model for the MRI Progression of Knee Osteoarthritis
$
$
Page 216
40,000.00 Research allowance: Development of a Model for the MRI Progression of Knee
Osteoarthritis
25,000.00 Clinician Scientist Phase I (renewal)
Annual Report 2004
Rheumatology
Rheumatology
Cibere
Cibere
Grant
Grant
Rheumatology
Cibere
Grant
Rheumatology
Rheumatology
Esdaile
Esdaile
Grant
Grant
CIHR
UBC - Departmental Scholar
Award
CIHR: Clinician Scientist Award
MC1-35439
Arthritis Society - BC & Yukon
CIHR, CAN
Rheumatology
Esdaile
Grant
$
53,500.00 Double-blind placebo-controlled glucosamine sulfate withdrawal study in
osteoarthritis
11,251.00 Salary for Allen Lehman
275,000.00 New Emerging Team (NET) - Tooling up for early osteoarthritis: Measuring what
matters
75,830.00 Development of a model for the diagnosis of early knee osteoarthritis
Rheumatology
Esdaile
Grant
$
150,000.00 Tooling Up for OA: Measuring What Matters
Rheumatology
Rheumatology
Esdaile
Esdaile
Grant
Grant
CIHR/Strategic: Request for
Applications (Full)
NCE/CAN: Research
$
$
Rheumatology
Garbuz
TAS
$
Rheumatology
Greidanus
BCMSF, VCHA
$
Rheumatology
Kelsall
Clinical Trial
Aventis
$
Rheumatology
Kelsall
Clinical Trial
Abbott
$
Rheumatology
Klinkhoff
Clinical Trial
Abbott
$
Rheumatology
Klinkhoff
Clinical Trial
Hoffmann-La Roche
$
Rheumatology
Klinkhoff
Clinical Trial
Hoffmann-La Roche
$
Rheumatology
Klinkhoff
Clinical Trial
Abbott
$
Rheumatology
Rheumatology
Kopec
Kopec
CIHR
CIHR
$
$
Rheumatology
Rheumatology
Rheumatology
Kopec
Kopec
Kopec
CIHR
TAS
WCB
$
$
$
Rheumatology
Rheumatology
Kopec
Lacaille
MSFHR - Senior Scholar Award
TAS
$
$
Rheumatology
Rheumatology
Rheumatology
Lacaille
Lacaille
Lacaille
TAS
NCE/CAN: Research
UBC - Departmental Scholar
$
$
$
150,000.00 Tooling Up for OA: Measuring What Matters
74,374.00 A randomized controlled trial of a prevention strategy for severe injury in youth
soccer
53,474.00 A randomized controlled trial of long vs short wait for primary total hip and knee
arthroplasty
29,000.00 A randomized controlled trial of outpatient physiotherapy (OP) versus a selfadministered Home Exercise Program (HEP) following discharge home from total
hip arthroplasty - A feasibility study
5,538.00 A Randomized, Placebo-Controlled, Double-Blind, Multi-Centre, Parallel Group,
Dose-Finding Study to Assess the Safety and Efficacy of Multiple Doses of HMR
3480 in Subjects with Rheumatoid Arthritis on a Stable Dose of Methotrexate:
Safety follow up
36,000.00 A Multicenter Study of the Safety and Efficacy of Human anti-TNF Monoclonal
Antibody Adalimumab in Patients with Active Rheumatoid Arthritis
13,500.00 Continuation study of D2E7 in RA multi-centre continuation of the human antiTNF antibody D2E7 administered as a subcutaneous injection in patients with
rheumatoid arthritis
44,668.00 A Randomized, Multifactorial, Double-Blind, Parallel-Group, Dose-Ranging Study
of the Efficacy and Safety of Rituximab in Combination with Methotrexate in
Patients with Active Rheumatoid Arthritis
28,500.00 An open label study of the efficacy and safety of re-treatments with rituximab in
patients with active rheumatoid arthritis
40,000.00 A Phase III Multicentre Study of the Safety and Efficacy of Human Anti-TNF
Monoclonal Antibody Adalimumab (D2E7) in Moderate to Severely Active
Psoriatic Arthritis Subjects with Inadequate Response to Disease Modifying AntiRheumatic Drug Therapy
2,949.00 Physical activity and osteoarthritis: A case-control study
147,147.00 OA Population-clinical simulation model of osteoarthritis: development and
applications (COAST)
64,799.00 Physical activity and joint health: An Internet-based cohort study
26,125.00 Measuring treatment preference in patients with OA of the hip & knee
19,997.00 Measuring health outcomes: An empirical comparison of adaptive and standard
questionnaires
100,000.00 Senior Scholar Award
20,903.00 Preventing work loss from inflammatory arthritis: Program development and pilot
testing
28,442.00 National Work Loss Program
44,250.00 Assessing the quality of care for rheumatoid arthritis (RA) at a population level
19,200.00 Departmental Scholar Award
Salary Award
Salary Award
$
$
$
$
$
Page 217
25,000.00 Clinician Scientist Phase II
15,000.00 Departmental Scholar Award
Annual Report 2004
Rheumatology
Lacaille
Salary Award
Rheumatology
Lacaille
Salary Award
Rheumatology
Rheumatology
Rheumatology
Lehman
Lehman
Shojania
Salary Award
Salary Award
Salary Award
Award
TAS, CIHR - New Investigator
Award
VHHSC - Research Scholar
Award
CIHR - Fellow Award
MSFHR - Fellow Award
TAS
$
50,000.00 New Investigator Award
$
10,000.00 Research Scholar Award
$
$
$
20,000.00 Fellow Award
2,667.00 Fellow Award
3,750.00 Clinician Teacher Award
$ 40,713,125.00
Page 218
Annual Report 2004

Annual Report - Department of Medicine

Transcription

Similar documents

Pocket Guide UBC - Freie Universität Berlin

Berklee School of Music Conference: Perspectives on Music

oo-k thefts- it new peak last session

1918 - UBC Library

Scrappy, Hard tackling FullbackBecomes Legend

W5 apologizes for racist report

During the beautiful summer days of Vancouver, one can

You want to cut my what? - UBC Library

BOG seat won by chem head

Money Neede d Donors Find Bleeding Eas y